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Abstract  
Background: Around 70% of people with dementia live with comorbidities and are subsequently 
prescribed multiple medications (polypharmacy). Some medicines are considered ‘potentially 
inappropriate’ when prescribed to older and cognitively impaired adults. Cognitive impairment, 
dementia and frailty may influence the prevalence and associated effects of polypharmacy and 
potentially inappropriate medicines (PIMs).  
Aims: To estimate prevalence trends of polypharmacy and PIMs (antipsychotics, antidepressants, 
benzodiazepines, anticholinergics and proton pump inhibitors) among people with dementia. To 
identify associated factors, including the impact of care and medication reviews and to 
understand the impact of polypharmacy, PIMs and frailty on health in people with cognitive 
impairment.  
Methods: Two cohorts were analysed, including primary care electronic medical records (Clinical 
Practice Research Datalink, 2015-2017) (n=22,448) and the Cognitive Function and Ageing Study 
(2008-2011) (n=1,154).  
Results: Polypharmacy and PIMs were prevalent in people with dementia and cognitive 
impairment. On average, people with dementia were prescribed 8 medications, 30% were 
prescribed inappropriate PPIs, 17% anticholinergics, 8% antipsychotics, 7% tricyclics and 4% of 
people with cognitive impairment were prescribed benzodiazepines. Dementia annual reviews 
and medication reviews were associated with medicines optimisation. Prevalence of PIM was 
greater in care homes and a medication review in a care home was associated with reduced use 
of PIMs. Polypharmacy was associated with worse survival. PIMs were not associated with worse 
survival, with the exception of antipsychotics (adjusted HR=3.24, 95% CI=1.83-5.73). Being 
cognitively impaired and frail was associated with worse survival overall but frailty was not found 
to moderate the relationship between polypharmacy, PIMs and survival.  
Conclusions: Few prescribing guidelines specifically address medicines use in people with 
cognitive impairment or dementia, despite the prevalence of polypharmacy and PIMs. The 
number of medicines prescribed should be carefully monitored to reduce harm. Incorporating 
medication reviews into annual dementia care reviews may optimise prescribing and identify 
people at increased risk of adverse effects. The findings from this thesis will improve 
understanding and support the optimisation of medicines for people living with dementia.  
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I. Chapter 1: Background and Introduction 
In the United Kingdom (UK) there are over 850,000 people over the age of 65 living with dementia 
[1] and there are more than 200,000 new cases of dementia every year [2]. Around 70% of people 
living with dementia also live with other health conditions and are subsequently prescribed 
multiple medications [3]. Multiple medication use is common in this increasingly large population, 
who are vulnerable to a range of associated side effects and adverse effects of potentially 
inappropriate prescribing practices.  
 
1.01 Dementia  
More than 44 million people live with dementia worldwide and there are an estimated 4.6 million 
new cases annually [4, 5]. Dementia is clinically defined as the broad term of major 
neurocognitive disorder. Dementia is a progressive neurodegenerative syndrome, largely 
characterised by memory deficits but also affects an individual’s communication, language, 
attention, perception, executive and motor functions and social cognition. Dementia is an 
umbrella term used to define a variety of conditions affecting the brain. Alzheimer’s disease is the 
most frequent cause of dementia, accounting for two-thirds of cases, followed by vascular 
dementia (20%), Lewy body dementia (15%), frontotemporal dementia (5%), Parkinson’s, 
Creutzfeldt-Jakob disease and other rarer forms of dementia. Each person’s experience of 
dementia is different. It is common for an individual to be living with a combination of dementia 
disease types. Each condition is characterised by a different set of symptoms, and associated with 
ongoing disease progression over time. In general, dementia is more common in women than 
men [1, 5] and the prevalence of dementia increases as people age, with one in fourteen adults 
over 65 years old at risk of dementia, increasing to one in six in adults over 80 years [1, 4, 6].  
 
1.02 Global burden of disease  
In 2015, the global cost of dementia was estimated at £631 billion (US $818 billion). Around 80% 
of the financial burden falls on health and social care services and informal carers, in comparison 
to costs directly associated with use of medical services [7]. In 2016, dementia was one of the 
highest causes of death globally after ischaemic heart disease, chronic obtrusive pulmonary 
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disease, intracerebral haemorrhage and ischaemic stroke, accounting for 2.2 million deaths 
worldwide [8].  
 
1.03 Burden of disease in United Kingdom  
By 2030, it is predicted that there will be over 1 million people living with dementia in the UK and 
over 1.2 million by 2040 [9]. Currently, dementia costs the UK economy £26 billion annually and 
the overall economic burden is expected to increase to £55 billion by 2040. Dementia costs the 
National Health Service (NHS) £4.3 billion each year and the cost of unpaid care is £11.6 billion 
[10].  Dementia is now the leading cause of death in adults over 80 years old in England and 
Wales, accounting for 20% of all deaths, ahead of ischemic heart disease and cerebrovascular 
disease [11].   
Improving the quality of life for people with dementia and their carers is a national priority. In 
England, the National Dementia Strategy (2009) and subsequent Dementia Challenge (2012), 
were launched by the government. Central to their aims was diagnosis, improving awareness, 
early interventions and quality of care. Similar strategies were launched in Scotland in 2010 and 
Wales in 2011 [12, 13]. Since 2006, general practitioners have been financially incentivised 
through the Quality and Outcomes Framework (QOF) to record dementia prevalence on dementia 
registers and to conduct annual care reviews for people with dementia. After the launch of the 
National Dementia Strategy in 2009, dementia diagnosis rates increased by 4% in 2010 and 12% in 
2011 [14].  
 
1.04 Cognitive impairment  
Cognitive function is the process of knowledge acquisition and understanding through thought, 
experiences and the senses. There are multiple cognitive functions that are integral for our day-
to-day lives. Cognitive functioning encompasses our response to emotional and social situations, 
decision making, memory, attention, reasoning, processing and response to people, our 
environment and experiences. Many older adults live with impairments across cognitive 
functions. Mild cognitive impairment (MCI) or mild neurocognitive disorder is the clinical term 
used to define a recognisable decline in cognition from previous level of functioning. Mild 
cognitive impairment is a recognisable decline, but does not significantly impact on the ability to 
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conduct day-to-day activities, and so does not meet the criteria to be formally labelled as 
dementia. In some cases, MCI reflects the early stages of dementia. However, longitudinal studies 
demonstrate that whilst some people with MCI go on to develop dementia, a significant 
proportion revert to normal cognition or remain stable [15]. Most commonly, MCI that is largely 
characterised by memory impairment is associated with progression to dementia [16]. Up to 36% 
of adults over 60 years old live with MCI [17] and around 60% of people with MCI progress to 
dementia [18]. For the purposes of this research, mild cognitive impairment, mild neurocognitive 
disorder and cognitive impairment that is not diagnosed as dementia, will be referred to as 
cognitive impairment. 
 
1.05 Risk factors  
There are a number of risk factors associated with dementia. This includes a number of comorbid 
health conditions that increase a person’s risk of developing the disease, as well as genetic and 
lifestyle factors [19]. Cerebrovascular disease and cerebral damage from haemorrhage and 
ischemic cortical infarcts associated with stroke are associated with an increased risk of dementia. 
Around 8% of people who have a stroke subsequently develop post-stroke dementia [20]. 
Cerebrovascular disease is most strongly associated with vascular dementia, which is largely 
characterised by reduced blood flow to the brain.  
Other physical comorbidities have been associated with an increased risk of dementia, including 
high blood pressure, high cholesterol and diabetes. High blood pressure in middle-aged adults has 
been associated with an increased risk of cognitive impairment, Alzheimer’s disease and dementia 
[21–23]. Unhealthy cholesterol levels are associated with cerebrovascular disease, increasing the 
risk of dementia. Observational studies have also shown that Type 2 diabetes is associated with 
twice the increased risk of Alzheimer’s disease [24–26]. A meta-analysis of longitudinal studies 
found an increased risk of 54% associated with Type 2 diabetes [27]. In addition, obesity,  a risk 
factor for high blood pressure, cholesterol and diabetes, is associated with an estimated 59% 
increased risk of dementia [27]. Age is the greatest risk factor for dementia and older age is also 
associated with increased comorbidities and health complications [1, 4, 6]. Although, 
approximately 5% of cases of dementia are considered ‘early-onset’ when the disease is 
diagnosed in people under the age of 65 [28].   
A number of psychosocial factors are also associated with increased risk of dementia. Evidence 
suggests that fewer years in education is associated with an increased risk of dementia, although 
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this is not conclusive [29]. Previous studies have also found an association between social 
isolation and cognitive impairment in older adults [30]. Depression is prevalent in people with 
dementia [31]. However it is difficult to determine the causal relationship between depression 
and dementia, particularly in the prodromal stages of disease presentation [32]. Many 
psychosocial factors, including social isolation and depression for example, are intrinsically linked 
with one another and often linked with physical comorbidity. Collectively, these factors contribute 
to increased vulnerability to the impact of risk factors associated with dementia. However, many 
of these risk factors are modifiable through lifestyle changes, psychological and pharmacological 
therapy. A recent report reported that modifiable risk factors could account for up to 35% of 
dementia burden [33].  
 
1.06 Pharmacological approaches to managing dementia  
There is no cure or disease modifying treatment for dementia. There are a small selection of 
medications prescribed to manage symptoms of the disease. The most commonly used 
medications are acetylcholinesterase inhibitors (donepezil, rivastigmine and galantamine), which 
inhibit the transmission of the neurotransmitter acetylcholine. These are used to manage 
symptoms of mild to moderate Alzheimer’s disease. Donepezil can be prescribed in people with 
severe Alzheimer’s disease. Memantine, which acts on the glutamatergic system, can be 
prescribed to people with moderate-severe Alzheimer’s disease, Lewy body dementia and mixed 
dementia. Overall, the symptom management options for dementia are limited [34] and with 
more clinical trials resulting in negative outcomes than successes, at a ratio of 100:1 compared 
with a 14.6:1 average across the pharmaceutical industry [35, 36].  
Since there are no disease modifying treatments, improving the quality of life for the individual 
and carers is a priority.  Enabling the person to live-well and within their own priorities for care, 
for as long as possible. Symptom and comorbidity management is associated with medication use. 
Comorbidities associated with the risk of dementia are usually treated with medicines. Managing 
the symptoms associated with cardiovascular disease, cerebrovascular disease, diabetes, high 
blood pressure, high cholesterol, and depression, for example. Additionally, medications are often 
prescribed to manage behavioural and psychological symptoms of dementia.  
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1.07 Care for people with dementia  
With two thirds of people with dementia living in the community, familial carers are a 
cornerstone for the provision of support and care of people living with dementia. For many 
carers, the experience can be associated with psychological, physical, emotional and economic 
strain. Many carers will experience caregiver burden, which is affected by the multiple dimensions 
of their role as a carers.  Defined as a multidimensional response to physical, psychological, 
emotional, social and financial stressors associated with the caregiving experience [37]. Carers will 
often play a key role in the management of medicines for people with dementia, including 
responsibility for taking medicines and involvement in decisions around prescribing [38]. The 
demands and time providing care increases as the disease progresses. Health and social care 
services need to find ways to support both the person with dementia and their carer across the 
disease progression [39].  
People with dementia live across the community and within institutional settings, including a high 
proportion of people with dementia in care, residential or nursing homes. In the UK, around one 
third of people with dementia live in a care home [28], often at later stages of the disease, are 
more frail and in need of more assistance in activities of daily living. People with dementia may 
live for a long time in their own home and often transition into a care home as the disease 
progresses, physical and cognitive capacity declines and need for support in conducting day-to-
day activities, such as washing, dressing and eating requires additional support. The experiences, 
patient preferences and health priorities will change across the progression of the disease. It is 
important to factor this variation into the development of patient-centred and individualised care 
plans.  
 
1.08 Frailty and dementia  
‘Frailty’ refers to the condition of being ‘frail’ that is commonly recognised in many older people. 
A person who is frail is typically but not exclusively less mobile, may have difficulty getting up 
from a chair, walk slowly, is easily tired or exhausted from small amounts of activity, and is 
generally less active on a daily basis. More formally, frailty is a term used to describe a state of 
age-related decline in functioning across multiple organ systems. Frailty is associated with an 
increased vulnerability to and diminished ability to cope, and recover from acute and everyday life 
events, also referred to as reduced physiological reserve. Frailty is now a recognised, 
multifactorial clinical state that affects health outcomes for older adults, although it is not 
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exclusively a gerontological issue.  A change in medication, minor infection, change of residence, 
bereavements, falls, hospital admission and operations are examples of potentially destabilising 
events. These events could significantly impact a frail adult and their ability to return to the same 
level of function as before the event. The consequences of these destabilising events in frail older 
adults may result in drastic change, such as from independent to dependent, lucid to delirious and 
stable to at risk of falls [40].  
There is some evidence of an association between frailty and cognitive impairment and dementia. 
Frailty and dementia share some common aetiologies and overlapping clinical features, including 
factors associated with increased dementia risk, such as diet, cardiovascular risk factors and 
depression [41]. Age is strongly associated with dementia and it is thought that there is an 
association between the age-related processes associated with frailty and cognitive impairment 
and dementia [41]. In the Rush Memory and Ageing Project, a longitudinal study of ageing, 
baseline frailty and annual frailty change was associated with incident dementia and MCI [42]. An 
ongoing debate centres on distinguishing frailty as a clinical syndrome distinct from comorbidity 
and disability. Frailty, disability and comorbidity are not mutually exclusive but there are features 
that do distinguish them, including decreased physiological reserve, impairment across multiple 
organ systems and capacity to recover after a stressful event [43]. Fried et al (2001) investigated 
the overlap between frailty, disability and comorbidity using the Cardiovascular Health Study, in 
21.5% of the sample frailty, disability and comorbidity were present. However, in 26.6% frailty 
was present without comorbidity or disability, supporting the argument that frailty is related to, 
but distinct from comorbidity and disability. On the other hand, frailty has been considered as a 
representation of an accumulation of comorbidities, disability, cognitive decline and any other 
age-associated deficits [44]. Through the operationalisation of frailty definitions in large 
epidemiological studies, frailty has been recognised as predictive of a number of adverse 
outcomes which include, increased risk of falls [45, 46], disability [45, 46], hospitalisation [47], 
admittance to a care home [48, 49] and mortality [45, 46, 48, 49]. More recently, frailty has 
started to be operationalised for use in clinical practice. Although, the concept of a ‘frail’ older 
adult has been recognised for a long time. More research is needed to validate the concept of 
frailty for use in clinical practice compared to translating findings from observational studies.   
The concept of frailty is continually under debate and other approaches to understanding 
variation in ageing have been proposed. As an alternative, the concept of intrinsic capacity, which 
has a capacity rather than disease focus has been proposed. Particularly for monitoring 
trajectories from independence to dependence in older populations [50]. Regardless of the 
concept used, the concepts must be validated to predict adverse outcomes. Further research is 
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needed to validate the constructs of frailty.  Moreover, in clinical practice the concept that will be 
able to be of most practical utility, feasibility, and able to identify those at risk of harm or who will 
benefit from intervention is of the utmost importance.  
 
(a) Defining frailty  
There are two dominant but very different frailty measurements that are most commonly used in 
research and clinical practice, the Frailty Phenotype [47] and the Frailty Index (FI) [44]. The 
phenotype is characterised as a syndrome with specific pathophysiological processes that are part 
of a cycle of frailty, whereas the FI characterises frailty much more broadly as a marker of the 
number of age-associated deficits that are predictive of adverse outcomes. 
 
(i) Frailty Phenotype  
Fried and colleagues initially developed a core set of frailty criteria in 2001 and operationalised 
these into the frailty phenotype, which was validated in the Cardiovascular Health Study [47]. The 
frailty phenotype is a pre-defined set of five criteria capturing a range of signs or symptoms 
(involuntary weight loss, exhaustion, slow gait speed, poor handgrip strength and sedentary 
behaviour). The frailty phenotype is dominated by physical factors that contribute to a syndrome 
of frailty. In the original development of the phenotype, people with cognitive impairment, 
Parkinson’s disease, previous stroke or depression were excluded from the sample. Furthermore, 
the concept does not directly account for changes in cognition or mental health. This challenges 
the validity of some of the criteria since mental health, particularly depression may be intrinsically 
linked to physical health. It is of debate whether frailty assessment should include a mental health 
assessment too. The relationship could be argued to be bi-directional too since people who are 
depressed are less physically active, and people who are less physically active are more likely to 
become isolated and depressed [51]. Although, it can be argued that mental health may be 
reflected within the manifestation of the criteria, such as exhaustion. The exhaustion questions 
often translates from depression scales and as such could be argued to account for mental health 
in the criteria. 
Although the frailty phenotype has since been validated in older, multimorbid populations [52], 
there are concerns about the predictive validity of specific criteria. According to the Fried 
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phenotype, obese people would not be considered frail. The criteria is characterised by rapid 
weight loss, even though people who are obese are less physically active and more likely to report 
exhaustion [53]. The overall phenotype construct is predictive of adverse outcomes, further 
research is required to evaluate the predictive validity of individual frailty criterion [54]. 
Furthermore, whether or not frailty is a useful predictor of vulnerability to adverse outcomes 
from another predictor, and therefore whether frailty moderates susceptibility to adverse 
outcomes is unknown.  
 
(ii) Frailty Index  
The Frailty Index (FI) is based on the characterisation of frailty as an accumulation of age-related 
deficits, with more deficits indicative of a frailer individual. To initially operationalise this concept, 
Rockwood and colleagues created the FI in 2005 using the Canadian Study of Health and Ageing to 
develop and validate the FI [44]. The FI is a clinical condition and disease checklist of up to 70 
items or deficits (as originally proposed). Symptoms, signs and diseases are classified as deficits 
[55] which therefore may include, clinical signs (e.g. tremor), symptoms (e.g. vision problems), 
diseases, disabilities and abnormal test values and are used to generate a cumulative FI score. The 
FI score is based on each item being present or absent as a proportion of the total number of 
items. This score has an advantage of being useful as a continuous measure or dichotomised 
variable classifying non-frail, pre-frail or frail and could be more sensitive to identifying change 
across frailty status [56] [57]. This approach includes cognitive and physiological vulnerabilities 
which are not accounted for in the phenotype. Some have argued that frailty should also account 
for social connections and relationships which when lacking can increase vulnerability to life 
events [58]. However, in applying a deficit accumulation approach, all potential age-related 
vulnerabilities that a person has are grouped together. No distinction can be made to understand 
individual contribution of comorbidity, cognitive impairment or physical frailty. The frailty 
phenotype is more suited to understanding the individual contributory risk associated with 
physical frailty, distinct from comorbidity and cognitive impairment.  
The clinical application of frailty has recently spiked further interest in the validity of the 
constructs. The routine identification of frailty has been included in the General Medical Services 
(GMS) General Practitioners contracts [59]. In practice, the identification of people who are frail 
can assist in recognising those who are most vulnerable to stressors and with complex care needs. 
Frailty is a good predictor of adverse outcomes and in practice will be more informative than age 
when assessing patients. However, much of the evidence is based on observational studies where 
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frailty is measured at a single time point, failing to account for the transitional nature of frailty. 
Both concepts of frailty have been widely replicated and adapted in observational studies and 
clinical settings meaning there has been little standardisation [60]. Moreover, there is a lack of a 
consensus on definition and measurement of frailty. This means that depending on the definition 
of frailty, different individuals may be identified as frail according to different definitions. This will 
continue to be a challenge in practice as there is limited guidance on the type of frailty measure 
that should be used. Standard definitions of frailty, particularly across different practices, will vary 
considerably [61].  
Through identifying frailty, there may be opportunities for interventions to improve factors 
contributing to frailty. Frailty assessments can provide useful information to help practitioners 
and patients in developing care plans and opportunities for interventions. This may include, 
exercise, caloric and protein support, vitamin D supplements and reducing polypharmacy [62]. 
However, for the individual the concept or label of frailty can negatively affect their self-identity 
and the way in which other people view them as the term is loaded with negative connotations 
[63]. Frailty can help in delineating the heterogeneity of physical and cognitive decline associated 
with ageing. However, further research is required to assess the predictive validity of individual 
frailty criteria. From a clinical perspective, this is important as identifying frailty is more readily 
incorporated into clinical practice. 
 
1.09 Comorbidity and dementia  
Comorbidity, the concomitant presence of more than one health condition in an individual, is 
common in up to 70% of people living with dementia [3]. The presence of multiple comorbidities 
(multimorbidity) is associated with adverse health outcomes, decreased quality of life, complex 
care regimes, increased use of health care services, and subsequent health costs [64]. In a study 
of over 10,000 people with dementia in UK primary care, people with dementia had on average 
2.9 physical comorbidities compared with 2.4 in age-matched controls [65]. A US study of over 
3,000 older adults with and without dementia estimated that people with dementia had 2.4 
chronic conditions. This was comparable to older adults without dementia in this population (2.3 
chronic medical conditions). As expected, there is considerable overlap between the 
comorbidities that are risk factors for dementia and those most commonly occurring in people 
with dementia. An estimated 41% of people living with dementia have high blood pressure, 32% 
depression, 27% heart disease, 18% cerebrovascular disease and 13% diabetes [66]. A scoping 
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review of the literature of comorbidities in people with dementia found that the prevalence of 
diabetes in people with dementia was as high as 39%. Thirty four percent  of people with 
dementia had also had a stroke [67].  
Psychiatric comorbidities are also common in people with dementia but symptoms can be difficult 
to differentiate from dementia symptoms. Depression is a risk factor associated with dementia 
and is prevalent in people with dementia [31]. Anxiety is also common in around 5% to 25% of 
people living with dementia and is associated with restlessness, fatigue, difficulty concentrating 
and worry [68]. Behavioural and psychological symptoms of dementia, including psychosis, 
hallucinations and wandering also impact on individual experience of living with and caring for 
someone with dementia [69]. Medications are commonly prescribed to manage behavioural and 
psychological symptoms and comorbidities.  
While the number of comorbidities may be similar across people with and without dementia, it is 
likely that managing comorbidities is more challenging in this population. People with dementia 
and comorbidity are particularly affected by a lack of care continuity, integration or 
communication across primary and secondary care and multiple specialists [67]. Many 
comorbidities are associated with an increased risk of dementia or are associated with 
consequential outcomes of dementia, such as depression in dementia. In clinical settings such as 
hospitals and care homes, dementia can affect and complicate care, including how the person’s 
individual needs are understood and the way in which services are used [70].  
As a direct consequence of comorbidity, many people with dementia are prescribed multiple 
medications, which is discussed further in the next section and is the motivating problem 
underlying the work presented in this research study. 
 
1.10 Polypharmacy   
Polypharmacy is the commonly used term to describe the prescription of multiple medications 
[71]. There are many different definitions of polypharmacy. A commonly used definition is five or 
more medications [72]. There is no consensus on whether polypharmacy refers to the 
concomitant use of multiple medications at the same time, or whether it refers to medications 
prescribed long-term, such as through a repeated prescription system [72]. Older adults are the 
largest consumers of medications compared with other groups of the population. Around one 
fifth of the UK population is over 60 years old, and this group receives around 60% of all 
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prescriptions, accounting for more than half of NHS prescribing costs [73, 74]. The increased use 
of symptom managing and treating medicines has been fundamental in improving the quality of 
health care provision, quality of life, recovery from illness, reducing disability, and increased 
longevity amongst the population [75]. In the past century, life expectancy in the UK has steadily 
increased. In 1910, male life expectancy was 51 and 55 for females. This has increased to 80 for 
males and 83 for females in 2012 [76]. Other factors such as improved nutrition, hygiene, housing 
and sanitation are important, but improvements in medicine and the introduction of the National 
Health Service (NHS) in 1948 has significantly contributed. Through improved control of infectious 
diseases, reduced mortality at birth and improvements in treatments, more and more people are 
able to live-well for longer.   
 
(a) Challenges of polypharmacy  
There are a number of challenges associated with polypharmacy for people with dementia with 
multimorbidity, for whom medicines are an integral part of everyday life. Appropriate and 
evidence based use of multiple medicines is made more difficult by the single disease focus of 
prescribing guidelines, limited external validity and generalisability of clinical trials, prescribing 
cascades, adherence, medication errors, a lack of guidelines for prescribing and increased 
susceptibility to adverse effects. Each associated challenge may also multiplicatively increase the 
potential for harm in a population who are already increasingly vulnerable to medication-related 
adverse effects and the subsequent consequences. More research is required to improve the 
quality of life for people with dementia and those managing multimorbidity and polypharmacy.   
 
(i) Prescribing guidelines take a single disease focus  
By taking a single disease focus, guidelines often fail to account for multimorbidity, drug-disease 
and drug-drug interactions that may increase the patient’s susceptibility to adverse effects and 
ineffective treatment. Previous research has found a lack of consistency in the way in which 
guidelines will account for comorbid health conditions and identified few disease-specific 
recommendations for prescribers [77]. Multiple medications are likely to be prescribed for a 
patient with multiple comorbidities. For example, a patient with five mild-to-moderate 
comorbidities such as, previous myocardial infarction, type-2 diabetes, osteoarthritis, chronic 
obstructive pulmonary disease (COPD) and depression, could be prescribed a minimum of 11 
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medications [77]. The patient could also be prescribed up to 10 additional medications depending 
upon the disease progression, side effects and outcomes. In addition, managing a complex 
medication regime can increase treatment burden to an individual. Additional treatment burden 
from multiple appointments, other recommended interventions and referrals, also recommended 
through the guidelines would accumulate to considerable treatment burden for the individual 
[77]. The single disease focus approach to guidelines can negatively affect the individual. Recent 
years have seen some improvement in the provision of guidelines that account for 
multimorbidity. The National Institute for Health and Care Excellence (NICE) have published 
guidelines for the clinical assessment and optimisation of care for people with multimorbidity, 
which includes optimising medicines and assessing frailty [78]. Furthermore, the Royal 
Pharmaceutical Society have published good practice guides for optimising medicines for 
pharmacists to support patients [79]. For a person living with dementia or cognitive impairment, 
managing medications can be increasingly difficult, however it is unclear the extent of harm that 
may be associated with multiple medication use in people with dementia and there is little 
research into prescribing in people with dementia in primary care [80].  
 
(ii) External validity and generalisability of clinical trials  
The evidence for the safety and efficacy of medicines may not be applicable to people with 
cognitive impairment and dementia. For a number of reasons, people with cognitive impairment 
are excluded from clinical trials. It would be unethical to conduct a trial in a sample where there 
was a potential for increased risk of harm. In addition, people with cognitive impairment or 
dementia may also be excluded from trials due to difficulties in recruitment and retainment in 
studies. It may also be more difficult to detect outcomes due to the complexities associated with 
dementia and comorbidities. Controlled clinical trials are generally conducted in younger and 
healthy populations, representing a population with a lower-risk profile. The impact of this is that 
older adults, adults with comorbidities, cognitive impairment, dementia, frailty and polypharmacy 
are excluded. Given this, it is unsurprising that older adults are often underrepresented in clinical 
trials [81, 82]. One study reviewing over 280 randomised controlled trials (RCT) over a 10 year 
period, found 81% of RCTs excluded participants because of comorbidities and 39% excluded 
people based on their age. Drug intervention trials often exclude participants because of other 
medication use [83].  
While reporting is mandatory, often adverse events go unrecognised or unreported. A recent 
review of the reporting of adverse events in published RCTs identified that of 184 trial studies, 
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30% reported methods to identify adverse event data during the trial. Therefore, only a small 
proportion of the trials reported using a mechanism through which an adverse event could be 
reported by a participant, meaning adverse events may have gone unrecognised. Moreover, 35% 
of the studies reported whether a withdrawal from the trial was due to an adverse event and may 
therefore be under reporting the incidence of adverse events [84]. In addition, a discussion of 
both the benefits and harms of a medication is often missing from findings in published trial 
studies [85]. Finally, the controlled environment of an RCT alongside selective sampling also limits 
the external validity, and consequently the clinical implications of prescribing in populations with 
high-risk profiles in an uncontrolled environment [86]. 
 
(iii) Prescribing cascade  
Prescribing cascades can occur in people with dementia, particularly if the individual has difficulty 
communicating adverse effects of medicines. Prescribing cascades occur when cumulative 
prescriptions for medication related adverse effects are prescribed. Prescribing cascades can 
occur inappropriately. Although, side effects of medicines can also be appropriately recognised 
and treated with another medicine to counteract the effect. Previous studies have found that 
people with dementia can be at an increased risk of being inappropriately prescribed 
anticholinergic medications to manage urinary incontinence [87]. In people with dementia, a side 
effect of acetylcholinesterase inhibitors is urinary incontinence, which is commonly associated 
with dementia and is often misinterpreted as a symptom of the disease, when in some cases it is 
representative of a medication-related adverse effect [87]. Inappropriately prescribing 
anticholinergic medication to a person with dementia could also accumulate subsequent adverse 
effects particularly as anticholinergics are associated with adverse cognitive effects [88]. 
Anticholinergic medications block the action of the neurotransmitter acetylcholine and are a 
broad drug class with a diverse range of indications across the central and peripheral nervous 
system. It is proposed that adverse cognitive effects arise through anticholinergic effects on the 
parasympathetic nervous system and cholinergic pathways associated with memory, perception 
and attention, contra to the indication of the medicine [89]. If a medication related side effect is 
inappropriately misinterpreted as a comorbidity and additional medications are prescribed, the 
risk of adverse effects increases and subsequently increases the risk of both inappropriate and 
unnecessary prescribing [90]. 
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(iv) Adherence  
Adherence to medication regimes is important in enabling the best possible outcomes of 
medication use. However, often medications are not taken as intended and increasing treatment 
burden and complex medication regimes from polypharmacy is associated with non-adherence  
[91, 92]. Between 30% and 50% of prescribed medications are not taken as intended [92]. For 
people with dementia, increasing cognitive impairment and multiple medication use is associated 
with up to 59% non-adherence to regimes [91]. Adherence to medicines is complex and there are 
a range of barriers associated with adherence. Barriers include a lack of knowledge about 
medicines, physical and cognitive ability to take medicines as prescribed, confidence in managing 
complex regimes, beliefs and doubt about the efficacy of medicines, motivation, memory, 
attention and decision making capacity and relationship with prescriber [93]. Increasing the 
number of prescribed medications may be counterproductive if this is associated with reduced 
adherence, increased burden and potential for adverse effects.  
 
(v) Medication errors  
The risk of a medication error increases with increasing medication use. There is potential for 
error to occur across the process of prescribing, dispensing, administration and monitoring and 
across primary and secondary care and in care homes [94]. While many medication errors have 
little or no potential for harm or are picked up before they reach the patient, it is estimated that 
66 million clinically significant errors occur each year across the NHS in England. When they do 
occur, medication errors are associated with considerable economic and patient burden. Costing 
an estimated £98.5 million each year, consuming over 180,000 hospital-bed days, are associated 
with 712 deaths and contribution to 1,708 deaths each year [94]. Increasing use of medications is 
associated with increased risk of medication errors. This can have clinically significant effects in 
patients, particularly in older adults who are vulnerable to such effects.  
 
(vi) Prescribing in people with dementia  
Medication management in people with dementia can be increasingly complicated as the disease 
progresses and decision making and cognitive capacity decreases [67]. Carers (formal and familial) 
will increasingly become integral in managing medicines, priorities for care will change, and 
medicines will need to be regularly reviewed to reflect this [95]. However, research into managing 
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comorbidities in people with dementia is limited [96] and there are few clinical guidelines to 
support prescribing for comorbidities in people with dementia. Clinical guidelines inform practice 
and assist health professionals to make informed decisions around prescribing and care provision 
for their patients.  
 
(vii) Vulnerability to adverse effects of medications  
An adverse drug reaction or adverse effect is defined as “a harmful or unpleasant reaction, 
resulting from medicinal intervention, which predicts hazard from future administration and 
requires prevention or specific treatment, or dose alteration or withdrawal” [97]. Physiological 
changes occur as a natural part of ageing and affects the way in which individuals respond to 
medications, including susceptibility to adverse effects [98]. There is limited research into specific 
physiological changes in people with dementia. Changes across different biological systems as a 
natural part of ageing also contribute to altered pharmacokinetics and pharmacodynamics in 
older adults and people with dementia [99]. Pharmacokinetic changes include changes in the 
absorption, distribution, metabolism and excretion of medications [100]. Evidence suggests that 
changes in the body composition associated with ageing, such as increased body fat and decrease 
lean body mass, can alter the distribution of medicines. Increased distribution is most commonly 
associated with medicines that are fat soluble and distributed via fatty tissues. Decreased 
distribution is associated with medicines that are largely water-soluble [101]. Moreover, 
metabolism of medicines, which largely occurs in the liver is often reduced. Reduced renal 
functions associated with advanced age affects the excretion or clearance of many medicines [98, 
99].  
Age-related changes in pharmacodynamics alter the way in which a medication has its effect 
within the body. Understanding of these factors is integral for effective medication management 
within older adults and people with dementia [102]. A systematic review of studies using 
biochemical or imaging techniques to examine blood brain permeability, found that older age was 
associated with significantly increased permeability. As was dementia, compared to age-matched 
controls without dementia in pooled estimates, although causality is unclear [103]. Collectively, 
age-related and potentially disease-related changes in response to medications are thought to 
underlie an increased susceptibility to adverse effects of medications in older adults and people 
with dementia [104]. 
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(viii) Potentially Inappropriate Medications  
Potentially inappropriate medication (PIM) is the term used when the potential harm of a 
medication outweighs the potential benefit, in patients with specific diseases or conditions. 
Criteria have been developed to identify PIMs in older adults and are used to identify PIM in 
specific patient groups, interactions and overuse of medicines that may increase the risk of 
adverse effects. In the US, Beers criteria for potentially inappropriate medication use in older 
adults are most commonly used. Beers lists medications or medication classes that should be 
avoided where possible for specific populations and specific disease-drug interactions that may 
cause more harm than good [105]. The Beer’s criteria are less helpful for UK and European 
healthcare practice as a large proportion of the medications in Beers are unavailable in these 
regions [106]. Hence, the Screening Tool for Older Person’s Prescriptions (STOPP) and the 
Screening Tool to Alert doctors to Right Treatment (START) physiological systems-based criteria 
were developed and are validated in the UK and Europe. The criteria identify potentially 
inappropriate prescribing and omissions. STOPP is categorised into 80 physiological systems-
based criteria to screen medications or classes of medications that are potentially inappropriate in 
older people [107]. 
 
1.11 Medication reviews  
Recently, NICE published guidelines for medicines optimisation in the general population and 
recommended that a medication review is integral in this process [108]. A structured medication 
review is a critical examination of medicines. The objective of a review is to work with the patient 
to make decisions about treatment, optimise medicines, minimise the number of medication 
related problems and reduce unnecessary medicines use. A review can help to identify 
medications that could be stopped, dosages reduced or new medications that are needed. The 
NICE guidelines recommend that people taking medicines for long-term conditions and people 
taking multiple medications would benefit from a review. A medication review should be a shared 
decision-making process that involves the patients preferences, values and needs [109, 110]. 
While guidelines recommend a person-centred approach, practical application and outcomes of 
this approach in practice is unclear. Moreover, the guidelines are unclear on how to support 
medicines optimisation in people with cognitive impairment, dementia or people without capacity 
and understanding the role of the caregiver will be important.   
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1.12 Dementia annual review  
National initiatives to improve the quality and standardisation of primary care provided to people 
with dementia have been introduced. In 2004 the Quality and Outcomes Framework (QOF) was 
introduced in the UK and is one of the largest pay-for-performance schemes in the world. The 
QOF consists of financial incentives, computerised decision supports and the promotion of 
structured and cohesive care for patients with the aim of achieving evidence-based targets. Since 
2006, QOF has included an annual review for every patient with dementia [111][112]. A dementia 
annual review should include a comprehensive physical, psychological and social care review, a 
carers assessment and assessment of access to secondary care services [111]. Previous research 
suggests that the quality and comprehensiveness of the reviews is varied [113]. Variation in 
implementation means that somewhere between 50% and 86% of people with dementia receive 
an annual review [114]. Whilst a medication review is not explicitly included, the annual review 
provides a vital opportunity to review medications as part of the comprehensive assessment, 
potentially reducing inappropriate polypharmacy and PIMs. There is little understanding of the 
impact of these annual reviews on the quality of care provided to patients. Further research is 
needed to understand the role of financial incentive schemes such as the QOF on the quality of 
patient care afforded to people with dementia, a key marker of which is appropriate medication 
optimisation. 
 
1.13 Observational studies  
A large number of studies understanding polypharmacy and potentially inappropriate medication 
use have applied observational methods to understand prescribing in a range of cohorts of older 
adults. Observational studies can be particularly informative in providing evidence to determine 
the implications of a medication in real-world, representative settings. This can include patient 
populations that are heterogeneous and representative of the general population. [115]. 
Electronic health records, for example have been widely used to inform research into prescribing 
[116], health care utilization, health economics [117], disease prevalence and incidence and risk 
factors. Using electronic health records to inform research is particularly useful for patient 
populations where disease cases are rare, and in situations where clinical trials are not ethical or 
feasible. Patient records can be used to assess how implementing national policy initiatives 
changes clinical practice. This approach provides an opportunity to analyse a rich and large source 
of important patient data to inform clinical practice. Observational cohort studies, such as the 
Cognitive Function and Ageing Studies or the English Longitudinal Studies of Ageing are integral to 
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our current understanding of the prevalence and incidence of diseases. This includes our 
understanding of dementia and associated risk and protective factors [1, 118].  
However, there are limitations to observational studies. Compared to a trial, the uncontrolled 
nature of an observational study means that causal relationships are difficult to ascertain. The 
relationship between a variable (e.g. a medication) and an outcome (e.g. mortality) can be 
understood in terms of an association. Although a range of factors can be adjusted for to more 
accurately understanding the relationship, residual confounding that is not accounted for can lead 
to biased findings [119]. Additionally, observational studies can be limited by the data that is 
collected or available. Increasingly, large, electronic patient medical records are used to 
understand prevalence and outcomes of prescribing in a patients. However, these datasets will 
generally be limited in the availability of key lifestyle factors such as diet, smoking, alcohol intake 
and socio-economic status [120]. Furthermore, data may be missing or unstandardized in studies 
using questionnaires as participants choose to omit responses within the survey or recording of 
data is not standardised across data collection methods. This could increase the risk of inaccurate 
recording of exposures, outcomes and covariates. 
 
1.14 Summary  
Cognitive impairment and dementia are prevalent in the older population and have a significant 
impact upon individuals, their family, carers, health professionals, healthcare service provision 
and the economy, in the UK and globally. Many people are also living with comorbidities and take 
multiple medications to manage these comorbidities, diseases and behavioural and psychological 
symptoms of dementia. However, we do not know the impact of prescribing in people with 
cognitive impairment or dementia and clinical guidelines are needed to support prescribers in 
making evidence-based, informed decisions around prescribing in this population. It is the aim of 
this research study to improve understanding of the challenges of multiple medication use in 
people with dementia and cognitive impairment and how this might be addressed.  
 
1.15 Outline of thesis  
The remaining chapters of this thesis report and discuss the studies I completed to understand 
the challenges of multiple medication use in people with dementia and cognitive impairment. My 
studies included a scoping review of the literature to understand the current evidence base and 
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motivate the subsequent research. The subsequent studies analyse two existing data sources, an 
electronic primary care health record dataset and the Cognitive Function and Ageing Studies. The 
remaining chapters are outlined.  
Chapter two outlines further contextual grounding for this study through a scoping review of 
research into potentially inappropriate prescribing and strategies for optimising medications in 
older adults and people with dementia. This review explores the prevalence of inappropriate 
prescribing, potential for adverse effects and the heterogeneity of the older population. 
Comprised of a huge variety of people with varying levels of physical, cognitive and psychological 
disability, disease and frailty. The gaps in understanding of inappropriate prescribing amongst 
people with dementia are identified and discussed, motivating the subsequent work. Chapter 
three outlines the aims and objectives of my study based within the findings of the review of the 
literature and the identified research and knowledge gaps. The pharmacoepidemiological 
approach used in this study and the existing data sources that are used to conduct the studies are 
introduced and set out in terms of the aims and objectives.  
Chapter four presents the methods and statistical approaches used to analyse a primary care 
cohort of patients with dementia in primary care in England (Clinical Practice Research Datalink, 
CPRD). This chapter describes the methods used to address two aims of my study, to estimate the 
prevalence of potentially inappropriate prescribing in people with dementia and to understand 
the factors associated, including the potential impact of primary care reviews on prescribing. 
Chapter five describes the results of my analysis of the CPRD cohort study, reporting prevalence 
estimates and the change in medication use associated with medication review and annual 
dementia care review.  
Chapter six presents the methodological approach used to analyse a subsample of the Cognitive 
Function and Ageing Studies (CFAS) cohort. This is a sample of older, cognitively impaired adults 
and the methods used address two aims of this research. First, estimating the prevalence of 
polypharmacy and potentially inappropriate medication use. Second, to understand the impact of 
polypharmacy and potentially inappropriate medication use on health and the potential role of 
frailty on this relationship. Chapter seven reports the findings of the analyses applied to the CFAS 
II subsample. Chapter eight and the final chapter in this study is a discussion of the findings, 
methodological approaches and implications of this research.  
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II. Chapter 2: Polypharmacy and Potentially Inappropriate 
Medication Use. A Scoping Review of Reviews  
(a) Objectives  
Polypharmacy and PIM are significant in the care of older adults with comorbid health conditions. 
Polypharmacy is associated with an increased risk of being prescribed a medication that is 
potentially inappropriate. Both polypharmacy and PIM are associated with increased risk of 
adverse effects including hospitalisation and mortality [121, 122]. Optimising medications for 
people with dementia may prevent exposure to medication related harm [123]. A large body of 
literature has estimated the effect of polypharmacy and PIM use in older adults, however the 
nature of polypharmacy and its impact among people with cognitive impairment are likely to be 
different  [123]. To develop research questions to help optimise medication use for people with 
dementia, first it is necessary to survey the available literature surrounding polypharmacy and 
PIM in older adults generally and people with dementia specifically, hence identifying pressing 
gaps in knowledge in this area. With this in mind, a scoping review of the literature was 
conducted with four key objectives:  
(1) To describe the range and nature of research into polypharmacy and PIM use in people with 
dementia and older adults 
(2) To assess the evidence of harm associated with inappropriate medication use in people with 
dementia 
(3) To identify gaps in the evidence base, including stated areas of future research  
(4) To inform the development of specific research questions for this study. 
 
2.02 Methods  
(a) Scoping review  
To review the current literature, I conducted a scoping review of review studies. A scoping review 
is one of many methodologies for reviewing and synthesising research and evidence. Arksey and 
O’Malley (2005) proposed the original framework and defined the aim of a scoping review as to: 
“map rapidly the key concepts underpinning a research area and the main sources and types of 
evidence available” [124]. Since then definitions have varied, but whilst there is no established 
definition, the concept is underpinned by mapping and understanding a wide range of literature 
and evidence [125].  
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(i) Why a scoping review? 
Scoping reviews describe the breadth of evidence across a given field, rather than answering a 
specific question. This is contrary to a systematic review which reviews evidence on the 
effectiveness of an intervention on specific outcomes, in a specific population, for example. 
Scoping reviews do not quantitatively synthesise evidence using meta-analysis. However like 
systematic reviews, scoping reviews have guidelines and frameworks such that they are replicable 
and adhere to specific standards. Frameworks for scoping reviews continue to be developed. 
Recently, reporting guidelines have been developed for scoping reviews. The process of a scoping 
review is becoming more established as an approach with clear advantages over a systematic 
review, in appropriate contexts.  
 
(i) Why a review of reviews?  
Multiple systematic reviews now exist that synthesise evidence from across many studies 
addressing similar research questions in polypharmacy and PIM among older people. As multiple 
reviews exist, there becomes a need to reintroduce clarity and understanding of the research 
area. A review of reviews enables synthesis across different research questions on similar areas, 
to understand levels of consensus or disagreement and nuances around this. Moreover, a review 
of reviews can include evidence from different types of interventions or from reviews of the same 
intervention with different outcome measures, for example. In addition, a number of reviews can 
be summarised addressing different problems or populations [126]. Although primary literature 
and studies that have not yet been included in a review may be missed, in applying this to the 
desired outcomes of conducting a review for this study, a review of reviews appeared to show 
considerable benefit. In particular, in understanding the research around different problems, such 
as polypharmacy and potentially inappropriate medication. As well as the effectiveness of 
different interventions and different outcomes. And, in different populations and settings, 
including older adults and people with dementia across primary and secondary care.  
 
(ii) Scoping review framework 
A scoping review framework was originally proposed by Arksey and O’Malley in 2005. Since then, 
it has been extended, developed and refined by Levac et al (2010) and by Peters et al (2015) [124, 
125, 127]. The framework was used to direct the review and is described in Table 1.   
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Tocca and colleagues recently re-developed the Preferred Reporting Items for Systematic Reviews 
and Meta-Analyses (PRISMA) checklist for application to scoping reviews. The reporting of this 
scoping review is therefore guided by the PRISMA Extension for Scoping Reviews (PRISMA-ScR) 
checklist [128] (Appendix 1 Section 10.01 ).   
 
Table 1 Framework used to inform the scoping review for this research study, based on the original framework proposed 
by Arksey and O’Malley (2005) and developed by Levac et al., (2010) and Peters et al., (2015) 
Step  Detail   
Step 1: Identify the research 
question 
Because the aim of the scoping review was to map the 
literature, the research question should be adequately 
broad to encompass this.  
Step 2: Identify relevant studies Including which sources were to be studied, the type of 
literature included in the review and restrictions that 
were influenced by time and resource capabilities. 
Step 3: Study selection Inclusion and exclusion criteria were refined to guide the 
systematic process of selecting relevant studies.  
Step 4: Charting the data or data 
extraction 
Key information from studies was extracted, charted and 
sorted to synthesise and interpret the studies. Charting 
extraction tools were pre-defined to agree on the data 
to be extracted from the studies that addresses the 
objectives of the review. 
Step 5: Collating, summarizing and 
reporting the results 
The collated data was summarised. A descriptive or 
narrative approach was taken rather than a synthesis of 
effectiveness or weight of the evidence. Possible gaps in 
the literature were identified.  
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(b) Eligibility criteria  
To be included in the review, reviews needed to include studies of older adults (primarily defined 
as over the age of 65 years) or people with a diagnosis of dementia. Studies needed to address 
polypharmacy (the use of multiple medications) according to any definition, or PIM use as 
identified through validated criteria. Reviews of studies addressing interventions were included if 
the purpose of the intervention was to address polypharmacy or medication appropriateness. 
Peer-reviewed journal publications were included if they were written in English, involved human 
participants and were review studies. Review studies were included if they were systematic or 
applied a systematic approach (literature search terms and methods for identifying literature 
were identifiable).  
Studies were excluded if they focused on older adults with comorbid health conditions other than 
cognitive impairment or dementia. Studies addressing end of life or palliative care and studies on 
medication adherence were excluded. Non-systematic literature review, opinion pieces and 
reviews of policy or industry documents were also excluded. 
 
(c) Information sources and selection of studies  
To identify potentially relevant review articles three databases were searched, MEDLINE, EMBASE 
and Cochrane Library for Systematic Reviews. Search terms included ‘polypharmacy’, 
‘inappropriate prescribing’, ‘potentially inappropriate medication’ and ‘older adults’ or 
‘dementia’. The full search strategy and terms for each database can be found in Appendix section 
10.02. I conducted all titles and abstract screening and full text reviews, the final search results 
were exported into Mendeley and duplicates were removed.  
 
(d) Data charting  
A data-charting form was used to extract relevant information from the reviews. Data from 
eligible studies were charted in the extraction tool in Excel, capturing relevant information on key 
study characteristics, including the number and type of studies included in the review, participant 
group and setting. Key findings were extracted along with descriptive estimates of polypharmacy 
and how polypharmacy was defined, and descriptive estimates and definitions of PIM. If relevant, 
interventions and outcomes, adverse effects associated with polypharmacy and PIM and key drug 
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classes were extracted. Suggestions for future research explicitly identified by the review authors 
were also extracted. An example of the data charting form exemplified with one review is 
provided in Table 2.  
Table 2 Example of completed data charting form used for extracting relevant information from the reviews included in 
the scoping review 
Data extraction  Review details  
Bibliographic 
information (Authors, 
year, title)  
Alldred, D. P., Kennedy, M. C., Hughes, C., Chen, T. F., & Miller, P. 
(2016).  Interventions to optimise prescribing for older people in care 
homes. 
Countries of included 
studies  
 Australia, Finland, Israel, Netherlands, New Zealand, Spain, Sweden, 
UK, USA, Canada 
Aims of review  Evaluate evidence for interventions to address suboptimal prescribing 
in care homes to identify how care can be improved in this frail and 
vulnerable population. 
Review design  Systematic review  
Types of studies 
included (n)  
RCTs (n=12)  
Study samples 
n, age group, care 
setting  
Older adults; n= 10,953; 65+ years; Care homes  
Key findings  Due to the quality of the evidence robust conclusions could not be 
drawn. The outcomes showed no evidence of effect of interventions 
on adverse drug events or mortality. Uncertain whether medication 
review reduces hospital admissions or improves quality of life. 
Medication review may lead to improvement in medication 
appropriateness and may lead to identification and resolution of 
medication related problems. Unclear about impact of medication 
review on decreasing medication costs.  
Descriptive statistics 
of PIM / 
polypharmacy  
Not assessed 
Definition of PIM  5/12 studies addressed medication appropriateness using: Medication 
Appropriateness Index (MAI), STOPP-START, and composite criteria of 
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Data extraction  Review details  
Beers, Anticholinergic Risk Scale, >2 psychotropic drugs, NSAIDs and 
proton pump inhibitors 
Intervention Medication review was included in 10/12 studies. Otherwise the 
interventions were multifaceted and diverse, included education of 
care home staff, clinical decision support technology and multi-
disciplinary case conferencing, pharmacist evaluation of medications 
(pharmacist conduct medication review) 
Purpose of 
intervention  
To optimise prescribing and reduce suboptimal prescribing in care 
homes 
Outcomes of 
intervention  
Primary outcomes: adverse drug events, hospital admissions, 
mortality. Secondary outcomes: quality of life, medication related 
problems, medication appropriateness, medicine costs 
Key drug classes  Appropriateness measured using tools but specifically also included 
anticholinergics, psychotropic drugs, NSAIDs and PPIs 
Harm associated with 
PIM / polypharmacy  
Not assessed  
Suggestions for 
future research 
High quality and powered RCTs needed to identify effective 
interventions to optimise prescribing in care homes. Effectiveness of 
clinical decision support systems and multidisciplinary interventions in 
this context is needed. Further work needed to develop consensus on 
identifying, defining, measuring, reporting and analysing important 
resident related outcomes, including quality of life to enable meta-
analyses to be conducted on future RCTs 
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(e) Synthesis of results  
Review study characteristics were summarised, including setting, population and study types 
included in the review. The results from the reviews were grouped and summarised by the 
various definitions of polypharmacy, prevalence of polypharmacy and PIMs in older adults and 
people with dementia. Criteria used to identify PIMs, PIMs in older adults and people with 
dementia were summarised. The adverse effects associated with polypharmacy and PIMs and key 
medication classes identified across the reviews were reported. Finally interventions and 
suggestions for future research identified from the reviews were summarised. For the purpose of 
this chapter, the findings from this scoping review are reported in an integrated synthesis and 
discussion.   
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2.03 Synthesis and discussion of review findings  
(a) Selection of sources of evidence  
Database searches were run to include review studies published until December 2018. An initial 
search was conducted in 2015 and the search and search terms were updated to include reviews 
published until December 2018. This scoping review covers reviews published from 2003-2018. A 
total of 54 review articles were eligible to be included, see Figure 1 for selection of sources flow 
diagram. Across the electronic databases searched 4,779 articles were initially identified 
(Cochrane n=556, Medline n=3,215, Embase n= 1,098). Based on the title and abstract 4,495 were 
excluded, 19 duplicates removed, 236 studies excluded because they were not review studies and 
119 full text articles were subsequently retrieved and assessed for inclusion. Of these 65 were 
excluded; reasons for exclusion included review focusing on medication adherence or palliative 
care (n=10), study design was not a systematic review (n=9), review focus was on other health 
conditions (n=13), pharmacological treatments evaluation (n=11), polypharmacy or PIM were not 
defined by criteria (n=10), or the purpose of the intervention did not meet the inclusion criteria by 
not addressing medication appropriateness (n=12). The authors of three studies were contacted 
for access to full-text manuscripts however they did not respond and therefore the final total of 
included studies was 51.  
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Figure 1 Selection of sources of review studies included in the scoping review flow diagram 
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(b) Characteristics of Reviews  
Of the 51 reviews included, 8 were systematic reviews with meta-analyses [129–136]; others were 
systematic reviews without meta-analysis or literature reviews applying an identifiable systematic 
approach.  An overview of review characteristics is in Table 3. A total of 1,391 primary studies 
were included across the 51 reviews. Although, this includes duplication of studies due to some 
studies being relevant to more than one review. Seven reviews specifically focused on care homes 
(including nursing and long-term residential care), four reviews included studies with exclusively 
community dwelling participants and four reviews included studies in hospital settings.  
There were eleven reviews of polypharmacy or PIM prevalence across community, care home and 
hospital settings [137–147]. Eight reviews of the outcomes of polypharmacy or PIM, including 
economic impact, risk of adverse reactions such as mortality, hospitalisation and physical function 
[141, 142, 148–153]. Fourteen were reviews of studies defining polypharmacy and PIMs, such as 
reviews of PIM criteria [154–167]. There were 21 reviews focused on or including studies of 
medicines optimisation interventions in older adults and people with dementia, across primary 
and secondary care [130–132, 134, 140, 145, 167–180]. There were two reviews of qualitative 
studies of prescriber and patient perspectives on prescribing PIMs and polypharmacy [181, 182].  
Of the reviews identified, eight included studies of people with dementia [136, 137, 142, 146, 156, 
165, 166, 169]. These reviews were largely conducted in nursing homes or long-term care facilities 
[156, 165, 169], hospitals [146] or in a variety of settings that included hospitals, care homes as 
well as community based studies [136, 137, 142, 166]. One systematic review focused on the 
identification of potentially inappropriate prescribing in advanced dementia or palliative care 
[156] and found evidence for a programme to support appropriate medicines in palliative care of 
people with advanced dementia. A second review sought to identify criteria for medication 
appropriateness and evidence for interventions to improve appropriateness in nursing home 
residents with advanced dementia [177]. The findings from this review were also used in a 
multidisciplinary Delphi panel consultation to identify categories of medication appropriateness in 
advanced dementia (generally, sometimes and rarely appropriate). A third review was of studies 
of polypharmacy and PIM prevalence in people with and without cognitive impairment in 
hospitals. This review indicated a high prevalence in both people with and without cognitive 
impairment (including people with dementia) [146]. One review included studies of interventions 
to reduce polypharmacy in people with dementia. The results from the meta-analysis of findings 
from five studies did not indicate any association with reduced mortality [171]. Another was a 
systematic review of studies of PIM use in people with cognitive impairment and dementia, 
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including evidence about the association of cognitive impairment or dementia with PIMs [142]. 
This review found that PIM prevalence ranged from 10.2% to 56.4% in people with cognitive 
impairment or dementia, and was higher in nursing homes than community settings. This review 
also found no evidence of a positive association between cognitive impairment or dementia and 
PIM exposure [142].   
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Table 3 Characteristics of review studies included in scoping review of reviews 
Reference  Review type  Type of studies included  Review topic  Studies 
(n) 
Participants  Setting  
Bokhof & Junius-
Walker (2016). 
 
Synthesis of 
qualitative 
studies  
focus groups, semi-
structured or in-depth 
interviews, Delphi 
approach 
Reducing 
polypharmacy 
from prescriber 
and patient 
perspective  
14 Older adults   Community, 
primary care  
Chang & Chan (2010) 
 
Systematic 
review  
Criteria for identifying 
PIM  
Defining PIM   - Older adults   Mixed  
Corsonello et al., 
(2012) 
 
literature 
review  
- Defining PIM   59 Older adults  Mixed  
Corsonello et al.,  
(2009). 
 
literature 
review  
Reviews and 
observational studies  
Defining PIM   - Older adults  Hospital  
Cullinan et al.,  
(2014). 
 
Systematic 
review and 
meta-
synthesis  
Qualitative  Understanding 
PIM prescribing 
from prescriber 
and patient 
perspective  
7 Older adults  Mixed  
Ćurković et al.,  
(2016) 
 
Literature 
review  
- PIM prevalence 
and risk factors  
138 Older adults  Care home, 
community 
Dimitrow et al., 
(2011) 
 
Systematic 
review  
Criteria for identifying 
PIM  
Defining PIM   16 Older adults  Mixed  
Disalvo et al (2016) 
 
Systematic 
review  
Cohort (longitudinal and 
cross-sectional), 
prospective cohort, , 
Delphi consensus, 
factorial survey design  
 
Defining PIM   8 People with 
dementia   
Nursing 
home, long-
term care, 
hospice, 
community  
Fulton et al., (2005). 
 
Systematic 
review  
Observational: 
Descriptive, cohort, 
cross-sectional, 
longitudinal, 
prospective, 
retrospective. Delphi 
survey 
 
Definition of 
polypharmacy, 
interventions  
16 Older adults Primary care  
Gallagher et al., 
(2007) 
  
Literature 
review  
- Prevalence, 
outcomes, 
criteria  
- Older adults  Mixed  
Guaraldo et al., 
(2011). 
 
Systematic 
review  
Studies of secondary 
source data i.e. 
insurance company and 
social security 
administrative data.  
 
Prevalence and 
risk factors  
19 Older adults  Community  
Hajjar et al., (2007) 
 
Literature 
review  
Observational and RCTs  Prevalence and 
interventions  
58 Older adults  Mixed  
Hill-Taylor et al,. 
(2013) 
 
Systematic 
review  
RCTs and observational 
studies  
Prevalence and 
outcomes  
13 Older adults  Community, 
acute care, 
long-term 
care  
Hyttinen et al.,  
(2016) 
 
Systematic 
review  
Cohort Outcomes (health 
care costs)  
39 Older adults  Mixed  
Johnell (2015)  
 
Systematic 
review  
Observational and RCTs  Prevalence and 
adverse effects  
22 People with 
dementia and 
cognitive 
impairment   
Community, 
nursing 
home, 
hospital  
Kouladjian et al.,  
(2014). 
 
Literature 
review  
- Defining PIM   - Older adults  Mixed  
Kroger et al., (2015). 
 
Scoping 
review  
- Defining PIM and 
interventions  
79 People with 
dementia  
Nursing 
home  
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Levy et al., (2010). 
 
Literature 
review  
Criteria for identifying 
PIM  
Defining PIM  8 Older adults  Community, 
nursing 
home, 
primary care 
Matanović et al., 
(2012). 
 
Literature 
review  
Criteria for identifying 
PIM  
Defining PIM  11 Older adults  Mixed  
Morin et al., (2016) 
 
Systematic 
review  
Observational, cross-
sectional  
Prevalence  48 Older adults  Nursing 
home  
Motter et al., (2018). 
 
Systematic 
review  
Criteria for identifying 
PIM  
Defining PIM   36 Older adults  Primary 
care, nursing 
home, 
hospital  
Muhlack et al., 
(2017). 
 
Systematic 
review and 
meta-analysis  
Prospective, 
retrospective cohort  
Adverse effects  16 Older adults  Community, 
nursing 
home, 
hospital  
Opondo et al., 
(2012). 
 
Systematic 
review  
Cohort, observational  Prevalence  19 Older adults  Primary care  
Pérez-Jover et al., 
(2018). 
 
Systematic 
review  
Empirical studies  Prevalence and 
interventions 
80 Older adults  Mixed  
Peron et al., (2011). 
 
Narrative 
review  
Observational or 
intervention  
Adverse effects  19 Older adults  Mixed  
Redston et al., (2018) 
 
Systematic 
review  
Observational studies  Prevalence  47 Older adults 
with and 
without 
cognitive 
impairment  
Hospital  
Rodrigues et 
al.,(2016). 
 
Integrative 
review  
Prospective, 
retrospective, case-
control, cross-sectional, 
cohort study, RCT, 
longitudinal, survey, 
intervention, single blind 
controlled study,  
 
Adverse effects  47 Older adults  Mixed  
Salahudeen et al.,  
(2015). 
 
Systematic 
review  
Criteria for identifying 
PIM  
Defining PIM   7 Older adults   
Santos et al,. (2015).   
 
Systematic 
review  
Criteria for identifying 
PIM  
Defining PIM   119 Older adults  Mixed  
Skinner (2015). 
 
Literature 
review  
Criteria for identifying 
polypharmacy  
Polypharmacy  16 Older adults  Primary care  
Storms et al,. (2017) 
 
Systematic 
review  
- Prevalence 21 Older adults Long-term 
care facilities  
Tommelein, et al,. 
(2015).   
 
Systematic 
literature 
review  
Observational studies  Prevalence  52 Older adults  Community 
Villalba-Moreno, et 
al., (2016) 
 
Systematic 
review  
Systematic review, cross-
sectional, cohort, 
experimental, 
longitudinal  
Defining PIM  25 Older adults  Mixed  
Wang et al,. (2018). 
 
Systematic 
review  
RCTs, cohort studies, 
case-control and case-
cross over  
Adverse effects  32 Older adults  Care and 
nursing 
home  
       
Intervention reviews       
       
Alldred et al., (2016) Systematic 
review  
RCTs Interventions 12 Older adults  Care home  
Christensen & Lundh 
(2016)  
Systematic 
review  
RCTs Interventions 10 Older adults  Hospital  
Clyne et al., (2012) Literature 
review  
Cluster-RCTs, RCTs, 
interrupted time series, 
cohort studies  
Interventions 14 Older adults  Ambulatory 
care, nursing 
home, 
hospital 
Clyne et al., (2016). Systematic 
review  
RCTs Interventions 12 Older adults  Community  
Cooper et al., (2015) Systematic 
review  
RCTs, cluster RCTs, 
controlled before-and-
after studies  
Interventions 12 Older adults  Mixed  
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Forsetlund et al., 
(2011) 
Systematic 
review  
RCTs Interventions 20 Older adults  Nursing 
homes  
Johansson et al., 
(2016) 
Systematic 
review and 
meta-analysis  
Controlled trials  Interventions 25  Older adults  Primary 
care, 
community, 
nursing 
home  
Kaur et al., (2009) Systematic 
review  
- Interventions 24 Older adults  Mixed  
Page et al., (2016) Systematic 
review and 
meta-analysis  
Experimental and 
observational  
Interventions 116 Older adults 
and people 
with dementia  
Mixed  
Page et al.,  (2016) Narrative 
review  
- Interventions - Older adults  Mixed 
Rankin et al., (2018) Systematic 
review  
RCTs, non-randomised 
RCTs, controlled before-
and-after, interrupted 
time series 
Interventions 32 Older adults  Hospital, 
primary 
care, nursing 
home  
Rollason & Vogt  
(2003) 
Systematic 
review  
RCTs, controlled trials  Interventions 14 Older adults  Outpatient 
settings, 
hospital  
Thillainadesan 
(2018) 
Systematic 
review  
RCTs Interventions 9 Older adults  Hospital  
Thiruchelvam et al., 
(2017). 
Systematic 
review  
RCTs and observational 
studies 
Interventions 22 Older adults  Care home  
Tjia et al., (2013) Systematic 
review  
Controlled trials, pre-
post interventions, case 
series  
Interventions  36 Older adults  Nursing 
home, 
hospice, 
community  
Walsh et al., (2016) Systematic 
review and 
meta-analysis  
RCTs and non-
randomised trials  
Interventions  4 Older adults  Hospital  
Wilsdon et al., (2017) Systematic 
review  
RCTs and non-
randomised trials  
Interventions 21 Older adults  Mixed  
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(c) Summary of evidence from the review findings  
There was strong evidence for the high prevalence of PIM among older adults. Weighted PIM 
prevalence estimated around one fifth of older adults were prescribed PIM (22.6% 95% CI 19.5%-
26.7%) in primary care [144, 183]. In addition, 43.2% (95% CI 37.3%-49.1%) of nursing home 
residents were prescribed PIM [143]. There was no consensus on a definition of polypharmacy 
and a range of definitions are applied across the literature [167]. There was consistent evidence 
that polypharmacy and PIM prevalence varied depending on the care setting, with variation in the 
use of multiple medicines across hospital, care home and community settings. Multimorbidity was 
also consistently associated with  increased medicines use [132, 167].  
There was some evidence that polypharmacy and PIM was associated with adverse drug reactions 
and drug-interactions, however these findings were not consistent across studies, quality of 
evidence was often not assessed and results from across studies were not statistically tested [141, 
184]. The scoping review indicated that there was conflicting evidence that PIMs were associated 
with hospitalisation. There was also conflicting evidence that psychotropic medicines were 
associated with hospitalisations in one review [148]. There was some evidence that some 
psychotropic medicines (namely, benzodiazepines) were associated with hospitalisation. But 
evidence from some studies of psychotropic medicines, including antipsychotics, found no 
evidence of association with hospitalisation, whereas other studies (rated as high quality) found 
association of antipsychotic medicines with cause-specific hospitalisations [148]. However, 
another review identified evidence that PIMs were associated with increased hospitalisation and 
health care utilisation [152], although the study estimates were not pooled for statistical testing 
of findings across studies. The evidence of the association of PIMs with length of hospital stay or 
readmission to hospital was inconclusive [152]. However, the current evidence may have been 
biased by the predominant use of prevalent rather than incident medication user study designs. 
Moreover, studies often failed to consider variation in medication use over time and subsequent 
impact on outcomes [148].   
There was conflicting evidence of the association between polypharmacy and PIMs and functional 
decline [150]. Some studies indicated that increased number of prescriptions, was associated with 
physical function decline but PIMs were not [150]. However, there was some evidence that 
specific PIMs, including benzodiazepines and anticholinergics were associated with worse physical 
function [150]. 
There was conflicting evidence of the association between PIM and mortality in older adults. One 
review found no association after combining studies in a meta-analysis [171]. Another review also 
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found no association in studies with high risk of bias from using prevalent user study designs. 
Once meta-analyses were restricted to incident-user designs (so that adverse events that occur 
early after the initiation of medication are accounted for), PIM was associated with significant 
mortality risk [151].   
There was strong evidence for the role of specialists such as pharmacists in interventions to 
improve medication appropriateness, particularly in care home settings [173, 177]. Furthermore, 
there was strong evidence for the effect of medication review to reduce polypharmacy and PIM 
use. However, there is limited evidence of the effect of a review on clinical and patient outcomes 
including on adverse drug events [129], mortality [129, 133, 169], falls [169] and hospital 
admission [133, 169], quality of life and medicine costs [129]. Although, there was some evidence 
that interventions were not associated with increase in drug withdrawal events [171].  
 
(d) Summary of evidence from reviews of studies of people with dementia and 
cognitive impairment  
Evidence from the scoping review indicated that the importance of medicines optimisation is a 
topical issue, when prescribing to people with advanced dementia, particularly in nursing homes. 
The evidence from the scoping review suggested that polypharmacy was common in people with 
dementia in hospitals and nursing homes [146, 156, 177]. There was some evidence that 
polypharmacy was prevalent in 53.2% to 89.8% of people with cognitive impairment in hospital 
settings [146]. Polypharmacy prevalence was slightly higher in people with dementia (56.7%-
83.7%) compared to people without dementia in hospital settings (51.5%-76.8%) [146]. 
Furthermore, PIM prevalence in people with cognitive impairment ranged from 20.6%to 80.5% 
(Beers criteria) and 39.3% to 88.5% (STOPP criteria) [146]. Whilst PIM use was prevalent in people 
with cognitive impairment, one review argued that there was no evidence of positive association 
between cognitive impairment and PIMs [142].  
From the reviews, it is clear that there are a number of medications that are considered 
potentially inappropriate for use in people with dementia. The findings from this scoping review 
suggested that there were few criteria that had been reviewed focusing on prescribing in this 
population. One system for appropriate prescribing in palliative care of people with advanced 
dementia was reviewed. The Palliative Excellence in Alzheimer Care Efforts (PEACE) program was 
applied in five studies included in one systematic review [156, 185]. A second criteria for 
identifying PIM in moderate or severe dementia was also identified in another review [165].  
53 
 
 
From one review, there was little evidence to suggest that dementia or cognitive impairment 
were associated with an increased likelihood of PIM prescription and in a number of studies, were 
associated with decreased likelihood of PIM [142].  One systematic review and meta-analysis 
included a sub-group analysis of intervention studies among people with dementia. This review 
found no evidence that interventions to reduce polypharmacy in people with dementia (and in 
older adults) were associated with reduced mortality [171]. The findings from the scoping review 
are discussed in the following sections.  
 
(e) Polypharmacy and PIM prevalence in older adults and people with dementia  
My scoping review found that polypharmacy and PIM use is prevalent in older adults and in 
people with dementia. Estimates of polypharmacy prevalence ranged from 5% to 78% in primary 
care [167] and around 50% in nursing home residents [137]. However, the review also highlighted 
the variety of definitions of polypharmacy used. There was conflicting evidence across the reviews 
on defining polypharmacy. Generally, more than four medications or more than five medications 
was considered as a cut-off for polypharmacy [130, 131, 134, 168, 180]. One review argued that 
five or more medications was established from animal and epidemiological studies and is 
predictive of clinically relevant adverse effects [136]. Without a consensus on a definition, 
comparable prevalence estimates are difficult to ascertain and estimates will vary widely.  
Polypharmacy and hyper-polypharmacy (>10 medications) were also recognised as key challenges 
among people with dementia. In hospital settings, prevalence of polypharmacy in people with 
dementia ranged from 30% to 97% [146]. A systematic review of PIM in people with dementia in 
hospitals was published after the searches for this review were completed. This review found that 
polypharmacy prevalence (defined as five or more medications) ranged from 25% to 98% in acute 
care settings [186]. Whilst estimates do vary, primary studies among people with dementia in the 
community also estimate relatively high prevalence of polypharmacy. A study conducted among 
French community dwelling cohort of people with dementia in the REAL.FR study, estimated that 
43% were prescribed polypharmacy (defined as five or more medications) [187]. In another study 
of 2,665 community dwelling people with dementia from the National Institute of Aging (NIA)-
funded National Alzheimer’s Coordinating Centre Uniform Data Set (UDS) (United States, 2005-
2007), polypharmacy was prevalent in over 50% of people with dementia [188]. In addition, 
evidence from people with dementia in primary care in Northern Ireland, estimates the 
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prevalence higher, with 85% exposed to 4 or more regular repeat medications [189]. Estimates 
will vary depending on the cohort, setting and definition of polypharmacy, and this will change 
with time. In view of this, it is important that we understand the prevalence of polypharmacy 
amongst people with dementia, particularly in primary care in the United Kingdom, where much 
prescribing occurs. Up-to-date and population representative estimates from large cohort studies 
are informative in understanding the extent of the problem. These studies can help inform the 
development of service priorities for prescribing to people with dementia.  
Exposure to PIMs varies across care settings, with around 20% of older adults in primary care and 
40% in care homes exposed to PIMs [143, 144, 183]. Three reviews estimated prevalence of PIMs 
in people with dementia (See Table 4). In nursing homes, prevalence of PIM use amongst people 
with advanced dementia was estimated as 29% to 54% [156] and from 39% to 88% among people 
with dementia in hospitals [146]. The recent review of PIM in people with dementia, estimated 
PIM prevalence as ranging from 14% to 74% across 26 studies [186]. Primary studies of PIM use 
amongst people with cognitive impairment or dementia in the UK are limited. As identified 
through this review, will often focus on people with dementia in care homes [190], hospital [146] 
and advanced dementia [156]. The impact of PIM on people with dementia is increasingly 
recognised and specific criteria have been developed for medicines management in people with 
advanced dementia and palliative care [191]. Priorities for care, including the persons and their 
carers priorities will change as the disease progresses and the management of medications as part 
of care planning will also change overtime [95]. We need to better understand the impact and 
predictors of polypharmacy and PIMs among people with dementia across the disease trajectory 
is valuable as more people are diagnosed, and efforts to reduce unnecessary hospital admissions, 
such as through medication error, are increased [94].   
There was some indication that people with dementia may be exposed to a greater number of 
PIMs and primary studies provide similar indications. In Denmark, a cross-sectional study (2014) 
of people with dementia (n=35,376) estimated around twice as many people with dementia (62%) 
compared to people without dementia (n= 994,231) (35%) were exposed to PIM [192]. Similar 
estimates were found across eight European countries involved in the ‘RightTimePlaceCare’ study 
including over 2,000 people with dementia, with around 60% prescribed at least one PIM and 26% 
at least two [193]. However, this sample included people with dementia if they were in long-term 
care or at risk of admission and therefore does not represent the majority of people with 
dementia living in the community. Previous primary studies of PIM use among people with 
dementia estimated around one fifth of people with dementia were prescribed one PIM (23%, 
95% CI 22.0-24.0) and one quarter were prescribed three PIMs (24.6% 95% CI 23.6-25.7%) [189]. 
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These findings may underestimate the extent of PIM prescriptions since only people prescribed 
medication for mild to moderate Alzheimer’s disease were sampled. The prescription of PIMs has 
also been estimated as higher among people with dementia who are living in care homes. A study 
estimating PIM use of people with dementia in care homes in England as part of the longitudinal 
EVIDEM – End of Life (EoL) study (n=133), found 46% of people with dementia were prescribed at 
least one PIM, nearly twice as high as those in the community [190]. However, these findings are 
from a small and unrepresentative sample. Further research is required to understand what 
individual and external characteristics, such as primary care prescribing practices, increase the risk 
of exposure to PIMs in people with dementia.  
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Table 4 PIM prevalence estimates amongst older adults, people with dementia or cognitive impairment from reviews 
Setting, Authors PIM prevalence (%)   PIM prevalence (%) by criteria 
Community-dwelling older adults 
Muhlack et al (2017) 5.2- 48.7   
Tommelein et al (2015) 22.6 (95% CI 19.2-26.7)  Beers (1997) 2.2 - 38.7 
Beers (2003) 5.8 - 38.5 
STOPP (2008) 5.8 - 42.0 
Clyne et al (2016)1 18 - 100   
Chang et al (2010)  Beers (2003) 18.3-41.9  
STOPP 21.4 
Guaraldo et al (2011) 11.5-62.5 Beers (1997) 14.3- 24.4 
Beers (2002) 18 - 62.5 
  
Primary care 
Opondo et al (2012) 20.0 (range 2.9-38.5 )  Beers (1997) 4.5-21.0 (median 12.7) 
Beers (2003) 2.9-38.5 (median 23.6) 
  
Care, nursing or long-term residential home 
Muhlack et al (2017)  2.3 -50.3   
Morin et al (2016)  43.2 (95% CI 37.3 - 49.1)   
Chang et al (2010)  Beers (2003) 18-34.9 
Storms et al (2017)   Beers (2003) 21.3-63.0 (median 
35.1) 
STOPP 23.7 - 79.8 (median 61.1) 
Hospital  
Muhlack et al (2017)  14.8 – 23.7  
Corsonello et al (2009)   Beers 16-49 
Chang et al (2010)  Beers (2003)  14-44.1 
STOPP 35.0 
  
Mixed settings  
Hill-Taylor et al (2013)  STOPP 21.4-79 
 
People with dementia or cognitive impairment  
Care home     
Disalvo et al (2016) 29-53.9   
Hospital  
Redston et al (2018)  53.2-89.8 Beers 20.6-80.5 
STOPP 39.3-88.5 
Mixed settings 
Johnell (2015)  10.2-56.4  Beers 10.2-56.4 
STOPP 46.2 
Baseline prevalence estimate from random and non-random trial studies  
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(f) Heterogeneity of the older adult population  
The scoping review has highlighted the importance of accounting for heterogeneity in the older 
population, particularly when it comes to prescribing. Older adults encompass a huge proportion 
of the population and whilst age is important, it is increasingly recognised that frailty and 
morbidity contribute more significantly to physical and mental health, quality of life and disability 
[47]. One review identified that research is needed to understand polypharmacy and PIM across 
the diverse population of older people to identify vulnerable, high-risk groups within this 
population [154].  
 
(i) Stratifying risk using frailty  
One means of stratifying the older population is through frailty classification. Increasing frailty is 
associated with decreased physiological reserve and greater vulnerability to adverse outcomes 
(such as morbidity and hospitalisation) compared to older adults of the same age [47]. The use of 
frailty to stratify the older population has been used widely across epidemiological studies and is 
increasingly applied in clinical settings [194, 195]. Frailty assessments are now incorporated into 
primary care practice to support the identification of people who are at increased susceptibility to 
adverse health outcomes [59]. A useful application of frailty assessments is to identify people who 
are at increased risk of adverse effects. Frailty is predictive of increased disability [45, 46], falls 
[45, 46] , hospitalisation [47], care home admission [48, 49] and mortality [45, 46, 48, 49]. Frailty 
is an increasingly important way of understanding ageing. We need to know what role frailty may 
play in understanding the relationship between prescribing and adverse outcomes.  
 
(ii) Validity of frailty criteria  
The validity of frailty measures is tested through the ability to predict adverse outcomes and 
identify resilience or susceptibility to other possible risk factors [196]. Polypharmacy is associated 
with incident frailty [197] and frail older adults may be at increased susceptibility to adverse 
effects associated with polypharmacy and PIMs [101]. Previous research suggests that 
polypharmacy is associated with frailty and both frailty and polypharmacy are predictive of 
mortality [198]. In addition, in a French cross-sectional study of adults over 70 years old 
(n=2,350), it was estimated that people who were prescribed 10 or more medications (hyper-
polypharmacy) and frail, were six times more likely to die over the follow-up period (mean 2.6 
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years) than people who were not frail and without polypharmacy [198]. This study suggested that 
frailty and polypharmacy were prevalent and frailty may be important in understanding the 
relationship between inappropriate medication use, including PIMs, and adverse effects. 
However, whether frailty moderates the relationship between inappropriate medication use and 
adverse outcomes, and therefore whether frailty is a useful means of identifying those at 
particular risk from inappropriate medication use is unknown. Furthermore, whilst the overall 
frailty phenotype is predictive of adverse outcomes, more research is needed to evaluate the 
predictive validity of individual criteria [54]. Research to understand the implications of 
polypharmacy and PIM among frail, multimorbid and cognitively impaired older adults will 
improve evidence-based prescribing guidelines, to account for specific diseases and make specific 
recommendations [77]. 
 
(g) Prioritising PIMs  
This scoping review identified a number of adverse effects associated with PIM use including, 
hospitalization [148, 153], urinary incontinence [140] and falls [139]. In a study including people 
with dementia, from eight European countries also found an association between PIM use and 
increased risk of falls and hospitalisation in people with dementia [193]. There was some evidence 
to suggest that polypharmacy but not PIM (identified using Beer’s criteria) was associated with 
worse physical functioning  [140, 150, 171]. The evidence associating polypharmacy and PIM with 
mortality was conflicting [140, 171]. One review pooled estimates from studies of the association 
of PIM and mortality in people with dementia and found no association [199]. One review of the 
association of PIM in older adults with mortality found that the association with mortality 
depended on the study design. In studies with prevalent PIM users, PIM was not significantly 
associated with mortality. However, in a meta-analysis of new-user design studies, which 
recorded adverse events proximal to the start of PIMs, PIMs were associated with a statistically 
significant increased risk of mortality (RR 1.59 95% CI 1.45-1.75) [135]. 
However, findings in the reviews were often limited by low quality primary studies conducted. 
The reviews highlighted that often studies had a high risk of bias, including from failure to adjust 
for comorbidity appropriately, leading to increased risk of bias by indication [151]. Many studies 
were of prevalent user designs which are affected by survivor bias, as people who have an 
adverse reaction to a drug when first prescribed are likely to stop treatment and these adverse 
reactions are not picked up in these study designs [134]. Well-designed and adjusted studies are 
required to understand the clinical outcomes of polypharmacy and PIM. To support prescribers in 
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making informed prescribing decisions among people with dementia, we need to understand the 
impact of polypharmacy and PIM in this population.  
Given the extent of research reviewed, it was evident that the appropriate use of medicines in 
older adults is important and where medicines are inappropriately prescribed there are potential 
adverse effects. Adverse drug reactions are a common consequence of polypharmacy and older 
adults are more susceptible than the general population [138, 184]. Moreover, people with 
dementia may be at increased susceptibility to medication related side effects, due to age-
associated changes in absorption, distribution, metabolism and elimination [98]. Likewise, there is 
some mechanistic evidence to suggest that increased blood-brain barrier permeability associated 
with the disease may subsequently increase the distribution of drugs to the brain and the 
susceptibility to adverse effects [200]. Understanding the impact of polypharmacy and PIM in 
people with dementia is a research priority given the increasing size of the population and limited 
available evidence to guide medication use currently available [201].  
My scoping review recognised the breadth of prescribing that may be considered potentially 
inappropriate. One included review estimated that there are over 900 medications or classes 
identified as PIM across more than 30 criteria used globally [162]. Despite this variety, there were 
a number of PIMs that repeatedly occur across criteria and across the scoping review. Given the 
limited research into PIM use in people with dementia, identifying priority medications of 
significant relevance to people with dementia and prescribers is important. This approach will 
direct research development and subsequently make clear recommendations for practice, based 
on polypharmacy and key medication classes.  
Commonly identified across PIM criteria were psychotropic medications, including antipsychotics, 
antidepressants and benzodiazepines [150]. Psychotropic medications are medications that affect 
mood and behaviour of an individual. They commonly act upon the central nervous system and 
are individually associated with a number of adverse effects in older adults and in some cases, 
particularly among people with dementia.  
 
(i) Antipsychotics  
Antipsychotic medications were initially developed for the treatment of schizophrenia and have 
since been more widely used to manage the symptoms of people with psychoses. There are two 
broad groups of antipsychotics, first generation (typical) and second generation (atypical). First 
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generation antipsychotics were associated with a number of serious adverse effects and second 
generation antipsychotics are considered to be comparatively safer and associated with less 
serious adverse effects. Antipsychotics are prescribed to manage the behavioural and 
psychological symptoms (BPSD) of dementia. They may be prescribed when a person with 
dementia is very agitated, aggressive, hallucinating, wandering, psychotic or affected by disturbed 
sleep. Sometimes antipsychotics are not prescribed to treat the underlying problem that is 
causing the agitated and aggressive behaviour but are used to sedate the individual. This may be 
appropriate if the underlying problem cannot be identified or treated. Whilst antipsychotics are 
prescribed to manage BPSD, people with dementia are generally older, frailer and living with 
other comorbid health conditions. A large body of evidence has identified that the use of 
antipsychotic medications in people with dementia is associated with serious cerebrovascular 
adverse events and 1.7 times increased risk of mortality [202, 203]. It is recommended that 
antipsychotics are used with caution in people with dementia. They should only be prescribed 
when the person is at risk of causing harm to themselves or others, and when non-
pharmacological approaches to managing behavioural symptoms have failed. In recent years, 
awareness of harms associated with antipsychotics has improved efforts to manage their use in 
people with dementia, including monitoring and audits. The mean prescription of antipsychotics 
has decreased from 19.9% to 7.4% per year among people with dementia in UK primary care 
(1995-2011) [204]. Although, despite improvements in the prescription of antipsychotics to 
people with dementia, we need to understand up-to-date prevalence of use across people with 
dementia in primary care and in care homes, particularly given the serious adverse effects 
associated with use.   
 
(ii) Antidepressants  
Antidepressants are used to treat moderate to severe depression, which affects around 15% of 
older community-dwelling adults [205]. Depression is associated with morbidity, decreased 
physical, social and cognitive function and reduced self-care [206]. In older adults, 
antidepressants are often prescribed to manage incontinence, pain, anxiety, irritable bowel 
syndrome and insomnia [207]. There are four main classes of antidepressants, tricyclic 
antidepressants, selective-serotonin re-uptake inhibitors (SSRIs), monoamine oxidase inhibitors 
(MAOIs) and ‘other’ antidepressants that do not fall within the three classes. Antidepressants 
have been associated with increased risk of adverse events in people with dementia [208] and 
increased risk of falls in older adults, across the classes of antidepressants. The increased risk of 
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falls may be explained by sedation, drowsiness and impaired balance as a side effect of the 
prescription [207]. Moreover, there is evidence that some antidepressants are not effective as 
first choice treatment of depression in Alzheimer’s disease [209]. A recent review found little 
evidence for the effectiveness of antidepressants for improving depression in people with 
dementia and found an increase in adverse effects compared to placebo [208]. However, the 
quality of the available evidence was poor, including evidence of poor reporting of adverse effects 
(selective reporting) and negative results and risk of selection and performance bias due to 
inadequate blinding in studies [208]. Further research is needed to understand the effect of 
antidepressants in people with dementia, including potential for adverse effects.  
All medications and therefore all antidepressants have the potential for adverse effects but the 
side effects associated with antidepressants do vary across the different types [210]. A large 
observational cohort study of older adults with depression (n=60,746) found all antidepressants 
were associated with increased risk of mortality, suicide or self-harm, falls and fractures 
compared to non-users. However risk varied across antidepressant class, SSRIs were associated 
with greatest risk of falls, MAOIs and other antidepressant medications were associated with 
greatest risk of mortality, suicide or self-harm, stroke, fractures and epilepsy. Tricyclics were not 
associated with greater risk compared to the other antidepressant classes [211]. Antidepressants 
have also been estimated to be associated with a small but significant increased risk of mortality 
in people with dementia as part of a national Veterans Health Administration registry [212]. 
However, this study excluded tricyclic antidepressants and MAOIs and the follow-up was over 180 
days. Further studies to understand the impact of all antidepressant use in people with dementia 
and with follow-up periods that account for long-term use, will add to our understanding of the 
impact of prescribing potentially inappropriate antidepressants in people with dementia.  
There is also evidence that tricyclic antidepressants are associated with sedation, orthostatic 
hypotension, and cognitive impairment [205–207]. The anticholinergic effects of tricyclic 
antidepressants are associated with detrimental effects on some cognitive domains [216]. 
Although, other studies observe impaired cognition at baseline in tricyclic antidepressant users, 
however no significant changes in decline were observed overtime in older adults [217]. Reducing 
exposure to medications with negative cognitive side effects is a priority for people living with 
cognitive impairment or dementia to reduce the potential for exacerbating the condition. This is 
an exemplar of the benefit compared to harm decision-making process associated with 
medication use in this population.   
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(iii) Benzodiazepines  
The findings from this review identified that benzodiazepines were among one of the most 
commonly identified PIM prescribed to older adults [147, 158, 180, 218]. Benzodiazepines were 
also prevalent in studies of populations in nursing homes [137, 219]. Benzodiazepines are a type 
of anxiolytic and hypnotic medication with sedative effects. Primarily benzodiazepines are 
indicated to relive anxiety and sleep problems in older adults. Some common side effects include 
drowsiness, dizziness and reduced coordination. The evidence from the review highlighted that 
long-term use is also associated with an increased risk of dependence, serious falls and fall-
related fractures [220], cognitive impairment [221], delirium. There is some observational 
evidence of an increased risk of dementia, however the evidence is inconclusive and 
benzodiazepine use may be an early marker of the disease [222]. Many older adults are 
prescribed benzodiazepines for long-term use, and may be prescribed to people with dementia to 
manage sleep disturbances, despite a lack of clinical benefit supporting their use in this way and 
increased prevalence of adverse effects. Until recently, there were no guidelines to support safely 
stopping benzodiazepines and only since 2019 have NICE endorsed guidelines developed in the 
Bruyère Deprescribing Research Team [108]. A lack of guidelines for safely stopping medicines 
and the associated dependence and withdrawal symptoms may have also impacted on the 
challenges associated with prescribing and deprescribing benzodiazepine prescriptions in older 
adults.  
 
(iv) Anticholinergics 
This scoping review also showed that anticholinergic medicines were included across a number of 
PIM criteria and are associated with particular adverse effects, including cognitive impairment, 
confusion, delirium, falls and hospital admission in older adults and people with cognitive 
impairment or dementia [129, 143, 150, 154, 161, 162, 166]. Anticholinergics work by blocking 
the action of acetylcholine, a neurotransmitter acting within the central nervous system, smooth 
muscles of the gut, some non-voluntary internal organs and the heart. Medications with 
anticholinergic effects account for a range of medications but includes medications used for 
gastro-intestinal disorders, incontinence, drugs for Parkinson’s, some antidepressants and 
antipsychotic medications. Previous studies have found observational associations of 
anticholinergic drugs with a number of consequential side effects including well established 
detrimental effects on cognition [216] and some evidence of increased risk of dementia [223]. 
However, a recent case-control study found an association of some but not all anticholinergic 
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medications. Antidepressants and definite anticholinergic medicines were associated with 
incident dementia [223]. The use of anticholinergic medications in older adults has previously 
been associated with increased delirium, sedation, urinary retention, falls, cardiovascular disease 
and mortality, although the evidence is not conclusive [213, 224, 225]. Evidence of an association 
of anticholinergics and mortality has been conflicting and somewhat limited by short follow-up 
periods and small sample sizes [226–229]. Moreover, previous studies have not accounted for 
physical frailty beyond the presence of comorbidities, or the use of other medications [230]. 
Measures of frailty are predictive of mortality and accounting for frailty may improve 
understanding of the relationship between anticholinergic medicines and mortality in people with 
dementia. Furthermore, a review of studies of anticholinergic medications and the association 
with delirium found the majority of studies did not find an association of anticholinergics with 
delirium [226]. Clinical guidelines suggest that anticholinergic medications should be avoided if 
possible in frail older adults [231]. Tricyclic antidepressants, are one example of a medication with 
high anticholinergic burden and it is recommended that they should be avoided in people with 
dementia due to associated adverse effects [107, 232]. Anticholinergic medications are a priority 
medication to be managed, particularly in people with dementia due to associated adverse 
effects, but more evidence is needed to understand the potential for adverse effects in this 
population given previous limited evidence.   
 
(v) Proton pump inhibitors  
Identified in a number of reviews was the high prevalence of inappropriately prescribed proton 
pump inhibitors (PPIs), which were cited as the most commonly occurring PIM [141, 168]. Used 
for the treatment of acid related indigestion and peptic ulcers PPIs are one of the most frequently 
prescribed medications globally [233]. PPIs are generally considered safe and effective and 
associated with few adverse effects. However, recent evidence has suggested that PPIs may be 
associated with hip and spine fractures [234, 235], hospital and community acquired pneumonia 
[236–238], Clostridium difficile infections [239, 240] and vitamin and mineral deficiencies [241]. 
However, findings are not consistent across observational studies and previous studies have been 
limited in their approach to adjusting for comorbidities and confounding by indication [242]. 
Around 23% of people with dementia are prescribed inappropriate PPIs [189]. In addition, for 27% 
of the older population PPIs are prescribed long-term, despite a lack of evidence supporting the 
efficacy and safety of their long-term use [242]. It is considered that PPIs should not be prescribed 
for longer than eight weeks in older adults [243]. PPIs are widely prescribed and account for 
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considerable prescribing costs. In England, over £100 million is spent annually on PPIs from NHS 
budgets [244], however as highlighted many PPIs are prescribed chronically and possibly 
unnecessarily. PPIs may be contributing to inappropriate polypharmacy when they are prescribed 
long-term and without clear indication. The implications of managing the inappropriate use of 
PPIs on clinical and economic outcomes are not yet known. PPIs are a useful target medication to 
monitor in future studies as a potential for improving patient safety, identifying inappropriate 
polypharmacy and medications to be deprescribed and have substantial financial implications for 
health care providers.  
 
(vi) Targets for deprescribing  
The process of reducing, tapering and ceasing a medication to improve medicines is known as 
deprescribing [245]. Deprescribing is an integral part of optimising medicines, particularly when a 
medication is potentially inappropriate. The scoping review identified a number of key 
medications that are useful targets for improving appropriate medication use. Given the large 
number of PIMs identified, prioritising which medications to deprescribe has been a priority 
within previous studies and is integral in informing the priority direction of this research. A Delphi 
consensus survey study consulted over 60 physicians, pharmacists, geriatricians and nurses to 
identify medications commonly used by older people, for which evidence-based deprescribing 
guidelines would be useful for practice [246]. The highest priority medications for deprescribing 
were benzodiazepines, antipsychotics, antidepressants, proton pump inhibitors and 
anticholinergics, statins and cholinesterase inhibitors, for which over 30% of Delphi participants 
indicated the medication as a high priority for deprescribing evidence. Other medication classes 
were opioids, bisphosphonates, anticonvulsants, beta-blockers and antiplatelet medications. A 
number of the reviews included in my scoping review also identified the need for deprescribing 
guidelines to support practitioners and to be incorporated into practice [136, 173, 181]. The 
corroboration between the medications identified in this scoping review and those identified as 
priority medications for deprescribing is important and provides a useful focus for future research 
[246].  
People with dementia may be at increased susceptibility to side effects of medications and there 
is evidence that people with dementia are particularly vulnerable to serious adverse effects of 
antipsychotic medications and detrimental cognitive effects of anticholinergic medications.  From 
this scoping review, it is apparent that whilst there is a large body of literature investigating 
polypharmacy and PIM among older adults, the evidence is limited amongst people with cognitive 
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impairment or dementia. This is despite the growing size of this population, who are often frail 
and living with multimorbidity alongside cognitive impairment or dementia.  
Guidelines are limited for prescribers in making evidence-based decisions about prescribing for 
comorbidities in people with dementia. Consideration needs to be given to specific medication 
classes when developing guidelines to support prescribing and deprescribing in people with 
dementia. Prioritising key medication classes that people with dementia may be exposed to, 
which could be targets for medication management interventions and building the evidence base 
around these key medications, is informative for the subsequent development of guidelines to 
inform prescribing.  
Clinical trials of medications are often conducted in younger, healthy populations, excluding frail 
older adults and people with dementia, comorbidity or polypharmacy and alternative approaches 
are needed to address this gap [81, 82]. Clinical trials have lacked external validity and 
generalisability but observational studies are key in addressing these shortcomings. Observational 
cohort studies are useful because they can include large, representative samples of people who 
would often be excluded from clinical trials. Incorporating samples with frailty, polypharmacy, 
dementia and comorbidity providing more representative sample of a heterogeneous older 
population, and the nuances of medication use in this population can be better understood and 
will inform the development of prescribing guidance in people with dementia and comorbidities.   
 
(h) Interventions to optimise medication use 
The scoping review revealed a range of interventions to address inappropriate polypharmacy and 
medication use in older adults. Interventions targeted prescribing, prescribers, methods of 
practice and care structures to improve prescribing and patient outcomes. This included, 
education of prescribers, the incorporation of specialists (geriatricians and pharmacists) into 
interventions, application of multidisciplinary teams and technology-assisted interventions to 
improve prescribing. However, common across interventions was the incorporation of a review of 
medications. The evidence suggested that medication review was an effective intervention in 
improving appropriate medication use, by reducing medications no longer indicated [175], 
reducing polypharmacy and reducing the number of PIMs [136]. Although medication review was 
effective in improving the quality of prescribed medications, the impact on patient outcomes was 
uncertain. On one hand, there was evidence that deprescribing was not associated with an 
increase in the number of drug withdrawal events [171]. On the other hand, there was little 
66 
 
evidence that medication review reduced adverse drug events [129], or hospitalisation [169] and 
there was unclear evidence whether a review improved quality of life or decreased medication 
costs [129]. In addition, the impact on mortality was only evident in non-randomised studies [129, 
169, 171]. The evidence for the impact of interventions on clinical outcomes was often low quality 
and susceptible to bias [130, 131, 168, 133, 135, 141, 146, 148, 150, 154, 163]. Interventions were 
often poorly described, particularly for complex interventions, and failed to adequately report 
adverse outcomes or negative findings (publication bias), no or limited blinding or randomisation 
methods in trials. Moreover, there was little research into the impact of medication review in 
community-dwelling people with dementia. Further research is needed to assess the usefulness of 
medication review to improve prescribing, particularly among people with dementia and the 
subsequent impact on patient outcomes. Moreover, a number of reviewers also identified the 
need for guidelines to be developed to support prescribers in deprescribing medicines [136, 181] 
[173]. 
In people with dementia, one review found that using medication review to target PIMs was 
effective in improving medication appropriateness. Medication review was associated with 11% 
to 78% reduction in PIMs and reduction of 2% to 8% in overall medication use [165]. However, 
this was a review of studies of care home residents with advanced dementia. In an environment 
where patients are being cared for consistently, staff may have a good understanding of the 
person with dementia, their behaviours and the day-to-day impact of medication use. Care home 
staff involvement in the review of medications may assist in the identification of PIMs or 
unnecessary medications that could be deprescribed, and monitoring potential adverse drug 
withdrawal events or symptom changes may be better managed. The potential for monitoring of 
patient safety and the controlled deprescribing of inappropriate medications may be easier to 
manage in a care home. In primary care, medication monitoring is much more reliant upon the 
patient and (if available) their carer to monitor changes day-to-day after medication review and 
deprescribing. From the scoping review, the impact of medication review on appropriate 
medication use in people with dementia was unclear and more research is needed to understand 
the role of medication review among people with dementia in primary care and beyond trial 
settings.  
  
(i) Patient and prescriber perspectives  
A growing body of qualitative research has sought to understand the perspectives of patients, 
carers and prescribers in the process of medicines optimisation. The scoping review identified two 
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systematic reviews synthesising qualitative studies [181, 182]. On one hand, prescribers identified 
a number of internal factors that were associated with prescribing and medicines optimisation. 
This included a sense of ‘powerlessness’ arising from self-perceived restrictions to optimising 
medicines. Prescribers felt that they needed to meet the demands and desires from patients to 
receive medicines at a consultation. Also, prescribers identified that in some cases of prescribing 
in particular nursing homes or care situations, that they felt forced to prescribe by nursing home 
staff or carers [182]. Despite this, it was also evident that some prescribers had developed their 
own approaches to manage polypharmacy, given their experience and knowledge of their 
patients [181]. On the other hand, extrinsic factors were also identified. This included 
consultation time, relationships with patients and coordination of care between care homes, 
hospitals and GPs. Furthermore, the impact of prescribing guidelines and a lack of deprescribing 
guidance was identified by GPs as impacting on medicines optimisation for their patients [181].    
The findings from reviews of a number of qualitative studies exploring patient perspectives of 
polypharmacy found a number of factors that were important to patients. The findings suggested 
that many patients took ownership over their medication regimes by experimenting with 
medicines. This would include prioritising certain medicines, taking breaks, stopping and reducing 
dosage. In addition, patients who had a good, trusting relationship with their GP were less 
worried about adverse effects and felt supported in medicines management. Like prescribers, 
patients felt that consultation times were too short and that there were multiple prescribers, who 
communicated poorly across health care systems. Of the patients who experienced adverse 
effects, the benefits of medicines did not outweigh the harms and they felt that medicines were 
less effective. Largely, patients did not want to take more medicines. There was both a resistance 
to taking medicines and an unwillingness to stop certain medicines [181]. These factors influence 
the experience of both patients and prescribers and may also influence the effectiveness of 
interventions to optimise medicines in practice.   
 
(j) Strengths and limitations of the scoping review  
There are a number of strengths to this review. To ensure a broad literature search, the search 
strategy used three databases and a comprehensive range of search terms that were developed 
with the guidance of a faculty librarian. This review provided an overview of the literature into 
polypharmacy and PIM in older adults. This enabled a process that was grounded within the 
literature to discuss previous literature and identified key areas for future research that are 
integral to this research project. Mapping the breadth of the literature is a key strength of the 
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scoping review methodology compared to a systematic review [125]. This was particularly 
informative in understanding the extensive and clinically significant field of prescribing and 
medication appropriateness, particularly within older adults. The use of scoping reviews as a 
methodology to review the literature is growing in application across the literature and are 
increasingly recognised as an incredibly useful tool, particularly within health services research 
[247]. The consistency of scoping reviews will be improved by the development of reporting 
guidelines, such as the PRISMA-SR used in this review (Appendix 1 Section 10.01) [128]. 
Conducting a review of reviews summarised a range of reviews addressing a number of research 
questions across related areas and understanding the extent of research evidence of different 
types of studies, interventions and outcomes across different populations [126]. This approach 
enabled this review to cover research across medication appropriateness including polypharmacy 
and PIMs, understand the impact of different interventions, outcomes and across older adults and 
people with dementia in a range of care settings.  
Limitations of the scoping review of reviews include the possibility that recent and primary 
literature may not have been included in a review yet, and other reviews may have been missed 
due to database selection, exclusion of grey literature, time and resource constraints. The studies 
were extracted by one reviewer which affects the validity of the extraction process. However, a 
scoping review differs from a systematic review in that the goal is not necessarily to identify all 
relevant literature to a specific question but to understand the breadth of research into an area, 
which in the case of this review is far reaching. Although, through this process it was necessary to 
rely on secondary interpretation of findings, which is additionally compounded in a review of 
reviews.  
It was also evident from the reviews that there were well established areas of research that have 
identified the challenge of prescribing in older adults. Despite this, there were identifiable gaps 
within the evidence base particularly around the understanding of the nuances of medicines use 
amongst this diverse population. Understanding the variation in this population will help 
prescribers manage medicines appropriately. A critical quality appraisal of the reviews included 
was not completed and is not a requirement from Arksey and O’Malley’s (2005) original 
framework, and is an optional addition according to the PRISMA-SR reporting system [128]. If a 
quality appraisal was undertaken in the included reviews, this was taken into account when 
evaluating the evidence. To improve the quality of the reviews included, only systematic reviews 
or literature reviews with a systematic approach were included. Grey literature and opinion 
pieces were not included to reduce author bias.   
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A limitation of a review is that the review inherits the limitations and quality of the studies 
included in the review. Across a number of the reviews, the diversity in study designs, range of 
measurements and outcomes made it unfeasible to pool estimates and conduct meta-analyses. It 
was difficult to assess comparisons across interventions because of variation in implementation.  
The quality of reporting about the methods and implementation of interventions in the reviews 
was often limited, inherited from poor quality of reporting in the primary studies, particularly 
when describing complex interventions. A lack of clarity when reporting within primary studies 
included in the reviews affects the understanding of the impact of findings. Quality appraisals 
reported in the reviews often reported the evidence as low quality, lacked rigour and was at high 
risk of bias. Often this was associated with poor blinding and randomisation procedures in clinical 
trials and failure to appropriately adjust for comorbidity, considerably increasing the risk of 
confounding by indication bias.  
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2.04 Summary  
Medicines optimisation in older adults is a clinically significant priority for practitioners, patients 
and researchers. The scoping review of reviews provided a comprehensive overview of existing 
research in this area. Polypharmacy and PIMs are associated with adverse effects in older adults. 
However, given the heterogeneity of the older population, further research is needed to refine 
risk estimates among vulnerable groups, including frail adults and people with dementia. 
Interventions to reduce PIMs and polypharmacy have been trialled but there has been little 
research into how these actually affect prescribing quality in practice, hence further research is 
needed to evaluate their impact both on prescribing and patient outcomes.   
For prescribers, systems that ease the process of identifying where care pathways and medication 
management can be optimised will be useful across care settings. This will support the routine 
identification and reduction of inappropriate polypharmacy and PIMs to optimise medications. A 
regular medication review is often included in clinical guidelines, particularly for people who are 
frail, taking multiple medications, or living with long-term health conditions [108]. This review has 
identified gaps in the current evidence base and priorities for medication optimisation in people 
with dementia. The older population is heterogeneous and prescribing is complex and challenging 
in the presence of cognitive impairment and dementia, comorbidities and frailty. Whilst there has 
been a large body of research into polypharmacy and PIM use in older adults, research in people 
with dementia (particularly at early stages) and cognitive impairment has previously been limited, 
largely by its focus on advanced stages of the disease and palliative care [191]. Mild cognitive 
impairment and mild dementia are particularly important stages for preserving function, adjusting 
to a diagnosis, preparing for the future and maintaining good quality of life.  
Given the lack of clinical guidelines to support prescribers when making evidence-based decisions 
about medication use in this population, further research is required to understand polypharmacy 
and PIM use. Antipsychotics, benzodiazepines, anticholinergics, antidepressants and PPIs were 
identified as key potentially inappropriate medication classes to direct a focus of the studies 
conducted in this research. These medications are implicated in both Beers and STOPP criteria 
[107, 232] and identified by prescribers as medications where evidence to support deprescribing 
would be of great value [246]. These medications are specifically associated with adverse effects 
in people with dementia or are widely used in the older population and deprescribing could 
reduce the impact of inappropriate polypharmacy. However, there is limited or conflicting 
evidence into the extent to which they are associated with harm. To add to this growing body of 
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evidence, further research is required to understand the prevalence of polypharmacy and PIM in 
people with dementia in primary care.  
It is with these findings in mind that the broad aim of this research study was established. The 
overarching aim was to understand the impact of polypharmacy and potentially inappropriate 
prescribing on people with dementia, and to understand the effectiveness of existing approaches 
to improving care in this patient group. The subsequent chapter outlines the specific aims and 
objectives that are addressed in this research study and a broad overview of the methodological 
approaches applied. 
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III. Chapter 3: Aims and Objectives   
3.01 Introduction 
The scoping review of reviews established that whilst there is a large body of research into 
polypharmacy and PIM in older adults, the research into people with dementia is limited. Further 
research is needed to understand the impact of inappropriate prescribing across this 
heterogeneous population. The central aim of this thesis was to understand the impact of 
potentially inappropriate prescribing in people with dementia, including the real world 
effectiveness of approaches to optimise medication use in this population. Applying 
epidemiological methods, two cohorts including people with cognitive impairment or dementia 
were analysed to address the aims and objectives of this thesis. This chapter provides an overview 
of the methodological approach, briefly introduces the two datasets that were analysed and 
outlines the aims and objectives addressed in the remaining chapters of this thesis.   
 
3.02 Pharmacoepidemiology  
Evidence for the efficacy and safety of medication use is often extrapolated from clinical trials 
that lack external validity and generalisability because they often use lower-risk samples, which 
would exclude older, multimorbid and frail adults, people with polypharmacy, cognitive 
impairment or dementia [81, 82]. Observational studies are able to mitigate these limitations 
through observing the effects of a disease or intervention, for example, in real-life environments 
and if sampled appropriately, also provide a representative sample of a population. In older 
populations, a truly representative sample may include a mixture of genders, care settings, ages, 
frailty, comorbidity, polypharmacy and cognitive impairments, representing the diversity of this 
population including the most vulnerable and traditionally inaccessible groups.  
As the study of the use and effects of medications in large cohorts, pharmacoepidemiology lends 
itself as an appropriate methodology for the studies I conducted, although this approach has 
limitations. Observational studies using existing data are restricted by the nature and quality of 
the data that is collected and made available. Secondary data analysis of cohort studies is 
dependent upon the reliability of the reporting of responses to answers in subjective 
questionnaires and the recording of responses by interviewers. Some data may be inaccurate, 
missing or recorded at particular or single time points. While a key strength of observational 
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studies is the observation of behaviour in real-world environments, this inevitably increases the 
susceptibility to any number of unmeasured confounders that may influence estimates. 
Accounting for these limitations, analyses of two distinct population representative cohorts with 
existing data were performed from (i) primary care patient records from Clinical Practice Research 
Datalink (CPRD) and (ii) participants from the Cognitive Function and Ageing Study.  
 
(a) Clinical Practice Research Datalink  
One of the world’s largest research databases using electronic health record data is the Clinical 
Practice Research Datalink (CPRD). Established in 1987 and previously known as the General 
Practice Research Database, CPRD is an active database of UK primary care. The CPRD has over 30 
years of longitudinal data from over 11.3 million patients, including 4.4 million active patients 
currently registered with over 600 practices. The CPRD covers 6.9% of the UK population and is 
broadly representative of the population in terms of age, sex and ethnicity [248]. The dataset 
contains recorded data from each patient consultation with a GP. The patient record includes key 
demographic information, consultation details, medical history, prescriptions, diagnoses, 
referrals, immunisations, and tests. Accordingly, the CPRD patient record contains information on 
diagnoses of dementia, prescriptions and records of patient reviews, such as the QOF dementia 
annual review and medication reviews.  
 
(b) Cognitive Function and Ageing Study  
The Cognitive Function and Ageing Study (CFAS) is a multi-centre, population-representative 
cohort study of ageing in the UK, including adults over 65 years living in the community and care 
homes. The original CFAS study (MRC CFAS) [249] began in 1989, the second CFAS study (CFAS II) 
started in 2008 [2] and CFAS Wales in 2011. My analysis used data collected as part of CFAS II, 
which included more than 7,700 older adults who took part in the CFAS interviews between 2008-
2011 from three geographical areas in England (Cambridgeshire, Nottingham and Newcastle). The 
CFAS interviews comprised an extensive and comprehensive collection of over 600 questions 
about demographics, health and lifestyle of the participant. This included cognitive assessments, 
medication use as well as assessments indicative of physical frailty.  
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3.03 Aims and objectives of this research  
(a) Aims  
The broad aims of this research project were to use existing data sources to understand the 
impact of potentially inappropriate prescribing on people living with dementia, and how effective 
existing approaches to improving care in this population are.  Specific aims were to: 
1. To estimate the prevalence of polypharmacy and of potentially inappropriate prescribing 
among people with dementia.  
2. To estimate the factors that predict the use of PIMs and polypharmacy, in particular the 
effect of dementia annual review and medication review on potentially inappropriate 
prescribing.  
3. To understand the impact of PIMs and polypharmacy on health among older cognitively 
impaired adults and the potential impact of frailty on this relationship.  
 
(i) Data sources  
To address the aims, two existing data sources were used (see Figure 2). To address Aim 1 and 
Aim 2, primary care electronic health record data were used that was extracted from the Clinical 
Practice Research Datalink (CPRD). Data from the second Cognitive Function and Ageing Study 
(CFAS II) was analysed to address Aim 1 and Aim 3. This thesis describes and discusses how each 
of the aims were addressed, through a series of analyses of the CPRD and CFAS II cohort 
addressing the subsequent specific objectives.  
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(b) Objectives  
(i) CPRD cohort study  
Objectives addressing Aim 1:  
1a. To estimate the prevalence of potentially inappropriate prescribing and average number 
of concurrent medications prescribed among patients with dementia in primary care in 
England over a two-year period.  
Objectives addressing Aim 2:  
2a. To estimate the probability of starting or stopping a PIM, and the change in the average 
number of medications prescribed after a review.  
2b. To estimate the association of dementia annual review and medication review (and other 
patient and practice level factors) associated with starting or stopping each class of PIM, 
and association with a change in the number of concurrent prescribed medications, in 
people with dementia. 
(ii) CFAS II subsample study  
Objectives addressing Aim 1:  
1b. To estimate the prevalence of PIM use and polypharmacy in frail and non-frail older 
adults with cognitive impairment.   
Objectives addressing Aim 3:  
3a. To estimate the association between PIM and polypharmacy use at baseline and 
subsequent survival, as an indicator of overall health.  
3b. To estimate the moderating role of baseline frailty on the relationship between 
polypharmacy, PIM use and mortality. 
3c. To assess the predictive validity of frailty phenotype and individual criteria to predict 
susceptibility to mortality. 
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Figure 2 Describing how the three aims of this research study are addressed through a series of objectives in a CPRD 
cohort study using electronic health record data (n=22,448) 1st January 2015 – 30th April 2017 and a cohort study of the 
second Cognitive Function and Ageing Study (CFAS II) (n=1,154) 2008 – 2016 
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IV. Chapter 4: CPRD cohort study Methods  
 
4.01 Overview of chapter  
This chapter presents the study design, methods and statistical approaches used to conduct the 
analyses of a primary care dataset of patients with dementia in England.  The CPRD cohort study 
of people with dementia in primary care in England is described. This study addressed Aim 1 and 
Aim 2 and objectives 1a, 2a and 2b of this research to estimate the prevalence of and factors 
associated with (and changes in) polypharmacy and PIM in people with dementia. This chapter 
describes the study design, the dataset used, sampling approach, exposures, outcomes and 
covariates and statistical analyses applied. The development of a multilevel mixed effects 
regression models to estimate transitions in prescribing is described. This model is used to 
estimate the association of medication review and annual dementia reviews on starting and 
stopping PIMs among people with dementia in primary care.  
The protocol for this study (16_240) was granted approval by an Independent Scientific Advisory 
Committee (ISAC) in February 2017 (Appendix Section 10.04: Appendix 4). The abstract is 
available online at: https://cprd.com/protocol/potentially-inappropriate-prescribing-people-
dementia-england-prospective-cohort-study  
 
4.02 Study design 
This was a prospective cohort study of people with dementia in primary care in England, extracted 
from CPRD. The study design is summarised in Figure 3. The study period ran from 1st January 
2015 until 30th April 2017. Patients with dementia diagnosis were followed from the point at 
which they entered the study until they left their general practice, died, the practice left CPRD or 
until the end of the study period (30th April 2017). Patients meeting the eligibility criteria and with 
a dementia diagnosis before 1st January 2015 were included at the start of the study period but 
patients could also subsequently enter throughout the study period, to include incident cases of 
patients with a dementia diagnosis, for example. This was done to ensure that at all time points, 
the study included a representative sample of all people with a dementia diagnosis. This included 
people entering the study as they were diagnosed or move to the practice and people leaving the 
study as they die or move.  
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For the purpose of the analyses, the study period was split into 14 time periods, each equivalent 
to two calendar months. Two month time periods were used to account for a change in a 
patient’s prescription being applied to the patient’s CPRD record. 
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Figure 3 Example of four patients with dementia entering and leaving the study, from the sample extracted from the Clinical Practice Research Datalink.  
Study period from 1st January 2015 - 30th April 2017 and is split into 14 two-month time periods. To be included, patients must have been registered at an English general practice, with 
a diagnosis of dementia. The patient must have been registered at a practice contributing good quality research data for at least one year to the CPRD. Patients needed to remain 
registered at the same practice, be alive and be included in the QOF data recording for the practice. 
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4.03 Setting  
This study used data extracted from the Clinical Practice Research Datalink (CPRD), a research 
database generated from UK electronic health records. CPRD contains anonymised records of 
consultations, diagnoses, referrals and prescribing for more than 11.3 million patients from 674 
primary care practices across the UK. In the UK, every consultation a patient has with a General 
Practitioner is recorded in the patient’s electronic health record. A range of software systems are 
used by general practices and CPRD collects coded data from practices using the Vision and 
recently from the EMIS systems. This study used the CPRD GOLD data, containing data collected 
from practices using Vision in England, which is the system used in an estimated 9% of all GP 
practices [250] [248]. 
Index of Multiple Deprivation data was also linked to the CPRD dataset. This is a government 
measure of relative deprivation based on income, employment, education, health and disability, 
crime, housing and living environment, linked from the general practice postcode [251].   
 
(i) Structure of CPRD dataset  
There are 10 separate data tables within the CPRD GOLD database, although not all tables were 
used for the current analyses (Figure 4) 
 
1) Data tables used in analyses 
1. Practice data table: contained practice level details of each practice, including regional 
location of the practice and data collection information, including the date when the 
practice joined CPRD and had up-to-standard data for research purposes that was 
collected.  
2. Patient data table: patient level demographic information.  
3. Consultation data table: contained data on the type of consultation, including the 
consultation location.   
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4. Clinical data table: contained patients’ medical history while registered with the practice, 
including clinical diagnoses and death. Coded using Read Codes.  
5. Additional clinical data table: contained additional structured data associated with and 
linked to the clinical file events, which may include the residential status of the patients.  
6. Therapy data table: contained the details of all prescriptions, including medicines and 
medical appliances issued by the GP, recorded using Gemscript product codes.  
 
2) Data tables not used in analyses  
7. Staff data table: included information on the practice staff.  
8. Referrals data table: contained any referrals to external organisations or systems, 
including hospital admissions or outpatient care.  
9. Immunisations data table: contained a record of any patient immunisations. 
10. Tests data table: contained a record of any test data recorded by the GP
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Figure 4 Hierarchal model explaining the CPRD data tables used in this study, of the 10 data tables available from CPRD, the staff, referrals immunisations and test data tables were not used for the purpose of 
this study. 
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4.04 Population and sample  
The target population was all people with a diagnosis of dementia in England. The study 
population was patients with a diagnosis of dementia in primary care in England registered at a 
general practice contributing to CPRD. A series of inclusion criteria were applied to the study 
population to identify the eligible sample. The sample inclusion criteria are provided and justified 
in Table 5. A figure explaining how patients entered and exited the study is provided in Figure 3.  
For a patient to enter the study, they needed to meet the inclusion criterion. In addition, the 
patient was required to meet a series of criterion to enter into and remain in the study, at each 
time period. This included: 
1. The last CPRD data collection date from the practice was required to be after the end of 
each time period. After a general practice stopped contributing the electronic health 
record data to the CPRD, the patients who were registered at this practice would no 
longer be eligible to be remain in the study. 
2. The patient must not leave the general practice until after the end of each two-month 
time period. If a patient leaves the general practice, there will be no future record in the 
CPRD of this patient. The patient might leave because they change address or move into a 
care home and are subsequently registered with a new general practice. It is not possible 
to match a patients’ record from their previous general practice to the new practice and 
subsequently no further data on that patient can be used.  
3. The patient must also be alive until the end of each time period. 
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Table 5 CPRD study inclusion criteria and supporting rationale.  
Inclusion Criteria  Rationale   
1. Diagnosis of dementia as 
defined by the presence of a 
record of a dementia diagnosis 
or a prescription of a cognitive 
enhancer (i.e. memantine, 
donepezil, rivastigmine, or 
galantamine) before the start of 
or during the study period (1st 
January 2015 – 30th April 2017). 
1. New diagnoses were also included to maintain a 
representative sample of dementia patients 
throughout the duration of the study period. 
Identifying dementia diagnosis using similar 
definitions has been validated in the CPRD with a 
positive predictive value (PPV) of 95% [252]. 
2. Currently registered at an 
English GP practice 
 
2. While CPRD does provide data from primary care 
practices across the United Kingdom, because health 
care provision is devolved across the four countries, 
clinical practice, guidelines and the use of pay-for-
performance schemes can vary greatly. The use of 
the Quality and Outcomes Framework, for example 
is different between countries in the United 
Kingdom, with Wales and Scotland recently radically 
changing their approach [253].  
 
In addition, the IMD linkage data is not comparable 
between countries in the UK.  
3. The patient must be registered 
with a practice that is 
contributing good quality 
research data for at least one 
year before entry into the 
study. 
 
3. The CPRD assess the quality of the data that is 
provided from primary care using an algorithm 
evaluating the practice recording of death and of 
gaps within the data. A variable is generated by 
CPRD to identify the date at which the practice data 
is of appropriate quality to be used for research 
purposes. For this study, I used data from patients 
registered with practices that had a minimum of one 
year of good quality data to allow for appropriate 
measurement of baseline confounders.    
4. Patients must be included in 
the QOF data recording for the 
practice.  
 
 
4. A GP can exclude patients from the QOF for example 
because it is deemed inappropriate to conduct the 
review due to significant frailty or the patient is in 
palliative care. Alternatively, the patient can choose 
to be not be included in the data collection. A 
patient can choose to not have a dementia annual 
review, for example and would therefore not count 
towards the QOF data recording and the practice 
score and practice income would not be affected.  
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4.05 Exposures  
The primary exposures of interest were the presence of a record of a dementia annual review or a 
medication review in each two-month time period across the duration of the study. The CPRD 
clinical data table contained Read Codes that were used to extract detail for medication reviews 
and dementia annual reviews from the patient records from 1st January 2015 until 30th April 2017 
(Figure 5). The presence of a record of a dementia annual review or a medication review, in each 
two-month time period was coded. Two binary variables were generated to account for a record 
of a dementia annual review and a medication review.  
 
(a) Dementia Annual Review  
In-line with the QOF guidelines, a record of annual dementia care plan review should be recorded 
in a patient’s file using one specified Read Code, in order for the practice to gain the associated 
income from QOF if they met the target. A record of a dementia annual review was identified as 
an event in the clinical data file with the Read Code 6AB..00 and was classified as a binary variable 
(1= dementia annual review, 0 = no dementia annual review) in each two-month time period for 
each patient.  
 
(b) Medication review  
Any record of an event in the clinical file with a Read Code identifying a medication review (see 
Table 6) within the two-month time period was used to generate a binary variable identifying 
medication review in each time period (1=medication review 0=no medication review). The Read 
Code lists to identify the record of a review were cross-checked by a practising general 
practitioner with experience of QOF recording and working with CPRD.  
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Table 6 Read Codes used to identify Medication Review, checked by a practising GP. 
Read 
Code Read Term 
8B31400 Medication review 
8B3y.00 Medication review of medical notes 
8B3x.00 Medication review with patient 
8B3V.00 Medication review done 
8B3S.00 Medication review 
8B3h.00 Medication review without patient 
8B31B00 Polypharmacy medication review 
8BIC.00 Medication review done by pharmacist 
8BIy.00 Medication review done by nurse 
8BIH.00 Medication review done by doctor 
8BMF.00 Medicine use review done by community pharmacist 
8BMH.00 Medication review done by pharmacy technician 
8BMY.00 Medication review done by medicines management pharmacist 
8BMJ.00 Dispensing review of use of medicines 
8BMX.00 Medication review done by medicines management technician 
8BT..00 Medication review - additional 
8BT2.00 Medication review by practice nurse 
8BM0.00 Mental health medication review 
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4.06 Outcome variables 
(a) Potentially inappropriate medications  
Selected potentially inappropriate medications (anticholinergics, antipsychotics, tricyclic 
antidepressants and proton pump inhibitors) were defined according to the World Health 
Organisation Anatomical Therapeutic Chemical Classification System (ATC) codes, the 
Anticholinergic Cognitive Burden scale and the STOPP criteria. A binary variable was generated for 
each of the selected PIMs, identifying the presence of a recorded prescription within each two-
month time period.  
 
(i) Anticholinergic medication  
Definite anticholinergic medications were defined as any medication with an Anticholinergic 
Cognitive Burden (ACB) score of three, where an ACB score of three indicates medications with 
definite anticholinergic activity  and severe negative cognitive effects [254]. The full list of 
anticholinergic medications from ACB included can be found in Appendix Section 10.05: Appendix 
5a.  
 
(ii) Antipsychotic medication  
Antipsychotic medications were defined using ATC code N0A5A.  
 
(iii) Tricyclic antidepressants  
Tricyclic antidepressants were defined using ATC codes. Antidepressants (ATC N06A) were 
grouped into tricyclic antidepressant sub-type. The ATC codes were cross-referenced with the 
British National Formulary (BNF) to identify those used in UK practice (ATC N06AA02, N06AA03, 
N06AA04, N06AA06, N06AA07, N06AA09, N06AA10, N06AA12, N06AA16, N06AX03 and 
N06AX05).   
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(iv) Proton pump inhibitors  
Proton pump inhibitors are considered to be potentially inappropriate, according to STOPP 
criteria when they are used at maximum therapeutic dose for more than eight weeks. For this 
study, PPI use was classified as long-term use when there was a record of a prescription of a PPI in 
at least two consecutive two-month time periods. Their use was defined using ATC code A02BC, 
see Appendix Section 10.05: Appendix 5b for full list of codes.  
 
(b) Total number of prescribed medications  
A continuous variable for the total number of different drugs prescribed within each two-month 
time period per patient was generated. This variable excluded all records of devices, dressings 
and topical preparations. Any repeat prescriptions within each two-month time period were 
removed.  
 
4.07 Covariates  
Covariates were selected due to their association with dementia or prescribing practices. An 
explanation of how the variables were derived from the CPRD is provided (see Figure 5).  
 
(i) Age 
To ensure anonymity CPRD only records the patient year of birth. An age variable was generated 
from year of birth based on the assumption that all patients are born on 1st July. The patients’ 
baseline age was included as a continuous variable. Age was included as a mean-centred variable 
when included as a covariate in the regression models.  
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(ii) Gender  
Patients were identified as male or female with a binary variable indicator from the patient file. 
Age and gender are associated with the prescribing and may be associated with medication 
reviews and dementia annual reviews, previous studies have observed gender differences and age 
associated increases in the use of health care services in older adults [255].  
 
(iii) Residence in a care home  
Around 39% of people with dementia in the UK are living in a care home [28]. Living in a care 
home is associated with polypharmacy, prescribing errors and mortality [256, 257] and reviews of 
medications should occur regularly in care homes, depending on the health needs of each patient 
[108]. The living situation of all patients in CPRD is not explicitly coded. Therefore, whether a 
patient lived in a care home or their own home was ascertained from available data. Bringing 
together patient data from multiple files in the CPRD, a single binary variable was created that 
identified if a patient was expected to be living in a care or nursing home. Using the data available 
within the CPRD, I was able to identify from a patient’s electronic health record an indication of 
their living situation, in particular when there was a reference to living in a care home, nursing 
home, in sheltered accommodation or in their own home. In the CPRD file describing some detail 
of each consultation with a patient for example, two Medcodes could be used to identify the 
location of the consultation as a care home.   
For this variable, patients who were living in a care home, nursing home or sheltered 
accommodation were grouped into one group identified as living in a ‘care home’. Therefore, the 
term ‘care home’ encompasses residential, nursing or sheltered accommodation. If there was no 
record of a care home in a patient’s electronic health record, the patient was assumed to not be 
living in a care home.  
The patient was identified as living in a care home from the date at which this first appears in 
their electronic health record, as gathered from the clinical files and consultation files. Before this 
date, the patient is assumed to be living in their own home and after this date, they are assumed 
to live in a care home. This is useful in identifying patients who move into a care home across the 
study period. Once the patient was considered to be living in a care home, it was assumed they 
did not leave the care home. In some cases this also coincided with the patient exiting the study 
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because they were simultaneously registered with another General Practice and CPRD cannot 
track patients across practices.  
 
(iv) Comorbidity  
Comorbid health conditions were defined using the Charlson Comorbidity Index (CCI) [258]. The 
CCI has been widely used and validated and has previously been applied to electronic health 
records and used in the CPRD to account for patient comorbidity [259, 260]. An adapted version 
of the CCI was used in this study, which translated the CCI to Read Codes that could be applied to 
electronic health record databases [261].  The CCI groups comorbid health conditions using the 
International Classification of Diseases (ICD) diagnosis codes. Comorbidities are allocated a 
weighted score, from one to six, based on their association with mortality. Comorbidities with the 
highest association with mortality and a CCI score of six includes AIDs and metastatic tumour. 
Cerebrovascular disease, chronic pulmonary disease, congestive heart failure and diabetes with a 
CCI score of one, for example. All patients in the sample have a minimum CCI score of one 
because of the dementia diagnosis (Appendix Section 10.06: Appendix 6). Each patient was 
allocated a CCI score, based on the summation of all the weighted comorbidity scores for the 
patient. Higher scores indicate greater comorbidity and greater associated risk of mortality.  
 
(v) Practice level area deprivation  
Deprivation is associated with health, and there is evidence to suggest that living in a deprived 
area is associated with worse health and mental health [262]. Previous studies have found 
variation in prescribing among people with dementia according to area-level deprivation [263]. 
Deprivation as identified from the English IMD 2015 data, linked through the General Practice 
postcode, provided the practice area-level deprivation. The IMD is a measure of relative 
deprivation and ranks every area from the most deprived to the least deprived area and are 
classified into deciles. The General Practices were ranked as being within the most deprived 10% 
up to the least deprived 10%, with higher scores meaning less deprivation. The IMD was coded in 
deciles and was recoded into quintiles for the purpose of analyses.    
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(vi) Polypharmacy  
A categorical variable to account for the overall number of medications prescribed was included 
and categorised as 0-4 medications, 5-9 (polypharmacy) and 10 or more medications 
(hyperpolypharmacy).  
 
(vii) Patient and practice random effects 
Previous studies using the CPRD have identified considerable variation between general practices 
in prescribing appropriateness and safety, particularly among older patients and those prescribed 
multiple medications [116]. The effect of the patient being registered at a particular general 
practice was included in regression analyses to account for the possibility of within and between 
practice variations.  
  
92 
 
Figure 5 structure of the CPRD GOLD data set and variables. Explaining which CPRD file the variables were derived from in the CPRD cohort study.  
There are 10 separate file types included with the CPRD dataset, not all of the files were used for analyses. The practice and file provided information on the practice and linked to patients who were 
registered with each practice, subsequently providing the sample of patients with dementia and patient age and gender variables. The therapy file contained details of patient prescriptions from which the 
total number of prescribed medications and PIM variables were derived. Medication review, dementia annual review and comorbidity were extracted using Read Codes from the clinical file. Residence in a 
care home was derived from the clinical, additional clinical and consultation files to create one care home variable. Linked data set, IMD, was linked to CPRD by the practice postcode. 
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4.08 Statistical analysis  
(a) Description of the sample  
The CPRD cohort study sample was described in terms of the inclusion and exclusion of patients 
with dementia between 1st January 2015 and 30th April 2017. This included a count of the incident 
cases of dementia and patient and practice factors associated with reasons for exclusion from the 
study sample.  
 
(b) Sample characteristics 
The patient characteristics, comorbidity, living situation and the general practice area-level 
deprivation were described for the sample as a whole and among patients with dementia who 
were living in a care home.  
 
(c) Prevalence of potentially inappropriate prescribing  
To address objective 1a of this study, the prevalence of each class of PIM and average number of 
concurrent medications prescribed among patients in primary care was estimated. The 
prevalence of each class of PIM (anticholinergics, antipsychotics, tricyclic antidepressants and 
long-term PPIs) and total number of prescribed medications, was estimated in each two month 
time period from 1st January 2015 until 30th April 2017, by dividing the total number of people 
with dementia with a recorded PIM prescription by the total number of people with dementia in 
the study, at each time period. The prevalence of each PIM and mean number of prescribed 
medications was also estimated according to a patient’s living situation. The proportion of 
patients with dementia with a record of each PIM was estimated with 95% confidence intervals.  
 
(d) Describing occurrence of dementia annual review and medication review   
Patient age, gender, comorbidity, living situation, practice area-level deprivation and proportion 
of patients with a prescription of PIM were described at the point of the first medication review 
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and the first dementia annual review. Kaplan-Meier survival curve graphs were used to estimate 
the time until the first dementia annual review and medication review and to estimate the 
proportion of patients who had had a dementia annual review or medication at different points 
across the study period.  
 
(e) Estimating the change in total medication use and the probability of being 
prescribed a potentially inappropriate medication before and after a review  
Addressing the second aim of this thesis, objective 2a was to estimate the change in the 
probability of a PIM prescription and change in total number of prescribed medications after a 
medication review or dementia annual review. For each patient the first medication review and 
dementia annual review within the study period was identified. The presence of each PIM and the 
average number of concurrent prescribed medications before and after the period including the 
review was identified. The analysis of each PIM class and concurrent prescriptions were treated 
separately in analyses. A prescription of each PIM in the time period after a review was compared 
to the prescription of each PIM in the time period before the review. A figure to explain the set-
up of the analysis is provided in Figure 6.
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Figure 6 explaining the setup of the McNemar analysis for the CPRD cohort study estimating the change in the probability of being prescribed a PIM before and after a dementia annual review or medication 
review. Reviews and each PIM were analysed separately.  
a = prescription before and after ie. No change; b = PIM Stopped; c = PIM Started; d = No PIM 
The McNemar test compares the proportion of patients who stopped PIM (b) to the proportion of patients who started PIM (c) after a review in the previous time period. For the purpose of the analyses, a lead variable and a lagged 
variable were used to compare PIM prescription in the time period before and after the time period when there was a review
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For the analysis of each PIM class, McNemar tests were used to test the hypothesis of no overall 
change in binary outcomes of PIM prescription before and after the review. The McNemar test 
compares the proportion of patients with dementia who have started compared to stopped a 
PIM, after a review. McNemar uses 2x2 contingency tables to test the proportion of 
disconcordant pairs, an example 2x2 table is shown in Table 7 and example of the Stata output is 
provided in Figure 6. The null hypothesis is H0 : pb = pc  where the probability of starting a PIM 
prescription is equal to the probability of stopping a PIM after a review i.e. a person with 
dementia is as likely to start a antipsychotic medication as they are to stop, after a review.   
To identify the presence of a PIM in 1) the next two month time period and 2) the previous two 
month time period, a lead variable and a lagged variable were generated using Stata’s Time Series 
operators. These variables were used to compare the PIM prescription before and after a record 
of a medication review or dementia annual review. Medication review and dementia annual 
review were analysed separately.   
A paired t-test was used to estimate the change in the average number of concurrently prescribed 
medications after a dementia annual review or medication review. The change in the mean 
number of prescribed medications in the time period after the first record of a review was 
compared to the mean number of medications in the time period before the review. A second t-
test was used for patients who did not have a review, to compare change in medication use 
regardless of a review.  
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Table 7 Example of McNemar 2x2 contingency table to explain the McNemar analysis used to estimate change in the 
probability of being prescribed a PIM after a review.  
 Proportion of patients with PIM after review 
Proportion of patients with PIM before 
review  
PIM = 1 PIM = 0 Row Total 
PIM = 1 a b a + b 
PIM = 0 c d c + d 
Column total a + c b + d n 
Explanation  
a = prescription before and after (no change) 
b = PIM Stopped   
c = PIM Started 
d = No PIM (no change) 
b & c = discordant pairs = outcome is different  
a & d = concordant = outcome is the same  
The McNemar test compares the proportion of patients who stopped PIM (b) to the proportion 
of patients who started PIM (c) after a review in the previous time period.  
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Figure 7 Example of the Stata output of the McNemar analysis in CPRD cohort study. Starting and stopping antipsychotic medications after the first record of a medication review.  
McNemar test in Stata is run using the mcc command. This McNemar test compares the number of patients starting an anticholinergic to the number of patients who stopped an 
anticholinergic at the point of the first record of a medication review. In the table, controls refers to antipsychotic prescription (exposed) or no antipsychotic prescription (unexposed) 
before the review. Cases refers to antipsychotic prescription (exposed) or no antipsychotic prescription (unexposed) after the first review.  
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(f) Estimating the predictors of stopping and starting each PIM  
The objective 2b of this thesis was to estimate the patient and practice level factors associated 
with stopping or starting each class of PIM and associated with a change in the number of 
concurrent prescribed medications. Two potential analysis approaches arose; a multistate model 
and a multilevel regression model. The multistate model approach provided a useful means for 
understanding the processes involved in prescribing, however limitations of this approach 
deemed it inappropriate for the needs of this analysis. A multilevel regression model was 
subsequently applied and accounted for these limitations outlined. 
 
(i) Multistate model for PIM use  
A multistate model was used for initial conceptual understanding of the process of prescribing 
and deprescribing in primary care, in order to inform the development of the multilevel 
regression models used in subsequent analyses.  
A multistate model can be used to describe the process of an individual moving through a series 
of states in continuous time. A multistate model describes a stochastic process, where at any time 
an individual can occupy one state, of a specified number of discrete states. The structure of the 
model specifies the states that are possible and the transitions from state to state which are also 
possible. A traditional Markov model assumes independence from previous transitions, meaning 
that only the current state is relevant and previous states or history are not accounted for [264].    
In this study the multistate model is understood in terms of two possible ‘states’ and four 
‘transitions’ that were used to develop the multilevel regression models for estimating the factors 
associated with PIMs and prescribing.  There were two possible states that each patient could 
occupy in terms of the prescription of each PIM. Each patient with dementia was either taking a 
PIM or not taking a PIM (Figure 8).
  
 
100 
 
 
 
 
 
 
 
 
 
 
Figure 8 the two possible states of the multistate model for conceptualising the analysis of the CPRD cohort study and the four possible transitions between the two states. 
 1) Patients can transition from no PIM use to PIM use (the patient starts a PIM prescription), 2) Patients can transition from PIM use to no PIM use (the patient stops a PIM prescription), 
3) Patients can ‘transition’ and remain in a state of no PIM use, 4) Patients can ‘transition’ and remain in a state of PIM use.  
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After a review, for example, at a basic level a GP would have, four options for prescribing; starting 
a medication, stopping a medication (if it is also assumed that the process of stopping included 
careful deprescribing processes such as dose reduction before cessation), continuing to prescribe 
a medication and continuing to not prescribe a medication.  
Therefore, there were four possible transitions between the two states.  
1. Starting PIM  
2. Stopping PIM 
3. Continued no PIM use  
4. Continued PIM use  
The transitions between the two states is illustrated in Figure 8. Within each two month time 
period all patients are within one of two possible states. Across two month time periods there are 
four possible transitions. 
1. Patients can transition from no PIM use to PIM use (the patient starts a PIM prescription) 
2. Patients can transition from PIM use to no PIM use (the patient stops a PIM prescription) 
3. Patients can ‘transition’ and remain in a state of no PIM use 
4. Patients can ‘transition’ and remain in a state of PIM use.   
Regression models were developed to reflect these two possible states and four transitions and 
therefore the process of both stopping PIM and starting PIM. Mixed effects regression equations 
were used to model the transitions. First, the odds of starting a PIM were compared to the odds 
of continuing not to take a PIM (among those starting in state 1). Second, the odds of stopping a 
PIM were compared to the odds of continuing to take a PIM (for those starting in state 2). This 
was the case until either the end of the study period or until the patient left the study e.g. having 
died or on leaving the GP practice. Two elements make this analysis different to a typical 
multistate model. First, the random effects of patient and practice are included in the regression 
equations. Second, the process is not assumed to be memoryless, by the inclusion of a variable 
accounting for the previous use of medicines, which would likely predict future use. 
 
(ii) Estimating transition probabilities using multilevel regression  
A multilevel model (also known as a hierarchal model) was used to model the relationship 
between an outcome variable and explanatory variables, which in this study included two 
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exposure variables and a set of confounding variables. Multilevel models are often used to model 
longitudinal data, with multiple data points on individuals over a specified time period. 
Distinct from a simple regression analysis, a multilevel model also accounts for clustering between 
observations. In this study, the relationship with the outcome of PIM prescription was modelled 
accounting for individual patient factors (level one) and factors associated with the GP practice 
where that patient was registered (level two). A multilevel model follows a hierarchal structure, 
with patients nested within practices, for example (see Figure 9) [265–267]. Including practice 
random effects and nesting patients within practices as random effects allows for the between 
practice variation in prescribing practices to be accounted for. Including practice associated 
effects was important because patients who are registered at the same GP practice are expected 
to be more similar to each other than patients registered with another practice. This may be due 
to the patients’ health being influenced by the area they live in and related to the prescribing 
behaviours of individual GPs or within individual practices.   
A multilevel regression model is characterised by the inclusion of variables accounting for the 
random effect of level one and level two factors. The patient random effects (level one) go some 
way to accounting for individual variation across the study period that is unmeasured by the 
confounding variables. The nesting of patients within each practice and the subsequent inclusion 
of practice random effects enabled some accountability for within and between practice 
variations. An example of the structure of the multilevel regression model is provided in Figure 9.  
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Figure 9 a visual example of the multilevel model used to estimate the factors associated with PIM and total medication use in people with dementia in primary care in England.  
The model includes two random effects terms, the first is a random intercept (constant only) at the practice level u"# and the second is the random intercept at the 
patient level	u%#	. Patients are nested within practices with estimated starting or stopping PIM at each two month time period (from 1st January 2015 until April 30th 
2017). Estimates are adjusted for a range of time varying covariates	X'#, time-constant covariates X#. modelled for patient i at time j. . u  is randomly distributed 
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(iii) Multilevel logistic regression model  
Multilevel logistic regression models were used to estimate patient and practice level factors 
associated with stopping and starting each PIM (antipsychotic, tricyclic antidepressants, definite 
anticholinergics and proton pump inhibitors) across the study period (1st January 2015 until 30th 
April 2017).  
The models included fixed effects of age, sex, comorbidities, area-level deprivation, dementia 
annual review in the previous period and medication review in the previous period, care home 
residence and polypharmacy and random effects of GP practice and within-patient variation. 
Conditional on these covariates the observations are assumed to follow a binomial distribution. 
All analyses were stratified by care home residence.  
The mathematical model for this multilevel logistic regression is provided below and explained in 
terms of the variables included in the model.  
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1) Mathematical model for multilevel logistic regression model 
 
!"# = %&		 + %)*"# 	+ %+*# 	+	%,	*"# + %-	*"# + %.	*# + %/	*# + %0	*"# + 1)# + 1+#	 
 
where, in the multilevel logistic regression model !	 is the log-odds of stopping or starting a PIM 
and in the linear mixed effects regression ! is the estimated change in total medication use.  
 
%)*"# 	+ %+*# 	+	%,	*"# + %-	*"# + %.	*# + %/	*# + %0	*"#  
represents the predictors at each time period, with time varying covariates	*"#, time-constant 
covariates *#   
 
1)# + 1+#	 
1)#  and  1+#		are randomly distributed practice and patient random effect variance components.  
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2) Example statistical model for stopping antipsychotic medication  
 
Log-Odds stopping antipsychotic medication = %&		 + %)	234 +	%+546274			 + %,894:";<=	94:"4>	 +	%-??@=A;94		 + %.	@BC			 + 	%/	A294	D;64	94="E4FA4		 + 	%0	8;7G8D2962AG		 + 	1)# + 1+#	 
!"#  = estimated log odds of starting or odds of stopping PIM for patient j at time i 
%& = constant  
%)	234 = age in years, estimates are centred on the sample mean of 82 years  
%+546274			= participant gender 1 = female, 0 = male  
%,894:";<=	94:"4>	= record of a medication review or dementia annual review in the previous two 
month time period 1= record of review, 0 = no record of a review  
%-??@=A;94		= patient total Charlson Comorbid Index score.  
%.	@BC()I.)			= relative deprivation quintiles, ranging from 1 to 5, where 1 indicated practices 
within the most deprived areas and 5 as practices in the least deprived areas. As a categorical 
variable, there were five associated %.	@BC			 included in the model.  
	%/	A294	D;64	94="E4FA4		= residential status, 1 = resident in a care home and 0 = community-based 
residence.  
%0	8;7G8D2962AG		= total mediation use, excluding PIMs in each time period. 0 = 0-4, 1 = 5-9, 2 = 
10+ prescribed medications  
1)#= randomly distributed practice level random effect variance component  
1+#= randomly distributed patient level random effect variance components, with patients nested 
within practices  
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(iv) Multilevel linear regression model  
As above, multilevel linear regression models were used to estimate patient and practice level 
factors associated with a change in total medication use across the study period. The models 
included fixed effects of age, sex, comorbidities, area-level deprivation, dementia annual review 
in the previous period and medication review in the previous period, care home residence and 
random effects of GP practice and within-patient variation. Analyses were stratified by care home 
residence.  
The multilevel linear model applied the same hierarchal structure described in Figure 9. The 
mathematical model is outlined below.  
 
1) Mathematical model for linear model  
!"# = %&		 + %)*"# 	+ %+*# 	+		%,	*"# + %-	*"# + %.	*# + %/	*# + 1)# + 1+#	 +	K"#  
where, in the linear regression ! is the estimated change in total medication use.  
%)*"# 	+ %+*# 	+		%,	*"# + %-	*"# + %.	*# + %/	*#  
represents the predictors at each time period, with time varying covariates	*"#  and time-constant 
covariates *#   
1)# + 1+#	 + K"#  
practice and patient random effect variance components plus the error termK"#  
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2) Example statistical linear mixed effects model  
Estimated change in total medication use = %&		 + %)	234 +	%+546274			 + %,894:";<=	94:"4>	 +	%-??@=A;94		 + %.	@BC			 + 	%/	A294	D;64	94="E4FA4		 + 	1)# + 1+#	 +	K"#  
 
!"#  = estimated change in total number of prescribed medications from time t-2 to time t.  
%& = constant , %)	234 = age (years),  	%+546274			= binary variable for participant gender 1 = female, 
0 = male  
%,894:";<=	94:"4>	= record of a medication review or dementia annual review in the previous two 
month time period 1= record of review, 0 = no record of a review  
%-??@=A;94		= Charlson Comorbid Index score.  
%.	@BC			= relative deprivation quintiles. As a categorical variable, there were five associated %.	@BC			 included in the model.  
	%/	A294	D;64	94="E4FA4		= residential status, 1 = resident in a care home and 0 = community-based 
residence.  
	1)#= practice level random effect estimated variance components  
1+#= patient level random effect estimated variance components, with patients nested within 
practices  
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(v) Example Stata model for mixed effects logistic regression  
All analyses were completed in Stata 14. An example of the Stata commands used for the 
multilevel logistic regression model is described below (Figure 10), followed by an explanation of 
the Stata output (Figure 11).  
The Stata model included a multilevel regression command, followed by the outcome (starting 
PIM, stopping PIM, total medication use), predictors (age, gender, previous review, Charlson 
Comorbidity Score, Indices of Multiple Deprivation Quintile, care home residence, previous total 
medication, and practice and patient random effect.  
 
 
 
Figure 10 Stata command example for multilevel logistic regression estimated in CPRD cohort study 
The model includes fixed and random effects equations, separated by | | the first is a random 
intercept (constant only) at the practice level, and the second is the random intercept at the 
patient level. The order is important as the command (melogit) assumes that patients are nested 
within practices. The order of nesting goes from right to left, from the biggest group, the patients 
at level one, to the smallest group, the practices at level two.  
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(vi) Example Stata output  
 
 
 
Figure 11 Example of Stata output for multilevel logistic regression model for the CPRD cohort study.  
The model includes two random effects equations, the first is a random intercept (constant only) 
at the practice level, and the second is the random intercept at the patient level. The model 
includes patients nested within practices. The output shows the estimated variance components 
for the random effects equations.  
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(g) Sample size considerations   
There were an estimated 33,000 patients with dementia based in English CPRD GOLD registered 
practices at the start of the study period (01/01/2015) (sample size estimated from October 
2016 version of CPRD GOLD). There were around 14000 patients with a dementia annual review 
and 16000 with a medication review Read code (CPRD GOLD 2015).  
 
The primary objective of this study was to estimate the effect of dementia annual review or 
medication review on changing prescription of PIM classes. Using data from a RCT of medication 
reviews in the general older population [268], I estimated the number of participants needed to 
demonstrate a change in potentially inappropriate medication (PIM) prevalence, considering a 
relatively rare PIM. This provided an illustrative example of the expected change in prescribing. 
The paired changes in PIM prescriptions before and after exposure (a medication review) are 
provided (Table 8).   
 
For a relatively PIM, where baseline prevalence was around 5%, with a 2% reduction in PIM and 
1% starting a PIM, to detect a difference following a exposure with 90% power (at significance 
level of p =<0.05) this would require a sample of 2600 patients (for rare PIM, such as tricyclic 
antidepressant medications). To reflect the multiple testing correction with a significance level 
of p=<0.05 at 90% power, this would require 4400 patients. More common PIM would require 
fewer participants, and this was comfortably within the 14000 patients with a dementia annual 
review code available in CPRD in the sample size considerations conducted prior to study 
initiation.  
 
Table 8 Proportion of rare PIM prescriptions, such as tricyclic antidepressants post-medication review, based upon Milos 
et al. (2013) 
  Post-review Total  
  PIM No PIM   
Pre-review 
PIM 0.03 0.02 0.05  
No PIM 0.01 0.94 0.95  
 Total 0.04 0.96 1  
n.b. Odds Ratio = 2, Proportion of discordant pairs = 0.03  
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4.09 Model checking  
To check the model assumptions and fit, Pearson residuals were plotted against the predicted 
probabilities, any outliers were investigated and the model was run without outliers and 
compared using likelihood ratio test. As accuracy is increased with the number of integration 
points, the model quadrature was tested by modelling with varied integration points and 
comparing the model fit. Increasing integration increases the number of computations, and 
therefore a balance between speed and accuracy was considered [267]. To assess correlation 
between the independent variables, collinearity was assessed using Variance Inflation Factor (VIF) 
estimates. Dependence among responses within practice and patient clusters (random effects) 
were assessed using Intraclass Correlation Coefficients (ICC).  
 
4.10 Summary  
Primary care electronic health records are a rich and valuable source of existing data on large 
cohorts of people with dementia, including medical records and primary care practices, and 
including the implementation of pay-for-performance incentivising schemes. This chapter has 
presented the approach used to estimate the prevalence of and factors associated with 
potentially inappropriate prescribing in people with dementia. The following chapter presents the 
findings addressing Aim 1 and Aim 2 of this research.   
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V. Chapter 5: CPRD cohort study results   
5.01 Introduction 
A sample of over 22,000 people with dementia in primary care in England were included in this 
study, using electronic health records sampled from CPRD. This chapter reports the results of 
analyses using this cohort of people with dementia. First the prevalence of medication use and 
PIMs in people with dementia is reported. Second, the change in total number of prescribed 
medications and individual PIMs associated with a review is presented. Third, patient and practice 
factors associated with the potentially inappropriate prescribing in people with dementia is 
presented.  
 
5.02 Description of the sample  
There were 22,448 patients with dementia included at any point during the study period.  Table 9 
is an overview of patients who entered and left the study within each two-month time period. At 
the start of the study (1st January 2015 – 28th February 2017) there were 16,061 patients with 
dementia who met the inclusion criteria while 6,024 patients remained at the end of the study 
period (1st March 2017 - 30th April 2017).  Across the study period, there were 10,911 incident 
cases of patients with a dementia diagnosis who were included in the study.  
Around 50% of the sample were included in the study for less than one year and there were a 
number of possible reasons for leaving the study, as described in Table 9. There were 3,732 
patients with dementia who died and 5,039 who left their GP practice. Reasons for leaving GP 
practice may include moving residence, transitioning into residential care and subsequently 
changing the GP practice they are registered with. There were 6,445 patients with dementia who 
left the study because the GP practice that they were registered with was no longer contributing 
data to CPRD after many practices changed the electronic health record system they used. 
Practices leaving CPRD are likely to be the major cause of the decrease in sample size over the 
course of the study as the study is designed so that the sample is representative of people with 
dementia at all of the time points.
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Table 9 Description of the sample entering and leaving the study across the study period (1st January 2015 – 30th April 2018) and within each two-month time period in CPRD   (n=22,448), including factors 
associated with the patient and factors associated with the GP practice.  
 Entering study  Reasons for leaving the study (n)  
  Patient factors  Practice factors  
Time Period  Sample size (n)1 Incident 
dementia cases6 
(n)  
Deaths  Cumulative 
Death2  
Not included in the 
QOF data recording4  
Patient leaves 
the practice  
Cumulative n 
patient leaves 
practice3  
Last CPRD data 
collection5 
Cumulative Last CPRD 
data collection  
2015           
1st Jan  – 28th Feb   16,061 - - - - - - - - 
1st March  – 30th April   15,519 606 469 469 103 614 614 529 529 
1st May  – 30th June   14,750 827  385 854 27 500 1,114 608 1,137 
1st July  – 31st Aug  13,128 1,115 374 1,228 31 466 1,580 1,161 2,298 
1st Sept – 31st Oct   12,085 1,451  343 1,571  36 489 2,069  750 3,048 
1st Nov  – 31st Dec  10,869 1,280  303 1,874 58 386 2,455 706 3,754 
2016          
1st Jan – 28th Feb   10,402 1,005  291 2,165 91 360 2,815  177 3,931 
1st March  – 30th April  9,882 452  338 2,503  95 463 3,278  165 4,096  
1st May  – 30th June  8,780 832  235 2,738  18 325 3,603  656 4,752 
1st July – 31st Aug  7,876 1,059 185 2,923 25 284 3,887 532 5,284 
1st Sept  – 31st Oct  7,247 694 183 3,106  17 278 4,165 486 5,770 
1st Nov  – 31st Dec   6,754 731 226 3,332  32 322 4,487  176 5,946  
2017          
1st Jan  – 28th Feb  6,204 417 236 3,568 80 306 4,793 290 6,236  
1st March – 30th April  6,024 442 164 3,732  51 246 5,039  119 6,445  
n = individual patients at any point in each period,  
1 total sample n = 22,448, n eligible for analysis (last collection date of CPRD data from practice after period end, registered with the practice before period start, CPRD research quality data, patient leaves practice after the end of the 
time period and died after time period and not excluded from Dementia Annual Review), including incident inclusion into the study based on index date of dementia diagnosis (the point at which patients become eligible for the study) 
2died after the end of the time period  
3 CPRD recorded ‘transfer out’, there is no longer a record of the patient at the practice due to the patient transferring out of the CPRD records before the end of time period. Transfers could occur due to the patient moving into a care 
home, for example, and the patient will be registered with a new practice and there will be no subsequent record in the CPRD.   
4 A practice can identify patients with dementia as exceptions to the Quality and Outcomes Framework indicators, meaning they are on the disease (dementia) register but are not included in the indicator denominator because they 
meet an exception criteria.  
5The last point at which the practice uploaded data to CPRD, therefore after point the practice is no longer contributing data to CPRD and therefore will not be included in the subsequent analyses after this point.  
6Incident cases of dementia. Also including patients with dementia joining a new practice.  
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5.03 Representativeness of CPRD of the population  
(a) Age and sex  
The age of the sample at the start of the study period was normally distributed for both men and 
women with dementia (see Figure 12). This is comparable to the population estimates of the age 
distribution of men and women living with dementia in the UK [1, 28] (see Figure 13 as example 
to compare the distributions).  
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Figure 12 the distribution of patients with dementia across each age category, stratified by gender at the start of the 
study period (January 2015) n=16,061 in the CPRD. 
.  
 
Figure 13 Frequency of people living with dementia in UK.  
Source: https://www.dementiastatistics.org/statistics/prevalence-by-age-in-the-uk/ 
 Prince et al.,(2014) Dementia UK: Update Second Edition report produced by King’s College London and the London 
School of Economics for the Alzheimer’s Society – Data from Expert Delphi Consensus of UK population-based studies of 
dementia prevalence, including CFAS estimates (Matthews et al., 2013)  
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(b) Deprivation  
The area-level deprivation at practice level was broadly representative of the country as a whole 
(see Figure 14). The percentage of practices within each decile of IMD ranged from 8.0% to 11.7%. 
There were 8.0% of practices that were in the most deprived decile and 9.8% in the least deprived 
decile. Although the two most deprived deciles were under-represented there was no obvious 
trend that indicated bias.  
 
Figure 14 percentage of the GP practices (n=282) within each decile of IMD at the start of the study period (January 
2015). 
Data is grouped into deciles at the 2015 National English level and are ranked from 1 to 10. 1 indicates that 
the GP practice falls within the most deprived area and 10 indicates that the GP practice is within the least 
deprived 10% of areas. 
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5.04 Sample characteristics  
There were a total of 22,448 patients with dementia included in the study (1st January 2015 – 30th 
April 2017), who were registered with 282 primary care practices (see Table 10).  
At the start of the study period, 65.8% of the sample were female and the mean age was 82.9 
years (SD 7.8). The mean CCI score was 2.8 (SD 1.8) and scores ranged from 1 to 15, with higher 
scores indicating worse comorbidity. There were 29.0% of patients with dementia who were living 
in a care home. People who were living in a care home were older (mean age 85.4 years SD 7.6) 
and there were more females living in a care home (75.8%) than in their own home (61.7%).  
The mean age of the sample was similar at the end of the study period (April 2017) (82.2 years SD 
7.7). There were less people with dementia from this sample living in a care home at the end of 
the study period (22.6%), likely because there were fewer people with dementia included in the 
study over time.   
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Table 10 characteristics of the CPRD cohort of patients with dementia in primary care in England from 1st January 2015 
until 30th April 2017, stratified by residential status.  
 Living situation  
Variable  Total sample  Care home Own home   
n 22,448 5,507 16,941 
Practice n 282    
% Female  65.81 75.84 61.71 
Average age (mean, 
sd) (years)  
82.93 (7.77) 85.42 (7.59) 81.91 (7.61) 
Comorbidity     
Mean CCI (SD)  2.76 (1.81) 2.74 (1.81) 2.77 (1.82) 
CCI Range  1-15  1-12 1-15 
IMD (%)    
Most deprived (1) 17.18 15.82 17.74 
2 20.60 21.01 20.44 
3 22.81 22.77 22.82 
4 19.79 21.46 19.11 
Least deprived (5) 19.61 18.95 19.88 
Care Home (%)  29.01   
n = total number of individual patients / practices  
Characteristics at the start of the study period, January 2015  
CCI: Charlson Comorbidity Index Score: higher scores = worse comorbidity  
IMD: Indices of Multiple Deprivation. Practice area-level deprivation quintiles.  
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(a) Comorbidity  
All patients included in the study had a minimum Charlson Comorbidity Index score of one, due to 
the presence of a dementia diagnosis and one third of the sample had the minimum comorbidity 
score of one (32.7%) (See Figure 15). As expected, an increase in comorbidity score was also 
associated with an increase in total number of prescribed medications. Patients with a CCI score 
of one were prescribed a mean of 6.2 (SD 3.7) medications and patients with a CCI score of six 
were prescribed a mean 10.0 (SD 4.4) medications.  
 
Figure 15 bar chart of the percentage of the Charlson Comorbidity Index (CCI) score across the sample of patients with 
dementia in January 2015 in primary care in England, greater scores indicate worse comorbidity.  
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5.05 Descriptive statistics: total medication use and PIMs  
(a) Total medication use of patients with dementia in primary care  
The median number of medications prescribed was 7 (IQR 5-10) across the study period. The 
mean number of medications prescribed to a patient with dementia in England was 7.7 (SD 4.2) at 
the start of the study period (1st January 2015) and was 7.6 (SD 4.3) at the end of the study (30th 
April 2017). On average, patients with dementia who were living in a care home were taking more 
medications (mean=8.5 SD 4.3) than patients with dementia who were living in their own home 
(mean=7.3 SD 4.1). The total number of prescriptions was remarkably stable over the study 
period.    
 
(b) Prevalence of potentially inappropriate medication use  
PIM were prevalent in this sample. At the start of the study 31.0% (95% CI 30.2-31.7) were 
prescribed long-term PPIs, 17.1% (95% CI 16.5-17.7) prescribed anticholinergics, 8.1% (95% CI 7.6-
8.5), 9.4% (95% CI 9.0-9.9) prescribed antipsychotics. Across the duration of the study period, 32% 
were ever prescribed PPIs for more than 8 weeks (31.5% 95% CI 31.2-31.7), 17% were prescribed 
anticholinergic medications (16.7% 95% CI 16.5-16.9), 8% were prescribed antipsychotics (8.5% 
95% CI 8.4-8.7) and 7% were prescribed tricyclic antidepressant medications (7.5% 95% CI 7.4-7.6) 
at any time during the study period. The prevalence of PIM use among patients with dementia 
remained stable across the study period. The biggest change was in antipsychotics that fell from 
9.4% (95% CI 9.0-9.9) at the start of the study (January 2015), to 8.0% (95% CI 7.3-8.7) at the end 
of the study period (April 2018) (see Figure 16).   
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Figure 16 prevalence and 95% CI of PIM prescription among patients with dementia in England from 1st January 2015 - 
30th April 2017, split across two-month time periods (n=22,448) 
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(c) Use of potentially inappropriate medication use according to living situation  
Overall, prevalence of PIM prescriptions was greater among patients with dementia who were 
living in a care home, compared to those living in their own home (see Figure 17), although there 
were some similarities. As in the whole sample of patients, the prescription of long-term PPIs was 
most prevalent. Long-term PPI average period prevalence from 1st May 2015- 30th June 2015 was 
slightly greater for prescribing long-term PPIs in care homes (34.5% 95% CI 33.1-35.9) compared 
to patients living in their own home (30.0% 95% CI 29-30.4). At the start of the study period (1st 
January 2015- 28th February 2015), 19% (95% CI 18.0-20.3) of people with dementia in care homes 
were prescribed anticholinergics. Compared to 16.3% (95% CI 18.0-20.3) of patients living in their 
own home. Twice as many patients were prescribed antipsychotics who lived in a care home. In 
care homes, 15.0% (95% CI 14.0-16.0) of people with dementia were prescribed antipsychotics. 
Compared to 7.2% (95% CI 6.7-7.7) of people with dementia living in their own home. And finally, 
10.1% (95% CI 9.3-11.0) of patients in a care home were prescribed tricyclic antidepressants, 
compared to 7% (95% CI 6.7-7.7) of patients in their own home. The average period prevalence 
estimates in each two month time period remained relatively stable over the study duration. In 
care homes, there was a small decrease in the prescription of tricyclic antidepressants from 10.1% 
to 8.7% (95% CI 7.4-10.4) in the last two month time period (March 1st 2017 - April 30th 2017).  
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Figure 17 Prevalence of PIM prescriptions among patients with dementia in England, stratified by living situation.  
 
Care home n= 5,507 and living in their own home n= 16,941. Average period prevalence estimates 1st May 2015 – 30th 
June 2015. Estimate from May time period due to long-term PPI prescriptions defined by prescription for more than 8 
weeks and therefore no data is available before this point.   
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5.06 Dementia annual review and medication review  
 
Less than half of all patients (40.9%) had a record of a dementia annual review. Within the first six 
months of entering the study, 40% of patients had had a medication review and 25% had had a 
dementia annual review (see Figure 18). Patient characteristics were similar across patients who 
did and did not have a record of a medication review. Patients were prescribed similar number of 
medications but only 57% had at least one medication review recorded across the study period 
(see Table 11 ). Patients who had a medication review were taking an average of 8 medications 
(SD 4.4), compared with an average of 7 medications (SD 7.6) among patients who did not have a 
review and there was relatively little difference in prevalence of PIM prescription.   
 
 126 
 
Table 11 characteristics of patients with dementia in primary care in England, stratified by review. 
 Medication review1  Dementia annual review1  
Variable  Total 
sample  
No review  1 or more   No review  1 or more  
n 22,448 9,649  
(42.98%)  
12,799 
(57.02%) 
13,260 
(59.07%) 
9,188 
(40.93%)  
% Female  64.65 64.64  64.94 64.63 64.95 
Age at baseline (mean, sd) 82.9 
(7.8) 
82.93  
(7.80) 
82.87 
(7.73) 
82.93 
(7.80)  
82.94 
(7.67)  
Median CCI (IQR)   2 (1-4) 2 (1-4) 3 (1-4)  2 (1-4) 2 (1-4)  
IMD (%)      
Most deprived  16.84 16.92 15.99 16.70 18.93 
Least deprived  21.41 21.25 23.00 21.57 18.98 
Care Home (%)  27.12 27.03 28.03 27.02 28.62 
PIM (% prescribed)2      
Anticholinergics 16.72 16.59 18.06 16.68 17.26 
Antipsychotics 8.51 8.43 9.36 8.46 9.28 
Tricyclics  7.49 7.45 7.94 7.48 7.69 
Long-term PPI  31.47 31.41 32.24 31.50 30.63 
Mean number of 
medications (sd) 
7.42 
(4.11) 
7.58 (4.18) 8.20 (4.36)  7.62 (4.20) 7.89 (4.27)  
1Estimates are at any point across the study period but relate to the first record of a dementia 
annual review and medication review.  
CCI: Charlson Comorbidity Index Score: higher scores = worse comorbidity  
IMD: Indices of Multiple Deprivation. Practice area-level deprivation quintiles.  
Total medications excludes topical, devices, dental, ocular and nasal products.  
2PIM prescription ever across the study period 
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Figure 18 Kaplan-Meier survival curve of time until the first record of a review from point of entrance into the study 
among patients with dementia in primary care in England.  
Analyses do not reflect whether patients have had a dementia review or medication review prior to entering the study. 
All patients were included from the point at which they entered the study, with the point of censoring identified as the 
first record of a review. Kaplan-Meier survival curves were estimated using Stata st commands.  
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(a) Estimating the change in total medication use after a review  
A review was associated with a small but statistically significant increase in the number of 
medications prescribed in the paired t-test comparing mean number of medications before and 
after a review (see Table 12). The first record of a dementia review was associated with a 0.17 
(95% CI 0.10-0.24) increase from a mean 7.37 (SD 4.05) medications to 7.53 (SD 4.03) mean 
medications. The first record of a medication review was also associated with a significant 
increase of 0.12 (95% CI 0.07-0.18) mean prescribed medications. Average number of medications 
increased from 7.54 (SD 4.04) to 7.67 (SD 4.10) after the first medication review. In comparison to 
patients with dementia who did not have a review, average number of medications also increased 
over the same time period. However, the average increase was around twice as high when there 
was a dementia review (0.17 95% CI 0.10-0.24) compared to no review (0.08 95% CI 0.07-0.09). 
Taken together, this suggests that people with dementia receive more medications over time.  
When the effect of review is estimated using a linear mixed model (Chapter 4 Section 4.08), 
dementia annual review remained associated with a small but significant increase in average 
number of prescribed medications (Table 13). The unadjusted linear regression model suggested 
that a dementia review, across the study period, was associated with a significant increase in the 
mean number of prescribed medications (0.10 95% CI 0.04-0.16). This effect remained after 
adjusting for covariates and patient and practice effects (0.10 95% CI 0.04-0.16). In the adjusted 
linear model, medication review across the study period, was associated with a small decrease in 
the average number of prescribed medications (-0.04 95% CI -0.07-0.01).  When analyses were 
stratified by residential status, medication review was associated with a small and significant 
decrease (-0.08 95% CI -0.16, -0.01) in average medication use in patients with dementia who 
were living in a care home.  
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Table 12 Paired t-test results of the difference in mean number of medications prescribed before and after the first 
record of a review. Comparison also provided for no record of a review in patients with dementia in comparative time 
periods.  
Total 
Medications1  
Before review  
(mean, SD) 
After review 
(mean, SD)  
Difference  95% CI  
Dementia annual 
review 
(n=4,354) 
7.37 (4.05) 7.54 (4.03) +0.17 (0.10-0.24) 
Medication 
review 
(n=7,474) 
7.54 (4.04) 7.67 (4.10) +0.12 (0.07-0.18) 
     
No dementia 
annual review 
7.44 (4.03) 7.52 (4.07) +0.08 (0.07-0.09) 
No medication 
review 
7.45 (4.03) 7.53 (4.07) +0.08 (0.06-0.09) 
*p=<0.05 CI = confidence interval  
1 paired t-test estimating the change in mean number of total medications from the two month 
time period before the review, compared to the time period after the review.  
 
Review is at the first record of a medication review or dementia annual review during the study 
period. Previous estimates of average number of prescribed medications vary as they are 
estimating in different time periods, here comparing the average prescriptions in the two 
month time period before the review to the prescribed medications in the two month time 
period after the review.  
Comparative estimates compare total number of medications before (t-2) and after (t) the 
study time periods when there is not a record of a review (t-1).  
 
Mean difference in total medications after any medication review, mean =0.09 (SD 2.25), 
difference without a medication review mean =0.06 (SD 2.45) 
Mean difference in total medications after dementia review mean = 0.17 (SD 2.35), difference 
without a review, mean = 0.08 (SD 2.28) 
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Table 13 Mixed effects linear regression model estimating the relationship between reviews and change in total number 
of prescribed medications in people with a dementia diagnosis in England. Clinical Practice Research Datalink (n=17,437) 
 Unadjusted model  Adjusted mixed 
effects model  
Home Residence stratification  
 
VARIABLES Change in mean 
number 
prescriptions  
Change in mean 
number prescriptions  
(n=17,437) 
Care Home  
(n=5,241) 
Not in Care Home  
(n=12,849)  
     
Age  -0.002 -0.002 -0.001 
  (-0.004 - 0.000) (-0.006 - 0.001) (-0.003 - 0.001) 
Female  -0.032* -0.095* -0.012 
  (-0.062 - -0.001) (-0.162 - -0.027) (-0.046 - 0.022) 
Previous Review      
     
Medication review  -0.038 -0.038 -0.081* -0.018 
 (-0.077 - 0.001) (-0.077 - 0.002) (-0.155 - -0.007) (-0.065 - 0.028) 
Dementia annual review  0.102* 0.103* 0.121* 0.094* 
 (0.043 - 0.162) (0.044 - 0.162) (0.007 - 0.235) (0.025 - 0.164) 
CCI  -0.004 -0.008 -0.003 
  (-0.012 - 0.004) (-0.024 - 0.008) (-0.012 - 0.006) 
IMD      
3-4  -0.013 -0.047 0.002 
  (-0.066 - 0.040) (-0.158 - 0.064) (-0.052 - 0.055) 
5-6  -0.016 -0.069 0.009 
  (-0.068 - 0.037) (-0.178 - 0.040) (-0.044 - 0.061) 
7-8  -0.007 -0.039 0.007 
  (-0.061 - 0.047) (-0.152 - 0.075) (-0.048 - 0.061) 
9-10, least deprived  0.002 -0.048 0.025 
  (-0.050 - 0.055) (-0.156 - 0.061) (-0.028 - 0.078) 
Care Home   -0.003   
  (-0.036 - 0.029)   
     
Constant coefficient  0.083* 0.121* 0.225* 0.089* 
 (0.067 - 0.098) (0.071 - 0.171) (0.118 - 0.332) (0.037 - 0.142) 
Random Effects1     
Practice  0.003 0.011 - 
  (0.001-0.006) (0.004-0.025) - 
Patients nested within 
practice2 
 - - - 
  - - - 
Residual variance  5.202 5.199 5.813 4.954 
 (5.156-5.248) (5.153-5.244) (5.718-5.901) (4.903-5.00^) 
Estimated coefficients *p<0.05  
CCI: Charlson Comorbidity Index Score: higher scores = worse comorbidity  
IMD: Indices of Multiple Deprivation   
1estimated variance components of the random effects equations. Variance components are estimates of the amount of variance in 
the dependant variable that is attributable to the random effects. There are two random effects equations, the first is a random 
intercept (constant only) at the practice level and the second is the random intercept at the patient level, with patients nested 
within practices.  
 
n= total number of individual patients with dementia included in analyses, smaller n than total sample as there is no available data 
for previous review in the first two month time period when a participant enters the study and some participants are included for 
one 2 month time period and there is no available data on the change in their total medication use.  
Number of patients transition to care home n=653  
2 Within patient and within practice correlations were both less than 0.01. Likelihood ratio tests comparing the model without the 
random effect estimations did indicate a statistically significant difference between the models (X2=8.33, df(2) p=>0.05)   
Collinearity between variables mean VIF = 1.07 
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(b) Estimating the association of dementia annual review and medication review with 
PIMs  
A summary of the results from McNemar tests at the first record of a review and the association 
of a review with starting and stopping PIM is provided in Table 14. The tables of results from the 
models for each PIM and McNemar tables are in Appendix Section 10.07-10.09.  
 
(i) Anticholinergics  
More patients with dementia started anticholinergic medications after the first record of 
medication review (started n=195, stopped n=188) and first dementia review (started n=112, 
stopped n=106). However, neither of the differences at the first record of a review were 
statistically significant (Table 14).  
 
Across the study period, the rate of starting anticholinergics was slightly greater when patients 
had a medication review (n=433, 2.6%) compared to when there was no review (n=1,844, 2.1%) 
(Table 14). However, the rate of starting was greater without a dementia annual review (n=2,118, 
2.2%), compared to when there was a review (n=159, 1.8%). The adjusted multilevel logistic 
regression model estimated that a medication review was associated with an increase in the odds 
of starting anticholinergic medication (OR 1.20 95% CI 1.06-1.36). In addition, a dementia annual 
review was associated with significantly less starting of anticholinergic medications (OR 0.77 95% 
CI 0.64-0.92), compared to when there was no record of a review.  
 
More patients stopped anticholinergics after a medication review than a dementia annual review. 
The rate of stopping anticholinergics after a review across the study period was greater in patients 
with a medication review (n=473, 11.8%, compared to no review n=1,871 10.4%). Fewer patients 
stopped an anticholinergic after a dementia review (n=146 8.0%) compared to when there was no 
record of a review (n=2,198 10.9%). The multilevel logistic regression estimated that, in patients 
who were prescribed anticholinergic medications, a medication review was associated with 
stopping anticholinergic medications (OR 1.21 95% CI 1.06 - 1.38). A dementia annual review was 
associated with a significant decrease in the odds of stopping anticholinergic medication, 
compared to when there was no record of a review (OR 0.58 95% CI 0.48-0.71) (Table 14).   
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Table 14 Estimating the association of dementia annual review and medication review with PIMs results from McNemar test at the first record of a review and the adjusted mixed effects logistic regression 
models 
 McNemar test at first record of a review Starting   Stopping 
 Patients 
stopping 
PIM (n) 
 
Patients 
continuing 
PIM (n) 
Patients 
starting 
PIM (n) 
Patients 
not 
taking 
PIM (n) 
p-value After any 
review  
n (%) 
Unadjusted Model  Adjusted model After any 
review  
n (%) 
Unadjusted Model  
 
Adjusted Model  
 
Medication review        
Anticholinergics 188 1141 195 5959 0.759 433 (2.6) 1.27* (1.14 - 1.41) 1.20* (1.06 - 1.36) 473 (11.8) 1.19* (1.06 - 1.32) 1.21* (1.06 - 1.38) 
Antipsychotics 52 320 64 3927 >0.001* 285 (1.6) 1.27* (1.11 - 1.45) 1.19*  (1.03 - 1.39) 224 (10.8) 1.08 (0.93 - 1.27) 1.07 (0.89 - 1.29) 
Tricyclics  70 512 79 6822 0.471 173 (0.9) 1.39* (1.17 - 1.64) 1.36* (1.12 - 1.67) 185 (10.6) 1.20* (1.01 - 1.42) 1.25* (1.01 - 1.54) 
Long-term PPI  85 1324 104 2900 0.167 259 (1.8) 1.01 (0.89 - 1.16) 0.95 (0.81 - 1.11) 261 (2.6) 1.33* (1.16 - 1.53) 1.39* (1.18 - 1.65) 
            
Dementia annual review       
Anticholinergics  106 622 112 3523 0.685 159 (1.8) 0.82* (0.70 - 0.97) 0.77* (0.64 - 0.92) 146 (8.0) 0.69*(0.58 - 0.82) 0.58* (0.48 - 0.71) 
Antipsychotics 80 536 128 6739 0.265 98 (1.1) 0.77* (0.63 - 0.95) 0.68* (0.54 - 0.86) 73 (7.5) 0.67* (0.52 - 0.86) 0.55* (0.41 - 0.73) 
Tricyclics 44 292 53 3974 0.361 64 (0.7) 0.89 (0.69 - 1.16) 0.90 (0.67 - 1.21) 58 (7.2) 0.70* (0.53 - 0.93) 0.62* (0.45 - 0.86) 
Long-term PPI  38 662 62 1397 >0.05* 93 (1.3) 0.67* (0.54 - 0.83) 0.65* (0.51 - 0.83) 68 (1.0) 0.42* (0.33 - 0.54) 0.39* (0.30 - 0.52) 
*p=<0.05  (OR, 95% CI)  
n = number of individual patients at first record of a review 
Starting and stopping without a review  
Starting anticholinergics without medication review n=1,844 (2.1%), without dementia review n=2,118 (2.2%), stopping anticholinergics without medication review n=1,871 (10.4%), without dementia review n=2,198 (10.9%)  
Number of patients starting without medication review n=1,211 (1.26%), without dementia review n=1,398 (1.33%), stopping antipsychotics without medication review n=914 (10.3%), stopping without dementia review 1,065 (10.7%)  
Starting tricyclic without review n=664 (0.7%), starting without dementia review n=773 (0.7%), stopping without medication review n=740 (9.2%), without review n=867 (9.7%) 
Patients not prescribed PPI or prescribed for less than 8 weeks after a review n=1,403 (1.83%), n=1571 (1.87%) not prescribed PPI for more than 8 weeks. Stopping long-term PPI without a medication review n=1,013 (2.1%), without a dementia review 
n=1,206 (2.3%)  
Disconcordant pairs used to estimate McNemar Chi-squared test highlighted in bold. Change in total number of cases of each PIM from t-1, compared with t+1, when there is a record of a review at t. Review is at the first record of a medication review 
or dementia annual review during the study period.  
Logistic regression models adjusted for age, gender, medication review, dementia annual review, comorbidity, living situation and patient and practice random effects.  
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(ii) Antipsychotics  
A medication review was associated with increased prescribing of antipsychotic medications in 
patients with dementia in primary care (Table 14). After the first record of a medication review, 
significantly more patients with dementia were prescribed antipsychotic medication (n=128) than 
having an antipsychotic medication stopped (n=80) (p=>0.001). Proportionally, there were slightly 
more patients who started an antipsychotic after a medication review (n=285, 1.6%), compared to 
when there was no record of a review (n=1,211, 1.3%) across the study period. The adjusted 
multilevel logistic regression model estimated that a record of a medication review, across the 
study period was associated with an estimated 19% increase in the odds of starting antipsychotic 
medication (OR 1.19 95% CI 1.03-1.39) (Table 14). There was no evidence to suggest that 
medication review was associated with stopping antipsychotic medications (OR 1.07 95% CI 0.89-
1.29).  
A dementia annual review was associated with decreased odds of stopping as well as decreased 
odds of starting antipsychotic medication. At the first record of a dementia review, there was little 
suggestion that a review was associated with increased stopping or starting of antipsychotic 
medications. However, across the study period, a dementia review was associated with 
proportionally less starting (n=98, 1.01%) compared to no review (n=1,398, 1.3%), in patients 
without antipsychotic prescription. Furthermore, a dementia review was associated with 
proportionally less stopping (n=73, 7.5%) compared to no review (n=1,065, 10.7%), in patients 
prescribed antipsychotic medications. The adjusted multilevel logistic regression model estimated 
that a dementia annual review was associated with 32% decreased odds of starting antipsychotic 
medication (OR 0.68 95% CI 0.54-0.86). Dementia review was also associated with 45% decreased 
odds of stopping antipsychotic medication (OR 0.55 95% CI 0.41-0.73) (Table 14).   
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(iii) Tricyclic antidepressants  
The McNemar test suggested that more patients started a tricyclic antidepressant after a review 
than stopped, although the difference between stopping and starting was not statistically 
significant (Table 14).  
Overall, a medication review was associated with both starting tricyclic antidepressants in 
patients who were not prescribed them and stopping in patients with a tricyclic antidepressant 
prescription. Across the study period and after a medication review, proportionally more patients 
started a tricyclic antidepressant (n=173, 0.9%) compared to when there was no review (n=664, 
0.7%). The adjusted multilevel logistic regression model estimated that a medication review was 
associated with 36% increase in the odds of starting tricyclic antidepressant medication, 
compared to no review (OR 1.36 95% CI1.12-1.67) (Table 14).  
Proportionally more patients stopped tricyclic antidepressant medication after a medication 
review (n=185, 10.6%), compared to no medication review (n=740, 9.2%). The adjusted model 
estimated that a medication review was associated with 20% increase in the odds of stopping 
tricyclic antidepressant medication (OR 1.20 95% CI 1.01-1.42).  
A dementia review was associated with a significant decrease in the odds of stopping tricyclic 
antidepressant medication (OR 0.70 95% 0.53-0.93). Proportionally, fewer patients stopped 
tricyclics after a dementia review (n=58, 7.2%) compared to no review (n=867, 9.7%). There was 
no evidence to suggest that a dementia review was associated with starting tricyclic 
antidepressant medications (OR 0.90 95% CI 0.67-1.21) (Table 14). 
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(iv) Long-term Proton Pump Inhibitor  
The McNemar test suggested that at the first record of a dementia annual review, more patients 
were prescribed a PPI for 8 weeks or more (n=62), compared to fewer patients who had a long-
term PPI stopped (n=38) (p=>0.05). However, across the study period, proportionally fewer 
patients were prescribed a long-term PPI after a dementia review (n=91, 1.2%), compared to no 
review (n=1,571, 1.9%) (Table 14). Furthermore, the adjusted multilevel logistic regression model 
estimated that a dementia annual review was associated with significantly decreased odds of 
being prescribed a PPI for more than 8 weeks (OR 0.67 95% CI 0.54-0.83). However, in patients 
who were prescribed long-term PPI, a dementia annual review was estimated to be associated 
with decreased odds of stopping (OR 0.39 95% CI 0.30-0.52). A medication review was associated 
with significantly increased odds of stopping a long-term PPI (OR 1.39 95% CI 1.18-1.65). There 
was no evidence to suggest that a medication review was associated with being newly prescribed 
a PPI for more than 8 weeks (Table 14).  
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(c) Estimating the association of living situation with stopping and starting PIMs  
Living in a care home was associated with greater PIM use in general. People living in care homes 
were more likely to start antipsychotic (OR 1.38 95% CI 1.33-1.87) and anticholinergic (OR 1.15 
95% CI 1.00-1.33) medications, but were less likely to start PPI (OR 0.73 95% CI 0.60-0.90). They 
were also less likely to stop antipsychotics, once initiated (OR 0.68 95% CI 0.55-0.83) (Table 15).  
For patients who were living in a care home, a medication review was associated with more 
stopping of antipsychotic medication (OR 1.45 95% CI 1.09-1.94) and tricyclic antidepressants (OR 
1.62 95% CI 1.12-2.36). Whereas there was no evidence of an association of medication review 
among patients living in their own home with antipsychotic prescribing (OR 0.86 95% CI 0.67-1.10) 
or stopping tricyclic antidepressants (OR 1.10 95% CI 0.86-1.42).  
Medication review in patients living in their own home was associated with significantly increased 
odds of starting anticholinergics, antipsychotics and tricyclic antidepressants (see Table 15). 
Whereas, stratified analyses did not indicate any association of a medication review among 
patients in a care home with starting PIMs. Conversely, a dementia annual review was associated 
with significantly decreased odds of starting all PIMs in patients who were living in their own 
homes. There was no evidence of an association of dementia annual review with starting PIMs 
among patients who were living in a care home (Table 15).
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Table 15 estimating the association of living situation with starting and stopping PIM amongst patients with dementia in England.  
 Adjusted regression 
model  
Stratified model  
Care home  
Stratified model 
Own home  
 Care Home  
 
Medication review  Dementia annual review  Medication review  Dementia annual review  
Stopping PIM  
 
Anticholinergics 0.99 (0.84 - 1.16) 1.64* (1.31 - 2.07) 0.66* (0.47 - 0.94) 1.04 (0.88 - 1.22) 0.55* (0.42 - 0.70) 
Antipsychotics 0.68* (0.55 - 0.83) 1.45* (1.09 - 1.94) 0.70 (0.46 - 1.08) 0.86 (0.67 - 1.10)  0.45* (0.30 - 0.66) 
Tricyclics  0.79 (0.61 - 1.02) 1.62* (1.12 - 2.36)  0.81 (0.46 - 1.43) 1.10 (0.86 - 1.42) 0.56* (0.38 - 0.83) 
Long-term PPI  1.03 (0.83 - 1.29) 1.54* (1.12 - 2.13) 0.31* (0.18 - 0.55) 1.31* (1.07 - 1.60)  0.42* (0.31 - 0.58) 
 
Starting PIM  
 
Anticholinergics  1.15* (1.00 - 1.33) 0.99 (0.80 - 1.24) 0.75 (0.54 - 1.04) 1.31* (1.13 - 1.51) 0.77* (0.62 - 0.96) 
Antipsychotics 1.38* (1.33 - 1.87) 1.01 (0.78 - 1.31) 0.76 (0.52 - 1.12) 1.30* (1.08 - 1.56) 0.62* (0.47 - 0.83) 
Tricyclics 0.80 (0.61 - 1.04) 1.18 (0.75 - 1.84)  1.33 (0.76 - 2.31) 1.44* (1.15 - 1.81)  0.78 (0.54 - 1.11) 
Long-term PPI  0.73* (0.60 - 0.90)  0.91 (0.64 - 1.27) 0.42* (0.24 - 0.75) 0.95 (0.79 - 1.14) 0.72* (0.55 - 0.95) 
*p=<0.05 OR (95% CI)  
Sample sizes mixed effects regression models: 
Stopping amongst patients prescribed PIM: Anticholinergic n= 2,344, antipsychotic n=1,138 , tricyclic n=925, PPI n= 1,274 
Starting amongst patients not prescribed PIM: anticholinergic n=2,277, antipsychotic n= 1,496 tricyclic n=837, PPI n=1,662  
 
Logistic regression models adjusted for age, gender, medication review, dementia annual review, comorbidity, living situation and patient and practice 
random effects.  
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(d) Other patient and practice level factors associated with stopping and starting PIM  
There were a number of patient and practice level factors associated with stopping and starting 
PIM. These results are summarised and the findings are presented in tables in the Appendix 
Section 10.08-10.09  
 
(i) Age 
Older age was associated with a decrease in the odds of being prescribed antipsychotics, 
anticholinergic medication and a long-term PPI. Older age was associated with decreased odds of 
having a long-term PPI prescription and antipsychotic medication stopped. Older age slightly 
increased the odds of stopping anticholinergic medication (OR 1.01 95% CI 1.00-1.02) and there 
was no association of age with prescribing tricyclic antidepressants.  
 
(ii) Gender 
Females were 22% less likely to be prescribed a long-term PPI and were 38% more likely to start 
tricyclic antidepressant medication (OR 1.38 95% CI 1.08-1.78). In patients prescribed long-term 
PPI, females were 19% less likely to stop than males (OR 0.81 95% CI 0.67-1.00). Furthermore, 
females were 32% less likely to stop tricyclics (OR 0.68 95% CI 0.52-0.87) and 18% less likely to 
stop anticholinergic (OR 0.82 95% CI 0.70-0.95). There was no association of gender with stopping 
or starting antipsychotics and no effect on starting anticholinergics.   
 
(iii) Comorbidity  
A one point increase in Charlson Comorbidity Index score was associated with a 10% increase in 
the odds of starting a PPI that was prescribed for 8 weeks or more (OR 1.10 95% CI 1.04-1.15) and 
a 7% increase in the odds of starting a tricyclic antidepressant. Greater comorbidity was also 
associated with increased odds of stopping long-term PPIs and antipsychotic medications (OR 1.09 
95% CI 1.04-1.15). Finally, greater comorbidity was associated with reduced odds of being 
prescribed antipsychotic medication (OR 0.95 95% CI 0.91-1.00).  
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(iv) Polypharmacy  
Amongst patients with dementia, being prescribed 5 or more medications (excluding PIMs) was 
consistently associated with statistically significant decrease in the odds of stopping PIM and 
significantly increased odds of starting a prescription of PIM, with the exception of tricyclic 
antidepressants. In addition, the odds of being newly prescribed a PIM were greatest in the 
patients who were already taking 10 or more medications, compared to 0-4 medications. 
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5.07 Summary  
This chapter presented the findings of my CPRD cohort study analysis of primary care data from 
patients with dementia in England. These findings demonstrated that patients with dementia 
were prescribed on average, 8 medications. The most prevalent PIM class examined were long-
term PPIs (32%), 17% of patients were prescribed anticholinergics, 8% prescribed antipsychotics 
and 7% prescribed tricyclic antidepressants, with little change in prevalence across the duration of 
the study period (1st January 2015 until 30th April 2017). PIM prevalence and average number of 
medications prescribed was consistently higher amongst patients with dementia who were living 
in a care home, compared to their own home. The prevalence of tricyclic antidepressants and 
antipsychotics was more than twice as high in patients with dementia living in a care home. 
Generally, PIMs were stopped less and started more in care homes. However, when a patient had 
a medication review in a care home the likelihood of stopping a PIM was much greater than 
among patients living in their own home who had a medication review.  
A dementia annual review appeared to be associated with optimising PIMs, particularly among 
patients with dementia who were living in their own home. A dementia review was associated 
with reduced initiation of new PIM prescriptions. A dementia review was also associated with 
reduced likelihood of stopping PIMs. This may indicate an appropriate prescription of a PIM that 
has been monitored in the review and is considered appropriate for the patient.  
Both a dementia annual review and medication review were associated with an overall increase in 
the average number of medications, compared to similar time periods where no review took 
place. Factors associated with PIM prescriptions included being older, female, and being 
prescribed 5 or more medicines. These findings are discussed in Chapter 8. The following chapter 
reports the methodological approach employed in my analysis of how these PIM affect survival in 
a cohort study (CFAS II) subsample of older adults with cognitive impairment.  
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VI. Chapter 6: Methods: CFAS II subsample cohort study  
6.01 Introduction  
The CPRD cohort study indicated the extent of potentially inappropriate prescribing in people 
with dementia in primary care and suggested the potential impact of medication reviews on 
optimising medicines in this population. This chapter reports the methods used to address Aim 1) 
describing the trends in prevalence of potentially inappropriate prescribing and Aim 3) to 
understand the impact of PIMs and polypharmacy on health and the potential impact of frailty in 
this relationship. This chapter outlines the study design and setting of the Cognitive Function and 
Ageing Study used for these analyses. The sample included in analyses, exposures, outcomes and 
covariates and the methods I used to operationalise frailty criteria in CFAS II are described. The 
statistical approaches used to estimate prevalence and survival analyses are presented. The 
findings from this CFAS II subsample cohort study have been peer-reviewed and published [269].  
 
6.02 Study design  
A prospective cohort study of people with cognitive impairment in England, using data collected 
as part of the second Cognitive Function and Ageing Study (CFAS II) (www.cfas.ac.uk). Cross 
sectional estimates of the prevalence of PIM prescription estimated using the CFAS II baseline 
interview (collected 2008-2011). Vital status of the CFAS II participants who met the eligibility 
criteria at baseline interview was then obtained until the point of censoring on 31st October 2016 
or until death.  
 
6.03 Setting  
The Cognitive Function and Ageing Studies is a longitudinal, multi-centre, population-based cohort 
study of ageing in the United Kingdom. The first MRC CFAS began in 1989 (CFAS I) in six centres 
across England and Wales, including Cambridgeshire, Gwynedd, Newcastle, Nottingham, Oxford 
and Liverpool [270]. The second study (CFAS II) conducted baseline interviews between 2008 and 
2011, replicating CFAS I interviews, with new cohorts of participants recruited from three of the 
original centres in England (Cambridgeshire, Nottingham and Newcastle) [2]. All surviving 
participants of CFAS II were re-interviewed at two years follow-up. (Figure 19) 
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Figure 19 Participant flow diagram of the CFAS II baseline and follow-up interviews. Non-participation from people who 
were eligible and approached (n=14,242) to take  part in CFAS II was 45% [271] 
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Participants were randomly sampled from primary care patient lists within the geographically 
defined regions in England. Using primary care registration provided a robust population sampling 
frame, which included individuals who were living in the community and those living in residential 
homes, and representative of both urban and rural populations. All participants were aged 65 
years and over and the sample was stratified by age group (under 75, 75 years and over) to allow 
sufficient numbers in the older age groups and oversampling allowed for losses due to death, 
ineligibility, GP, participant or care provider refusals.  
An introductory letter was sent by the GP to randomly selected eligible participants, followed by a 
visit for initial screening and baseline interview with a trained interviewer in the participants’ 
usual place of residence. The interview comprised an extensive collection of demographic, health 
and lifestyle questions. Including current and previous health conditions, current prescribed and 
over-the-counter medicines, physical activity, smoking and alcohol consumption history and 
current habits, and markers of physical frailty, measured using gait-speed and Sit-To-Stand tests. 
Cognition was assessed during interviews using Mini-Mental State Examination (MMSE) score 
[272], Cambridge Cognitive Examination (CAMCOG) [273] and a GMS-AGECAT algorithmic 
approach was applied for dementia diagnosis. The algorithmic approach allowed for stability in 
diagnoses over time that would not be subject to change in diagnostic practices. Participants were 
flagged on the UK Office of National Statistics National Health Service Central Register for 
notification of date of death.  
In circumstances when a participant was unable to answer questions, a proxy informant, where 
available would be interviewed to answer on the participant’s behalf and the interviewer 
recorded whether a proxy had been required to provide the response. A proxy informant could be 
someone who lived with the participant, visited regularly or had been in touch with the 
participant for a long time. This could include the participant’s formal or informal carer, family, 
friend or neighbour or, for care home residents, a member of staff. For a stratified sub-sample of 
participants with impaired cognition and random sub-sample of those without, participant proxy 
informants History and Aetiology Schedule (HAS) was requested, for 20% of the entire CFAS II 
sample [1]. Here informants were asked a series of questions that related to the participant’s 
previous history of physical and psychiatric symptoms [274].  
 
6.04 Population and sample  
The target population for CFAS II was adults aged 65 years and over in England. The study 
population was drawn from patients registered with a participating GP based around the three 
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study centre locations, Nottinghamshire, Cambridgeshire and Newcastle. The study sample for 
CFAS II was randomly selected and stratified by age group. There were n=17,237 people originally 
sampled from GP records, 14,242 were eligible and approached to take part, of which 54.7% were 
interviewed. This resulted in n=7,796 CFAS II participants. For the purposes of this study, an 
analysis sample was drawn from the CFAS II sample based on the following inclusion and 
exclusion criteria.  
 
6.05 Inclusion and exclusion criteria  
Participants were included if, at baseline CFAS II interview, they were cognitively impaired and 
had reliable data of their medication use. In this study, reliable data of medication use was 
defined when the MMSE score was at least 18 points or higher. Alternatively, if the MMSE score 
was less than 18 points and there was a proxy available who provided the information on 
medication use, information on medication use was deemed reliable. Cognitive impairment was 
defined as a baseline MMSE score of 24 points or less. An MMSE score can range from 0-30 with 
higher scores indicating better cognitive function. A score of 24 points or less indicates clinically 
significant levels of cognitive impairment [15].   
Participants were excluded if there was no recorded medication prescription information from 
the baseline CFAS II interview. In addition, participants with severe cognitive impairment (MMSE 
score of less than 18) who did not have a record of a proxy-informant reported medication use 
were excluded as this data was considered to lack reliability. A participant inclusion flow diagram 
exemplifying how the sample for this study was selected is provided (see Figure 20).  
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Figure 20 CFAS II analysis sample inclusion and exclusion participant flow diagram. 
Reasons for there being no medication data include participants declining to provide information on the 
medications they are prescribed, the interview may have been terminated before getting to the medication 
data section or that the participant was unable to provide this data.  
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6.06 Exposures 
The exposures of interest for this analysis were prescription of PIMs, polypharmacy and frailty. 
The data was ascertained from the baseline CFAS II interview (2008-2011), from a series of 
questions and objective tests in the interviews to both the participants and where available proxy 
informants.  
 
(a) Medication use  
The information on the current use of medications, including prescribed and over the counter 
medicines, was ascertained from the question: “Do you take any medicine, tablets or injections of 
any kind that either you buy yourself or that are prepared by your doctor?” The accuracy of this 
primarily self-reported medication use data collection was improved by the reported medicines 
being cross-checked with available medication packs by the CFAS II interviewer. This method is 
based on a process known as brown-bag medication review, where patients are encouraged to 
bring all of their medication packs for a clinical review [275]. In this circumstance, the brown-bag 
process was used to cross-check the participant reported medication use. If a participant was 
interviewed in a care home, staff cross-checked the reported medications with the participant 
medication lists. All medications were recorded as current medications by the interviewer, new 
medications compared to prevalent medications were not differentiated. All medications were 
coded using Read Codes [276].  
 
(b) Potentially inappropriate medications  
As identified in the scoping review, some key medication classes were specified to focus the 
analyses in this research. The identified PIMs were recognised across the scoping review as 
priority potentially inappropriate medications and were also highlighted by practitioners as key 
targets for further evidence to support deprescribing these medicines [246]. The PIMs were 
specifically associated with exacerbating dementia symptoms and adverse effects in people with 
dementia or were commonly prescribed in older populations with potential for adverse effects 
associated with prolonged use [243, 277]. The PIMs included in analyses in this study included 
medications from Section D of STOPP; Central Nervous System Criteria, including anticholinergics, 
antidepressants, antipsychotics and benzodiazepines [243]. Medications were defined using the 
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Anatomic Therapeutic Chemical (ATC) system and were identified from the CFAS data through 
corresponding Read Codes. The identified lists of medications were cross-checked by pharmacists 
to ensure key medications within each broad medication class were not missing. For analyses, 
medications were grouped into mutually exclusive categories due to cross-over between 
medication classes and medications with anticholinergic effects (Appendix Section 10.05).  
 
(c) Anticholinergic medication  
Medications with anticholinergic effects are often prescribed to treat or manage conditions or 
symptoms for which the medication is indicated, and the anticholinergic effect of a medication is 
overlooked. As identified from the scoping review, a number of anticholinergic medication scales 
have been developed to identify medications with anticholinergic effects, although there is no 
established consensus. One of the most frequently validated scales is the Anticholinergic 
Cognitive Burden Scale (ACB), which was used to classify anticholinergic medications in this study 
[254, 278]. The ACB has been predictive of a range of adverse effects, validated across a number 
of studies including quality of life, cognitive function, mortality, and activities of daily living, 
dementia and physical function [161]. The ACB classifies medications by known level of 
anticholinergic activity, as identified through a systematic review of medicines with 
anticholinergic activity and including medications where there is evidence of a relationship with 
detrimental effects on cognitive functioning. The identified medications were reviewed by a panel 
of experts from across disciplines and assessed each medication as having no anticholinergic 
properties, possible, or definite anticholinergic properties. According to the final ACB scale, 
medications were classified as having possible or definitive anticholinergic effects impacting on 
cognition (scores ranged from 1 to 3). Medications with definite anticholinergic properties are 
allocated an ACB score of 3. For the purpose of this study, medications for which there was 
certainty in regard to their anticholinergic effects, therefore those with an ACB score of 3, were 
included in this analysis (Appendix Section 10.05) [254]. Individual medications reported in CFAS II 
had been previously coded according to the ACB scale, and I applied these medication lists to 
operationalise anticholinergic medication use in my sub-sample of participants from CFAS II. 
 
(d) Antipsychotic medication  
Antipsychotic medications were defined using the ATC code N05A. Some antipsychotic 
medications also have anticholinergic effects and therefore medications were groups into 
 148 
 
mutually exclusive categories of ‘anticholinergic antipsychotics’ and ‘other antipsychotics’ using 
the ACB scale. To create the mutually exclusive medication categories I used the ACB scale to 
distinguish and separate the antipsychotic medications with anticholinergic effects and 
antidepressants with anticholinergic effects (tricyclic antidepressants) from the remaining 
anticholinergic medications, then grouping the medications into the mutually exclusive 
medication groups used in this analysis (Appendix Section 10.05).  
 
(e) Antidepressant medication 
Antidepressant medications were defined as any medication with ATC code starting N06A and 
were subsequently classified from the CFAS II medication lists. Tricyclic antidepressant 
medications are particularly associated with a negative impact on cognition due to the high 
anticholinergic effects of these drugs and therefore the antidepressant medications were also 
grouped into two categories of ‘tricyclic antidepressants’, identified from the ACB scale due to the 
anticholinergic properties of tricyclic antidepressants, and ‘other antidepressants’.  
 
(f) Benzodiazepine medication  
Benzodiazepine medications were defined using the ATC code N05CD and N05CF, which included 
benzodiazepine derivatives and benzodiazepine related medications, which were classified from 
the coded medication lists from CFAS II.  
 
(g) Proton pump inhibitors  
Proton pump inhibitors (PPI) were defined using the ATC code A02BC. According to STOPP criteria, 
PPIs are potentially inappropriate when they have been prescribed for 8 weeks or more, however 
due to the cross-sectional nature of the CFAS II interviews I was unable to ascertain the duration 
of use. However, PPIs are often used chronically in older adults [242] and it is possible that many 
of the people reporting PPIs in CFAS were reporting prevalent medications, rather than those that 
were new or used temporarily.  
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(h) Polypharmacy  
The total number of medications that each CFAS II participant included in this sample was 
recorded during the interview, including both prescribed and over-the-counter medications. The 
total number of medications prescribed, excluding PIMs was categorised into three groups, zero 
to four medications, five to nine (polypharmacy) and ten or more (hyper-polypharmacy), as in 
previous studies [122, 198].  
 
(i) Continuation of medication use  
To assess the variation of the PIM exposure over time the proportion of participants who 
continued to be prescribed PIM was ascertained from a sub-sample of the participants who were 
assessed and provided medication data at the two-year follow-up interview.  
 
6.07 Outcome variable  
The outcome variable used in the analyses to address objectives of this study was survival. All 
CFAS II participants were flagged on the UK Office of National Statistics National Health Register 
for notification of date of death. This analysis included deaths up to 31 October 2016, providing 
up to eight years follow-up.  
 
6.08 Confounding variables  
Potentially confounding variables were coded from the CFAS II interviews and adjusted for in 
multivariable analyses. This included age and gender, the living situation, cognitive function, 
number of medications excluding PIMs and number of self-reported comorbidities. These 
potentially confounding variables were coded as follows:  
 
(a) Age and sex 
From the original primary care records used to sample participants, age and gender were known 
to the interviewer before the interview. At the start of the interview, the participants’ age and 
date of birth were confirmed.  
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(b) Living situation 
The CFAS interviews took place in the participants usual place of residence and the CFAS II 
interviewer rated the living situation of the participant as living in an ‘institution’ or not. 
Interviewers were provided with an outline for classifying institutions. Institutions included 
residential homes, nursing homes and long-stay hospitals, whereas day hospitals or sheltered 
accommodation were not considered institutions.  
 
(c) Cognitive function  
The baseline cognitive function was ascertained from the Mini-Mental State Examination (MMSE) 
score from the interview [272]. The MMSE is used widely as a test of cognition in older adults. The 
test is made up of a series of questions assessing attention, memory, language, visual-spatial and 
attention skills. Scores can range from 0 to 30 with higher scores indicating better cognition. 
 
(d) Comorbidities  
The CFAS II participants were asked a series of questions on whether they ‘had ever had or 
suffered from any of the following health conditions.’ This was asked of the following health 
conditions that were reported by the participants: angina, arthritis, asthma, cancer, chronic 
bronchitis, depression, diabetes, epilepsy, heart attack, high blood pressure, intermittent 
claudication, low blood pressure, Parkinson’s disease, peptic ulcers, pernicious anaemia, stroke. A 
cumulative count of the total number of self-reported comorbidities was created as a continuous 
variable for analyses. 
 
6.09 Frailty  
Frailty was classified based on the frailty ‘phenotype’ first described by Fried et al in 2001 [45]. 
Fried et al (2001) first developed and operationalised the phenotypic definition of frailty in a 
prospective cohort study of older adults from the Cardiovascular Health Study (CHS) in the United 
States. In the CHS study, standardised interviews took place at baseline (n=5,201) with annual 
follow-ups and examination of outcomes including hospitalisation, disability, falls and mortality. 
During the CHS interviews, a series of objective and self-report measures were used which were 
then subsequently operationalised into what became the frailty phenotype. Fried et al., proposed 
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that frailty was identifiable through the presence of three or more frailty components. These 
components were shrinking, weakness, poor endurance and energy, slowness and low physical 
activity. Due to variation in study designs and measurements, the phenotypic criteria cannot be 
operationalised exactly as in the original Cardiovascular Health Study [47] but as in other 
epidemiological studies of ageing [194, 195], I operationalised each component of the criteria 
using the data available from the CFAS II interview.  
A comparison of the operationalisation of the Fried frailty phenotype as originally proposed in the 
Cardiovascular Health Study compared with how I operationalised the phenotype using CFAS II is 
provided in Table 16. The frailty phenotype was proposed as a clinical syndrome associated with a 
number of signs and symptoms that had been associated with frailty, including loss of strength, 
muscle mass, reduced resting metabolic rate, reduced walking speed, reduced activity, reduced 
overall energy expenditure, long-term undernutrition, and weight loss. The measures used (Table 
16) were used to characterise the areas across the clinical syndrome of frailty (Figure 21).  
  
 
152 
 
 
Figure 21 clinical syndrome of frailty as hypothesised by Fried et al (2001) based on clinical signs and symptoms of frailty.  
Model based on cycle of frailty in Fried et al (2001), additional inclusion of operationalisation of frailty criteria from CFAS II questionnaires for this study.
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Table 16 Operationalisation of Fried et al (2001) frailty phenotype in the Cardiovascular Health Study and CFAS II 
Frailty phenotype  Cardiovascular Health Study 
Measure  
CFAS II operationalisation  
Shrinking: 
unintentional 
weight loss  
Baseline: >10 lbs lost 
unintentionally in the previous 
year  
Self-reported unintentional weight 
loss 4.5kg (10lbs) or more in previous 
six months or less  
Weakness1  Grip strength test: lowest 20% (by 
gender and BMI)  
Sit-To-Stand test: time taken to 
complete five stands 
Poor endurance; 
Exhaustion  
Self-reported exhaustion  Self-reported exhaustion  
Slowness1  Walking time across 4.5m: 
Slowest 20% (by gender, height)  
Average time across two gait speed 
test across 2.4m  
 
Low activity2  Kcals per week: lowest 20% 
males <383 Kcals/week  
females <270 Kcals/week  
Self-reported time spent doing 
physical activity 
Cardiovascular Health Study Measure – originally used to propose the Fried frailty phenotype 
(2001)  
Frailty defined as impaired on 3 or more criteria  
Pre-frail defined as impaired on 1 or two criteria  
CFAS II: People who did not consent or could not complete the test were considered impaired 
on that frailty criterion 
1People in slowest quartile of average time across the CFAS II sample are considered impaired 
2Operationalised through a cumulative score of time spent doing mildly, moderate and vigorous 
activities, participants with the lowest levels of activity (quartile) across the whole CFAS II 
sample were considered impaired on this criterion  
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(a)   Slowness 
The CFAS II participants were asked to complete a gait-speed test as part of the interview. This 
provided an objective measurement of the participants walking speed that I could use to 
operationalise the slowness frailty criteria. The gait speed test is a simple and objective measure 
of the individual walking speed that provides an indication of functional mobility, balance and 
endurance in older adults. Participants were allowed to use their usual walking aid if appropriate. 
The time taken to complete each test was recorded by the CFAS II interviewer. The average time 
to complete the walk was collated across all CFAS II participants, and split into quartiles with any 
participant within the slowest quartile coded as impaired for this frailty component. Any CFAS II 
participants who did not consent to take part in the gait-speed test, who were deemed unsafe to 
attempt the test by the interviewer or who could not complete both tests were considered to be 
impaired for this frailty criterion.  
 
(b) Weakness 
All CFAS II participants were asked to also take part in a Sit-To-Stand test, an objective 
measurement and a marker of the participant’s endurance and strength, particularly of the lower-
limbs [279]. Participants were asked to stand from a seated position, with their arms folded 
across their chest. The time taken for the individual to complete five repeated stands was 
recorded by the interviewer. I grouped the times from all 7,692 CFAS II participants in the test into 
quartiles. Participants with a time that fell within the slowest quartile across the entire CFAS II 
sample were coded as impaired for this criterion. Any participant who did not consent to take 
part in the Sit-To-Stand test, who was deemed unsafe to attempt or who could not complete the 
tests was considered impaired on this criterion.  
 
(c) Exhaustion  
The participant’s level of exhaustion was ascertained from a self-reported answer to one question 
in the CFAS II interview: “Do you get worn out or exhausted towards the evening?” with possible 
responses of ‘no’, ‘mildly exhausted’ or ‘severe exhaustion’. I operationalised this recorded data 
from CFAS II interviews by coding participants who reported mild or severe exhaustion that was 
not explained by strenuous activities as impaired on this criterion. If there was no response, the 
interviewer rating of observed slow movement, not readily explained by physical illness, was used 
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instead. The subjective interviewer rating was categorised as ‘no’, ‘mild’ or ‘severe’ and I coded 
participants recorded as ‘mild’ or ‘severe’ slow movement as impaired on this frailty criterion.  
 
(d) Weight loss  
The participants self-reported recent weight loss as reported through one question asking 
whether they had lost 4.5kg (10lbs) or more in the past six months or less in CFAS II interviews. 
Unintentional or rapid weight loss can be common among older adults and particularly in frail 
older adults, and is associated with increased risk of hospitalisation, decline in day-to-day 
functional ability and care home admission [280]. If participants reported in the interview that 
they had lost 4.5kg (10lbs) or more in the past six months or less, they were coded as impaired on 
this frailty criterion.   
 
(e) Low physical activity  
Physical activity levels were ascertained through a series of answers to self-reported questions on 
the time spent doing vigorous, moderate or mildly energetic activities. An initial question asked 
the participants if they took part in vigorous activity, if the participant answered ‘yes’ in the 
interview to this question they were asked a series of questions regarding the amount of time 
spent doing specific activities including running, swimming or cycling, for example. If the 
participant answered ‘no’ to the initial question, the interviewer proceeded to the next question, 
regarding moderate activity and subsequently mildly energetic activity.  When asked about 
specific activity, participants’ answers could be categorised as ‘no’, ‘more than once a week’, 
‘once a week’, ‘one to three times a month’ or ‘hardly ever or never’. An example of the physical 
activity questions asked and operationalised for this frailty criterion are provided (see Table 17).  
 156 
 
Table 17 Example of questions about physical activity asked in the CFAS II interviews, used to identify low levels of 
physical activity in the sample. Not all example activities are shown, other activities were included in the questionnaire.  
Vigorous activities  
Q375 Do you take part in sports or activities that are 
vigorous?  
0. NO 
1. YES  
Specify which activity then as how often participant 
takes part in the activity  
If rated NO skip to moderate activities  
Example vigorous activities: Running or jogging, 
swimming, cycling, tennis… 
Each activity rated: 
0. No 
1. More than once a week 
2. Once a week 
3. One to three times a month  
4. Hardly ever, or never 
Moderately energetic activities  
Q383 Do you take part in sports or activities that are 
moderately energetic? 
0. NO 
1. YES 
Specify which activity then as how often participant 
takes part in the activity  
If rated NO skip to mild activities 
 
Example moderately energetic activities: Moderate 
gardening, mowing lawn, cleaning the care, walking at a 
moderate pace…  
Each activity rated: 
0. No 
1. More than once a week 
2. Once a week 
3. One to three times a month  
4. Hardly ever, or never 
Mildly energetic activities  
Q391 Do you take part in sports or activities that are 
mildly energetic? 
0. NO 
1. YES  
Specify which activity then as how often participant 
takes part in the activity  
If rated NO skip to next set of questions  
Example of mildly energetic activities:  
Light gardening, bowls, light housework, home repairs  
Each activity rated: 
0. No 
1. More than once a week 
2. Once a week 
3. One to three times a month  
4. Hardly ever, or never 
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To classify participants as impaired on this frailty criterion, I created a scoring system where 
participants were scored based on the amount of time the participant spent doing each specific 
activity. For each activity, participants answering ‘no’, ‘one to three times a month’, or ‘hardly 
ever or never’, were allocated a score of 1. Participants answering, ‘more than once a week’, or 
‘once a week’ were allocated a score of 0. I created a total score across each of the specific 
activities by summing scores to create a continuous variable, with higher scores indicating less 
reported physical activity. I categorised the scores into quartiles and participants in the highest 
quartile (indicating the lowest level of physical activity), were coded as impaired on this frailty 
criterion.  
Participants who answered ‘no’ to the primary question regarding time spent doing mild, 
moderate or vigorous activities skipped the questions on specific activities and were considered 
as reporting low physical activity and I therefore classified them as impaired on this criterion.  
 
(f) Identifying frailty  
Participants could be identified as impaired or not on each of the frailty criterion. Participants 
were identified as frail if they were considered impaired on three or more criteria. Participants 
who were considered impaired on one or two criteria were considered pre-frail and those who 
were free of impairment classification were identified as not frail (Table 18).
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 Table 18 Operationalisation of frailty criteria from CFAS II interview data 
Frailty criteria  CFAS Questions  Operationalisation from CFAS II 
interview data  
Impaired on criteria  Incomplete data   
Slowness  Timed Gait Speed Test  Average time to complete two 
tests  
Participants in the slowest quartile  No consent, unsafe to complete or unable to 
complete were considered impaired on criteria  
Weakness  Timed Sit-To-Stand Test  Overall time take for five 
completed stands  
Participants in the slowest quartile  No consent, unsafe to complete or unable to 
complete were considered impaired on criteria 
Exhaustion  Do you get worn-out / 
exhausted towards the 
evening?  
No, mildly exhausted or severe 
exhaustion as options for 
response. Missing data, 
interview report was used  
Mild or severe exhaustion not explained by 
strenuous activity  
Or  
Mild or severe slow movement (interviewer 
reported)  
Interview rating of observed slow movement used 
instead  
Physical activity  Vigorous, moderate or 
mildly energetic activities  
Scored based on time spent 
doing each activity, higher 
scores indicates less activity  
Participants in the highest quartile (least active 
quartile)  
No to first question on overall activity time 
classified as impaired  
Weight loss  Weight loss  Loss of 4.5kg (10lbs) or more in 
the past six months or less  
Impaired if reported they had lost 4.5kg or more in 
the past six months  
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6.10 Statistical analysis 
The statistical analyses used to address the objectives of this study outlined in Chapter 3 are 
described below, starting by describing the descriptive analyses, followed by a description of the 
statistical methods used to address objectives,1b, 3a-3c.  
 
(a) Descriptive statistics  
Participant characteristics and proportion of PIM use was reported, stratified by frailty. 
Additionally, descriptive statistics of the proportion of patients diagnosed with dementia, within 
each categorical MMSE score (<=18, 19-21, 22-24), resident in a care home, death before 
31/10/2016 and total number of participants classified as positive on each frailty component. 
Means and standard deviations were used to describe age (years), number of comorbidities and 
number of other medications reported. Descriptive statistics were also stratified by frailty group 
(not frail, pre-frail, and frail). 
 
(b) Prevalence of PIM use and polypharmacy  
Addressing objective 1b, the prevalence of PIM use in the sample was estimated using inverse 
probability weighting to provide an estimation of the proportion of the population with cognitive 
impairment prescribed PIMs and polypharmacy. Inverse probability weights were used in the 
CFAS studies to reduce the likelihood of biased estimates, giving each participant a weight 
inversely proportional to the probability of non-response during recruitment. This helps to 
balance the impact of estimates associated with people who were more or less likely to  take part 
in CFAS and reduces bias in the estimates that correspond to the population [281]. Weights were 
applied to the CFAS cohort to adjust for non-response based on the following factors: birth 
cohort, gender, care setting and deprivation status of postcode [1]. Prevalence estimates from 
CFAS I and II have been widely used to estimate dementia prevalence in the UK and this method 
was applied to the CFAS to estimate the proportion of people with a dementia diagnosis in the UK 
[28]. The weights estimated for the CFAS II sample were applied to estimates of PIM and 
polypharmacy proportions in this study sample to estimate the proportion of the population with 
cognitive impairment with polypharmacy and PIM.  
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To estimate the association between polypharmacy, PIM use and survival (objective 3a), the 
moderating role of frailty on this relationship (objective 3b) and the predictive validity of the 
frailty phenotype (objective 3c), Cox proportional hazards regression models were estimated 
[282].   
 
(c) Cox proportional hazards regression  
Multiple Cox proportional hazards regression models were estimated to address the objective of 
aim three of this research. A Cox proportional hazards model is a regression model used in the 
analysis of time-to-event data, for example time to death or disease incidence. In this study, the 
Cox model is used to estimate the hazard ratio amongst people with cognitive impairment who 
are PIM users compared to non-users. Multiple predictor variables can be included in a Cox 
model. The association of each predictor variable with time until mortality can be estimated. A 
key assumption of the Cox proportional hazards regression model is that the hazards between the 
groups are proportional, meaning that the hazard ratio does not change over time. The Cox model 
equation is provided and explained below (see Figure 22).   
 161 
 
 
 
Figure 22 Cox proportional hazards regression model equation.  
Where t is survival time, h(t) is the expected hazard at time t, b1, b2…bp are the coefficients of the 
covariates (predictors) X1, X2...Xp. The predicted hazard is a product of baseline hazard and 
exponential function of the linear combination of the predictors. The predictors have a 
multiplicative or proportional effect on the hazard at each time point, which is the probability of 
the occurrence of an event at that time, in this case the event being death. h0(t) is the baseline 
hazard function, that is the hazard at each time when all predictors are equal to 0. The effects of 
predictors (exposures and confounding variables) are measured by the exponential coefficients 
(exp(b)) which are hazard ratios (HR); a HR of 1 (corresponding to b=0) indicates no effect on 
mortality, greater than 1 is an increased risk of mortality and less than 1 is a decreased risk of 
mortality associated with that predictor, all other predictors adjusted for.  
 
(i) Cox proportional hazards regression model with interaction terms 
 ℎ(#) = ℎ&(#)exp	(+,-, + +/-/ + ⋯+ +121++3-456789:-6;971<:=>?97=  
Example of a Cox proportional hazards regression model equation with interaction terms used to 
test frailty and PIM interactions. Where x@ABCDEF is the dichotomous variable of frailty, with three  
levels of not frail, pre-frail and frail and xBGECHIFJKLECJ  as a binary variable for antipsychotic 
medication use (exemplar of the other PIMs also analyzed). Therefore there were six levels, 
represented by five coefficients in the model  for each PIM; not frail by PIM, pre-frail by no PIM, 
pre-frail by PIM, frail by no-PIM and frail by PIM. The final group is the baseline (no PIM and not 
frail).  
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(d) Association between PIMs, polypharmacy and survival  
For time-to-event analyses, participants were considered ‘at risk’ of death from the time of CFAS II 
interview, until their death or censoring on 31st October 2016. Time since interview was the time 
scale for all analysis. 
To address objective 3b, to estimate the association between polypharmacy and PIMs at baseline 
and subsequent survival, separate univariate analyses were first estimated. For univariate 
analyses, Kaplan-Meier survival curves were used to visualise the proportion surviving over time, 
corrected for censoring, log-rank tests to assess the null hypothesis of no difference (p=<0.05) and 
unadjusted Cox regression models estimating unadjusted hazard ratios (95% CI). Multivariate 
analyses estimated Cox regression models adjusted for potentially confounding covariates, 
estimating hazard ratios and 95% confidence intervals.  
 
(e) Univariate analyses for polypharmacy and survival  
Kaplan-Meier survival curves were used to estimate survival probabilities from baseline until 
censoring or death for users of zero to four medications, five to nine (polypharmacy) and ten or 
more (hyperpolypharmacy) medications that excluded PIMs. Log-rank tests were used to assess 
the null hypothesis of no difference in survival between users of polypharmacy and 
hyperpolypharmacy compared to zero to four medications. Unadjusted Cox regression model 
estimated univariate hazard ratios (with 95% confidence intervals) for participants with 
polypharmacy and hyper-polypharmacy compared to participants who reported zero to four 
medications.  
 
(f) Univariate analyses for PIM and survival  
Kaplan-Meier survival curves were used to estimate survival probabilities from baseline until 
censoring or death in reported users compared to non-users of each PIM. Log-rank tests were 
used to assess null hypothesis of no difference in survival between users and non-users of each 
PIM (p=<0.05). Cox regression models estimated univariate hazard ratios (95% confidence 
intervals) for each PIM. 
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(g) Multivariate analyses for polypharmacy, PIM and estimated survival  
Cox proportional hazards regression models were used to estimate the independent effect of 
polypharmacy and PIMs on survival, controlling for potentially confounding variables. Hazard 
ratios (95% CI) were estimated for polypharmacy and each PIM class. The models were adjusted 
for age, sex, baseline cognitive impairment, living situation and comorbidities. Subsequent models 
were also adjusted for frailty.  
 
(h) Frailty as a moderator  
To address objective 3c of this research, to estimate the moderating role of frailty on the 
relationship between polypharmacy, PIM use and survival, three approaches were applied. First, 
the multivariate analyses described above were adjusted for frailty. Second, analyses were 
stratified by frailty to estimate differences in survival between patients with different frailty 
status. And finally, interaction terms were used to estimate the effect of frailty on the association 
between each PIM and polypharmacy on subsequent survival. Likelihood ratio tests were used to 
assess the statistical significance of the PIM and polypharmacy and frailty interactions (p=<0.05) 
compared to the adjusted model without frailty and PIM or polypharmacy interaction term.  
 
(i) Testing the proportional hazards assumption  
The key assumption of the Cox proportional hazards regression model is that the hazards are 
proportional, meaning that the hazard between groups are proportional to each other and 
therefore their ratio does not change over  time. The proportional hazards assumption was tested 
using Schoenfeld residuals, testing the independence between residuals and time. Kaplan-Meier 
survival curves were also used as a visual assessment of the proportionality of the hazards and the 
assumption was subsequently tested with scaled Schoenfeld residuals [283]. 
 
(j) The association of frailty phenotype with mortality  
To assess the predictive validity of the phenotype criteria and addressing objective 3c of this 
research, I also estimated the independent association of the five frailty phenotype criteria with 
mortality, rather than considering a single ‘frailty’ variable, as in the main analysis. Firstly, each of 
the frailty criteria (weakness, slowness, low physical activity, weight loss and exhaustion) were 
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included in an unadjusted Cox regression model as separate variables and second, a multivariate 
model was estimated adjusting for age, sex, living situation and comorbidities. The independent 
hazard ratios (95% confidence intervals) for each of the frailty criteria were estimated.  
 
(k) Sensitivity analyses  
(i) Behavioural and psychological symptoms of dementia  
A subset of the CFAS II sample also had proxy informants who completed the HAS questionnaire. 
This questionnaire was used to gauge further information relating to the history and aetiology of 
disease or related behaviours. The informants were asked about previous and recent behaviours 
and about the participants’ education, memory, cognitive abilities, aphasia, apraxia, personality, 
behaviour, delirium, depression, and judgment. They were asked about noticeable changes and 
when these changes in these behaviours were recognised.  
Antipsychotic medication is often prescribed to manage behavioural and psychological symptoms 
of dementia. Although the CFAS II interview data does not collect information about medication 
indications, the HAS informant questionnaire answers were used as a proxy indicator of 
antipsychotic indication for behavioural and psychological symptoms of dementia. Behavioural 
and psychological symptoms of dementia were operationalised from a series of questions around 
apathy, sleep problems, irritation, suspicion, hallucinations and wandering. Sensitivity analyses 
estimated an adjusted Cox regression model in the sub sample who had HAS informant 
questionnaires, adjusted for BPSD symptoms.  
 
(ii) Measure of cognitive impairment  
Sensitivity analyses were used to assess the robustness of the results using an alternative 
measure of cognitive impairment used in the CFAS II interview. An alternative measure of 
cognitive function, the Cambridge Cognition Examination (CAMCOG) was also completed as part 
of the CFAS interviews. The CAMCOG includes questions relating to orientation, memory, 
language, attention, calculation, perception, praxis and abstract thinking. The maximum score on 
the CAMCOG is 107 and higher scores indicate better cognitive function. The CAMCOG is a widely 
used and validated measure of cognitive function [284]. However, there is evidence to suggest 
that the CAMCOG is less sensitive in identifying people with milder levels of cognitive impairment 
[285] and has shown mixed effectiveness in accurately predicting people who would later go on to 
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develop dementia [286, 287]. A sensitivity analysis was used to compare the estimation of 
cognitive impairment within the sample to the MMSE estimation.   
Scores from the CAMCOG [273] were used as an indicator of baseline cognitive impairment and a 
Cox regression model was estimated to compare the estimates using CAMCOG to the estimates 
from the model using MMSE as a baseline marker of cognitive impairment. Models were adjusted 
for age, sex, and total medication use excluding PIMs, living situation, comorbidities and frailty.  
 
(iii) Adjusting for comorbidities  
A sensitivity analysis was used to estimate the model adjusting for individual comorbidities and 
compared to the main model adjusting for number of comorbid health conditions. Each individual 
comorbid health condition (angina, arthritis, asthma, cancer, chronic bronchitis, depression, 
diabetes, epilepsy, heart attack, high blood pressure, intermittent claudication, low blood 
pressure, Parkinson’s disease, peptic ulcers, pernicious anaemia, stroke) was adjusted for in 
separate binary variables in the full multivariate Cox regression model.   
 
(iv) Frailty criteria  
A sensitivity analysis was undertaken using the lowest quintile, as in the original study by Fried et 
al, (2001). The variables operationalising the slowness, weakness and low physical activity 
criterion were estimated with the lowest quintile (compared to quartile) being operationalised as 
impaired on these criteria. A second frailty variable was then generated to account for the 
changes in the slowness, weakness and physical activity criteria. As before, individuals were 
classified as not frail, pre-frail or frail. Individuals were classified as frail if they were impaired on 
three or more individual frailty criteria, pre-frail if they were impaired on one or two frailty 
criteria.  
The univariate and multivariate association of frailty with mortality according to this criteria was 
estimated. The model adjusting for frailty operationalised using the lowest quintile was compared 
to the main model adjusting for frailty using lowest quartile, estimated in multivariate Cox 
regression models.   
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(l) Sample size considerations  
The original aim of this CFAS II study had been to estimate the risk of mortality associated with 
PIM use in people with dementia, however given the small sample of people with dementia (n= 
154, 13%), people with severe cognitive impairment were also included in analyses. The sample 
would have likely been underpowered to detect effects had the sample been limited to people 
with dementia. This was an important part of the decision to include people with cognitive 
impairment in the sample, rather than restricting the sample to people with dementia.  
When exploring the data set of the people in the CFAS II subsample who were prescribed PIMs, 
there was 1 (0.6%) person with dementia prescribed antipsychotics, 7 (4.6%) people prescribed 
tricyclic antidepressants, 7 (4.6%) prescribed other anticholinergic medications, 21 (13.7%) people 
with dementia prescribed antidepressants and 48 (31.2%) people with dementia prescribed PPIs. 
It was therefore expected that within the sample of people with dementia, there would have 
been too few instances of PIM prescriptions to be able to detect an effect.  
Based on estimates from a previous large cohort study of people with dementia who were 
prescribed antipsychotic medications (n 10,615) [288]. An estimated hazard ratio of 1.30 of 
mortality associated with antipsychotics with 80% power and 5% significance level test, and an 
estimated 0.77 probability of the event (death), the estimated required sample size of people 
with dementia prescribed antipsychotics would be 593 with 457 events (deaths). Given the 
limited number of people with dementia (n=154) available in the CFAS II sample, the sample was 
expanded to include people with cognitive impairment (MMSE less than or equal to 24 points) 
(n=1,154).  
It is notable that the sample size analyses for the CFAS II and CPRD studies presented in this thesis 
were considered using different approaches, given the differences in the databases that were 
used.   
 
(m) Data quality and missing data  
One of the inevitable and often unavoidable challenges of conducting surveys in epidemiological 
studies, using questionnaires and interviews is the quality of the data and missing data. Given this, 
considerable time was needed to clean the raw data so that it was suitable for analyses. This was 
a particular challenge for the operationalisation of the frailty criteria from the available data. A 
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participant is always able to make the choice to miss a question or series of questions, the 
interviewer may also decide to miss a question or series of questions if they deem it inappropriate 
or if it may harm the participant. In addition, whenever answers and information is manually 
inputted into a database there is a possibility of human error when inputting the data and a lack 
of consistency in how missing data is coded.  
Decisions about coding of variables from the CFAS dataset were made alongside in-depth 
discussions with researchers and interviewers with experience of working with the CFAS data. 
Given the understanding of the process of the interviews, multiple imputation was not applied to 
the missing data as the data were not deemed to be missing at random but were missing due to 
considered processes, involving the participant and the interviewer in choosing whether to 
complete particular questions or tests. Examples of this process of understanding the CFAS 
interview procedures are explained.  
 
(i) Medication use  
To cross-check the reliability of reporting of medication use, the interviewers would ask to see 
medication prescriptions or boxes. Participants were excluded if they did not have data that was 
considered reliable for the primary exposures of medication use. Reliable medication data was 
considered when the participant had a MMSE score of more than 18 points. Furthermore, those 
with severe impairment were required to have their medication data reported by a proxy.  
 
(ii) Frailty  
When investigating the missing data in the objective frailty criteria tests (gait speed and Sit-To-
Stand test), whether or not the participant agreed to do the test, on the grounds of safety, was 
used to understand firstly, who had not consented to the test and secondly who had given 
consent but did not complete the test.  
Firstly, there were 237 (20.6%) participants who did not consent to the gait speed test. On 
average, those who did not consent were older (mean age non-consent= 81 years, consent = 78 
years), had greater cognitive impairment (mean MMSE score non-consent=20.8, consent=22.2), 
were more likely to live in a care or residential home (non-consent=11%, consent =2%) the 
distribution of males and females within those who did vs those who did not consent (non-
consent =63% female, consent =62% female) and the average number of comorbidities (non-
consent = 2.7, consent =2.3) was similar. Overall, 244 (21.1%) participants had a missing time 
score, of which the majority (n=237) did not consent and the remaining 7 consented but did not 
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complete the test. For the gait speed test, it was clear that those who had missing data on the 
specific question of time taken to complete the test had missing data because they had not 
consented to the test or the interviewer had deemed it unsafe to allow them to do the test. 
Alternatively, as amongst the remaining 7 participants, they did not complete the test.  
In the interviews, the Sit-To-Stand test was conducted after the gait speed test. The Sit-To-Stand 
test required participants to fold their arms across their chest and from a chair, stand five times 
consecutively. A larger proportion of the sample did not consent to the chair rise test, which is 
likely due to fatigue or safety concerns leading on from the gait speed test. Overall, there were 
482 (42%) participants who did not consent to the chair rise test. Overall, there were missing data 
for the chair rise test from 603 (52%) participants. The majority of these participants did not 
consent to the test (n=482) and the remaining did not complete the test. The test stipulated that 
the chair rise had to be repeated 5 times for the time to be recorded. Therefore, it was 
understood that the remaining missing data came from people who attempted but could not 
complete the test.   
The inability to complete these tests was characterised by people who were older, more likely to 
live in a care home and were more cognitively impaired. There were 229 participants who did not 
consent to either test. The average age of these participants was 81 years, 63% were female, 
mean baseline MMSE score was 20.8, with an average of 2.7 comorbid health conditions and 11% 
lived in a care or residential home. The inability to complete the test was therefore deemed 
consistent with the positive indication of frailty within these criterion, and the missing data from 
the Sit-To-Stand and gait speed test was therefore classified as identifying people who were 
impaired on these frailty criterion.   
Participants, with missing MMSE scores were excluded from the subsample. Missing MMSE scores 
were an indication of severe cognitive impairment and an inability to complete large portions of 
the interview. There is a possibility that this may have introduced selection bias into these results, 
however based on understanding of the interview process, it is assumed that MMSE scores were 
missing only if it was deemed inappropriate by the interviewer to complete the test and were 
therefore indicative of severe cognitive impairment.  
Due to the inclusion and exclusion criteria that were applied, there is little data missing for the 
majority of the covariates and none for the exposures (medication use) and the outcome 
(mortality).  
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6.11 Summary  
The CFAS II is a population representative cohort of older adults and a subsample with cognitive 
impairment was sampled and used in analyses described in this chapter. The Fried et al (2001) 
frailty phenotype was operationalised using the data available from CFAS II interviews to estimate 
the role of frailty on the relationship between polypharmacy, PIM use and mortality and to assess 
the predictive validity of the frailty phenotype criteria. Chapter 7 will present the results of the 
analyses described.  
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VII. Chapter 7: Results: CFAS II subsample analysis  
7.01 Introduction 
This chapter reports the findings from the CFAS II subsample analysis, reporting prevalence 
estimates of polypharmacy and PIM use and estimating the impact of potentially inappropriate 
prescribing on survival amongst older adults with cognitive impairment. The association of frailty 
on this relationship and the predictive validity of frailty criteria are presented.  
 
7.02 Description of the sample  
There were 7,762 participants in CFAS II, of these 1,154 met the inclusion criteria. Of these , 
62.1% were female and the mean age of the sample was 79 years (SD =7.4) (see Table 19). There 
were 789 (68.4%) people who had a MMSE score of 22-24 points, 283 (24.5%) had a MMSE of 19-
21 points and 82 (7.1%) had a MMSE of 18 points or less. There were 154 (13%) people who had a 
diagnosis of demenita as diagnosed by the GMS-AGECAT algorithm. There were 47 (4.1%) people 
who were living in a care or residental home at the time of the CFAS II interview. The small 
proportion of people who were living in a care home may be accounted for by the exclusion of 
people without a MMSE score or a proxy informant to answer questions. 
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Table 19 Unweighted sample characteristics of older adults with cognitive impairment sampled 
from CFAS II (n=1,154), stratified by frailty 
Characteristic Total 
sample 
n=1,154 
Not frail 
n = 204 
Pre-frail 
n = 530 
Frail 
n = 420 
Gender (% female)  717 (62.1) 96 (47.1) 314 (59.3) 307 (73.1) 
Mean age (years, SD)  78.8 (7.4) 75.7 (6.5) 78.8 (7.4) 80.4 (7.3) 
PIMs (count, %)      
Antipsychotics 21 (1.8) 4 (2.0) 7 (1.3) 10 (2.4) 
Anticholinergics  78 (6.8) 6 (2.9) 36 (6.8) 36 (8.6) 
Tricyclic 
Antidepressants  
76 (6.6) 5 (2.5) 30 (5.6) 41 (9.8) 
Other Antidepressants  119 (10.3) 14 (6.9) 35 (6.6) 70 (16.7) 
Benzodiazepines  46 (4.0)  4 (2.0) 14 (2.6) 28 (6.7)  
Proton Pump Inhibitors  331 (28.7) 34 (16.7) 149 (28.1) 148 (35.2) 
Polypharmacy      
0-4 551 (47.8) 143 (70.1) 260 (49.1) 148 (35.2) 
5-9 493 (42.7) 56 (27.5) 229 (43.2) 208 (49.5) 
10+ 110 (9.5) 5 (2.5) 41 (7.7) 64 (15.2) 
Cognitive impairment     
Dementia (count, %)  154 (13.3) 16 (7.8) 79 (14.9) 59 (14.1) 
MMSE score (count, %)      
 22-24 789 (68.4) 164 (80.4) 362 (68.3) 263 (62.6) 
 21-19 283 (24.5) 37 (18.1) 127 (24.0) 119 (28.3) 
 <=18 82 (7.1) 3 (1.5) 41 (7.7) 38 (9.1) 
     
Number of 
Comorbidities (mean, 
SD)  
2.4 (1.6) 1.6 (1.2) 2.3 (1.5) 2.9 (1.7) 
Care home resident 
(count, %)  
47 (4.1) 2 (1.0) 22 (4.2) 23 (5.5) 
MMSE: Mini-Mental State Examination score (0-30 higher scores indicate better 
cognition).   
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7.03  Prevalence of PIM and polypharmacy use in people with cognitive 
impairment  
Around 40% of older, cognitively impaired adults were prescribed at least one PIM. The weighted 
proportional estimate of any PIM use in the population of older adults with cognitive impairment 
was 41.1% (95% CI 38.2 - 44.0) (see Table 20). In the sample, this equated to 40.6% with a 
prescription of at least one PIM (n=469). The most prevalent PIM was PPIs with an estimated 
28.6% (95% CI 26.0 – 31.3, n=331) of older cognitively impaired adults prescribed PPIs. 
Antidepressant medication (excluding tricyclic antidepressants) was the second most prevalent 
PIM (10.3% 95% CI 8.6-12.2, n=119). Tricyclic antidepressants were prescribed in an estimated 
6.8% (95% CI 5.4-8.4, n=76) of cognitively impaired older adults, as were anticholinergic 
medications (excluding tricyclics) (6.8% 95% CI 5.4-8.3, n=78). An estimated 4.2% (95% CI 3.1-5.6, 
n=46) were prescribed benzodiazepines and 2.1% (95% CI 1.3-3.2, n=21) were prescribed 
antipsychotic medications.  
Polypharmacy (5-9 medications) was prevalent in an estimated 43.3% (95% CI 40.4-46.3 n=493) of 
older adults with cognitive impairment and 9.8% (95% CI 8.1-11.7) were prescribed hyper-
polypharmacy (10 or more medications), excluding PIMs.   
 
(a) Weighted prevalence stratified by frailty  
Frailty was associated with greater PIM use and polypharmacy in older adults with cognitive 
impairment. The weighted prevalence estimates for tricyclic antidepressants, other 
antidepressant medications, benzodiazepines and other anticholinergic medicines were at least 
twice as high in frail participants compared to participants who were not frail. Prevalence 
estimates of antipsychotic medication use were similar across frailty (see Table 20).  
 173 
 
Table 20 Weighted polypharmacy and PIM prevalence amongst older adults with cognitive 
impairment, estimated from CFAS II sample (n=1,154) stratified by frailty.  
PIM Prevalence 
estimate  
(95% CI) 
Frailty 
Not frail Pre-frail Frail 
Antipsychotics 2.1 (2.3-3.2) 2.2 (1.0-5.8) 1.6 (1.0-3.5) 2.6 (1.4-4.9)  
Anticholinergics  6.7 (5.4-8.3) 2.7 (1.2-5.9) 6.9 (5.0-9.5) 8.2 (5.9-11.2) 
Tricyclic 
Antidepressants  
6.8 (5.4-8.5) 2.9 (1.2-6.9) 5.7 (3.9-8.3)  9.6 (7.1-12.9) 
Other 
Antidepressants  
10.2 (8.6-12.2) 7.0 (4.1-11.6)  6.7 (4.8-9.3) 15.9 (12.6-19.7)  
Benzodiazepines  4.2 (3.1-5.6) 2.0 (1.0-5.5)  2.8 (1.6-4.6)  6.8 (4.7-9.8)  
PPI  28.6 (26.0-31.3) 16.7 (12.1-22.6)  28.3 (24.5-32.4) 33.9 (29.5-38.7)  
Polypharmacy      
0-4 46.9 (44.0-49.9) 69.2 (62.4-75.4) 48.1 (43.7-52.5) 36.2 (31.6-41.1) 
5-9 43.3 (40.4-46.3) 27.5 (21.7-34.2) 44.0 (39.7-48.4) 49.0 (44.1-53.9) 
10+ 9.8 (8.1-11.7) 3.3 (1.3-7.7) 7.9 (5.8-10.7) 14.8 (11.6-18.6)  
Weighted prevalence (95% CI)  
Prevalence estimates weighted using CFAS inverse probability weighting sampling weights  
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(b) PIM use in care home residents  
Around 4% of the sample lived in a care or nursing home (n=47, 4.1%). PIM use was greater in 
care home residents for all PIMs, with the exception of other anticholinergic medications, with 
4.2% of care home residents reporting use of other anticholinergics compared with 6.9% of 
people living in their own home (see Figure 23). The use of antipsychotic medications was ten 
times greater in people living in a care home, compared to those living in their own home. 
Reported use of benzodiazepines and antidepressant medications (not tricyclic antidepressants) 
was nearly twice as high in people living in a care home compared to those living in their own 
home.  
 
Figure 23 Percentage of PIM use in people with cognitive impairment (MMSE<=24) from CFAS II, stratified by living 
situation 
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(c) Characteristics of PIM users and polypharmacy compared to non-users  
There were a few differences between participants who reported taking 0-4 medications 
compared to those with polypharmacy or hyperpolypharmacy (see Table 21). Participants with 0-
4 medications reported fewer comorbidities (1.7 SD 1.3) compared to people with polypharmacy 
(2.9 SD 1.5) and hyperpolypharmacy (3.8 SD 1.7). Fewer participants with 0-4 medications were 
living in a care home (n=15 2.7%) compared with people with polypharmacy (n=24 4.9%) and 
hyperpolypharmacy (n=8 7.3%).    
Of the participants reporting antipsychotic medication use, 23.8% (n=5) were care home 
residents, 4.8% (n=1) were diagnosed with dementia according to the CFAS algorithm and the 
mean MMSE score of antipsychotic users was 21 (SD 3.9). Among participants reporting taking 
other anticholinergics, 9.0% (n=7) were diagnosed with dementia according to CFAS algorithm 
and 2.6% (n=2) were living in a care home. The mean number of comorbidities was similar in users 
compared to non-users of PIMs. The exception was for tricyclic antidepressant users who had 3.1 
(SD 1.5) comorbidities compared to non-users who had 2.4 (SD 1.6) and benzodiazepine users 
who had 3.5 (SD 1.9) comorbidities compared to 2.4 (SD 1.6) among non-users.   
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Table 21 Characteristics of participants reporting 0-4 medications, polypharmacy and 
hyperpolypharmacy from CFAS II subsample analysis (n=1,154)  
 Medication use 
Characteristic 0-4  
(n=551) 
Polypharmacy (5-9)  
(n=493) 
Hyperpolypharmacy 
(10+)  
(n=110) 
Gender (%, female)  334 (60.6) 321 (65.1)  62 (56.4)  
Age (years)  78.3 (7.6)  79.6 (7.1)  78.9 (7.4)  
Dementia (count, %)  76 (13.8)  65 (13.2)  13 (11.8) 
MMSE score (count, %)     
22-24 393 (71.3)  321 (65.1)  75 (68.2)  
21-19 125 (22.7) 131 (26.6)  27 (24.6)  
<=18 33 (6.0) 41 (8.3) 8 (7.3)  
    
Number of Comorbidities 
(mean, SD)  
1.7 (1.3)  2.9 (1.5) 3.8 (1.7)  
Care home resident 
(count, %)  
15 (2.7)  24 (4.9)  8 (7.3)  
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7.04 Survival among the sample  
By the end of the follow-up period (October 2016), 489 (42.4%) of the people with cognitive 
impairment included in this sample had died (see Table 22). Of those who reported PIM use, the 
largest proportion of people who had died were those who reported antipsychotic medication 
use. Overall, 52.3% (n=11) of those using antipsychotics, 47.4% (n=37) of those using other 
anticholinergic medications died. In addition, 43.4% (n=33) of tricyclic antidepressant users, 46.5% 
(n=21) of benzodiazepine, 46.2% (n=55) of other antidepressant and 44.0% (n=145) of those using 
PPIs had died. Among those experiencing polypharmacy and hyper-polypharmacy, 45.2% (n=233) 
and 55.4% (n=60) had died, compared to 33.0% (n=182) of people who reported taking 0-4 
medications.   
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Table 22 Table of sample characteristics of survival across each exposure and covariate  
Characteristic Total sample 
n=1,154 
Death by 31/10/16 
n=489 
Gender (% female)  717 (62.1) 222 (44.4)  
Mean baseline age (years, SD)  78.8 (7.4) -  
PIMs (count, %)    
Antipsychotics 21 (1.8) 11 (52.3)  
Anticholinergics  78 (6.8) 37(47.4)  
Tricyclic Antidepressants  76 (6.6) 33 (43.4)  
Other Antidepressants  119 (10.3) 55 (46.2)  
Benzodiazepines  46 (4.0)  21 (46.5)  
Proton Pump Inhibitors  331 (28.7) 145 (44.0)  
Number of medications    
0-4 551 (47.8) 182 (33.0) 
5-9 493 (42.7) 223 (45.2) 
10+ 110 (9.5) 60 (55.4) 
Cognitive impairment    
Dementia (count, %)  154 (13.3) 112 (72.7)  
MMSE score (count, %)    
 22-24 789 (68.4) 282 (35.7)  
 21-19 283 (24.5) 150 (53.0)  
 <=18 82 (7.1) 57 (69.5)  
   
Number of Comorbidities (mean, SD)  2.4 (1.6)  
Care home resident (count, %)  47 (4.1) 33 (70.2)  
Frailty (count, %)   
Not frail  204 (17.7) 45 (22.1)  
Pre-frail 530 (45.9)  226 (42.6)  
Frail  420 (36.4)  281 (51.9)  
MMSE: Mini-Mental State Examination score (0-30 higher scores indicate better 
cognition).   
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7.05 Estimating the association between polypharmacy and survival  
(a) Univariate analyses  
Kaplan-Meier survival curves suggested a difference in survival associated with polypharmacy and 
hyper-polypharmacy (see Figure 24). Log-rank tests estimated a statistically significant difference 
in survival across the categories for polypharmacy, excluding PIMs (M/ = 23.15	ST = 2, V =<0.01).	 Unadjusted Cox regression model estimates also suggested that polypharmacy and hyper-
polypharmacy were both significantly associated with mortality, hazard ratio of 1.39 (95% CI 1.14-
1.70) and 1.95 (95% CI 1.45-2.61) respectively, compared to people who reported using 0-4 
medications (Table 23). The proportional hazards assumption was tested using Schoenfeld 
residuals and the assumption was not violated (M/ = 1.63	V = 0.443).  
 
(b) Multivariate analyses  
Adjusting for potentially confounding variables accounted for around half of the univariate effect 
of polypharmacy on mortality, reducing the hazard ratio to 1.21 (95% CI 0.97-1.50). Hyper-
polypharmacy remained significantly associated with increased risk of mortality (HR 1.60 95% CI 
1.16-2.22). The proportional hazards assumption was not violated in the multivariate model, as 
confirmed in tests of proportional hazards for the hazard associated with polypharmacy (M/ =1.36	V = 0.243) and hyper-polypharmacy	(M/ = 0.01	V = 0.968) and in the global test of the 
model (M/ = 13.88	V = 0.383).     
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Figure 24 Unadjusted Kaplan-Meier survival curves estimating time until mortality in people with cognitive impairment taking 0-4, 5-9 and 10 or 
more medications. CFAS II (n=1,154). Hazards were assumed to be proportional (!" = 1.63	) = 0.443). 
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7.06 Estimating the association between PIMs and survival  
(a) Univariate analyses  
Kaplan-Meier survival curves suggested there was a substantial difference in survival of users of 
antipsychotics compared to non-users, and a small difference in survival amongst users of PPIs 
compared to non-users. However there appeared to be relatively little difference in survival 
amongst the remaining PIM users compared to non-users (Figure 25). A statistically significant 
difference was estimated in users of antipsychotic medications, compared to non-users (!" =8.21	)* = 1, , =< 0.01). Unadjusted Cox regression models estimated that antipsychotic 
medication use was associated with 2.19 increased hazard of mortality (HR 2.19 95% CI 1.26-3.81) 
and PPIs were associated with 16% increased risk of mortality, however this was not statistically 
significant (HR 1.16 95% CI 0.95-1.42). In addition, whilst the hazard associated with the 
remaining PIM were all above 1, none of the remaining PIMs were associated with a statistically 
significant difference in mortality in users compared to non-users.  
On inspection of the Kaplan-Meier survival curves (Figure 25), the hazard associated with 
antipsychotic medication and tricyclics use appeared to lack proportionality, however the 
univariate estimate was tested and results suggested no significant difference in the 
proportionality of the hazards associated with antipsychotics (!" = 1.16	, = 0.282) or tricyclics ( !" = 0.30	, = 0.585) .   
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Figure 25 Kaplan-Meier survival curves comparing survival time in users compared to non-users of PIMs. CFAS II (n=1,154).  
Schoenfeld residuals were used to test the proportionality assumption in the univariate models. Tricyclics  !" = 0.30	( = 0.585, other anticholinergics !" = 1.28	( = 0.257,  other 
antidepressants !" = 0.47	( = 0.495,	benzodiazepine !" = 0.08	( = 0.772, PPI !" = 3.48	( = 0.062, antipsychotic !" = 1.16	( = 0.282.	
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(b) Multivariate analyses  
Estimates from the Cox regression models, adjusted for age, sex, baseline cognitive impairment, 
living situation and comorbidities saw an increase in the hazard associated with antipsychotic 
medication use to 3.24 (95% CI 1.83-5.73) (see Table 23). With the exception of antipsychotic 
medications, PIM were not associated with increased risk of mortality in this sample of cognitively 
impaired older adults.  
The other covariates included in the model were also significantly associated with mortality in this 
sample (see Table 23). In this sample of cognitively impaired adults, being male, older and having 
worse cognitive impairment and more comorbid health conditions was independently associated 
with an increased risk of mortality, after adjusting for potential confounders.  
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Table 23 Unadjusted and adjusted potentially inappropriate medication use hazard ratios for 
survival, univariate and multivariate models. Cognitive Function and Ageing Study (CFAS) II 
n=1,154. 
Variables  Univariate Multivariate Frailty modela 
PIM    
Antipsychotics (n=21) 2.19* (1.26 – 3.81) 3.24* (1.83 - 5.73) 3.28* (1.85 - 5.80) 
Tricyclic Antidepressants 
(n=76) 
1.01 (0.70 - 1.47) 1.11 (0.76 - 1.63) 1.06 (0.72 - 1.55) 
Anticholinergics (n=78) 1.29 (0.92 - 1.80) 1.18 (0.83 - 1.67) 1.17 (0.83 - 1.66) 
Other Antidepressants 
(n=119)  
1.21 (0.91 - 1.61) 0.94 (0.70 - 1.28) 0.90 (0.66 - 1.22) 
Benzodiazepines (n=46)  1.08 (0.67 - 1.72) 0.75 (0.47 - 1.21) 0.72 (0.45 - 1.16) 
Proton Pump Inhibitor 
(331)  
1.16 (0.95 - 1.42) 1.08 (0.88 - 1.33) 1.05 (0.86 - 1.30) 
Polypharmacy     
0-4 (n=551)  1 1 1 
5-9 (n=493)  1.39* (1.14 - 1.70) 1.21 (0.97 - 1.50) 1.17 (0.95 - 1.45) 
10+ (n=110)  1.95* (1.45 - 2.61) 1.72* (1.24 - 2.38) 1.60* (1.16 - 2.22) 
Covariates     
Age at interview (per year)  1.10* (1.09 - 1.12) 1.10* (1.09 - 1.12) 1.10* (1.08 - 1.12) 
Gender (female)  0.76* (0.63 - 0.91) 0.62* (0.51 - 0.75) 0.57* (0.46 - 0.69) 
MMSE score (per point)  0.88* (0.85 - 0.90) 0.91* (0.88 - 0.94) 0.91* (0.89 - 0.94) 
Care Home Residence 2.36* (1.63 - 3.42) 1.23 (0.83 - 1.84) 1.20 (0.81 - 1.80) 
Comorbidities  1.06* (1.00 - 1.13) 1.08* (1.01 - 1.15) 1.05 (0.98 - 1.13) 
Frailty     
Pre-frail 2.22* (1.59 - 3.09)  1.56* (1.11 - 2.20) 
Frail 2.92* (2.09 - 4.07)  1.90* (1.32 - 2.72) 
MMSE: Mini-Mental State Examination score (0-30 with higher scores indicating better cognition). 
aMultivariate model adjusted for frailty*p<0.05 HR(95% CI) 
Proportional hazards assumption assessed using Schoenfeld residuals, overall both models did not violate 
proportional hazards assumption and hazards were estimated as not violating assumption for significant 
exposures (antipsychotics and hyperpolypharmacy). Multivariate model (!" = 13.88	) = 0.383), 
antipsychotics test (!" = 0.05	) = 0.819), hyperpolypharmacy (!" = 0.01	) = 0.968). Frailty model 
(!" = 16.91	) = 0.324), antipsychotics ((!" = 0.09	) = 0.760), hyper-polypharmacy (!" = 0.01	) =0.977). 
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7.07 Estimating the association of potentially inappropriate prescribing, survival 
and frailty  
People who were frail were exposed to a greater number of medications and PIMs. In this sample, 
a greater proportion of people who were frail were taking polypharmacy (n=208 49.0% 95% CI 
44.1-53.9) and hyperpolypharmacy (n=64 14.8% 95% CI 11.6-18.6) compared to people who were 
pre-frail and not frail (see Table 20). In addition they were more exposed to all PIMs. There were 
only marginally more people who were frail (n=23, 5.5%) who were living in a care home 
compared to those who were pre-frail (n=22, 4.2%), however there was a greater proportion of 
people who were pre-frail and frail living in a care home, compared to not frail people (n=2, 1%).   
 
(a) Proportion of PIM and polypharmacy by frailty status  
At baseline 36.4% of the sample were classified as frail (n=420), while 45.9% were pre-frail 
(n=530) (Table 19). Use of multiple medications was associated with increasing levels of frailty. 
People who were not frail were taking a mean of 3.2 (SD 2.7) medications, people who were in 
the pre-frailty state were taking a mean of 4.8 (SD 3.3) medications and frail adults were taking 
6.0 (SD 3.3) medications. The proportion of people with cognitive impairment who reported PIM 
use was greatest amongst those who were identified as frail (see Figure 26). PPI use was twice as 
common in people who were identified as frail (35.2%) compared to not frail (16.7%). The use of 
antidepressants (not including tricyclic antidepressants) was twice as great among people who 
were considered frail (16.7%) compared to pre-frail (6.6%) or not frail (6.7%). Similarly, the 
reported use of benzodiazepines, tricyclic antidepressants and other anticholinergics was twice as 
high in people who were pre-frail and frail compared with people who were not frail.  
 
(b) Association of frailty with mortality  
At the point of censoring, around half of those who were frail at baseline (51.9% n=218), 42.6% 
(n=226) pre-frail and 22.1% (n=45) of non-frail participants had died. In the univariate analyses, 
mortality was greater in those classified as pre-frail (HR 2.22 95% CI 1.59-3.09) and frail (HR 2.92 
95% CI 2.09-4.07) (see Table 23) compared to those not considered frail. The proportional hazards 
assumption was not violated (!" = 3.45	) = 0.179). After adjusting for PIM use, polypharmacy 
and other covariates, people who were considered pre-frail and frail remained independently 
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associated with a significantly increased risk of mortality compared to non-frail people (HR 1.56 
95% CI 1.11 – 1.20 and HR 1.90 95% CI 1.32-2.72 respectively).   
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Figure 26 proportion of reported PIM use in people with cognitive impairment, stratified by frailty 
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(c) Frailty as a moderator of the effect of PIM and polypharmacy 
Cox regression models were estimated adjusting for PIM, polypharmacy, age, sex, baseline 
cognitive impairment, and comorbidities and were stratified by frailty status (see Table 24 and 
Figure 27). Stratified analyses suggested that polypharmacy (5-9 medications) was associated with 
an increased risk of mortality across frailty status however the risk was greatest among people 
who were considered not frail (HR 2.34 95% CI 1.16-4.70). Similarly, the risk associated with 10 or 
more medications was greatest among people who were not frail. However, this was not 
statistically significant (HR 4.22 95% CI 0.90-19.90). For people who were identified as frail, use of 
10 or more medications was associated with an 80% increased risk of mortality compared with 
frail older adults with cognitive impairment taking 0-4 medications (HR 1.80 95% CI 1.15-2.82). 
Terms representing the interaction of frailty with polypharmacy were added into the model and 
there was no significant interaction of frailty with polypharmacy. 
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Figure 27 Unadjusted Kaplan-Meir survival curve of polypharmacy, stratified by frailty status.  
Hazard ratio associated with polypharmacy and hyper-polypharmacy compared to survival in people taking 0-4 medications; Adjusted hazard ratios, not frail participants: 5-9 medications 
HR 2.34 95% CI 1.16-4.70 n=56, 10+ medications HR 4.22 95% CI 0.90-19.90 n=5; pre-frail 5-9 medications HR 1.07 95% CI 0.78-1.45 n=229, 10+  medications HR 1.31 95% CI 0.75-2.29 
n=41; frail 5-9 medications HR 1.17 95% 0.84-1.64 n=208, 10+ medications HR 1.80 95% CI 1.15-2.82 n=64. 
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The hazard ratio associated with each PIM was consistent across all levels of frailty in adjusted 
models. In antipsychotic users compared to non-users, the hazard in non-frail participants was 
3.60 (95% CI 0.40-31.99), 2.89 (95%CI 1.26-6.66) in pre-frail participants and 3.34 (95% CI 1.37-
8.12) in frail participants (see Figure 28 and Table 24).  However, the number of deaths in across 
the frailty groups was very small, particularly among people who were not frail, making it difficult 
to draw strong conclusions. 
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Figure 28 Unadjusted Kaplan-Meier survival curve of antipsychotic medication users compared to non-users, stratified by frailty. 
Antipsychotic use in not frail n= 4, pre-frail n=7 and frail n=10. Adjusted HR non-frail participants 3.60 (95% CI 0.40-31.99), 2.89 (95%CI 1.26-6.66) in pre-frail participants and 3.34 (95% CI 1.37-8.12) in frail participants. 
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(d) Frailty and exposure interaction  
Terms representing the interaction between frailty statuses with each of the medication 
exposures were entered into the model (see Table 24). Likelihood ratio test of the interaction for 
frailty and benzodiazepine use was statistically significant, however there were very few deaths in 
the not frail group (n=1) (!" 6.05 p=0.049). There were no other statistically significant 
interactions for the PIM exposures and polypharmacy. Frailty did not moderate the effect of the 
remaining PIM exposure or polypharmacy on the risk of mortality in cognitively impaired older 
adults. 
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Table 24 Hazard ratios estimated by Cox regression models for association between potentially 
inappropriate medication use and mortality, stratified by frailty. Cognitive Function and Ageing 
Studies II (CFAS II) 
 Cox regression analysis stratified by frailty classificationa P-value for 
interaction  
 
Variables  Not frail 
n=204 
Pre-frail  
n=530 
Frail 
n=420 
PIM      
Antipsychotic  3.60 (0.40 - 31.99) 2.89* (1.26 - 6.66) 3.34* (1.37 - 8.12) 0.995 
Tricyclic Antidepressant  0 1.84 (0.98 - 3.44) 0.90 (0.55 - 1.48) 0.060 
Anticholinergics  1.29 (0.16 - 10.61) 1.05 (0.61 - 1.79) 1.23 (0.76 - 2.01) 0.854 
Other Antidepressants 0.86 (0.23 - 3.20) 1.12(0.67 - 1.89) 0.74(0.49 - 1.12) 0.230 
Benzodiazepines 0.92 (0.11 - 7.78) 1.40 (0.66 - 2.97) 0.43* (0.21 - 0.86) 0.049* 
Proton Pump Inhibitor  1.05 (0.43 - 2.59) 1.04 (0.76 - 1.42) 1.09 (0.80 - 1.49) 0.808 
     
Polypharmacy      
0-4 1 1 1 0.102 
5-9 2.34* (1.16 - 4.70) 1.07 (0.78 - 1.45) 1.17 (0.84 - 1.64)  
10+ 4.22 (0.90 - 19.90) 1.31 (0.75 - 2.29) 1.80* (1.15 - 2.82)  
Covariates      
Age at interview 1.13* (1.07 - 1.19) 1.11* (1.09 - 1.13) 1.08* (1.06 - 1.11)  
Gender (female)  0.71 (0.35 - 1.43) 0.67* (0.50 - 0.89) 0.43* (0.31 - 0.58)  
MMSE score (per point) 0.87* (0.77 - 0.98) 0.92* (0.88 - 0.96) 0.91* (0.87 - 0.96)  
Care Home Residence 0 0.92 (0.50 - 1.71) 1.68 (0.98 - 2.88)  
Comorbidities  1.16 (0.90 - 1.50) 1.03 (0.93 - 1.14) 1.02 (0.92 - 1.12)  
MMSE: Mini-Mental State Examination score (0-30 with higher scores indicating better cognition). 
aClassified as positive on individual frailty components if score, rating or time within the upper quartile. 
Classified as frail if positive on 3-5 individual frailty components and pre-frail if 1-2 components.  
bLikelihood ratio test comparing exposure*frailty interaction models with multivariate frailty model with 
pre-frail group as baseline.   
*p<0.05 HR (95% CI) 
Proportional hazards test: not frail (#" = 5.12	* = 0.972), pre-frail (#" = 23.72	* = 0.034), and frail 
(#" = 11.3	* = 0.586). Test suggests hazards were not proportional over time in the model with pre-
frail participants, proportionality was assumed however hazard may be varied across the time period.   
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7.08 Proportional hazards assumption  
The proportional hazards assumption, assessed using Schoenfeld residuals was not violated in the 
model estimating the effect of PIM and polypharmacy exposure on mortality, adjusting for 
potentially confounding variables and frailty (#" = 16.91	45 = 15, * = 0.324). The proportional 
hazards assumption was tested across analyses for each covariate the results are included in the 
relevant tables in-line with the analyses that were conducted.  
 
7.09 Predictive validity of frailty phenotype criteria  
The proportion of the sample who were impaired on each frailty criteria is described in Table 25. 
Close to 70% (n=802) of the sample were impaired on the weakness criteria (Sit-To-Stand test), 
60% (n=702) were impaired on the slowness criteria from the gait-speed test, 29% (n=334) were 
impaired on the self-reported exhaustion criteria and 27% (n=313) were impaired on the physical 
activity criteria.  
 
Table 25 proportion of the sample impaired on each frailty criteria, stratified by frailty 
Frailty criteria   
(count, %) 
Frailty phenotype  
Not frail 
n = 204 
Pre-frail 
n = 530 
Frail 
n = 420 
Low physical activity 313 (27.1) - 58 (10.9) 255 (60.7) 
Weight Loss 122 (10.6) - 29 (5.5) 93 (22.1) 
Weaknessa  802 (69.5) - 388 (73.2) 414 (98.6) 
Slownessb 702 (60.8) - 313 (59.1) 389 (92.6) 
Exhaustion  334 (28.9) - 74 (14.0) 260 (61.9) 
     
MMSE: Mini-Mental State Examination score (0-30 higher scores indicate better 
cognition).   
aMissing n=603: categorised as impaired, missing due to inability to complete the test   
bMissing n=244: categorised as impaired, missing due to inability to complete the test 
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Three of the five frailty criteria were univariately associated with an increased risk of mortality. 
Low physical activity, weakness and slowness were each independently associated with mortality 
risk in unadjusted Cox regression estimates. The greatest unadjusted risk was associated with 
weakness (HR 2.23 95% CI 1.77-2.83), followed by slowness (HR 1.99 95% CI 1.62-2.45) and low 
physical activity (HR 1.41 95% CI 1.15-1.71). The independent effect is illustrated in the Kaplan-
Meier survival curves in Figure 29. Both exhaustion and weight loss were associated with an 
increased hazard but this was not statistically significant (see Table 26). After adjustment for PIM 
use, polypharmacy and the other potentially confounding variables, slowness was the only frailty 
criteria with an independent and significant association with mortality. Being impaired on the 
slowness frailty criteria was associated with a 42% increased risk of mortality (HR 1.42 95% CI 
1.12-1.81).  Including the individual frailty components rather than the composite frailty 
categories did not affect the overall estimates associated with PIMs or polypharmacy previously 
estimated.  
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Figure 29 Unadjusted Kaplan-Meier survival curves estimating survival associated with individual frailty component, unadjusted estimates.  
Cognitive Function and Ageing Study II (CFAS II) n=1,154. 0 = unimpaired on frailty criteria, 1 = impaired on frailty criteria. Adjusted hazard ratios for each criteria: physical activity HR 1.22 95% CI 0.98 - 1.51, weight loss HR 1.19 95% CI 
0.89 - 1.60, weakness HR 1.13 95% CI 0.86 - 1.49, slowness HR 1.42 95% CI 1.12 - 1.81, exhaustion HR 0.98 95% CI 0.79 - 1.22.  Proportional hazards assumption test: Low physical activity (χ" = 0.62	p = 0.430), weight loss (χ" =1.27	p = 0.261), weakness (χ" = 3.09	p = 0.079), slowness (χ" = 6.02	p = 0.01), exhaustion (χ" = 1.45	p = 0.229). The test suggests that the hazard for the slowness frailty component was not proportional, visual inspection of 
Kaplan-Meier curves appears to show a small variation in the hazards over time, therefore hazard is assumed to be proportional for the purpose of this analysis.
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Table 26 Risk of mortality associated with the use of PIM and individual frailty components in 
univariate and multivariate models. Cognitive Function and Ageing Studies (CFAS II) n=1,154. 
 Univariate  
HR (95% CI) 
Multivariatea  
HR (95% CI) VARIABLES 
   
Antipsychotic  2.19* (1.26 – 3.81) 3.30* (1.86 - 5.86) 
Tricyclic antidepressant  1.01 (0.70 - 1.47) 1.04 (0.71 - 1.53) 
Anticholinergic 1.29 (0.92 - 1.80) 1.17 (0.83 - 1.66) 
Other Antidepressants 1.21 (0.91 - 1.61) 0.88 (0.65 - 1.20) 
Benzodiazepines 1.08 (0.67 - 1.72) 0.73 (0.46 - 1.18) 
PPI 1.16 (0.95 - 1.42) 1.05 (0.85 - 1.29) 
Polypharmacy    
0-4 1 1 
5-9 1.39* (1.14 - 1.70) 1.17 (0.95 - 1.46) 
10+ 1.95* (1.45 - 2.61) 1.65* (1.19 - 2.29) 
Frailty components    
Low Physical Activity   1.41* (1.15–1.71) 1.22 (0.98 - 1.51) 
Weight loss 1.25 (0.94–1.66) 1.19 (0.89 - 1.60) 
Weakness 2.23* (1.77–2.83) 1.13 (0.86 - 1.49) 
Slowness 1.99* (1.62-2.45) 1.42* (1.12 - 1.81) 
Exhaustion  1.10 (0.90–1.35) 0.98 (0.79 - 1.22) 
aAdjusted for age, sex, MMSE, care home residence and comorbidities (heart attack, diabetes 
mellitus, bronchitis, stroke, arthritis, asthma, angina pectoris, hypertension, epilepsy, thyroid 
problems, Parkinson’s disease, pernicious anaemia, and depression). 
*p<0.05 
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7.10 Continuation of medication use  
There were 561 (48.6%) people included in this sample who had two year follow-up data that 
could be used to understand the continuation of medications they reported taking at baseline. 
The majority of people who reported taking PIMs at baseline, also reported taking the same 
medications two years later. PPIs were the PIM with the largest proportion of people who 
reported taking the medication at baseline and at two year follow-up with 85% (n=136/160) 
reporting long-term use. At least 60% of the people who reported taking any of the PIMs at 
baseline also reported the same PIMs at follow-up. There were 29 people (69%, n=29/42) who 
reported other anticholinergic medications at both baseline and follow-up. There were 5 people 
who were taking antipsychotics at follow-up in the sample and three of these were prevalent 
users who also reported antipsychotic use at baseline interview. In addition, around 76% of 
people reported tricyclic antidepressants and other antidepressant medications at both baseline 
and follow-up (n=31/40 tricyclics, n= 43/56 other antidepressants).  
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7.11 Sensitivity analyses  
(a) Adjusting for behavioural and psychological symptoms of dementia  
There was little difference in mortality estimates associated with polypharmacy and 
hyperpolypharmacy in the sub-sample analysis of participants who had responses to HAS 
informant questionnaires (n=214) (Table 27). Polypharmacy and hyper-polypharmacy were both 
associated with similar hazard estimates as in the overall sample, however the effects were not 
statistically significant. Hyper-polypharmacy was associated with a hazard ratio of 1.60 (95% CI 
1.16 - 2.22) in the overall sample and a hazard of 1.50 (95% CI 0.72 - 3.12) in the sub-sample. In 
this sub-sample, antipsychotic medications remained associated with a significant increase in 
mortality (adjusted HR 4.10 95% CI 1.42 - 11.89). This subsample analysis included adjustments 
for behavioural and psychological symptoms of dementia including irritability, hallucinations, 
wandering and sleep problems.  
In this analysis, other anticholinergic medications were also associated with increased risk of 
mortality (HR 1.99 95% CI 1.07 - 3.73). This may be attributable to the adjustment for behavioural 
and psychological symptoms of dementia, consequences of medication use or to differences in 
the sample and sub-sample. A larger proportion of the sub-sample were male than the whole 
sample (52% female sub-sample 62% female in the sample) a larger proportion had a dementia 
diagnosis at baseline (47.7% dementia) and a larger proportion of the sub-sample had died by the 
end of the follow-up period (57.5% died compared with 42% in the sample).  
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Table 27 Cox regression models estimating survival associated with exposures and covariates in sub-sample with information on BPSD, BPSD symptoms are adjusted for individually in the 
model and collectively to compare estimates as the symptoms are adjusted for in the model.  
 Adjusted frailty model  Adjusted BPSD symptoms  Sleep Problems  Irritability  Hallucinations Wondering  
Variables (n=1,154) (n=214) (n=214) (n=214) (n=214) (n=214) 
PIMs       
Antipsychotic  3.28*(1.85 - 5.80) 4.10*(1.42 - 11.89) 4.16*(1.49 - 11.61) 4.46*(1.60 - 12.46) 4.00*(1.41 - 11.29) 4.60*(1.66 - 12.75) 
Tricyclic antidepressant  1.06(0.72 - 1.55) 0.78(0.28 - 2.15) 0.76(0.28 - 2.07) 0.71(0.26 - 1.91) 0.73(0.27 - 1.97) 0.75(0.28 - 2.02) 
Anticholinergic  1.17(0.83 - 1.66) 1.99*(1.07 - 3.73) 1.96*(1.06 - 3.64) 1.96*(1.05 - 3.66) 1.97*(1.06 - 3.66) 1.95*(1.05 - 3.64) 
Other Antidepressants 0.90(0.66 - 1.22) 0.90(0.50 - 1.61) 0.86(0.48 - 1.54) 0.87(0.49 - 1.57) 0.89(0.50 - 1.58) 0.87(0.49 - 1.55) 
Benzodiazepines  0.72(0.45 - 1.16) 0.66(0.22 - 2.01) 0.66(0.22 - 2.00) 0.59(0.20 - 1.73) 0.61(0.21 - 1.78) 0.59(0.20 - 1.70) 
PPI 1.05(0.86 - 1.30) 1.09(0.70 - 1.69) 1.08(0.70 - 1.67) 1.06(0.68 - 1.66) 1.07(0.69 - 1.66) 1.07(0.69 - 1.66) 
Polypharmacy        
5-9 1.17(0.95 - 1.45) 1.04(0.66 - 1.64) 1.02(0.65 - 1.60) 1.02(0.65 - 1.61) 1.02(0.65 - 1.59) 1.03(0.66 - 1.62) 
10+ 1.60*(1.16 - 2.22) 1.50(0.72 - 3.12) 1.55(0.76 - 3.15) 1.49(0.73 - 3.03) 1.46(0.72 - 2.97) 1.53(0.75 - 3.12) 
Frailty        
Pre-frail  1.56*(1.11 - 2.20) 1.54(0.78 - 3.05) 1.59(0.81 - 3.15) 1.56(0.79 - 3.08) 1.54(0.78 - 3.05) 1.55(0.78 - 3.06) 
Frail 1.90*(1.32 - 2.72) 1.89(0.91 - 3.93) 1.88(0.91 - 3.88) 1.94(0.94 - 4.01) 1.91(0.93 - 3.92) 1.91(0.93 - 3.94) 
BPSD         
Sleep problems   0.76(0.34 - 1.73) 0.73(0.32 - 1.63)    
Irritability – mild   1.08(0.67 - 1.74)  1.09(0.68 - 1.75)   
Irritability – severe   0.90(0.37 - 2.17)  0.93(0.39 - 2.21)   
Hallucinations   1.79(0.59 - 5.42)   1.87(0.63 - 5.50)  
Wondering – mild   1.17(0.48 - 2.84)    1.19(0.49 - 2.88) 
Wondering – severe   1.89(0.52 - 6.85)    1.84(0.52 - 6.53) 
HR (95% CI) *p<0.05 Likelihood ratio test (chi, p=<0.05) Individual symptoms added into model and model estimated including all symptoms. Models were adjusted for age, gender, care home residence baseline cognitive impairment, number of self-reported 
comorbidities and frailty  
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(b) Adjusting for alternative measures of cognitive impairment  
Including the CAMCOG as the marker of baseline cognitive impairment instead of MMSE provided 
similar hazard estimates associated with PIM use (see Table 28). The mean CAMCOG score in the 
sample was 75.7 (SD 10.8), scores ranged from 19 to 98. There were 123 participants in the 
sample who did not have a CAMCOG score and thus were missing in the CAMCOG model. In 
models including the MMSE or CAMCOG, the hazard associated with antipsychotic use was 
similar, but slightly higher in the CAMCOG model. The risk associated with antipsychotics in the 
MMSE model was 3.28 (95% CI 1.85-5.80) compared with 3.43 (95% CI 1.89-6.22) in the CAMCOG 
model. The association of polypharmacy varied in the different models. Polypharmacy was not 
associated with significant increased risk of mortality in the MMSE model, but was associated 
with a 26% increased risk in the CAMCOG model (95% CI 1.00-1.59). However, this just reached 
the statistical significance threshold and is interpreted with caution. Hyper-polypharmacy was 
associated with an increased risk of mortality in both models. Across the remaining covariates 
included in the model, the estimates were comparatively similar. Overall, a model including 
MMSE or CAMCOG as the baseline measure of cognitive impairment provides remarkably similar 
estimates.  
 
(c) Adjusting for comorbidities  
Including each comorbidity separately in the full multivariate Cox regression model made little 
difference to the model estimates compared to the number of comorbid health conditions (Table 
29).  
 202 
 
Table 28 Cox regression model estimates using alternative measures of baseline cognitive 
impairment. Cognitive Function and Ageing Study (CFAS II) (n=1,154). 
 Adjusted Cox regression models 
Cognitive impairment measure  
Variables MMSE  
(n=1,154) 
CAMCOG 
(n=1,031)  
   
Antipsychotic  3.28* (1.85 - 5.80) 3.43* (1.89 - 6.22) 
Tricyclic antidepressant  1.06 (0.72 - 1.55) 1.03 (0.68 - 1.56) 
Anticholinergic  1.17 (0.83 - 1.66) 1.17 (0.80 - 1.71) 
Other Antidepressants 0.90 (0.66 - 1.22) 0.86 (0.61 - 1.20) 
Benzodiazepines  0.72 (0.45 - 1.16) 0.70 (0.41 - 1.18) 
PPI 1.05 (0.86 - 1.30) 1.10 (0.88 - 1.37) 
Polypharmacy    
5-9 1.17 (0.95 - 1.45) 1.26* (1.00 - 1.59) 
10+ 1.60* (1.16 - 2.22) 1.46* (1.01 - 2.10) 
Covariates    
Age at interview 1.10* (1.08 - 1.12) 1.10* (1.08 - 1.11) 
Gender (female)  0.57* (0.46 - 0.69) 0.52* (0.41 - 0.64) 
Care Home Residence 1.20 (0.81 - 1.80) 1.29 (0.83 - 1.99) 
Comorbidity 1.05 (0.98 - 1.13) 1.06 (0.98 - 1.14) 
Frailty    
Pre-frail 1.56* (1.11 - 2.20) 1.69* (1.16 - 2.45) 
Frail 1.90* (1.32 - 2.72) 2.03* (1.37 - 3.01) 
Cognitive impairment measure    
MMSE at w1 0.91* (0.89 - 0.94)  
CAMCOG  0.98* (0.97 - 0.98) 
MMSE: Mini-Mental State Examination score (0-30 with higher scores indicating better 
cognition). 
CAMCOG: Cambridge Cognition Examination (higher scores indicative of better cognition) 
  
*p<0.05 HR (95% CI) 
 
 203 
 
Table 29 Adjusted hazard ratios for survival comparing models with alternative comorbidity 
variables. Cognitive Function and Ageing Study (CFAS II n=1,154) 
Variables Multivariate  
Number of 
comorbidities  
Multivariate  
Individual 
comorbidities  
PIM    
Antipsychotics  3.28* (1.85 - 5.80) 3.58* (1.99 - 6.45) 
Tricyclic Antidepressants  1.06 (0.72 - 1.55) 1.16 (0.78 - 1.71) 
Anticholinergics  1.17 (0.83 - 1.66) 1.16 (0.82 - 1.64) 
Other Antidepressants 0.90 (0.66 - 1.22) 0.89 (0.65 - 1.22) 
Benzodiazepines  0.72 (0.45 - 1.16) 0.74 (0.46 - 1.20) 
Proton Pump Inhibitor  1.05 (0.86 - 1.30) 1.08 (0.87 - 1.34) 
Polypharmacy    
0-4   
5-9 1.17 (0.95 - 1.45) 1.16 (0.93 - 1.45) 
10+  1.60* (1.16 - 2.22) 1.59* (1.13 - 2.22) 
Covariates    
Age at interview (per year)  1.10* (1.08 - 1.12) 1.11* (1.09 - 1.12) 
Gender (female)  0.57* (0.46 - 0.69) 0.62* (0.50 - 0.77) 
MMSE score (per point)  0.91* (0.89 - 0.94) 0.92* (0.89 - 0.95) 
Care Home Residence 1.20 (0.81 - 1.80) 1.11 (0.74 - 1.68) 
Frailty    
frailty = 1, pre-frail 1.56* (1.11 - 2.20) 1.56* (1.10 - 2.21) 
frailty = 2, frail 1.90* (1.32 - 2.72) 1.82* (1.26 - 2.62) 
Comorbidities    
Number of comorbid health conditions  1.05 (0.98 - 1.13)  
Comorbidities    
Heart attack  1.30 (0.97 - 1.74) 
Fits or epilepsy   1.24 (0.70 - 2.21) 
Chronic bronchitis  1.18 (0.89 - 1.57) 
Asthma  1.09 (0.81 - 1.46) 
Parkinson’s disease  1.98* (1.01 - 3.87) 
Peptic ulcers   1.36 (0.98 - 1.87) 
Vitamin B12 deficiency  1.47 (0.95 - 2.27) 
Arthritis  0.99 (0.80 - 1.21) 
Stroke  1.30* (1.01 - 1.67) 
Angina  0.85 (0.64 - 1.12) 
High blood pressure  0.80* (0.65 - 0.97) 
Cancer  1.17 (0.90 - 1.52) 
Diabetes  1.43* (1.10 - 1.85) 
Cardiovascular disease  0.68 (0.30 - 1.57) 
Depression   0.76 (0.55 - 1.03) 
MMSE: Mini-Mental State Examination score (0-30 with higher scores indicating better 
cognition). 
*p<0.05 HR(95% CI) 
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(d) Frailty Criteria  
Adjusting for frailty criteria, operationalised using the lowest quintile, rather than lowest quartile, 
made no difference to the association of PIMs and polypharmacy with mortality (Table 30). As in 
the main analyses, being pre-frail and frail remained associated with mortality in univariate and 
multivariate adjusted models. Fewer people were classified as frail when frailty was 
operationalised using the lowest quintile (n=373 32.3%), compared to quartile (n=420 36.4%). 
Marginally more people were classified as pre-frail when frailty was operationalised using the 
lowest quintile (n=533 46.2%), compared to quartile (n=530 45.9%). More people were classified 
as not frail when frailty was operationalised using the lowest quintile (n=248 21.5%), compared to 
quartile (n=204 17.7%).   
Table 30 Sensitivity analysis adjusting for frailty operationalised using lowest quintile as in Fried et al., 2001 study. 
VARIABLES Main analysis 
multivariate model 
Sensitivity analysis 
multivariate model  
PIM   
Antipsychotic 3.28*(1.85 - 5.80) 3.29* (1.86 - 5.82) 
Tricyclic antidepressant  1.06 (0.72 - 1.55) 1.04 (0.71 - 1.53) 
Anticholinergic 1.17 (0.83 - 1.66) 1.20 (0.85 - 1.70) 
Other Antidepressants 0.90 (0.66 - 1.22) 0.87 (0.64 - 1.19) 
Benzodiazepines 0.72 (0.45 - 1.16) 0.72 (0.45 - 1.16) 
PPI 1.05 (0.86 - 1.30) 1.07 (0.87 - 1.31) 
Polypharmacy    
5-9 1.17 (0.95 - 1.45) 1.17 (0.94 - 1.45) 
10+ 1.60* (1.16 - 2.22) 1.59* (1.14 - 2.20) 
Covariates   
Age (per year) 1.10* (1.08 - 1.12) 1.10* (1.08 - 1.12) 
Gender (female) 0.57* (0.46 - 0.69) 0.58* (0.47 - 0.70) 
MMSE score (per point)  0.91* (0.89 - 0.94) 0.91* (0.88 - 0.94) 
Care Home Residence 1.20 (0.81 - 1.80) 1.19 (0.80 - 1.77) 
Comorbidities 1.05 (0.98 - 1.13) 1.05 (0.99 - 1.13) 
Frailty (quartile)   
Not frail (n=204)   
Pre-frail (n=530) 1.56* (1.11 - 2.20)  
Frail (n=420) 1.90* (1.32 - 2.72)  
Frailty (quintile)   
Not frail (n=248)   
Pre-frail (n=533)  1.45* (1.07 - 1.98) 
Frail (n=373)  1.83*(1.32 - 2.55) 
MMSE: Mini-Mental State Examination score (0-30 with higher scores indicating better 
cognition). 
*p<0.05 HR(95% CI) 
n=1,154 
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7.12 Summary  
In the CFAS II subsample analysed, around 28% reported use of PPIs, 10% reported antidepressant 
medications (excluding tricyclics) around 7% were reported tricyclic antidepressants, 7% reported 
anticholinergic medications (excluding tricyclics and antipsychotics). Around 4% of the sample 
reported benzodiazepine use and around 2% reported antipsychotic medications. Reported PIM 
use was consistently greater among people living in a care or residential home compared to 
people living in their own home.  
Polypharmacy and hyperpolypharmacy were associated with increased risk of mortality. In 
general, there was no evidence of an association of PIMs with subsequent survival. With the 
exception of antipsychotic medications, which were associated with increased risk of mortality in 
unadjusted and adjusted model estimates and across different levels of frailty status.  
Frailty was associated with increased medication use and PIM use. The prevalence of 
antidepressants (excluding tricyclics) in people who were frail was twice as high as in people who 
were pre-frail. There were twice as many frail people reporting PPIs than people who were not 
frail. Baseline frailty was independently associated with an increased risk of mortality in both 
unadjusted and adjusted model estimates. Although there was little evidence of a moderating 
role of frailty between the majority of PIMs and subsequent mortality. In addition, polypharmacy 
was associated with the greatest risk of mortality in people who were not frail and hyper-
polypharmacy was associated with the greatest risk of mortality in people who were frail, 
however when tested, there was no evidence of a moderating role.  
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VIII. Chapter 8: Discussion  
8.01 Introduction 
The overall aim of this research was to understand the impact of potentially inappropriate 
prescribing in people with dementia and the effectiveness of existing approaches to improving 
care in this population. The three key aims of the research were (1) to describe the prevalence of 
PIMs and polypharmacy among people with dementia, (2) to estimate factors predicting the use 
of PIMs and polypharmacy, particularly the effect of dementia annual review and medication 
review, and (3) to understand the impact of PIMs and polypharmacy on the health of older 
cognitively impaired adults and the impact of frailty on this relationship.  
The process of prescribing medicines is multifactorial and involves complex and careful decision 
making for the prescriber, patient and carer. Polypharmacy and PIMs are prevalent amongst 
people with dementia and cognitive impairment and there is potential for adverse effects. 
Optimising medicines in this population is a clinical priority.  
In this chapter, first I outline the key findings of my research and then I discuss the findings and 
methods used to address the aims and objectives of this research and present ways in which 
these findings may be applied to help optimise medicines among people with dementia.  
 
8.02 Central findings  
It was the central aim of my research to understand potentially inappropriate prescribing in 
people with dementia. My findings from the scoping review of reviews highlighted the breadth of 
research into polypharmacy and PIMs in older adults but the lack of research into the impact of 
polypharmacy and PIMs among people with dementia. The optimisation of medications was 
recognised as a priority across numerous studies included in the review, specifically amongst 
vulnerable older adults and those with cognitive impairment, who may be at increased risk of 
adverse effects associated with polypharmacy and PIMs. The scoping review was used to inform 
the development of the aims and objectives of my CFAS II and CPRD analyses.   
(a) Prevalence of polypharmacy and PIM  
Prevalence estimates from CFAS II and CPRD were consistent for tricyclic antidepressants and 
PPIs, with PPIs consistently estimated as the most prevalent PIM (see Table 31). Antipsychotics 
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were more prevalent in CPRD cohort of people diagnosed with dementia, compared to the less 
cognitively impaired CFAS II sample. Findings from CPRD estimated that people with diagnosed 
dementia were prescribed 7.7 medications on average, and 5.5 mean medications in the less 
cognitively impaired CFAS II subsample.  
Prescribing varied across severity of frailty and across care settings. Findings from CFAS II 
estimated that PIM prevalence was greater in frail, cognitively impaired older adults compared to 
people who were less frail or not frail. In the CFAS II and CPRD cohort, the prevalence of PIM was 
consistently higher among patients with dementia who were living in a care home, compared to 
their own home.  
 
Table 31 Comparative reported and prescribed PIM and mean number of prescribed medications in CFAS II subsample 
and CPRD cohort 
PIM CFAS II subsample 
n= 1,154 
CPRD Cohort 
n=22,448 
Antipsychotics 2.1 (1.3-3.2) 8.5 (8.4-8.7) 
Anticholinergics 6.8 (5.4-8.3) 16.7 (16.5-16.9) 
Tricyclic 
antidepressants 
6.8 (5.4-8.4) 7.5 (7.4-7.6) 
PPIs 28.6 (26.0-31.3) 31.5 (31.2-31.7) 
Mean number of 
prescribed 
medications 
5.5 (3.6) 7.7 (4.2) 
Mean (95% CI); Mean (SD) 
Benzodiazepines (CFAS II) 4.2 (3.1-5.6) 
CFAS II analysis of anticholinergics excluding tricyclic antidepressants  
CFAS II subsample; cognitively impaired participants 
CPRD; patients with dementia diagnosis 
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(b) Factors associated with polypharmacy and PIMs  
(i) Medication review and dementia annual review  
The scoping review of reviews indicated that further research was required to evaluate the effect 
of interventions to minimise PIM use, particularly outside of clinical trial settings to evaluate the 
effect of interventions in practice [131, 133, 169, 172, 176, 182, 289]. My CPRD cohort analysis 
suggested that when a medication review takes place in primary care, most of the PIMs analysed 
were more likely to be stopped in patients with dementia who were prescribed them. With the 
exception of antipsychotics, where there was no difference associated with a medication review 
or not. Comparatively, a medication review was also associated with increased prescribing of 
anticholinergics, antipsychotics and tricyclic antidepressants in patients who were not currently 
prescribed these PIM. My analysis also suggested that a record of a dementia annual review was 
associated with less stopping and also less starting of all PIM that were analysed. 
In the CPRD cohort PIM prescriptions were higher in care homes and living in a care home was 
associated with greater likelihood of starting a PIM. However, when a medication review took 
place for a patient who was living in a care home, the review was associated with more stopping 
of PIM.  
 
(ii) Patient factors associated with polypharmacy and PIM  
My scoping review also suggested that further research was needed to verify risk factors for PIM 
use [160, 290]. The findings from the CPRD cohort suggested that there were a number of patient 
characteristics associated with both starting and stopping PIMs. Although, given that there were 
multiple hypotheses tested, there remains a possibility that there are some false positive results. 
Being older was associated with less new prescriptions of antipsychotics, anticholinergics and 
long-term PPIs. However, in patients with dementia who were already prescribed antipsychotics 
and long-term PPI, being older was also associated with less stopping of these PIMs. Female 
patients with dementia were less likely to stop long-term PPIs, tricyclic antidepressants and 
antipsychotic medications than male patients with dementia. Multimorbidity was also associated 
with increased new prescribing of long-term PPI and tricyclic antidepressants. In addition, 
multimorbidity was associated with more stopping of long-term PPI and antipsychotic 
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medications. Being prescribed 5 or more medications was consistently associated with reduced 
stopping and greater likelihood of starting PIM in patients with a dementia diagnosis.  
 
(c) Understanding the impact of PIM on health  
The CFAS II analysis suggested that the use of 5 or more medications was associated with an 
increased risk of mortality in cognitively impaired older adults. Polypharmacy and 
hyperpolypharmacy remained associated with mortality risk after adjustment for covariates. 
Hyperpolypharmacy was associated with the greatest risk of mortality in cognitively impaired 
older adults. With the exception of antipsychotic medications, PIMs were not associated with 
mortality. Antipsychotic medications were associated with increased risk of mortality in adjusted 
models and for all levels of frailty.  
 
(i) Frailty   
Frailty was independently associated with mortality in older cognitively impaired adults from the 
CFAS II cohort, although frailty did not moderate the association between polypharmacy or PIMs 
and mortality. The results did suggest that frailty attenuates the risk of mortality associated with 
benzodiazepine use, however given the small number of deaths that occurred across levels of 
frailty, it is difficult to draw conclusions from this finding. In stratified analyses, frailer people with 
hyperpolypharmacy were at the greatest risk of mortality, however relative risk of mortality 
associated with polypharmacy was greatest among people who were not frail.  
My findings from the CFAS II cohort partially supported the validity of the frailty phenotype in 
predicting risk of adverse outcomes among people with cognitive impairment. Slowness, was the 
only phenotype criterion to independently predict mortality and there was no evidence that the 
remaining criterion were predictive of adverse outcomes.  
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(d) The key findings of my research  
• People with dementia and cognitive impairment are exposed to polypharmacy and 
PIMs.  
• Polypharmacy and PIM use among people with dementia is greater in care homes.  
• Polypharmacy and PIM prescriptions are more prevalent in people who are frail.  
• In general, PIMs are not associated with increased risk of mortality in people with 
cognitive impairment, with the exception of antipsychotic medications.  
• Polypharmacy was associated with increased risk of mortality in cognitively impaired 
older adults and particular attention should be given to reducing the overall number 
of medications prescribed to reduce potential for harm.  
• Medication reviews used in primary care and in care homes are effective tools for 
identifying and reducing exposure to PIMs.  
• Around half of all patients with dementia in primary care receive a dementia annual 
review.  
• Dementia annual review was associated with less starting and less stopping of PIM.   
• Frailty was independently predictive of mortality but is not predictive of vulnerability 
to another risk factor, such as potentially inappropriate prescribing. Hence, frailty as 
operationalised by the Fried criteria does not provide a way to identify those more 
susceptible to polypharmacy.  
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8.03 Discussion of key findings  
Prevalence of PIMs and polypharmacy in people with dementia  
My findings showed that the use of PIMs was prevalent in people with cognitive impairment and 
people with dementia, with around 40% (95% CI 37.8-43.5) of people with cognitive impairment 
reported at least one PIM. These findings are comparable to some previous research and present 
a picture of a population at risk of high levels of exposure to PIMs. A previous study of PIM 
prescriptions amongst people with dementia in the UK estimated 29% of people with dementia 
were prescribed at least one PIM [291]. A systematic review of PIM in people with cognitive 
impairment and dementia found that prevalence was estimated between 20% and 56% [142]. 
Although, it remains unclear whether cognitive impairment is consistently associated with greater 
risk of PIM use as previous studies have also estimated a lower likelihood of PIM in people with 
cognitive impairment [142].  
Similarly to the findings from my research, different care settings are associated with differences 
in PIM prevalence. My findings showed a greater prevalence of PIM in care homes and although I 
did not estimate prevalence in hospital settings, previous studies have found that PIM prevalence 
is often, but not consistently, higher among people with cognitive impairment (39% to 88%) 
compared to people without (20% to 63%) [292]. Estimates from the RightTimePlaceCare (RTPC) 
study across 8 European countries also estimated a high prevalence of PIM according to the 
European Union(7)-PIM list, with 60% of participants with dementia prescribed at least one PIM 
[193]. However, the RTPC study is representative of a cohort distinct from the CFAS II as the CFAS 
subsample was predominantly people with cognitive impairment living in the community. The 
higher prevalence of PIM in the RTPC study likely represents more severe cognitive and physical 
impairment, as this sample was characterised by people recently admitted to long-term care or at 
risk of admission within 6 months.  
The high prevalence of PIM amongst the CFAS II subsample could reflect changes in prescribing 
around the time of a dementia diagnosis. My CFAS II analysis was conducted in a sample 
characterised by significant cognitive impairment, a common symptom of prodromal stages of 
dementia. Previous studies have found that the diagnostic process for dementia is associated with 
an increase in total medication use and PIMs and this increase varied by dementia sub-type. 
Previous studies found that total medication use increased by 10% in the first year following 
incident Alzheimer’s disease diagnoses and by 15% for people with Lewy body dementia. Use of 
 212 
 
anticholinergic medications increased by 39% in the first year following diagnosis, among people 
with Lewy body dementia [293]. However, in a recent study comparing PIM prescription around 
dementia diagnosis with matched controls, total medication use and exposure to PIMs increased 
within the year leading to and the year after diagnosis. However, PIM use also increased in 
matched controls across the same period, meaning that people both with and without dementia 
were increasingly exposed to PIMs overtime [294]. In summary, while PIM prevalence appeared 
to be high amongst the CFAS sample, this is comparable to previous estimates and may reflect 
prescribing across the dementia diagnosis process. However, previous studies also suggest that it 
may reflect a pattern of high exposure to PIMs across the older population rather than a trend 
specific to cognitive impairment and dementia diagnosis. 
 
(a) Proton Pump Inhibitors  
My findings consistently found PPIs as the most prevalent PIM across the two cohorts. In my 
analyses, 28% (95% CI 26.0-31.2) were prescribed PPIs in CFAS II and 32% (95% CI 30.0-31.7) of 
people with dementia in CPRD. It is unsurprising that PPIs were the most prevalent PIM across the 
two cohorts. PPIs are one of the most commonly prescribed medications to older adults and are 
often cited amongst the most commonly prescribed PIMs [189, 193, 291]. In one observational 
study, 23% of people with dementia in the Northern Ireland primary care prescribing study were 
prescribing potentially inappropriate PPIs [189]. Similar estimates have been found across Europe 
with 19% prevalence of PPI in the RightTimePlaceCare study [193]. The lower prevalence 
estimates can likely be explained by differences in estimating inappropriate PPI use because 
therapeutic dose was not accounted for in the analyses employed in this research. Previous 
studies have also found that that 26% of people prescribed PPI are continually prescribed for over 
1 year, despite limited evidence of long-term efficacy and safety [242]. Given that PPIs are 
generally considered safe and effective, it is possible that heuristics play a key role in individual 
cognitive decision making processes around when to continuing to prescribe. Heuristics make 
decision making processes easier and are often associated with intuition and previous experience 
and with appropriate decision making. However, this can also lead to biases and affect the 
individuals subjective interpretation of evidence that is contrary to the status quo [295]. The 
evidence for adverse effects associated with PPIs is largely limited to observational studies and 
the risk to benefit considerations may weigh predominantly in favour of the perceived benefits.  
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However, there is a considerable economic argument for reducing unnecessary prescriptions, of 
which PPIs may be considered if they continue to be prescribed beyond the point of clinical 
benefit. The prescription of PPIs is costing the NHS over £100 million annually and PPIs may be 
unnecessarily adding to medication burden and increasing polypharmacy in many patients [244]. 
Deprescribing guidelines have recently been developed based on evidence that PPI are suitable 
targets for deprescribing, through processes of reducing dose, prescribing to be used as needed 
or stopping the prescription all together [296]. This is not to say that PPIs should always be 
deprescribed. PPIs should be prescribed as required, for as long as needed. Previous studies have 
estimated around 60% of older adults prescribed PPIs should be considered for deprescribing, 
with 20% prescribed PPIs without a clear indication [297]. PPIs should be reviewed and the 
process of deprescribing considered, with the individual priorities and decision-making 
incorporated. PPIs may be a suitable target for deprescribing in people with dementia to reduce 
overall medication burden and overall prevalence of PIMs in this population.  
 
(b) Anticholinergics  
Despite the known evidence for adverse effects, particularly amongst people with cognitive 
impairment, my findings estimated that one fifth of people with dementia in England are 
prescribed anticholinergic medications (17% 95% CI 16.5-17.7) [225]. These prevalence estimates 
are also comparable to previous estimates of anticholinergic drug use amongst people with 
dementia in different populations. A US sample of community dwelling people with dementia 
from the Medical Expenditure Panel Surveys (MEPS) estimated 23% of people with dementia 
were prescribed level 2 or 3 anticholinergic drugs according to the anticholinergic drug scale (ADS) 
[298]. Whilst estimates are not directly comparable due to differences in populations and 
anticholinergic drug scale used, previous studies comparing estimates between ACB and ADS 
scales have found little difference in the results depending on the scale use [223]. Similarly, cross-
sectional estimates from US Medical Expenditure Panel Survey participants (2009-2010) 
estimated 27% prevalence of anticholinergic medication use amongst people with dementia 
[299]. In addition, estimates of anticholinergic use amongst people with dementia living in care 
homes was comparatively lower (19% 95% CI 18.0-20.3) in this cohort compared to other studies. 
Previous studies have estimated that 31% of people with dementia living in a nursing home were 
prescribed anticholinergic medications [300]. Differences in estimates may be reflective of 
variation in prescribing practices in the UK and US. The slightly lower prevalence estimates in my 
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study could also represent a greater awareness of adverse cognitive effects in people with 
dementia and recent initiatives to reduce exposure of anticholinergic medicines in people with 
dementia [231]. However, there is established evidence of adverse cognitive effects associated 
with anticholinergics and anticholinergics are consistently included in PIM criteria [225, 277]. 
Reducing exposure to anticholinergics should be a priority. Recent evidence from a clinical trial in 
residential homes in New Zealand indicates that deprescribing of anticholinergics is acceptable to 
patients and associated with improved outcomes on frailty, falls and adverse drug reaction 
outcomes that were evident at 6 months post-intervention [301].   
 
(c) Polypharmacy and PIMs in care homes  
Across both cohorts, polypharmacy and PIMs were more prevalent amongst people who were 
living in a care home. In CPRD, people with dementia living in a care home were taking 8.5 
medications, compared to 7.3 in the community. Previous studies have estimated that advanced 
dementia in care homes is associated with hyperpolypharmacy. One study estimated that people 
with advanced dementia were receiving 14 different medications on average [302]. The presence 
of advanced dementia may be associated with greater medication use as symptoms become more 
complex, which may explain  my finding that prevalence is greater in care homes, which are more 
likely to include people at later stages of the disease. However more conservative estimates have 
been observed in other studies. In the Services and Health for Elderly in Long Term Care 
(SHELTER) study from 1,449 residents across 57 nursing homes in eight countries, the mean 
number of prescribed drugs was 6 for residents with severe cognitive impairment [303]. Variation 
between the findings from the SHELTER study and the results in this thesis are likely accounted 
for by different ways in which total number of prescribed medicines are measured, including self-
report or patient records and the decision to include or exclude over the counter medicines. In 
the CFAS II cohort, it is possible that medications recorded as part of the CFAS interview were 
more reliably reported in care homes as reported medications were either provided by care home 
staff or were cross-checked with medication records. It is interesting that prescribing practices 
vary across different care settings and ought to be considered when understanding prescribing in 
a people with dementia because they are cared for across a range of settings. However,  it is 
somewhat unsurprising that medication use was found to be greater in care homes as people 
living in care homes are often more frail, multimorbid and living at more severe stages of the 
disease.  
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8.04 Adverse effects of PIM and polypharmacy  
(a) Antipsychotics  
The findings from my CFAS II analysis suggest that antipsychotic medications should continue to 
be prescribed with caution in people with cognitive impairment and dementia. The results 
showed that antipsychotics were the only PIM associated with mortality. This finding is consistent 
with a large body of literature into the adverse effects of antipsychotics in people with dementia 
[304]. My findings are important because they add to this body of literature by demonstrating the 
potential for adverse effects in people with cognitive impairment too.  
In response to the building evidence of serious adverse effects, the practice of prescribing 
antipsychotics to people with dementia has changed over recent years and there has been a 
cultural shift in attitudes towards antipsychotic prescribing in this population in primary care. A 
previous study by Martinez et al, (2013) of people with dementia in UK primary care (1995-2011) 
estimated that antipsychotic prescribing had decreased from 12.5% in 1995 to 7.4% in 2011 [204], 
similar to my finding of 8% (95% CI 7.3-8.7) prevalence in people with dementia in primary care in 
April 2017. However, estimates in the Martinez et al (2013) study were at the first recording of a 
dementia medications which are more commonly prescribed at the point of diagnosis for 
managing symptoms in mild-moderate stages of the disease and are not indicated in severe 
dementia. Therefore this may underestimate the prevalence of antipsychotics at later stages of 
the disease.  
Moreover, contrary to the observed decrease in primary care, my findings consistently estimated 
greater exposure to antipsychotics in care homes. A study estimating prevalence of antipsychotic 
use in care homes before and after the launch of the National Dementia Strategy in 2009 found 
no significant difference in antipsychotic prescribing in care homes across a 4 year period [305]. 
People who are living in care homes may be more physically and cognitively impaired and 
behavioural and psychological symptoms of dementia can be more severe. Antipsychotics may be 
prescribed to manage behaviours in this context however, the potential for serious adverse 
effects should still be considered and discussed with the patient and family when possible. 
Recommendations to regularly review antipsychotics were incorporated into the National 
Dementia Strategy in 2009 [306] and despite national initiatives to reduce exposure to 
antipsychotics in people with dementia, their use is still prevalent in care homes. The findings 
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from this thesis indicate that risk of adverse effects of antipsychotics should also be carefully 
considered in people with severe cognitive impairment, regardless of dementia diagnosis and 
particularly amongst people living in care homes who may be at greater risk of exposure to 
inappropriate antipsychotic use. 
 
(b) Benzodiazepines  
In the findings from my CFAS II analysis, it was surprising to observe that benzodiazepines were 
not associated with mortality in this sample, which was contrary to what I had expected to find, 
given the existing evidence base. A number of previous studies have reported higher risk of 
mortality in people who are prescribed benzodiazepines. In one large retrospective cohort study 
of over 34,000 people with a first prescription of an anxiolytic and hypnotic medication, use was 
associated with mortality. There was evidence of a dose response relationship and the risk was 
greatest in the first year after initial prescription [307]. Moreover, a systematic review and meta-
analyses of 25 observational studies estimated a 43% higher risk of mortality in users of anxiolytic 
and hypnotic drugs. However, the evidence is not always consistent and there have been 
contradictory findings observed in other studies [308]. The quality of previous studies has often 
been limited by the failure to appropriately adjust for important confounders such as depression 
[309].  
A plausible explanation for the difference in my findings compared to some of the previous 
literature is that the users of benzodiazepines in my CFAS II sample are likely to be representative 
of prevalent benzodiazepine users, rather than newly initiated users of the drug. In CFAS II, 
medication data was collected at baseline interview and my findings suggest that use was long-
term, with 60% of people who reported taking PIM at baseline also reporting PIMs at the two-
year follow-up. Including prevalent users of drugs may introduce survivor bias, particularly in 
studies when the risk varies with time, such as the risk of falls in benzodiazepine users is greatest 
around the initiation of the drug. Therefore the sample of prevalent drug users have already 
‘survived’ the higher risk period associated with the initiation of a new benzodiazepine 
prescription [310]. Similarly, the CFAS II sample of prevalent users may include fewer people who 
experience adverse effects associated with the drug as it is more likely that there is early attrition 
amongst people who stop taking the drug early on if they are experiencing adverse effects [311]. 
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Compared to prevalent user study designs, new-user study designs are more comparable to the 
intervention element of a RCT, as the cohort is sampled based on the initiation of a prescription of 
a drug (i.e. the intervention) [312]. The participants in previous studies were incident 
benzodiazepine users (new-users) and enter the study at the point when the prescription is given 
[307]. New-user designs are argued by some to alleviate some of the biases that are inherit in 
prevalent user study designs [313]. Moreover, in some cases it has even been argued that 
prevalent users should be excluded from pharmacoepidemiologic studies because of the inherent 
bias associated with prevalent user-designs [310]. However, studies of prevalent users answer 
different questions to studies of incident users. Careful consideration of prevalent or new-user 
study design and adjustment of covariates is required when interpreting pharmacoepidemiologic 
studies. My findings therefore may be representative of prevalent users of benzodiazepines in the 
CFAS II sample, who are introducing survivor bias into the estimates, are able to tolerate the drug 
and are less susceptible to adverse effects of benzodiazepines. Therefore, the different study 
designs are asking different research questions of different populations. In new users of 
benzodiazepines, risk may be greater but in prevalent users, their use may not be associated with 
such harm.   
 
(c) Mortality associated with polypharmacy  
The results from my CFAS II analyses indicated an increased risk of mortality associated with 
polypharmacy in older, cognitively impaired adults. These findings are comparable to previous 
studies, including a meta-analysis of pooled estimates from a number of studies analysing 
polypharmacy and mortality. This review also found an increased risk associated with the number 
of medications prescribed and a dose response relationship across categorical polypharmacy 
thresholds [314]. Residual confounding associated with poor adjustment for indications and 
comorbidities is recognised as a possibility across studies of medication use. However, my 
analyses adjusted for all available comorbidities, frailty and use of other medications to reduce 
the implications of residual confounding on the results. My findings are similar to those found in 
reviews of studies that have accounted for the quality of adjustment for comorbidities and 
polypharmacy remained associated with mortality, hospitalisation, adverse drug events and falls 
[315]. Recent studies have sought to further delineate the association between polypharmacy and 
mortality by using propensity score matching. This study found that when propensity score 
matching was used, hazard ratios attenuated some of the association (HR 1.26 95% CI 0.70-2.28)  
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compared with adjusting for a comorbidity index (HR 2.01 95% CI 1.15-3.51) [316]. My findings 
suggest that careful consideration should be afforded to the number of medicines prescribed and 
whilst these findings add to the literature in this area, future studies may benefit from further 
understanding the role of propensity score matching in adjusting for confounding by indication to 
further understand the association between polypharmacy and mortality.  
My results suggested that the adverse effect associated with polypharmacy was observed 
regardless of exclusion of PIMs. Previous studies have also found that polypharmacy but not PIM 
criteria was predictive of functional status decline [150]. Polypharmacy may be a more suitable 
marker of the quality of prescribing and prediction of some adverse effects than PIM criteria. 
Moreover, PIM criteria do not account for the potential serious adverse effects of polypharmacy 
and hyper-polypharmacy in older adults [107, 277]. Consideration of the evidence of harm 
associated with polypharmacy ought to be accounted for in PIM criteria, like clinical practice 
guidelines that recommend regular medication review, in older adults with polypharmacy [108].  
 
8.05 Moderating role of frailty  
In this novel investigation of frailty and PIM use in people with cognitive impairment, frailty was a  
marker of mortality, as expected, but was not found to identify susceptibility to adverse effects 
associated with another risk factor (polypharmacy or PIM). The level of excess risk associated with 
antipsychotics, for example was similar regardless of frailty. The results from stratified analyses 
did suggest that whilst hyperpolypharmacy was associated with the greatest risk of mortality in 
people who were frail, polypharmacy was associated with greatest risk in people who were not 
frail. However, there was no significant evidence of a moderating role of frailty in my analysis. The 
role of frailty in understanding susceptibility to another risk factor is not clear and frailty may not 
be a useful marker for identifying people at greatest risk of harm associated with polypharmacy or 
PIM. Previous studies in older adults have also found that polypharmacy and use of sedative and 
anticholinergic medications was associated with the greatest risk of death in people who were not 
frail. Additionally, in previous studies there was no association between medication use and 
transitions across levels of frailty and death [317]. In a study of delirium in hospital admissions, 
mortality risk associated with delirium was particularly high amongst fitter individuals [196]. A 
recent pathology analysis of participants from the Rush Memory and Ageing Project suggested 
that frailty (measured using the Frailty Index) moderated the relationship between Alzheimer’s 
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disease pathology and dementia (diagnosis of Alzheimer’s disease or not) [318]. Although there 
was some evidence of a moderating role of frailty, this was associated with the presence of 
dementia diagnosis or not, however whether the relationship with frailty was incrementally 
associated with the severity of cognitive impairment in people with dementia was not assessed. 
The potential moderating role of frailty and the utility of frailty as a predictor of vulnerability to 
the adverse effects of another risk factor is not well established and requires further 
investigation, because the identification of vulnerability is such a key claim of the benefit of frailty 
measures.  
My findings showed some evidence that the least frail group of people with polypharmacy were 
at increased risk of mortality (compared to people who were not frail and without polypharmacy). 
This finding may understood by considering the sample, who are cognitively impaired and may 
therefore be inherently living with a underlying level of frailty that is not accounted for in the 
Fried frailty classification [47]. Therefore the sample may be living with an underlying level of 
vulnerability to the adverse effects of polypharmacy, regardless of frailty. Interestingly, similar 
findings have been seen in previous studies involving samples with an inherit and underlying level 
of vulnerability to adverse outcomes, such as older, multimorbid adults. Previous studies in older 
adults have found that people who are frail with hyperpolypharmacy were six times more likely to 
die during follow-up, compared to people who were not frail and without polypharmacy [198]. 
However in this study of community dwelling older adults in France (n=2,350), the study findings 
were also comparable to my results as the risk of mortality amongst non-frail people with 
hyperpolypharmacy was greater than the risk in people who were more frail. However, in a study 
of hospitalised older adults, where an underlying level of vulnerability may be expected, there 
was no evidence of an effect in people who were the least frail. Moreover, it was estimated that 
the least frail group with hyperpolypharmacy were least likely to experience adverse outcomes 
[319]. In addition, in a Spanish cohort (Frailty and Dependence in Albacete study), participants 
were grouped according to frailty and polypharmacy status and estimated that people who were 
frail with polypharmacy had five times greater odds of mortality or disability, compared to people 
without frailty and without polypharmacy [122]. However, around one third of this cohort were 
hospitalised during follow-up and may therefore be representative of a cohort with high baseline 
vulnerability to adverse effects. As my findings suggest, the relationship between frailty, 
polypharmacy and mortality is complex and there is no evidence of a linear relationship. In 
addition, it is difficult to make comparisons across studies due to lack of consistency in approach 
to operationalising frailty, including failing to objectively measure slowness and strength. [198]. 
Furthermore, whether the population includes people with dementia clearly impacts on findings, 
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as dementia may overshadow prescribing decisions and outcomes in many cases [320]. Therefore, 
these findings suggest that whilst frailty is a useful way to identify sub-groups of the older 
population who are particularly vulnerable to adverse effects, frailty is not necessarily a viable 
tool for identifying people who are at risk of adverse effects associated with potentially 
inappropriate prescribing.  
 
(a) Predictive validity of frailty phenotype  
Applying the frailty phenotype criteria among people with dementia may not be the optimal way 
to identify those at risk, particularly when the evidence suggests that individual criteria are not 
consistently associated with adverse outcomes. The findings from my study showed that 
slowness, as measured by the gait speed test, was the only frailty criterion independently 
associated with the outcome of mortality. These findings are consistent with previous studies 
assessing the prognostic value of frailty criteria which also found that individual frailty criteria 
were not consistently associated with adverse effects. Another study also found that in adjusted 
models, slowness was the strongest predictor of disability and falls [54]. Slow gait could be 
considered a reflection of a range of physiological processes, comorbidity, and effect of 
medications, loss of strength and endurance, exhaustion and low mood. However, this study also 
found that low physical activity and weight loss were associated with disability, nursing home stay 
and mortality [54]. My unadjusted analyses of the CFAS II sample were comparable and low 
physical activity was associated with mortality but there was no evidence of the association of 
weight loss with mortality in my findings. The difference may be explained by the operationalising 
of the weight loss criteria, which in CFAS II was a self-reported unintentional weight loss 4.5kg 
(10lbs) or more in previous six months or less. In the original operationalisation of the Fried frailty 
criteria [47], weight loss was estimated over one year rather than six months. This could mean 
that the number of people who were impaired on the weight loss criteria may be underestimated 
in the CFAS II sample analysis.   
As part of the GP contracts and recommendations from NICE [78], it is a requirement that frailty is 
assessed in older people. Understanding frailty is considered a clinical priority but in practice a 
frailty assessment will vary considerably between practices and practitioners and there is limited 
standardisation of frailty assessment in practice [321]. Resource and time constraints will 
invariably impact upon the comprehensiveness of frailty assessments used in practice [322]. My 
findings support previous studies that suggest that the gait speed test is a simple and valid initial 
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indicator of frailty and vulnerability to adverse effects [323]. However, detailed assessment as 
part of a comprehensive geriatric assessment may be important in identifying factors that are 
contributing to frailty and where interventions may be possible [324].   
 
8.06 Interventions to optimise prescribing in people with dementia  
(a) Effectiveness of medication review and dementia annual review on PIMs  
My findings show that a record of a medication review was associated with reducing the 
prescription of PIMs in people with dementia in primary care in England. Medication review was 
also associated with increased newly prescribed PIMs. This finding somewhat corroborates with a 
number of reviews of intervention studies that were included in the scoping review of the 
literature, which found that medication review was commonly used and was effective in reducing 
PIMs across a range of clinical trial intervention studies [134, 173, 325]. To my knowledge, this is 
the first study of the impact of medication review outside of a clinical trial and reflecting real-
world clinical practice. In practice, medication reviews were associated with stopping PIMs in 
patients who were already prescribed them. However, medication reviews were also associated 
with initiating new PIM prescriptions. Guidelines from NICE recommend medication reviews to 
patients with polypharmacy and my findings indicate some effectiveness of these reviews [78]. 
My findings also indicate that further awareness of PIMs in people with dementia is needed 
among some prescribers to improve prescribing quality.  
The purpose of a comprehensive medication review is to critically consider the safety, efficacy 
and acceptability of medicines with the aim of optimising medications [78]. The individual’s 
preferences, beliefs, values and goals should also be accounted for in prescribing decisions. A 
dementia annual review should take place in primary care but there are no stipulations as to who 
would conduct the review in practice [111][112]. The current QOF dementia annual review does 
not stipulate a medication review is required, however the review clearly represents an 
opportunity for a comprehensive assessment of the patient, which should include a review of 
medications to manage symptoms of dementia and comorbidities, if necessary. Guidelines from 
NICE suggest that medications should be reviewed regularly in people who are prescribed 
multiple medications or prescribed medications for long-term conditions [108, 109]. Given the 
potential for adverse effects associated with PIMs and polypharmacy in people with dementia, 
optimising medicines should continue to be a public health priority in this population. Medication 
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management can be challenging and complex for people with dementia [326]. Previous 
qualitative studies highlight the integral role carers play in medicines management, which can 
provide a number of challenges including a sense of responsibility for adherence [38] The 
incorporation of a medication review into a dementia annual review could improve 
standardisation of practice in the regular review of medicines in this population, which may 
reduce overall treatment burden if medications that are no longer indicated are deprescribed and 
reduce the potential for adverse effects.  
My findings showed that a medication review was associated with deprescribing of 
anticholinergics, tricyclics and long-term PPIs amongst people with dementia in primary care in 
England. These findings indicate that PIMs are being identified and stopped, although medication 
review was also associated with newly prescribed PIMs, which indicates a review may also 
recommend an appropriately required medication. While medication reviews may be effective in 
reducing PIM use and does not increase adverse withdrawal events [173], the impact of reviews 
on subsequent health outcomes, such as adverse drug events [129], hospitalisation [169], quality 
of life, physical functioning [173] or medication costs [129], is not well established. My findings 
also indicate that it may not be PIMs per se that are the issue but that polypharmacy may be 
associated with more harm, which may explain why there is limited evidence for the subsequent 
benefits of deprescribing PIMs.  
The results from my analyses suggested that whilst care home residence was associated with 
greater medicines use in both cohorts, the results from the CPRD cohort suggested that living in a 
care home was associated with improved management of potentially inappropriate medicines. 
This was evident when there was a medication review for a patient living in a care home. 
Antipsychotics were more than twice as prevalent in people with dementia in a care home (14%) 
compared to those living in the community (6%). However, the results showed that when a 
medication review was recorded in a care home, the likelihood of an antipsychotic (and all PIMs) 
being stopped was significantly increased (association of medication review with stopping 
antipsychotic in care home OR 1.45 95% CI 1.09-1.94) compared to patients in their own home 
(OR 0.86 95% CI 0.67-1.10) (see Table 14). This finding may be an example of how the populations 
and prescribing in care homes, compared to people in primary care, varies and should be 
accounted for in studies. As care home residents have access to regular care, the opportunities 
for effectively monitoring medications may be greater than for those with dementia living alone 
in the community. Previous studies have recognised that incorporating a specialist practitioner, 
such as a geriatrician or pharmacist into nursing home staff is associated with medicines 
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optimisation in care homes [303]. However, the resource costs associated with this would be 
extensive and the practical application of this may be limited in reality. Further training 
opportunities and access to deprescribing resources for nurses and care providers to recognise 
potential medication-related adverse effects which are flagged for review with the residents GP 
may be a more feasible alternative for future research to investigate [327, 328].  
 
(b) Incentivising the quality of health care  
My findings suggested that a dementia annual review may be associated with changes in the 
prescription of PIMs, which could be indicative of the reviews being associated with optimisation 
of medicines in people with dementia. However, my findings also found that less than half of all 
patients had a record of a review across the study period. It is difficult to ascertain the true quality 
of the QOF reviews conducted in primary care and there is evidence to suggest the quality is 
below the expected standard set by QOF [113] [263]. Moreover, previous studies also suggest 
that the quality of care lacks standardisation across people with dementia and there are 
inequalities in care provision compared to people without dementia [263]. A dementia review is 
intended to be a holistic process and there may be gains for a person with dementia and their 
carer that are not medication related. However, because the quality and content of the reviews is 
not accounted for in QOF scorings, there is no guarantee that the areas expected within the 
review are taking place. The quality of holistic indicators like the dementia annual review ought to 
be accounted for in QOF scorings. Moreover, given the key opportunity an annual review 
presents, future studies should evaluate the effectiveness of the inclusion of a medication review 
in the optimisation of medicines for people with dementia.   
The QOF has been a contentious issue since its inception in 2004 with mixed evidence for its 
effectiveness and impact on increasing workloads. While standardisation of care provision across 
primary care practices levelled and there was an initial modest improvement in care, reaching 
quality markers for many long-term conditions hit a ceiling effect soon after [329, 330]. In 
addition, there is evidence that the quality of care for non-incentivised conditions was negatively 
affected and the system is often viewed as a ‘tick-box’ exercise, increasing workloads and 
reducing opportunities for patient-centred, individualised care [331]. In 2017 QOF in England 
underwent a considerable review [332] and QOF in English primary care practices is evolving in 
response to the findings and feedback from practitioners. From 2019, QOF will now also include 
Quality Improvement modules that will change each year and for 2019/2020 this will include two 
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modules on prescribing safety and end of life care. The findings from my research are timely as 
medicines optimisation is prioritised across practice, the overprescribing of medicines is reviewed 
in the NHS, and role of clinical pharmacists in primary care is expanded.  
 
8.07 Understanding potentially inappropriate prescribing in people with dementia  
My findings indicate a number of associated factors that help in understanding how and why 
potentially inappropriate medications are prescribed to people with dementia, despite the known 
adverse effects. Over the course of the research I’ve have completed, the findings from my 
studies, alongside the existing literature, collectively present a vast and complex set of factors 
that are associated with prescribing. Specifically, my findings have identified that age, gender, 
cognitive impairment, frailty, comorbidities, and polypharmacy, living in a care home, prescribing 
in primary care, medication reviews and dementia annual reviews are all factors associated with 
prescribing in people with dementia. In order to interpret and discuss the complex and 
multifactorial processes associated with prescribing in people with dementia, I applied an 
established model of health service use, The Andersen Behavioural Model, to my findings [333, 
334].  
Under the Andersen Behavioural Model of health service use [333, 334], there are predisposing, 
enabling and need factors that are associated with access to and use of services (Figure 30 Model 
1). My findings apply this model to understand potentially inappropriate prescribing in people 
with dementia. The results have shown that there are additional factors particular to the 
experience of people with dementia that are important in this process (Figure 30 Model 2). The 
model shows factors that have been identified from my findings, and other relevant factors from 
the existing literature. My results have shown that age, frailty, cognitive impairment, 
comorbidities and living situation are influential factors that may predispose individual exposure 
to polypharmacy or PIMs. If this model is applied to these findings, with the outcome identified 
as a dementia annual review or prescribing as the provided health care service, it is clear from 
my research that there are many factors that influence provision of services to patients. 
Moreover, there are factors that are unique to prescribing to people with dementia. These are 
additional factors that need to be considered when understanding the process of prescribing in 
this population. Other factors include frailty and care home residence, as my findings showed 
that people who were frail, and people with dementia who were living in care homes were 
prescribed more PIM and were taking more medications on average. Previous literature has 
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also identified other factors that are influential in the process of prescribing in people with 
dementia, including medication adherence. Cognitive impairment has previously been 
associated with up to 60% non-adherence to medication regimes [91]. Non-adherence will 
make managing the potential for side effects of medications more complicated for prescribers, 
if they are uncertain about the level of adherence to the prescribed medication regime. 
Prescribers need to understand their patients holistically, with all available information from 
the patient or from their carer and consider these factors when prescribing, deprescribing or 
managing polypharmacy.  
My findings also demonstrated the potential for medication review to reduce PIMs. The model 
is useful in understanding the range of factors that may also be at play when a medication 
review is requested and completed in primary care. As the model suggests (Figure 30, Model 2), 
there are also a number of factors associated with the prescriber that influence the evaluated 
need around prescribing decisions. Previous studies have identified that individual factors such as 
prescriber experience and confidence are influential in the individual prescribing decisions for 
general practitioners prescribing to complex, multimorbid patients, for example [335]. In addition, 
my findings indicated that top-down regulatory practices such as recommendations for 
medication review from NICE guidelines [108] and the QOF dementia annual review [111][112] 
may influence the prescribers evaluated needs around prescribing decisions. By incorporating 
medication review into QOF incentivised dementia annual review, reviews of medications in a 
population vulnerable to serious adverse effects of PIMs could reduce the exposure to potential 
for harm. Moreover, improve standardisation of prescribing practice and reviews across 
primary care practices, if appropriately accounted for in QOF scoring systems.  
Furthermore, previous qualitative studies involving people with dementia and their carers have 
highlighted that the role of managing medicines often shifts from the individual, as carers of 
people with dementia will often take responsibility for managing medications. Medication 
management can add challenges to the caring role and increase emotional load, particularly as 
the disease progresses alongside more complex medication regimes [38]. Carers are integral 
enabling factors in managing medicines. Their role should also be considered in dementia annual 
reviews. To ensure carers are well-supported, and the views, beliefs and goals of care for the 
individual with dementia and their carer are accounted for (Figure 30 Model 2).  
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8.08 Deprescribing 
The process of withdrawal and dose reduction of medicines is known as deprescribing and 
involves the consideration of the risk and benefits of individual medicines and the cumulative risk 
associated with the use of multiple medicines [336]. Optimising medicines can be additionally 
challenging among people with dementia because of changes in decision making, communication, 
cognitive capacity and increased carer involvement across disease progression [38, 337]. A lack of 
guidelines and training in deprescribing as an integral element of the prescribing process can also 
impede prescribers. Recent development of evidence-based deprescribing guidelines should 
progressively enhance the opportunities and support for deprescribing. Using deprescribing 
patient handouts and pharmacist and GP education materials has supported 30% deprescribing of 
chronic benzodiazepines through patient education (compared with 5% in the control group) and 
43% deprescribing (12% in control group) in practitioner education in studies from the Canadian 
Deprescribing Network [338, 339]. Future developments are also expected within the UK as the 
English Deprescribing Network launches in 2019 [340]. The process of prescribing occurs across 
drug initiation, monitoring, adjustments and reviews and should also include evidence-based 
support for deprescribing medicines. For older adults and people with dementia this is a priority 
given their increased susceptibility to adverse effects and the change in the benefits to harm ratio 
across physiological and cognitive decline. A medication review and dementia annual review may 
be enhanced with the support of guidelines to deprescribe in primary care and previous research 
suggests that patients can also be educated about the options for deprescribing. Further research 
is needed to understand the impact of deprescribing guidelines and education on people with 
dementia and their carers.  
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Figure 30  Model 1: Andersen Behavioural Model (Andersen & Newman 1973, Andersen, 1995) of health service use. Model 2: Andersen model applied to findings from scoping review, 
CFAS II and CPRD cohorts, understanding the use of potentially inappropriate medication in people with dementia. 
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8.09 Potentially ‘inappropriate’ medicines  
Whilst the medications included in the analyses for these studies and those which are also 
included in prescribing criteria such as Beers and STOPP are considered potentially inappropriate, 
it is also important to recognise that these medications are often prescribed appropriately, with 
careful consideration of both benefits and harms. The results suggested that a medication review 
was associated with an increase in the odds of starting anticholinergics, antipsychotics and 
tricyclic antidepressants, which suggests that there were considerations accounted for in the 
review which continued to lead to the prescription of these PIMs in people with dementia. 
Nevertheless, it is difficult to ascertain the nuances associated with prescribing decisions from 
routinely collected observational data.  
The careful consideration of patient and practice level effects accounted for in the multivariate 
analyses can only go so far in understanding the within patient and within practice variation in 
prescribing practices. In addition, where the results have also corroborated with other studies in 
identifying increased prescription of PIMs in care homes, this could reflect greater disease and 
symptom severity in this population. Antipsychotics, for example, may be prescribed to people 
with dementia where behavioural symptoms are severe and distressing, and in care homes a 
prescription of antipsychotics may be prescribed to be used ‘as needed’. What we cannot 
ascertain from these findings is how often an antipsychotic is actually used.  
It is not the position of this thesis to argue that all prescriptions of PIMs are inappropriate but 
rather, given the evidence there is a potential for increased risk of harm, to highlight the clinical 
importance of carefully reviewing prescriptions of these medications regularly. The prescription 
choice may be considered appropriate after consideration of benefits and harms, patient and 
carer preferences, beliefs and values. It is important that researchers recognise and do not 
underestimate the care with which prescribing decisions are made.  
 
8.10 Methodological discussion  
My studies have used epidemiologic methods to understand potentially inappropriate medication 
use in people with dementia. Using these methods is a considerable strength particularly in these 
large, population-representative datasets because of the analytical power to investigate potential 
harms, which would be unethical to conduct in a clinical trial. In addition, these methods are able 
to supplement the gaps in the literature into our understanding of the safety of medicines in this 
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population due to exclusion from clinical trials [341]. However, using secondary datasets for these 
analyses has not come without challenges [342].  
Data entry lacked standardisation in some of the CFAS II questions, including the timed Sit-To-
Stand and gait-speed test. Having standardised validation at the point of data entry would 
improve the reliability of the operationalisation of the frailty variable.  
In the CFAS II cohort, the original aim had been to complete the analyses in a sample of people 
with dementia. However, the sample was expanded to include people with severe cognitive 
impairment. A number of factors informed this decision. People without medication data were 
excluded. As were people with severe cognitive impairment, if they did not have a proxy to 
provide medication information. From the potential sample of people with dementia, after the 
inclusion criteria were applied this left a sample that would have been underpowered to detect 
associations. For many reasons throughout the CFAS II interviews the interviewer could skip 
questions. This would often occur when the individual being interviewed was unable to answer 
questions due to cognitive or physical impairment and these participants are more likely to have 
dementia than those able to answer the questions. Cognitive impairment with no dementia is a 
understudied group and it was interesting to observe that in a sample of people with MMSE 
scores equal to or less than 24 points, around 13% had a dementia diagnosis according to the 
CFAS algorithm. Often, MMSE of 24 is applied as marker of severe impairment or dementia and 
this may indicate that the CFAS algorithm used to diagnose dementia may be specific but lack 
some sensitivity in diagnosing dementia.  
 
8.11 Strengths and limitations  
My studies comprised two large, population representative cohorts, providing up-to-date 
estimates of the prevalence of polypharmacy and PIM use amongst people with cognitive 
impairment and dementia in primary care in England. My analyses demonstrated the successful 
application of the Fried frailty phenotype to the CFAS dataset. Through this I was able to uniquely 
examine the association of potentially inappropriate prescribing with adverse outcomes and 
understand the predictive validity of the frailty phenotype. While there are alternative measures 
of frailty that could have been used, applying the frailty phenotype enables the distinction 
between factors that are contributory to frailty. Including the distinction between frailty and 
other impairments that increase older adults vulnerability as they age, such as cognitive 
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impairment or comorbidities. In doing so, my results can be used to understand the predictive 
validity of frailty, compared with cognitive impairment and comorbidity on the outcome. 
Mortality was selected as an outcome measure in my analyses of CFAS II subsample as mortality is 
a valuable indicator of overall health, disease burden and the effectiveness of and access to 
health care. Moreover, mortality as the outcome indicator avoided any loss to-follow up as all 
participants were flagged for notification of death with the Office for National Statistics. Other key 
outcomes such as falls, hospitalisation, care home admission, activities of daily living and quality 
of life are important to patients and would have further strengthened the analysis if these 
outcomes were available in this cohort.  
The PIMs used in my analyses are a specific selection of PIMs that are included in a number of 
criteria, including STOPP and Beers. These PIMs were identified from the scoping review and have 
been recognised as medications which prescribers have requested as priority medications for 
deprescribing guidance to be developed [246], however my finding challenges some assumptions 
regarding their harms. It has been common in previous studies to measure the association of PIMs 
with an outcome from any PIM prescription, from a long list of criteria. Using individual PIMs 
enabled an in-depth understanding of the role of individual PIMs on harms and prescribing in 
primary care rather than a general understanding of the prescription of a number of PIMs 
according to criteria. Benzodiazepines were not included in CPRD analyses and therefore 
estimates of use could not be compared with CFAS. Moreover, future studies would benefit from 
operationalising full PIM criteria to further understand the extent of inappropriate prescribing in 
this population.   
A limitation of my research is that the beliefs, views and opinions of people with dementia, carers 
and prescribers could not be measured in terms of outcomes or predictors. A growing body of 
literature has sought to understand barriers and enablers to addressing PIM in older adults and a 
smaller number of studies in people with dementia which further highlight the complexities 
involved in prescribing. For prescribers, there are many factors that influence the prescription of 
PIMs. This includes awareness (or lack) of the problem and lower perceived value attached to 
ceasing compared to continuing PIMs. In addition, experience and confidence to change 
prescribing, particularly when going against the decisions of another prescriber. The feasibility of 
changing prescriptions without clinical guidelines, alternative therapeutic options and external 
constraints such as limited time and resource also impact self-perceived confidence and ability to 
manage PIMs [335]. While my studies could not measure the perspectives of prescribers, my 
findings did suggest a very small practice-level effect associated with stopping and starting PIMs. 
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This may suggest little variation across practices. However, this approach may not be sensitive 
enough to detect such individualised characteristics that influence prescribing in practice. The 
findings from previous qualitative studies are useful in understanding the multifactorial model 
previously discussed (Figure 30). Prescribing and deprescribing are complex multifactorial 
processes but there are clear opportunities for interventions such as training and clinical guideline 
development to improve prescriber confidence and awareness of PIMs in this population.  
In CPRD analyses, the dose of medication use was not used and in CFAS II this detail was not 
available. Understanding the dose of a prescription may enlighten further understanding of the 
amount of PIM prescription that are associated with potential adverse effects. In CPRD the 
analyses were not designed to ascertain changes in dose of PIM, which may have indicated more 
deprescribing processes, including reducing dose or tapering medicines. Furthermore, 
medications are not always taken as prescribed and non-adherence to medication regimes is 
common. There are many barriers to adherence for patients [93] and cognitive impairment may 
further impede medication management and increase non-adherence in patients with dementia 
[343].  
My findings are based on samples with prevalent medication use and on a population who may 
have been stable on the medications they were prescribed, as opposed to being new users. In 
studies applying a new-user design, where an individual is included in the study at the point at 
which they are first prescribed a medication, results vary compared to prevalent users [344]. 
Prevalent users are more likely to be representative of healthier users, as people who have an 
adverse reaction close to initiation of the drug may not survive or are likely to cease this 
medication due to the adverse reaction to it. Moreover, people who stop a drug or die soon after 
initiation of a drug may be living with greater comorbidity and vulnerability to adverse effects and 
as such these adverse events will not be picked up in the prevalent user sample. However, 
practically introducing a new-user cohort design would not have been feasible with the data 
available from CFAS II interviews as there was no data available on when a prescription was 
initiated or the duration of medication use.  
My CPRD cohort analysis was strengthened by disaggregating the analysis into starting and 
stopping PIMs, rather than investigating the probability of PIM, which was originally considered as 
an approach to the analysis. In doing so, this separates people who are currently prescribed PIM 
from those who are not exposed to each PIM and reflects two important component parts of the 
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prescribing process. Moreover, the process of stopping and starting a medication, whilst occurring 
for different reasons, are both integral in the prescribing process.  
While analyses were well adjusted for comorbidities, cognitive impairment and frailty there 
remains the possibility that a proportion of the observed association between polypharmacy and 
mortality may be biased by residual confounding. It is possible that the comorbidities adjusted for 
did not fully account for indications of prescribed medications. All possible comorbidities were 
adjusted for from the data that was recorded as part of the CFAS II interviews. By also adjusting 
for frailty this improved the analyses by adjusting for increased susceptibility to adverse effects.  
The predominant focus of my analyses has been on the potential for harm associated with use of 
PIMs in people with cognitive impairment and dementia, which may overlook the potential 
benefits. While there is a clearly recognised need to understand the potential for harm in this 
vulnerable population it will also be important to consider the extent of benefits that can be 
accrued. Understanding both the benefits and harms of a medication is integral to prescribing 
decisions and since clinical trials of the efficacy and the safety of medicines will generally exclude 
these vulnerable populations, further research could be beneficial to supporting prescribers. 
Furthermore, for patients and carers, an understanding of the risks compared to the benefits will 
be important in enabling them to be effectively and confidently involved in prescribing decisions.   
My analyses were unable to account for variation according to dementia subtype. It is possible 
that there may have been variation in the outcome from the CFAS II subsample analysis 
associated with dementia sub-type. Previous studies have found that potentially inappropriate 
prescribing can vary according to the sub-type of dementia. People with Lewy-body dementia had 
a higher exposure to PIMs, for example [345] although this may be expected due to common 
symptoms including hallucinations and sleep disturbance. However, although my analyses did not 
account for dementia sub-type the analyses did adjust for cognitive impairment, frailty and living 
situation as useful markers of severity.   
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8.12 Implications  
• For clinicians and prescribers, my findings can be used as evidence to inform prescribers 
and increase awareness of the risk of harm associated with polypharmacy and particularly 
hyper-polypharmacy amongst older adults with cognitive impairment. Careful 
consideration should be afforded when making decisions to prescribe to patients with 
cognitive impairment and dementia and current medicines should be regularly reviewed 
in order to reduce unnecessary and potentially inappropriate medicines.  
• My findings suggest that while particular caution should be applied when prescribing 
amongst the frailest individuals, even amongst people who are identified as not frail, 
caution should continue to be applied when considering prescribing of additional 
medicines.  
• These results can be used to inform the development of prescribing guidelines amongst 
people with severe cognitive impairment and dementia.  
• These findings can be used to inform the current national and local initiatives into the 
optimisation of medicines, particularly highlighting the importance of polypharmacy and 
ways to reduce polypharmacy in practice.  
• For health service providers, these findings have implications for the future direction of 
the provision of dementia annual reviews. The reviews could provide a key opportunity 
for the ongoing care of the individual and the needs of their carers to be reviewed, 
alongside an opportunity to review and optimise medicines.  
• Further research implications include the practical application of a multilevel modelling 
approach to estimate changes in medication use amongst populations that are more likely 
to be excluded from clinical trials, and to detect changes in rarer outcomes from large 
scale datasets.  
• Frailty phenotype has been operationalised and the methodological approach detailed in 
publication which can then be replicated for future studies within the CFAS II cohort or as 
an example case for application in different cohort studies [269].  
• Importantly, for people with dementia or people caring for someone with dementia, 
these findings can provide support for requesting a medication review and frailty 
assessment, as part of a comprehensive geriatric assessment in order to identify 
opportunities for intervention, including reducing PIMs and polypharmacy. 
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8.13 Suggestions for future research  
My findings improve our understanding of polypharmacy and PIM use in people with dementia, 
however future research is needed to build on these findings. Future studies into the adverse 
effects of PIM in people with dementia should investigate the adverse effects of all medications 
included in STOPP criteria using new-user (incident user) designs in large, representative cohorts 
of electronic health records, such as the CPRD in order to operationalise STOPP fully. Previous 
studies suggest that new-user cohort studies may see different results to prevalent user studies 
[310]. These studies will benefit from matched-controls and an adequate ‘wash-out’ period, when 
the patient is prescribed a drug, however the feasibility of operationalising this for the entire 
STOPP criteria may be challenging.  
Future studies should also evaluate the impact of polypharmacy and PIMs on outcomes other 
than mortality, including outcomes that are identified as important to people with dementia and 
their carers. Outcomes of interest for patients and carers can include risk of falls, hospitalisation, 
and quality of life, impact on activities of daily living, caregiving burden and medication burden. 
The impact of medication management for a person with dementia and their carer requires 
further research, particularly amongst carers who generally become increasingly responsible for 
medication management. Moreover, the impact of interventions to reduce polypharmacy or 
exposure to PIMs should also be evaluated in terms of the impact on patient and carer relevant 
outcomes.  
In light of my findings, future research should assess the effectiveness of a medication review 
included into a dementia annual review. In a trial, the impact of a medication review incorporated 
into the required procedure of a dementia annual review across a cluster of general practices in 
different geographical locations could be used to assess the impact on total number of prescribed 
medications, where my findings identified potential for harm.  
Moreover, further research is required to understand if dementia annual reviews and other pay-
for-performance incentives have a beneficial impact on improved outcomes for patients. The 
fidelity of dementia annual reviews in practice should also be evaluated in order to inform the 
ongoing discussion into the effectiveness of pay-for-performance schemes, particularly on patient 
experience and quality of care provision. 
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8.14 Conclusion  
The older adult population are the largest consumers of medications and are more likely to live 
with comorbidity, disability and frailty. Cognitive impairment and progressive decline in 
functioning as part of ageing also reduces independence and increases dependence on care and 
support from others. The older population is heterogeneous and the results from this thesis have 
also demonstrated important heterogeneity amongst people living with dementia. My findings 
have shown variation in prescribing across the frailty syndrome and care settings. In addition, 
prescribing and deprescribing practices vary. My research findings suggest that consideration of 
the number of medications, rather than specific medication classes may more effectively reduce 
potential adverse outcomes. In primary care, there was some evidence to suggest that prescribing 
practices around PIMs are well managed when medications are reviewed. Incorporating a 
medication review into the dementia annual review may improve standardisation of medicines 
management across this heterogeneous population. This may then improve quality prescribing, 
reduce medication burden, provide regular opportunity for medication review and to discuss 
opportunities for deprescribing when possible. However, given around half of people with 
dementia in primary care received a dementia annual review and the increasing dismay at the 
application of pay-for-performance schemes in primary care, adding additional work to the 
already sparsely applied dementia annual review could have counterproductive effects.  
Optimising medications in people with dementia requires a carefully considered and holistic 
approach. Patients with dementia and their carers should feel able to have their perceived needs, 
preferences and values accounted for. Prescribers may be aware of the potential for adverse 
effects associated with potentially inappropriate prescribing but will be enabled through 
evidence-based guidance to recognise the evaluated need and support for safe and effective 
prescribing and deprescribing. While prescribing in people with dementia can be challenging due 
to the complexities and diversities of symptoms, comorbidities, disability and frailty, it is a mark of 
the quality of the care provided to people with dementia how medications are optimised, just as 
it is the mark of a civilised society how we aim to treat those who are most vulnerable. 
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X. Appendices 
10.01 Appendix 1: Preferred Reporting Items for Systematic reviews and Meta-
Analyses extension for Scoping Reviews (PRISMA-ScR) Checklist 
SECTION ITEM PRISMA-ScR CHECKLIST ITEM REPORTED ON PAGE # 
TITLE 
Title 1 Identify the report as a scoping review. 36 
ABSTRACT 
Structured 
summary 2 
Provide a structured summary that includes (as 
applicable): background, objectives, eligibility 
criteria, sources of evidence, charting methods, 
results, and conclusions that relate to the review 
questions and objectives. 
n/a within 
thesis 
chapter  
INTRODUCTION 
Rationale 3 
Describe the rationale for the review in the 
context of what is already known. Explain why 
the review questions/objectives lend themselves 
to a scoping review approach. 
36 
Objectives 4 
Provide an explicit statement of the questions 
and objectives being addressed with reference to 
their key elements (e.g., population or 
participants, concepts, and context) or other 
relevant key elements used to conceptualize the 
review questions and/or objectives. 
36 
METHODS 
Protocol and 
registration 5 
Indicate whether a review protocol exists; state if 
and where it can be accessed (e.g., a Web 
address); and if available, provide registration 
information, including the registration number. 
-  
Eligibility criteria 6 
Specify characteristics of the sources of 
evidence used as eligibility criteria (e.g., years 
considered, language, and publication status), 
and provide a rationale. 
40 
Information 
sources* 7 
Describe all information sources in the search 
(e.g., databases with dates of coverage and 
contact with authors to identify additional 
sources), as well as the date the most recent 
search was executed. 
40 
Search 8 
Present the full electronic search strategy for at 
least 1 database, including any limits used, such 
that it could be repeated. 
Appendix 2 
Selection of 
sources of 
evidence† 
9 
State the process for selecting sources of 
evidence (i.e., screening and eligibility) included 
in the scoping review. 
40 
Data charting 
process‡ 10 
Describe the methods of charting data from the 
included sources of evidence (e.g., calibrated 
forms or forms that have been tested by the 
team before their use, and whether data charting 
was done independently or in duplicate) and any 
processes for obtaining and confirming data from 
investigators. 
40 
Data items 11 
List and define all variables for which data were 
sought and any assumptions and simplifications 
made. 
40-41 
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SECTION ITEM PRISMA-ScR CHECKLIST ITEM REPORTED ON PAGE # 
Critical appraisal 
of individual 
sources of 
evidence§ 
12 
If done, provide a rationale for conducting a 
critical appraisal of included sources of evidence; 
describe the methods used and how this 
information was used in any data synthesis (if 
appropriate). 
-  
Synthesis of 
results 13 
Describe the methods of handling and 
summarizing the data that were charted. 43 
RESULTS 
Selection of 
sources of 
evidence 
14 
Give numbers of sources of evidence screened, 
assessed for eligibility, and included in the 
review, with reasons for exclusions at each 
stage, ideally using a flow diagram. 
44-45 
Characteristics of 
sources of 
evidence 
15 
For each source of evidence, present 
characteristics for which data were charted and 
provide the citations. 
46 
Critical appraisal 
within sources of 
evidence 
16 If done, present data on critical appraisal of included sources of evidence (see item 12). -  
Results of 
individual sources 
of evidence 
17 
For each included source of evidence, present 
the relevant data that were charted that relate to 
the review questions and objectives. 
48 
Appendix 3 
Synthesis of 
results 18 
Summarize and/or present the charting results 
as they relate to the review questions and 
objectives. 
51-53 
DISCUSSION 
Summary of 
evidence 19 
Summarize the main results (including an 
overview of concepts, themes, and types of 
evidence available), link to the review questions 
and objectives, and consider the relevance to 
key groups. 
53-69 
Limitations 20 Discuss the limitations of the scoping review process. 70 
Conclusions 21 
Provide a general interpretation of the results 
with respect to the review questions and 
objectives, as well as potential implications 
and/or next steps. 
71 
FUNDING 
Funding 22 
Describe sources of funding for the included 
sources of evidence, as well as sources of 
funding for the scoping review. Describe the role 
of the funders of the scoping review. 
n/a 
JBI = Joanna Briggs Institute; PRISMA-ScR = Preferred Reporting Items for Systematic reviews and Meta-
Analyses extension for Scoping Reviews. 
* Where sources of evidence (see second footnote) are compiled from, such as bibliographic databases, 
social media platforms, and Web sites. 
† A more inclusive/heterogeneous term used to account for the different types of evidence or data sources 
(e.g., quantitative and/or qualitative research, expert opinion, and policy documents) that may be eligible in a 
scoping review as opposed to only studies. This is not to be confused with information sources (see first 
footnote). 
‡ The frameworks by Arksey and O’Malley (6) and Levac and colleagues (7) and the JBI guidance (4, 5) refer 
to the process of data extraction in a scoping review as data charting. 
§ The process of systematically examining research evidence to assess its validity, results, and relevance 
before using it to inform a decision. This term is used for items 12 and 19 instead of "risk of bias" (which is 
more applicable to systematic reviews of interventions) to include and acknowledge the various sources of 
evidence that may be used in a scoping review (e.g., quantitative and/or qualitative research, expert opinion, 
and policy document). 
From: Tricco AC, Lillie E, Zarin W, O'Brien KK, Colquhoun H, Levac D, et al. PRISMA Extension for Scoping Reviews 
(PRISMA-ScR): Checklist and Explanation. Ann Intern Med. ;169:467–473. doi: 10.7326/M18-0850 
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10.02 Appendix 2: Search terms used in literature review  
Table 32 Table of search terms used across three databases for the literature review 
Database 
Searched  
Search Terms  
Cochrane  #1 MeSH descriptor: [Polypharmacy]  
#2 MeSH descriptor: [Inappropriate Prescribing]  
#3 MeSH descriptor: [Potentially Inappropriate Medication List]  
#4 MeSH descriptor: [Medication Errors]  
#5 polypharma*:ti,ab  
#6 ((concomitant* or concurrent* or inappropriat* or appropriat* or 
suboptim* or sub-optim* or unnecessary or incorrect* or excess* or multip* or 
inadvert* or discontinu*) near/1 (medicine* or medicat* or prescrib* or 
prescription* or drug*)):ti,ab  
#7 ((over near/1 (prescrib* or prescript*)) or (over-prescrib* or 
overprescrib*) or ("or more" near/1 (medication* or prescrib* or 
prescript*))):ti,ab  
#8 ((under near/1 prescrib*) or underprescrib* or under-prescrib*):ti,ab  
#9 (stopp criter* or stopp list?).ti,ab.  
#10 ((forta or rasp or priscus) adj3 (criter* or list? or instrument)).ti,ab.  
#11 (stopp frail criter* or stopp frail list?).ti,ab.  
#12 ("fit for the aged" adj3 (criter* or list? or instrument or classif*)).ti,ab  
#13 "medication appropriateness index*".ti,ab.  
#14 ((beer* or shan? or mcleod?) adj3 criter*).ti,ab.  
#15 (acb criter* or acb scale or "anticholinergic cognitive burden scale" )  
#16 {or #1-#15}  
#17 MeSH descriptor: [Geriatrics] explode all trees  
#18 (elder* or geriatric*):ti,ab  
#19 ((old* or aged) near/1 (person* or adult* or people or patient* or 
inpatient* or outpatient*)):ti,ab  
#20 {or #17-#19}  
#21 #16 and #20  
#22 (dement* or Alzheimer*)  
#23 MeSH descriptor: [Dementia] explode all trees  
#24 {or #22-#23}  
#25 #16 and #24  
#26 #21 or #25  
 
Medline 
(EBSCO)  
((MH "Polypharmacy+") or  (MH "Potentially Inappropriate Medication List") or 
(MH "Inappropriate Prescribing") or (MH "Medication Errors+") or (stopp criter* 
or stopp list*) or ((forta or rasp or priscus) (criter* or list? or instrument)) or (("fit 
for the aged" (criter* or list? or instrument or classif*)) or ((beers criter*) or 
(beers list*)) or  ((mcleod criter*) or (mcleod list*))) AND (old* or age* or elder* 
or geriatric*) 
 
((MH "Polypharmacy+") or  (MH "Potentially Inappropriate Medication List") or 
(MH "Inappropriate Prescribing") or (MH "Medication Errors+") or (stopp criter* 
or stopp list*) or ((forta or rasp or priscus) (criter* or list? or instrument)) or (("fit 
for the aged" (criter* or list? or instrument or classif*)) or ((beers criter*) or 
(beers list*)) or  ((mcleod criter*) or (mcleod list*)))  AND (MH "Dementia") OR 
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(MH "Frontotemporal Dementia") OR (MH "Dementia, Vascular") OR (MH 
"Dementia, Multi-Infarct") OR (MH "AIDS Dementia Complex") OR (MH 
"Alzheimer Disease") OR (MH "Lewy Body Disease") 
 
((MH "Polypharmacy+") or  (MH "Potentially Inappropriate Medication List") or 
(MH "Inappropriate Prescribing") or (MH "Medication Errors+") or (stopp criter* 
or stopp list*) or ((forta or rasp or priscus) (criter* or list? or instrument)) or (("fit 
for the aged" (criter* or list? or instrument or classif*)) or ((beers criter*) or 
(beers list*)) or  ((mcleod criter*) or (mcleod list*))) AND (dementia or alzheimers 
or vascular dementia or lewy body or frontotemporal) 
 
Embase 
(OVID)  
(polypharmacy* or "potentially inappropriate prescr*" or "inappropriate 
prescr*").ab. polypharmacy.mp. or exp polypharmacy/ inappropriate 
prescribing.mp. or exp inappropriate prescribing/ or exp elderly care/ 
prescription.mp. or exp prescription/ exp drug safety/ or exp medication error/ 
old.mp. or exp aging/ geriatric.mp. or geriatrics/ geriatric.mp. or exp geriatrics/ 
stopp criteria.mp. "(stopp criter* or stopp list*) or ((forta or rasp or priscus) 
(criter* or list* or instrument)) transformed to (stopp criter* or stopp list*) or 
((forta or rasp or priscus) (criter* or list* or instrument))".af. (stopp criter* or 
stopp list*).af.  
(forta criteria list* or rasp criteria* list* or priscus criteria* list*).af. (forta or "fit 
for the aged").af. ("beers criter*" or "beers list*").af. ("mcleod criter*" or 
"mcleod list*").af. exp Alzheimer disease/ or demenita.mp. or exp dementia/ 
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10.03 Appendix 3: Scoping review tables of included studies  
(a) Table of review aims and key findings from scoping review  
Table 33 Table of review aims and key findings of reviews included in the scoping review 
Citation, population, 
setting    
Review aims Key findings  
Bokhof & Junius-
Walker (2016). 
Older adults, 
community  
Explore the perspectives of GPs and older patients in reducing polypharmacy 
and identify approaches already being practiced 
• Patients felt unprepared to deal with complex medication regimes. GPs felt pressurized to prescribe or to follow 
evidence-based guidelines.  
• Deprescribing was not deemed easy because there was no guidance available and when their patients were older, 
multimorbid and more complex to manage.  
• System-wide factors such as multiple prescribers and inadequate consultation time impacted prescribers and 
patients.  
 
Chang & Chan (2010) 
Older adults, mixed 
setting  
Summarize and compare criteria for PIMs to enable informed choices about 
their use 
• Seven criteria were identified.  
• Explicit criteria to define PIMs were varied across the world; benzodiazepines and tricyclic antidepressants were 
consistently identified as PIMs across criteria.  
• Beers, Rancourt and Wint-Watjana criteria were most similar.  
• Prevalence of PIMs was varied and the association of PIMs and health outcomes was inconclusive.  
 
Corsonello et al., 
(2012) 
Older adults, mixed 
setting  
Summarize the evidence about the use of explicit criteria for PIMs to reduce 
the risk of adverse drug reactions (ADRs) in older people. 
• Some evidence of association between Beers and mortality, healthcare utilisation, adverse drug events, quality of life 
and functional decline.  
• Beers criteria were not applicable to European countries due to variation in prescribing practices. 
• STOPP/START address many limitations of Beers by also including prescribing omissions, are classified by 
physiological systems and empathises drug-drug interactions.  
 
Corsonello et al.,  
(2009). 
Older adults, 
hospital  
Reviewing evidence of the application of Beers criteria in elderly hospitalized 
patients and Italian studies that have focused on the role of PIMs as potential 
predictors of negative hospital outcomes.  
• The application of Beers criteria may be limited in reliability in hospital settings, particularly in European countries.  
• Prevalence of PIMs was high in hospital settings and some evidence that Beers identified PIMs were associated with 
ADRs and length of hospital stay.  
 
Cullinan et al.,  
(2014). 
Older adults, mixed  
Synthesise qualitative studies exploring PIM in older patients to understand 
why it happens from a prescriber perspective and to generate new theory to 
guide future interventions aimed at minimising it in older people 
 
• Factors associated with reasons for prescribing PIMs included the need to please the patient, feeling forces to 
prescribe, tension between prescribing experience and guidelines and prescriber self-perceived restrictions.  
Ćurković et al.,  
(2016) 
Older adults, mixed 
settings  
To describe the prevalence and prevention of inappropriate prescribing and 
risk factors associated with psychotropic medications 
• PIM prescription and the prescription of psychotropic drugs was higher amongst nursing home residents.  
• Polypharmacy was associated with PIM and psychotropic drug prescription.  
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Citation, population, 
setting    
Review aims Key findings  
Dimitrow et al., 
(2011) 
Older adults, mixed 
setting  
To systematically review articles prescribing criteria for assessing PIM in 
individuals ages 65 years or older and to define circumstances of their use 
(explicit and implicit), origins, development processes and content 
• Fourteen criteria were identified, seven originating in the US. Most criteria were explicit, consensus validated and 
often based on Beers.  
• Explicit criteria need to be updated regularly but implicit criteria also require up-to-date knowledge and prescriber 
skill.  
• Most criteria measure appropriateness of medicines, Australian and MAI also assess the medication management 
process.  
• Most require clinical information to be implemented, NORGEP was the only criteria that did not require clinical 
information.  
 
Disalvo et al (2016) 
Older adults and 
people with 
dementia, mixed 
setting  
To identify and synthesise published systems for identifying PIM and make 
recommendations for identifying PIM in advanced dementia.  
• One system was in place to identify PIMs in patients with advanced dementia where palliative care was appropriate.  
• Patient comfort and symptom management was emphasised when reducing polypharmacy and preventative 
treatments.  
• Lack of evidence based guidelines and difficulties identifying advanced dementia were cited as reasons for 
inappropriate medication use in advanced dementia.  
 
Fulton et al., (2005). 
Older adults, 
primary care  
To review literature addressing polypharmacy in adults 60 years and older to 
1) determine primary care providers definition of polypharmacy 2) explore 
how polypharmacy was assessed in primary care and 3) seek tested 
interventions that address polypharmacy 
 
• Polypharmacy is a considerable issues and little research has been conducted into the methods primary care 
providers use to assess polypharmacy and interventions used.  
Gallagher et al., 
(2007) 
Older adults, mixed 
setting  
Overview of the literature on potentially inappropriate prescribing in the 
elderly and to review explicit criteria that have been designed to detect 
potentially inappropriate prescribing in the elderly 
 
 
• Prescription of PIMs in older people was prevalent in UK and Europe, ranking from 12% in the community to 40% in 
nursing home residents.  
• PIMs were associated with adverse drug events but limited evidence on health outcomes.  
Guaraldo et al., 
(2011). 
Older adults, 
community  
To describe studies using information from insurance company and social 
security administrative databases to assess PIM among community dwelling 
elderly and present risk factors most often associated with PIM 
 
• Prevalence of PIMs was high among community-dwelling elderly  
• PIM use was associated with being female, advanced age and number of prescribed drugs.  
• PIM prevalence’s varied depending on criteria used but ranged from 11.5% to 62.5%.  
 
Hajjar et al., (2007) 
Older adults, mixed 
setting  
Describe observational studies examining the epidemiology of polypharmacy 
and review RCTs designed to reduce polypharmacy in older adults 
 
 
• Polypharmacy has increased and is a risk factor for mortality and morbidity.  
• There were few rigorous interventions that have shown to reduce unnecessary polypharmacy in older adults.  
Hill-Taylor et al,. 
(2013) 
Older adults, mixed 
setting  
Conduct a systematic review of studies to describe the application of 
STOPP/START criteria and examine evidence of the impact of STOPP/START on 
clinical, humanistic and economic outcomes in older adults 
• STOPP/START were more sensitive than Beers in six studies but less sensitive in identifying adverse reactions.  
• Limited evidence of STOPP/START as effective in optimising prescribing.  
• STOPP can be used to identify avoidable adverse drug events but the evidence is not robust.  
 
Hyttinen et al.,  
(2016) 
Older adults, mixed 
setting  
Evaluate recent evidence on health care utilization and health care costs 
associated with PIM use in older adults. 
• Most studies found a significant effect on health care service use, including hospitalisation, among older adults. 
Findings on the impact of length of hospital stay were inconclusive.   
Johnell (2015)  To identify, assess and summarize available studies about potentially 
inappropriate drug use in cognitive impairment and dementia and to present 
• Prevalence of inappropriate drug use among people with cognitive impairment or dementia ranged from 10.2% to 
56.4%.   
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Citation, population, 
setting    
Review aims Key findings  
People with 
cognitive 
impairment or 
dementia, mixed 
setting  
findings about whether cognitive impairment and dementia are associated 
with inappropriate drug use.  
• A lower likelihood of inappropriate drug use in people with cognitive impairment or dementia in 6/8 studies. The 
remaining two articles showed no statistically significant association between cognitive impairment or dementia and 
inappropriate drug use.    
 
 
Kouladjian et al.,  
(2014). 
Older adults, mixed 
setting  
Evaluate and summarize the theoretical and practical aspects of Drug Burden 
Index (DBI), the effect of anticholinergic and sedative medications in older 
adults, discuss evidence supporting utilisation in practice and compares DBI 
with other pharmacologically developed models measuring anticholinergic or 
sedative exposure in older adults 
 
• The Drug Burden Index is a method used to identify anticholinergic and sedative drug burden, the DBI has been 
associated with poorer physical function, falls, frailty, hospitalisation and mortality.  
Kroger et al., (2015). 
Dementia, nursing 
home  
Identify categories of appropriateness for medications as well as successful 
interventions or elements of to improve medication use in nursing home 
residents with severe dementia, suitable for use in Canada. 
• Including healthcare professionals is important for improving medication use among nursing home residents with 
severe dementia  
• Interventions should include education, medication review or multidisciplinary teamwork.  
• Evidence for outcomes other that appropriate prescribing is mixed and it is unclear what the impact is on quality of 
life.  
 
Levy et al., (2010). 
Older adults, mixed  
To provide a comparative overview of explicit criteria that have been 
developed since 2003 for inappropriate prescribing and to contrast these 
newer criteria with Beers 2003 criteria 
• Criteria developed since 2003 include Beers, the French Consensus Panel list, STOPP/START, the Australian 
Prescribing Indicators tool and the Norwegian General Practice Criteria.  
• More recent criteria offer improvements on Beers, including around drug-drug interactions, prescribing omissions 
and wider application, with STOPP/START showing improvements in the application of criteria more widely.  
 
 
Matanović et al., 
(2012). 
Older adults, mixed  
To review and critically evaluate available protocols for detecting PIMs in the 
elderly and summarize these into a new comprehensive and widely applicable 
protocol 
 
 
• Many strategies are there to improve drug prescribing in older adults, who are at greater risk of adverse effects.  
Morin et al., (2016) 
Older adults, nursing 
home  
To systematically review the prevalence of potentially inappropriate 
medication use in nursing home residents 
• Pooled point prevalence estimates were 43.2% (95% CI 37.3%-49.1%) in nursing homes 
• Prevalence increased from 30% in studies from 1990-1999 to 49.8% in studies conducted after 2005.  
• Prevalence was higher in European countries compared to North America.  
• The total number of prescribed medications was consistently reported as the main driving factor for PIM use.  
 
Motter et al., (2018). 
Older adults, mixed  
To provide summaries and comparisons of validated PIMs lists published 
between 1991 and 2017 and summarize the medications and drug-disease and 
drug-drug interactions listed in different PIM lists 
 
• Approaches to identify PIM have increased (over 36 different PIM criteria) however there was limited overlap 
between the different PIM lists and some do not provide considerations of use or alternative therapies to use.   
 
Muhlack et al., 
(2017). 
Older adults, mixed  
To identify, evaluate and meta-analyse cohort studies reporting the 
association of PIM intake with mortality and cardiovascular events 
• When restricted to new user designs, the association between PIM use and mortality was statistically significant (RR 
1.59 95% CI 1.45-1.75).  
• One study focused on cardiovascular events and there was no significant association 
 
Opondo et al., 
(2012). 
To quantify the extent of inappropriate prescription to elderly persons in the 
primary care setting 
• Around 1/5 prescriptions to elderly primary care is inappropriate, despite the attention to quality of prescribing.  
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Citation, population, 
setting    
Review aims Key findings  
Older adults, 
primary care  
 
 
 
Pérez-Jover et al., 
(2018). 
Older adults, mixed  
Review published literature on the inappropriate use of medicines and to 
articulate recommendations on how to reduce it in chronic patients, 
particularly those who are elderly, poly-medication or multi-pathological. 
 
• Most older adults take 5 or more medications daily  
• Older people with polypharmacy are at a greater risk of medication error 
• Tools can be used to reduce prescribing errors.  
 
Peron et al., (2011). 
Older adults, mixed  
To critically review articles that have examined the relationship between 
medication use and functional status decline in the elderly. 
 
 
• No relationship between Beers criteria and functional status  
• Polypharmacy was associated with functional status decline. 
Redston et al., 
(2018) 
Older adults with 
and without 
cognitive 
impairment  
To quantify and compare the prevalence of PIMs in older inpatients with and 
without cognitive impairment. 
• High prevalence of PIMs in older inpatients with and without cognitive impairment  
 
Rodrigues et 
al.,(2016). 
Older adults, mixed  
to identify and summarize studies examining both drug-drug interactions and 
adverse drug reactions in older poly-medicated adults 
 
 
• Polypharmacy is multifactorial and is associated with negative health outcomes, drug-disease interactions and 
adverse drug reactions.  
 
Salahudeen et al.,  
(2015). 
Older adults 
To compare anticholinergic burden quantified by the anticholinergic risk scales 
and evaluate associations with adverse outcomes in older people. 
• There were 7 expert-based anticholinergic rating scales identified, ACB scale was the most frequently validated scale 
for adverse outcomes.  
• Cohort studies show that higher anticholinergic burden is associated with negative brain effects, poorer cognitive and 
functional outcomes.  
• Rating of anticholinergic activity for medicines was not consistent across scales. 
 
Santos et al,. (2015).   
Older adults, mixed  
Assess the tools used to detect PIMs in various studies and to determine 
which terms are used to refer to potentially inappropriate drug therapy in 
practice. 
 
 
• Beers criteria was the most commonly used and there were more than 50 different terms used to identify potentially 
inappropriate drug therapy. There was no consensus for a term used to describe this. 
Skinner (2015). 
Older adults, 
primary care  
To critically evaluate evidence-based protocols on polypharmacy in elderly 
patients in primary care. 
• No standardized protocol for addressing polypharmacy in primary care was found although there were a range of 
practice guidelines, algorithms and clinical strategies that were employed across various settings. 
 
Storms et al,. (2017) 
Older adults, care 
home 
assess the prevalence of inappropriate medication use in residential long-term 
care facilities 
 
 
 
• Beers and STOPP were most frequently used to determine PIM in long-term care facilities, prevalence varied 
depending on the criteria used and the study. 
Tommelein, et al,. 
(2015).   
To determine prevalence and type of PIM in community dwelling older people 
across Europe as well as identifying risk factors for PIM. 
• 1/5 older adults are exposed to PIM in Europe (overall weighted prevalence 22.6%).  
• Prevalence was varied with various criteria that are used across studies.  
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Citation, population, 
setting    
Review aims Key findings  
Older adults, 
community  
• Polypharmacy, low functional status, depression, economic situation, comorbidity and reduced cognition are 
associated with higher risk of PIM. Age was associated in around half of studies that investigated age as a risk factor 
for PIM. 
 
Villalba-Moreno, et 
al., (2016) 
Older adults, mixed  
to identify anticholinergic scales described in the literature that are applicable 
to polypathological patients and analyse their clinical outcomes 
• 10 scales were identified, exposure to anticholinergics was linked to cognitive disorders but the evidence associated 
with mortality was not clear. 
 
 
Wang et al,. (2018). 
Older adults, care 
home  
To systematically review the association between medication or prescribing 
patterns and hospitalizations from long-term care facilities. 
• In care homes, polypharmacy and PIM were consistently associated with increased hospital admission 
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(b) Table of reviews of intervention studies included in the scoping review  
Table 34 Table of reviews of intervention studies included in the scoping review 
Reviews of interventions  
Authors (year)   Types of 
studies 
included  
Population, 
Setting  
n studies 
(participants)    
Review aims Types of interventions  Key findings  
Alldred et al., 
(2016) 
RCTs  Older adults, 
care home  
12 (10,953)  Evaluate evidence for interventions to address 
suboptimal prescribing in care homes to identify how 
care can be improved in this frail and vulnerable 
population. 
• Medication review  
• Multifaceted interventions, including 
education of care home staff, clinical 
decision support technology, multi-
disciplinary case conferences, pharmacist 
medication review 
o In care homes, medication review may improve medication appropriateness and the 
identification and resolution of medication related problems.  
o There was no evidence of an effect of interventions on mortality and adverse drug 
events.  
o Uncertain whether medication review improved hospital admissions or quality of life.  
o Robust conclusions could not be drawn due to the quality of the evidence.  
Christensen & 
Lundh (2016)  
RCTs Older adults  10 (3,575)  Evaluate whether a medication review leads to 
improvement in health outcomes of hospitalised adult 
patients compared with standard care. 
 
• Medication review in hospital setting  o In hospitals, there was no evidence that medication review reduced mortality or 
hospital readmissions 
o Some evidence that medication review may reduce the number of emergency 
department contacts compared with standard care.  
Clyne et al., 
(2012) 
RCTs, cluster 
RCTs, cohort 
studies, 
interrupted 
time series 
Older adults, 
ambulatory 
care, nursing 
home, 
hospital  
14 To identify studies on the effectiveness of assistive 
prescribing technologies for older people.  
• e-prescribing  
• computerised decision support systems 
• Drug-specific alters on prescribing systems 
with recommendations on dose and 
alternatives.  
o 11/14 studies identified that the use of prescribing technologies (e-prescribing and 
computerised decision support systems) lowered inappropriate prescribing and 
polypharmacy.   
o In nursing homes, implementing prescribing technologies was more challenging.   
Clyne et al., 
(2016). 
RCTs Older adults, 
community-
dwelling  
12 (156,529)  Identify and determine the effectiveness of interventions 
to reduce PIM in community dwelling older adults 
• Organisational – changing structure of 
services  
• Professional – targeting professionals to 
improve practice, including education  
• Multifaceted interventions e.g. 
computerised decision support systems and 
academic detailing  
o Organisational interventions, including pharmacist medication review, showed a 
reduction in PIM.  
o The evidence of effectiveness of multidisciplinary teams was weak.  
o Computerised clinical decision support systems were effective in reducing new PIM 
prescriptions but did not impact existing PIMs.  
o Some evidence that multifaceted approaches were effective.  
o Overall, effect sizes were modest and the impact on clinically relevant patient 
outcomes is unclear.   
Cooper et al., 
(2015) 
RCTs, cluster 
RCTs, 
controlled 
before and 
after studies  
Older adults  12 (22,438)  To update a review of interventions aimed at improving 
the appropriate use of polypharmacy in older adults 
• Organisational interventions – multifaceted 
pharmaceutical-care based interventions 
• Medication review  
• patient education  
• health professional education  
• Computerised decision support   
o Interventions showed a reduction in PIMs and improvements in appropriate 
polypharmacy.  
o Clinically relevant effects were unclear, evidence was conflicting on the effect of 
interventions on hospital admissions and medication related problems.  
o No evidence associated with health related quality of life.  
Forsetlund et 
al., (2011) 
RCTs Older adults, 
nursing 
home  
20  To identify and summarise the effect of interventions 
aimed at reducing PIM in nursing homes 
• Education interventions  
• medication review by pharmacists  
• Multidisciplinary teams  
 
 
 
 
 
o In nursing homes, education interventions and pharmacist medication review may 
reduce PIMs, however the evidence was low quality.  
o Contextual factors within nursing homes influence the effect of interventions.  
o The evidence was limited on the impact of health-related outcomes.  
 
Johansson et 
al., (2016) 
RCTs, non-
randomised 
Older adults, 
mixed  
25 (10,980)  Explore the impact of strategies to reduce polypharmacy 
on mortality, hospitalization and change in number of 
drugs 
• Pharmacist-led interventions  
• Education  
• Discussion with patients  
o Meta-analysis showed no effect of interventions to reduce polypharmacy overall on 
mortality. 
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controlled 
trials  
• Medication review by physicians  
• Multidisciplinary teams  
o Some evidence of an association with reduced hospital admissions but the evidence 
was not robust and due to heterogeneity of studies results could not be compared.  
o There was no robust evidence of a reduction in polypharmacy or subsequent impact 
on mortality or hospitalisation.  
Kaur et al., 
(2009) 
 Older adults, 
mixed  
24 (56- 
124,802)  
Identify interventions and strategies that can significantly 
reduce inappropriate prescribing in the elderly. 
• Education 
• Medication review  
• Multidisciplinary teams  
• Computerised decision support systems  
• regulatory policies  
• Regulatory policies  
o Various interventions showed a positive effect on reducing PIM, 
o Combined efforts not relying on primary care prescribers (e.g. including pharmacists) 
are required.  
o Education interventions showed mixed effects.  
o Computerised decision support showed positive effects and majority of studies 
involving pharmacists showed positive effects.  
o Mixed effects of multidisciplinary teams.  
Page et al., 
(2016) 
Experimental 
and 
observational 
studies  
Older adults  116 (34,14, 
6,090 people 
with 
dementia) 
To determine whether or not deprescribing is safe, 
effective and feasible intervention to modify mortality 
and health outcomes in older adults 
• Deprescribing single medications 
• Deprescribing polypharmacy  
• Education  
o Deprescribing reduced the number of medicines and PIMs prescribed and was not 
associated with an increase in adverse drug events. 
o In non-randomised studies, deprescribing polypharmacy was significantly associated 
with decreased mortality, however there was no evidence of an association in 
randomised studies.  
o Interventions involving medication reviews were associated with significant reduction 
in mortality however general prescriber education interventions were not.  
o Deprescribing did not change cognitive function, risk of falls or quality of life.  
 
Page et al.,  
(2016) 
 Older adults, 
mixed  
 To describe the genesis of deprescribing as an 
increasingly accepted medical and pharmaceutical 
intervention (to manage polypharmacy and PIM) and an 
overview of deprescribing 
• Deprescribing: The process of supervised 
withdrawal of inappropriate medications 
with the goal of managing polypharmacy  
• Medication review 
• Education  
o Medications should be review to ensure appropriate and optimal use.  
o Deprescribing is the process of supervised medication withdrawal, with the aim of 
managing polypharmacy and improving outcomes.  
o There is evidence suggesting that deprescribing is effective in managing polypharmacy 
and PIMs and used in combination with other interventions, could also improve health 
outcomes.   
Rankin et al., 
(2018) 
RCTs, non-
randomised 
controlled 
trials, 
controlled 
before and 
after studies 
and 
interrupted 
time series  
Older adults, 
mixed  
32 (28,672)  To determine which interventions, alone or in 
combination, are effective in improving the appropriate 
use of polypharmacy and reducing medication-related 
problems in older people. 
• Computerised decision support  
• Multifaceted pharmaceutical-care e.g. 
including medication review, education of 
patient or prescriber  
o Results were unclear whether pharmaceutical care improved appropriate 
polypharmacy and number of PIMs.  
o Some evidence that pharmaceutical care reduces potential prescribing omissions, 
however risk of bias high.  
o Little or no evidence of impact on hospital admissions, quality of life and medication-
related problems.   
Rollason & 
Vogt  (2003) 
RCTs, 
controlled 
trials  
Older adults, 
nursing 
home and 
hospital  
14 Examine the effectiveness of interventions led by 
pharmacists in reducing polypharmacy 
• Pharmacist-led or included interventions  
• Medication review 
• case conferencing  
• Education interventions  
• Some interventions involved patients, 
multidisciplinary teams  
 
 
 
o Whilst the number of medications reduced was often small, the studies were in favour 
of the effectiveness of pharmacist-led interventions overall.  
o An intervention of any kind by or involving a pharmacist could reduce the number of 
drugs in older adults.  
Thillainadesan 
(2018) 
RCTs Older adults, 
hospital  
9 (2,522)  To investigate the efficacy of deprescribing interventions 
in older inpatients in hospital to reduce PIMs and impact 
on clinical outcomes 
• Deprescribing interventions  
• Pharmacist-led  
• Physician-led 
• Multidisciplinary teams  
• Tools to identify PIMs 
• medication review 
• Computerised decision support  
o Deprescribing interventions in hospitals are effective at reducing overall number of 
PIMs, however the evidence of the impact on clinical outcomes was not well 
measured and was unclear.  
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Thiruchelvam 
et al., (2017). 
RCTs and 
observational 
studies  
Older adults, 
care homes 
22 Assess the impact of medication reviews in aged care 
facilities with additional focus on types of medication 
reviews, using RCTs and observational studies 
• Medication reviews by pharmacists or 
multidisciplinary teams involving 
pharmacists  
o In care homes, medication reviews conducted by a pharmacist as part of a team or 
independently appeared to improve quality of medicines.  
o Medication reviews may slightly reduce number of medicines prescribed and PIMs.  
o There was some evidence to suggest a positive effect of medication review on 
mortality, hospitalisation and disability.   
Tjia et al., 
(2013) 
RCTs, pre-
post 
interventions, 
case series  
Older adults, 
mixed  
36 (13,906)  Identify unnecessary medications, the intervention 
process of medication reduction and the effectiveness of 
these interventions 
• Medication review  
• Education interventions  
• Pharmacists involvement  
 
 
 
 
o 22/26 studies reported a significant reductions or differences associated with 
interventions to reduce unnecessary medicines.  
o Pharmacist involvement in medication reviews was important but clinician-led reviews 
were more consistently associated with a positive outcome across studies.  
Walsh et al., 
(2016) 
RCTs and 
non-
randomised 
controlled 
trials  
Older adults, 
hospital  
4 (1,164)  Collate available evidence on the effectiveness of 
pharmacist interventions on the quality of prescribing to 
older hospitalised patients. 
• Pharmacist included in ward teams 
• Clinical pharmacists in multidisciplinary 
teams  
 
o Evidence that interventions involving pharmacists were associated with reduction in 
PIMs. 
o In hospitalised older adults, multidisciplinary teams involving pharmacists may 
improve the appropriate of medicines.  
Wilsdon et al., 
(2017) 
RCTs and 
non-
randomised 
controlled 
trials  
Older adults, 
mixed  
21 determine the effectiveness of interventions to 
deprescribe inappropriate Proton Pump Inhibitors (PPIs) 
in older adults 
• Population-wide education strategy  
• Academic detailing for general practitioners  
• in-patient geriatrician-led deprescribing  
• discharge letters  
• education  
• medication review  
o Some interventions were effective in reducing PPIs, including population-wide 
education and deprescribing promotion strategies, academic detailing and geriatric 
assessment.  
o Whether the impact of these interventions translates into clinical outcomes is unclear.   
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(c) Table of criteria for identifying potentially inappropriate medications in older adults from 1991-
2017 
Table 35 criteria for identifying potentially inappropriate medications from 1991-2017  
Criteria for identifying PIM  Year  Country of origin  Reference  
2017    
Khodykov criteria  2017 USA  Khodyakov et al (2017)  
Mazhar criteria  2017 Pakistan  Mazhar et al (2017)  
2016    
Chilean criteria  2016 Chile  Passi et al (2016)  
GheOP(3)S-tool  2016 Belgium  Tommelein et al (2016)  
2015    
EU(7) PIM list  2015 Germany   Renom-Guiteras et al.  2015 
Korean Criteria  2015 South Korea Kim et al (2015)  
NORGEP-NH  2015 Norway  Nyborg et al (2015)  
Beers 2015 USA  Beers 2015  
Swedish National Board of Health and Welfare  2015 Sweden  Fastborn & Johnell (2015)  
STOPP/START 2015  Ireland  Gallagher 2015  
2014     
Fit for the Aged (FORTA) (2014)  2014 Germany  Kuhn-Thiel et al (2014)  
Galan-Retamal criteria  2014 Spain  Retamal et al (2014)  
2013     
Czech national Criteria (CNC)  2013 Czech Republic  Fialova et al (2013)  
Castillo-Paramo criteria  2013 Spain  Castillo-Paramo et al., 2013  
OPTI-SCRIPT  2013 Ireland  Clyne et al (2013)  
2012    
Beers  2012 USA  
Australian Prescribing Indicators Tool (APIT)  2012 Australia  Basger et al (2012)  
New Mexico criteria  2012 New Mexico  Bachyrycz et al (2012)  
Taiwan criteria  2012 Taiwan  Chang et al (2012)  
2010     
PRISCUS  2010 Germany  Holt et al (2010)  
Korean criteria  2010 South Korea  Kim et al (2010)  
Italian criteria  2010 Italy  Maio et al (2010)  
2000-2009     
Beers  2003 USA  
STOPP/START  2008 Ireland  
Assessing Care of Vulnerable Elders (ACOVE)  2001 USA Wenger & Shekelle (2001) 
Hyperpharmacotherapy Assessment Tool (HAT)  2008 USA Bushardt et al (2008)  
Association of Nursing Home Surveyors 
Interpretative Guidelines 
2007 USA (Lapane et al (2007)  
French Consensus panel List  2007 France  (Laroche et al., 2007 
Improved Prescribing in the Elderly Tool (IPET)  2000 Canada  Naugler et al (2000)  
Phadke criteria  2004 India  Phadke (1998)  
Rancourt criteria  2004 Canada  Rancourt et al (2004)  
Norwegian General Practice Criteria (NORGEP) 2009 Norway Rognstad et al (2009)  
Zhan criteria  2001 USA Zhan et al (2001)  
Healthcare Effectiveness and Data Information Set 
(HEDIS)  
2006 USA Pugh et al (2006)  
Lindblad criteria  2006 USA Lindblad et al (2006)  
Japanese Beers criteria  2008 Japan Imai et al (2008)  
Thailand Criteria  2008 Thailand  Winit-Watjana et al (2008)  
1991-1999     
Beers 1991 USA  
Beers  1997 USA  
Medication Appropriateness Index (MAI)   1992  USA (Hanlon et al., 1992)  
Assessment of Underutilization of medication 
(AOU) 
1999  USA Jeffrey et al (1999)  
McLeod Criteria  1997 Canada  McLeod et al (1997)  
Stuck  1994 USA Stuck et al (1994)  
Lipton implicit criteria  1993 USA Lipton et al (1993)  
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A. Study Title§ 
Potentially inappropriate prescribing in people with dementia in England: a prospective cohort study. 
 
B. Lay Summary (Max. 200 words)§ 
People with dementia are often prescribed many different medicines for symptoms of dementia or other health 
conditions. Some medicines may be inappropriate if they have been used for too long or their harms outweigh their 
benefits.  
 
Doctors are expected to manage medications and are paid to hold an annual dementia care review with every 
patient. We do not know what effect these opportunities to review medication have on quality of care, an important 
part of which is reducing the amount of medicines that may be harmful in people with dementia.  
 
Detailed medication recommendations have been created to help health professionals reduce harmful prescriptions. 
We have used these guides to select four groups of medications that may be inappropriate for people with 
dementia. They are antipsychotic medications, tricyclic antidepressants, anticholinergics (defined according to 
Anticholinergic Cognitive Burden scale score = 3) and proton pump inhibitors. We will look at how often these 
medicines are prescribed and the impact of dementia annual reviews and other medication reviews on their use, 
using GP records of all people with dementia available in the Clinical Practice Research Datalink in 2014 and 2015.  
 
 
C. Technical Summary (Max. 200 words)§ 
§Please note: This information will be published on CPRD’s website as part of its transparency policy 
Objective: To estimate the (i) prevalence of potentially inappropriate medication use, and overall medication burden 
among people with dementia between 2015 and 2017 (ii) and the factors associated with potentially inappropriate 
medication use, in particular the effect of medication reviews and dementia annual review.  
Methods. A 2-year cohort study following all prevalent cases of dementia at the start date of 01/01/2015, and 
incident cases between the start date and the study end date of 30/04/2017. Prescriptions of four classes of 
potentially inappropriate medications (antipsychotics, tricyclic antidepressants, anticholinergics and proton pump 
inhibitors) will be extracted, as well as any medication review or dementia annual review (exposures) during that 
period and potentially confounding variables.  
Statistical analysis. We will estimate the prevalence of potentially inappropriate medication use in people with 
dementia across the study period. McNemar and Wilcoxon signed rank tests will test the change in each outcome 
before and after a medication review or dementia annual review. Multilevel logistic regression analyses will then be 
used to estimate the factors associated with each outcome, and in particular the effect of medication review or 
dementia annual review on subsequent prescriptions controlling for age, sex, time varying comorbidity, area-level 
deprivation, GP practice and exception from QOF dementia indicators.  
D. Objectives, Specific Aims and Rationale 
Objectives  
1. To estimate the (i) prevalence of potentially inappropriate medication (PIM) prescription among people with 
dementia (ii) factors associated with PIM, in particular the effect of medication review (MR) and dementia 
annual review (DAR) on PIM.  
Specific aims  
1. To estimate the prevalence of PIM use in people with dementia in primary care in England between 2015 and 
2017. 
2. To estimate the change in probability of being prescribed a potentially inappropriate medication before and 
after a MR or DAR.  
3. To estimate the patient and practice level factors associated with each PIM in people with dementia, including 
the effect of age, sex, comorbidity, recent review, area-level deprivation, residual between practice variation 
and exception from QOF dementia indicators.     
 
The potentially inappropriate medications are selected through consultations with experienced prescribers and from 
explicit criteria (Beer’s, STOPP) as those specifically implicated in people with dementia. Specifically the  prescription 
of:  
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a. Any antipsychotic (vs no antipsychotic prescription) 
b. Tricyclic antidepressants (vs no tricyclic antidepressant)   
c. Any definite anticholinergic (defined using Anticholinergic Cognitive Burden score=3 [254] vs no ACB=3 
anticholinergic)  
d. Any inappropriate PPI (defined as use for >8 weeks at maximum therapeutic dose [232, 243]) (vs no PPI 
prescription).  
e. Overall medication burden as measured by a continuous variable for the total number of prescribed 
medications. Excluding devices, dressings and topical preparations.   
 
Rationale  
By addressing the aims identified above, we will be able to estimate the prevalence of potentially inappropriate 
prescribing in people with dementia in England. We will be able to understand the impact of MR and DAR on these 
prescriptions. This will provide a means of assessing the extent of the problem of PIM in people with dementia and 
impact that contact with GP services through medication reviews and QOF incentives have on specific patient-
focused outcomes such as appropriate prescribing.   
E. Study Background 
‘Dementia’ refers to a syndrome of terminal decline in multiple aspects of cognitive function and consequent 
independence in daily functioning, caused by one of a number of different underlying neurodegenerative diseases. 
In the UK there are over 800,000 people living with dementia [28]. People with dementia often have many comorbid 
conditions for which they are prescribed medications. However the harms of many commonly used medications can 
outweigh the benefits in people with dementia and much of this prescribing is considered ‘potentially 
inappropriate’. 
 
One of the most commonly used criteria for identifying potentially inappropriate prescribing is Beer’s criteria for use 
in older adults [232]. Beer’s includes medications or classes that should be avoided and disease-specific drugs to 
avoid and has been applied across healthcare settings [346]. However, a large proportion of medicines in Beer’s are 
unavailable in the UK and Europe [106]. An alternative criteria, validated in the UK and Europe, is the Screening Tool 
of Older Person’s Prescriptions (STOPP). This consists of 80 physiological systems-based criteria for screening 
inappropriate medication use in older adults [243]. Despite their differences in approach there is overlap in the 
medications and classes that are identified as potentially inappropriate in older people [347]. In people with 
dementia, antipsychotics, antidepressants and anticholinergics are implicated in both criteria for their potential 
adverse harms or for worsening cognitive impairment.  
 
Increasing awareness of harms, including stroke and excess mortality, has led to a decrease in the prescription of 
antipsychotic medications following a dementia diagnosis in primary care in the UK (19.9% to 7.4%), whereas the use 
of antidepressant medications (10.7% to 26.3%) has risen across the same time period (1995 – 2011) [204]. During 
2013 in Northern Ireland, 25.2% of people with dementia were being prescribed an anticholinergic medication [189] 
and in 2007 around 29% of people with dementia in the UK were prescribed any potentially inappropriate 
medication [291].  
 
Potentially inappropriate medication use occurs where the associated harms outweigh potential benefit and in 
people with dementia there are a number of medications that are associated with particular adverse effects.  The 
use of anticholinergic mediations is associated with delirium, sedation, urinary retention and increased cognitive 
impairments in people with dementia [213, 225]. Tricyclic antidepressants also have a high anticholinergic load and 
it is recommended that they are avoided in people with dementia due to their associated harms [232]. Tricyclics are 
also associated with orthostatic hypotension, sedation and cognitive impairment [213, 215, 348, 349]. All 
antidepressants have the potential for multiple adverse effects and the side effect profiles differ between the 
different types [348].   
 
Used to treat acid related indigestion and peptic ulcers, proton pump inhibitors (PPIs) are one of the most frequently 
prescribed medications in the world [233] and are generally associated with few adverse effects, however they are 
costly and their frequent use significantly impacts NHS budgets, with over £100 million spent annually on PPIs in 
England [244]. In STOPP, PPIs are deemed inappropriate when used for peptic ulcer disease at maximum therapeutic 
dosage for >8 weeks. There have been several serious adverse effects associated with long-term PPI use, the 
strongest evidence is for Clostridium difficile infection and increased risk of bone fractures and there is some 
evidence for increased risk of pneumonia [238, 244, 350, 351]. Monitoring long-term PPI use could have implications 
on prescribing costs and appropriate and safe prescribing for patients. The prevalence of inappropriate PPI use 
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ranges from 3.7% using UK Clinical Practice Research Datalink in 2007 (CPRD) to 22.9% using the Northern Ireland 
Enhanced Prescribing Database in 2013 [189, 291]. 
 
Primary care provides an integral role in the detection, diagnosis, management and support of people with dementia 
and their carers [352]. GPs are important in prescribing, managing and reviewing potentially harmful medications, 
such as the regular review of antipsychotic medications. The use of antipsychotic medications in people with mild-
moderate dementia is not advised due to serious adverse effects [203, 353, 354]. When antipsychotics are used to 
manage severe and distressing behavioural and psychological symptoms it is recommended that they are used at the 
lowest dose for a limited time and regularly reviewed (every 3 months) [355].  
 
Potentially, every GP consultation provides an opportunity for medications to be reviewed and changes to be 
implicated. Medication review (MR) is a term that encompasses a range of interventions that may be carried out by 
GPs, prescribing nurses or pharmacists, with and without the patient being present and can range from a token 
check to a full clinical review [356]. For older adults, government policy documents, such as the National Service 
Framework for Older People advocate that medications are reviewed at least annually and every 6 months for 
patients taking four or more medications [357].  
 
In 2006, the dementia annual review (DAR) was introduced as a Quality Outcomes Framework (QOF) indicator for 
dementia care, providing a payment-based reward for quality GP practice care. The DAR is a yearly comprehensive 
review of the patients’ physical, mental health and social review, access to support services, and a carer’s 
assessment [111]. Variation in practice implementation means that the number of patients receiving a DAR ranges 
from around 50% - 86% [114] and previous research suggests that the quality and comprehensiveness of the reviews 
being conducted are variable [113]. Although not explicitly implicated, the DAR provides an opportunity to review 
and reduce potentially inappropriate medications implicated in people with dementia. The impact of DAR as an 
effective means of achieving this is unknown.  
 
This study will estimate the recent prevalence of potentially inappropriate prescribing in people with dementia in 
primary care in England and the effect of medication review and DAR on these prescriptions. Specifically we will 
describe the prescription of four exemplar classes of PIM use including antipsychotics, anticholinergics, 
antidepressants and proton pump inhibitors, as well as the overall medication load. 
 
F. Study Type 
Prospective cohort study.  
G. Study Design 
The study period is 01/01/2015 to 30/04/2017.  People with dementia diagnosed before or during the study period 
will be followed until death, leaving the practice or the end of the study period.  A prospective cohort study method 
will be used to estimate the prevalence of a prescription of the selected potentially inappropriate medication in 
people with dementia between January 2015 and April 2017.  
 
Within this period we will use longitudinal modelling to estimate the effect of the exposures (DAR and MR) on the 
prescription of potentially inappropriate medications in months following review, to determine how DAR and 
medication reviews affect inappropriate prescribing. 
H. Feasibility counts 
 
Using a restricted set of the most common diagnosis codes, there are 32,970 people with dementia in CPRD GOLD 
(October 2016 version) at some point during 2014 or 2015 period. Between 01/01/2014 – 31/12/15, 3434 of these 
were prescribed a tricyclic antidepressant on at least one occasion.  
 
This is one of the rarer medication classes we are investigating, suggesting that all PIM groups in this cohort will be 
sufficiently frequent to permit our analysis. There are also an estimated 9,000 people with dementia who have a 
record of both a DAR and MR. 
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I. Sample size considerations 
There are an estimated 33,000 patients with dementia based in English CPRD GOLD registered practices at the 
start of the study period (01/01/2015) (sample size estimated from October 2016 version of CPRD GOLD). There 
are around 14000 patients with a dementia annual review and 16000 with a medication review Read code (CPRD 
GOLD 2015).  
 
Our primary objective is the effect of DAR or MR on changing prescription of PIM classes.  We have estimated the 
number of participants needed to demonstrate a change in potentially inappropriate medication (PIM) prevalence, 
using data from a recent RCT of medication reviews in the general older population [268], and considering a 
relatively rare PIM.   
 
This has provided an illustrative example of the expected change in prescribing. The paired changes in PIM 
prescriptions before and after exposure (a medication review) are given in the table below. 
 
 
Table 1. Proportion of rare PIM prescriptions, such as tricyclic antidepressants post-
medication review, based upon Milos et al. (2013).  
  Post-review Total  
  1 0   
Pre-review 
1 0.03 0.02 0.05  
0 0.01 0.94 0.95  
 Total 0.04 0.96 1  
n.b. Odds Ratio = 2, Proportion of discordant pairs = 0.03  
For a rare PIM, where baseline prevalence is around 5%, with a 2% reduction in PIM and 1% starting a PIM, to 
detect a difference following a exposure with 90% power (at significance level of p =<0.05) we will require a 
sample 2600 patients (for rare PIM, such as tricyclic antidepressant medications). To reflect the multiple testing 
correction with a significance level of p=<0.005 at 90% power we will require 4400 patients. More common PIM 
will require fewer participants, and this is comfortably within the 14000 patients with a dementia annual review 
code available in CPRD. 
 
J. Data Linkage Required (if applicable):§ 
§Please note that the data linkage/s requested in research protocols will be published by the CPRD as part of its 
transparency policy 
IMD. Index of multiple deprivation quintile at the practice level is needed as a potential confounder. 
 
K. Study population 
All cases will be selected who meet the following criteria:  
 
Diagnosis of dementia as defined by the presence of a record of a dementia diagnosis (see Appendix 1) or a 
prescription of a cognitive enhancer (i.e. memantine, donepezil, rivastigmine, or galantamine) before the start date 
(01/01/2015) or during the study period (01/01/2015 – 30/04/17). Including new diagnoses will maintain a 
representative sample of dementia patients throughout the study period. 
 
• Dementia diagnosis using similar definitions has been validated in CPRD with a positive predictive 
value (PPV) of 95% [252].  
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• Cognitive enhancers as a diagnosis of dementia will be used with caution. In some cases rivastigmine 
is used in patients with Parkinson’s, without a clear diagnosis of dementia. However a limited number 
of diagnoses are identified through rivastigmine (approximately 0.3%) so this is unlikely to be a 
problem.  
• The study period has been selected in order to provide the most current estimate of the prevalence of 
medication use within this population and to account for at least one dementia annual review in 
every eligible patient.  
• Patients excepted from the QOF indicator for dementia annual review will also be included in 
analyses. On average 12.7% of patients were excepted for dementia QOF indicators (2015-2016). Any 
potential confounding effect of QOF exception will be controlled for by adding a covariate indicating 
QOF exception at or before any point during each time period into the analysis. Exceptions will be 
defined using Read Codes 9hD..00 (Exception reporting: dementia quality indicators), 9hD0.00 
(Excepted from dementia quality indicators: Patient unsuitable) 9hD1.00 (Excepted from dementia 
quality indicators: Informed dissent) and 8CMZ200, 8IAe000, 8IAe200 and 8CMZ300.  
 
Registered with an ‘Up To Standard’ (research quality) practice in England for 1 year before study entry. This will 
allow for appropriate measurement of baseline covariates.  
• We will restrict to practices in England to ensure the quality of DAR recording, as QOF guideline 
agreements are different in England compared to agreements in Scotland, Northern Ireland and 
Wales [358].     
 
The study population included in the analysis addressing aim 2, estimating the change in probability of being 
prescribed a potentially inappropriate medication before and after a MR or DAR, will by necessity only include 
patients with dementia who have a record of i) dementia annual review ii) medication review iii) dementia annual 
review and medication review.   
• Dementia annual review will be defined by the presence of the Read Code 6AB..00 within the defined 
follow-up time points.   
 
• The presence of a Read code identifying that a medication review took place within the follow-up time 
points (see Appendix 2 for codes). 
 
L. Selection of comparison group(s) or controls 
There are no controls or comparison groups in this study.  
 
M. Exposures, Health Outcomes§ and Covariates  
§Please note: Summary information on health outcomes (as included on the ISAC application form  above )will be 
published on CPRD’s website as part of its transparency policy 
 
Exposures: 
Dementia Annual Review: Dementia annual review will be defined by the presence of the Read Code 6AB..00 within 
the defined follow-up time points.   
 
Medication review: The presence of a Read code identifying that a medication review took place within the follow-
up time points (see Appendix 2 for codes). 
 
*Incident cases for the first year since diagnosis, another code of newly diagnosed – may not always be possible  
 
Health outcomes: 
We will extract the presence of a prescription for the selected potentially inappropriate medications, defined using 
World Health Organisation Anatomical Therapeutic Chemical Classification System (ATC) codes. 
 
The presence of each of the following PIMs will be coded within each of 12 2-month time periods between January 
2015 and April 2017 for each patient conditional on their inclusion in the study for the whole of that period. 
 
1. Antipsychotic medication will be defined using ATC code N0A5A (see Appendix 3a).  
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2. Tricyclic antidepressants will be defined using ATC codes. Antidepressants (ATC N06A) are grouped 
into tricyclic antidepressant sub-type, according to ATC cross-referenced with the British National 
Formulary (BNF) to identify those used in UK practice (ATC N06AA02, N06AA03, N06AA04, N06AA06, 
N06AA07, N06AA09, N06AA10, N06AA12, N06AA16, N06AX03 and N06AX05) (see Appendix 3b).  
 
3. Definite anticholinergic medication will be defined as any medication with an Anticholinergic 
Cognitive Burden (ACB) score of 3. An ACB=3 score indicates medications with definite anticholinergic 
activity and severe negative cognitive effects [254] (see Appendix 3c). 
 
4. Proton pump inhibitors are implicated as potentially inappropriate, according to Beer’s and STOPP 
criteria when they are used to treat peptic ulcer disease at maximum therapeutic dose for >8 weeks. 
Their use will be defined using ATC code A02BC (see Appendix 3d), at maximum dose and the 
presence of a Read code indicating peptic ulcer disease (J13y200, J13z.00, 12E1.00, 14C1.00, J130200, 
J13y100, J13..00).   
 
5. A binary indicator representing the use of any of the above PIMs 
 
6. A continuous indicator of the total number of prescribed medicines within the 2-month time periods. 
This will include all prescribed medications but exclude devices, dressings and topical preparations.  
 
All health outcomes will be measured as the presence of a prescription at any point within the 2-month time 
periods.  
 
Covariates 
Potentially confounding variables will be coded at the date of study entry. Demographic factors including age, sex, 
comorbidity, IMD and GP practice were selected on the basis of factors that are potentially linked to the 
prescription of potentially inappropriate medications and use of DAR.  
• Comorbidity will be defined using the Charlson Comorbidity Index (CCI) [258]. The CCI is the most widely 
validated and used comorbidity score [260]. Comorbidity score will be calculated using Read Codes that 
have been validated for use in CPRD [259, 261].  
• IMD for England [359] is based on levels of income, employment, health, education, crime, access to 
services and living environment. Differential prescribing according to area-level deprivation has been 
identified in people with dementia [360].  
• GP practice-level variation in safe prescribing has previously identified in CPRD [116].   
 
An additional covariate to account for QOF exception patients will also be included at each time point.  
• Between 2015-2016 an average of 12.7% of patients in England were excepted from QOF dementia 
indicators. Exceptions to QOF indicators can occur when a patient is deemed clinically unsuitable or the 
patient declines.  
• Exceptions will be defined using Read Codes 9hD..00 (Exception reporting: dementia quality indicators), 
9hD0.00 (Excepted from dementia quality indicators: Patient unsuitable) 9hD1.00 (Excepted from 
dementia quality indicators: Informed dissent) and 8CMZ200, 8IAe000, 8IAe200 and 8CMZ300.  
 
An additional covariate to account for care home residence will be included to account for variation in prescribing in 
care homes compared to patients with dementia living in the community. Whether a patient is resident in a care 
home will be defined using Med Codes indicating care/nursing/residential home and Consultation Type codes 
indicating that the consultation took place in a care home.   
 
 
N. Data/ Statistical Analysis 
Aim 1) To estimate the prevalence of PIM use in people with dementia in primary care in England between 2015 
and 2017. The prevalence of each health outcome (antipsychotics, tricyclic antidepressants, definite 
anticholinergics and proton pump inhibitors) and the mean number will be estimated in each 2 month period 
across the study period.  For each period we will include patients with a dementia diagnosis at or before the 
start of that period and who remained in the study for its duration.  
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Aim 2) To estimate the change in probability of being prescribed a potentially inappropriate medication before 
and after a MR or DAR. For each participant the first DAR and first medication review within the study period 
will be identified. The presence of each binary outcome, and the number of prescriptions will be described in the 
2 month period preceding the one including the index review and in the two month period after the period 
including index review. The DAR and medication review will be treated separately in analyses.  
 
The presence of PIM will be described in the 2 month period preceding and post the index review to reliably capture 
the effect of the review on changes in prescriptions, comparing the prescriptions before and after the review.  
 
McNemar tests will be used to test the hypothesis of no change in binary outcomes PIM (antipsychotics, tricyclic 
antidepressants, definite anticholinergics, proton pump inhibitors) before and after the review. Wilcoxon signed 
rank tests will test the hypothesis of no change in the number of prescriptions in the periods before and after 
the review.  
 
Aim 3) To estimate the patient and practice level factors associated with each PIM in people with dementia, 
including the effect of age, sex, comorbidity, area-level deprivation, residual between practice variation and 
QOF exception.  Multilevel mixed effects logistic regression models will be used to estimate patient and practice 
level factors associated with each PIM (antipsychotic, tricyclic antidepressants, definite anticholinergics and 
proton pump inhibitors) during each 2 month period. The regression models will include fixed effects of age, sex, 
comorbidities, area-level deprivation, DAR in the previous period and MR in the previous period, care home 
residence and as well as random effects of GP practice and within-patient variation. The DAR and MR will be 
treated separately in analyses.  
 
For primary outcomes we will set the threshold for significance following the Benjamini-Hochberg (41, 42) procedure 
to control the false discovery rate at 0.05, using 12 tests corresponding to six primary outcomes and two primary 
exposures.   
 
Analyses will be stratified by care home residence to account for confounding.  
 
Sensitivity analyses  
 
Sensitivity analyses will be performed repeating analyses addressing Aim 1) Estimating the prevalence of PIM use in 
people with dementia in primary care in England between 2015 and 2017. The analysis will be repeated in 1 
month and 3 month time periods, instead of 2 months as per primary analysis.  
 
 
O. Plan for addressing confounding 
Using logistic regression analyses we will be able to adjust for age, sex, comorbidity, deprivation and random 
practice and individual variation. Patients will be censored at the time-period in which they leave the practice, die or 
at the end of the study period (30/04/2017). The main effect of interest will be estimated primarily based on within-
patient comparisons and so the potential for patient-level confounders to affect results is limited.  Dementia review 
should be scheduled annually irrespective of patient-level factors.  It is likely that practice level variation exists so we 
will adjust for random effect of practice in our analysis. 
 
Potential confounding may occur due to the patients living in a care/nursing/residential home. This will be adjusted 
for by stratifying analyses by care home residence to explore the confounding role of residential status on PIM 
prescription.  
 
P. Plans for addressing missing data  
Since the exposure of a DAR or medication review, the outcomes of potentially inappropriate prescriptions and 
comorbidity will be treated as binary variables (present in the patient record or not), there is no potential for data to 
be ‘missing’. We will only include patients from practices with practice level IMD available. Patients with no 
information on age or sex will be excluded. 
 
The residential status of the patients is often unclear, we will be able to ascertain if a patient has had a consultation 
in a care home using Consultation Type codes. These provide an indication that the patient was resident in a care 
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home. An alternative assumption will be that if there is no record of ‘care home’ then the patient is resident in their 
own home or at least, not in a care home. Therefore, whilst there will be data missing, this will be recorded as ‘not 
care home’ and will be assumed they are resident in their own home.  
 
Q. Patient or user group involvement (if applicable) 
Carers of people with dementia and health professionals working with people with dementia have been involved in 
various projects within the pharmacoepidemiology research group at the University of East Anglia and will continue 
to be involved in separate advisory groups throughout this study. The advisory groups and Alzheimer’s Society 
Research Network Volunteers have assisted in the development of the protocol and will continue to inform the 
study and the dissemination of the findings. 
 
R. Plans for disseminating and communicating study results, including the presence or absence of any restrictions 
on the extent and timing of publication  
 
We will be working towards publication and dissemination by January 2018. We plan to present the work in 
academic papers and at international (such as Alzheimer’s Disease International 2017 and UK dementia conferences 
(Alzheimer’s Society Research conference 2017) and one health professionals conference (e.g. British Society of 
Gerontology, 2017). 
 
S. Limitations of the study design, data sources, and analytic methods  
Study design: We cannot measure and so cannot account for the potential confounder of the patient’s residential 
status (community or care home). Medicine use can vary across these settings and there is likely to be more 
potentially inappropriate prescribing in care homes [361–363]. Additionally, the use of DAR may be less in care 
homes as exceptions can be made, making the patient exempt from the review if the patient is terminally ill, 
extremely frail or the severity of their condition may inhibit their engagement with the review [111].  
 
We have selected medications using advice from prescribers and used STOPP and Beer’s to identify medications that 
are specifically implicated in people with dementia. This provides a means of focusing on medications that can be 
targeted and are indicative of an overall pattern of prescribing quality, however these are not exhaustive and we will 
not be accounting for the range of potentially inappropriate prescribing that may exist in primary care in this 
population.  
 
Inappropriate PPI use is implicated when it is used to treat peptic ulcer disease at maximum therapeutic for >8 
weeks. We will measure PPI use as a single prescription within each 2 month period however we will not know 
whether the PPI use is continuous for 8 weeks across this time. Additionally, we may not have the full comorbidity 
information that is required to implement the STOPP or Beer’s Criteria for PPI use. Inappropriate PPI use in this case 
is indicated for peptic ulcer disease. We will account for this by identifying patients who also have a Read code for 
‘peptic ulcer disease’, but it may be difficult to account for the duration of use in relation to this disease and the 
duration of medication use. 
 
Data sources: We will not know the severity of the dementia, which would be implicated in the prescription of 
antipsychotic medications which are used to manage severe behavioural and psychological symptoms of dementia. 
We will not know the indications for most medications so we will be unable to make individual judgments about 
whether a medication is appropriate or not. PIM criteria are an indication that medications are likely to be 
inappropriate, and so are useful to judge the quality of prescribing in a population rather than within individuals.  
 
Analytic methods: By using binary outcomes to assess the presence or not of particular PIM we may miss subtle 
changes in medication dosage that may change as a result of the medication review. However, the selected 
medications are implicated in criteria that suggest stopping rather than reducing the dosage.  
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10.05 Appendix 5 Medication coding lists  
(a) Anticholinergics  
ATC Anticholinergic drug ACB 
    3 
N06AA09 Amitriptyline 3 
A06AA17 Amoxapine  
N06AA09 Amitriptyline 3 
N06AA09 Amitriptyline 3 
A03BA01 Atropine 3 
A03BA01 Atropine 3 
N04Ac01 Benztropine  
R06AB01 Brompheniramine 3 
R06AA08 Carbinoxamine  
R06AB04 Chlorphenamine 3 
 R06AB04 Chlorphenamine 3 
N05AA01 Chlorpromazine 3 
R06AA04 Clemastine 3 
N06AA04 Clomipramine 3 
 N05AH02 Clozapine 3 
 G04BD10 Darifenacin 3 
N06AA01 Desipramine  
A03AA07 Dicyclomine 3 
 R06AA52 Dimenhydrinate 3 
R06AA02 Diphenhydramine 3 
N06AA12 Doxepin 3 
R06AA09 Doxylamine 3 
 G04BD011 Fesoterodine fumarate 3 
G04BD02 Flavoxate 3 
A02BX03 Homatropine 3 
N05BB01 Hydroxyzine 3 
N05BB01 Hydroxyzine 3 
A03BA03 Hyoscymine 3 
N06AA02 Imipramine 3 
R06AE05 Meclizine   
M03BA03 Methocarbamol 3 
N06AA10 Nortriptyline 3 
N06AA10 Nortriptyline,flupenazine 3 
 N05AH03 Olanzapine 3 
M03BC01  Orphenadrine 3 
G04BD04 Oxybutynin 3 
N06AB05 Paroxetine 3 
N05AB03 Perphenazine 3 
R06AD02 Promethazine 3 
A03AB05 Propantheline 3 
 G04BD06 Propiverine hydrochloride 3 
 N05AH04 Quetiapine 3 
 G04BD08 Solifenacin succinate  3 
 G04BD05 Terodiline 3 
N05AC02 Thioridazine 3 
G04BD07 Tolterodine 3 
 G04BD07 Tolterodine 3 
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N05AB06 Trifluoperazine 3 
N04AA01 Trihexyphenidyl 3 
N06AA06 Trimipramine 3 
 G04BD09 Trospium chloride 3 
 
(b) Proton Pump Inhibitors  
Proton Pump Inhibitors 
 CIMETIDINE   *CIMETIDINE+ALGINIC chew tabs  RANITIDINE 150mg/10mL s/f syr 
 TAGAMET 200mg tablets   *CIMETIDINE+ALGINIC chew tabs   RANITIDINE 150mg/10mL s/f soln  
 TAGAMET 400mg tablets   *CIMETIDINE+ALGINATE susp   RANITIDINE 150mg tablets  
 TAGAMET 800mg tablets   *CIMETIDINE+ALGINATE susp   *RANITIDINE 150mg disp tabs  
 TAGAMET 200mg/5mL syrup   CIMETIDINE 200mg tablets   RANITIDINE 300mg tablets  
 *TAGAMET 200mg/2mL injection   CIMETIDINE 400mg tablets   RANITIDINE 50mg/2mL injection  
 *TAGAMET 4mg/mL i-v inf 100mL   CIMETIDINE 800mg tablets   PIRENZEPINE  
 *DYSPAMET CHEWTAB 200mg tabs   CIMETIDINE 200mg/5mL syrup   *GASTROZEPIN 50mg tablets  
 *DYSPAMET 200mg/5mL suspension   *CIMETIDIN 200mg/2mL injection   *PIRENZEPINE 50mg tablets  
 *CIMETIDNE 200mg/5mL sus 600mL   *CIMETIDINE 4mg/mL i-v inf   BISMUTH CHELATE  
 *GALENAMET 200mg tablets   RANITIDINE   *DE-NOL 120mg/5mL liquid 100mL  
 *GALENAMET 400mg tablets   ZANTAC 150mg tablets   *DE-NOL 120mg/5mL liquid 560mL  
 *GALENAMET 800mg tablets   *ZANTAC 150mg disp tabs   DE-NOLTAB 120mg tablets  
 *CIMETIDINE 400mg eff tabs   ZANTAC 300mg tablets   *BISMUTH CHELATE 120mg/5mL liq  
 *CIMETIDINE 200mg chew tabs   ZANTAC 50mg/2mL injection   BISMUTH CHELATE 120mg tablets  
 *PHIMETIN 200mg tablets   ZANTAC 150mg/10mL sf syr 300mL   SUCRALFATE  
 *PHIMETIN 400mg tablets   ZANTAC EFFERVESCENT 150mg tabs   ANTEPSIN 1g tablets  
 *PHIMETIN 800mg tablets   ZANTAC EFFERVESCENT 300mg tabs   ANTEPSIN 1g/5mL suspension  
 CIMETIDINE 200mg/5mL s/f soln   RANITIDINE 150mg eff tabs   SUCRALFATE 1g/5mL suspension  
 *CIMETIDINE 400mg/100mL inf   RANITIDINE 300mg eff tabs   SUCRALFATE 1g tablets  
 *ZITA 200mg tablets   *RACIRAN 150mg tablets   CARBENOXOLONE SODIUM [GI]  
 *ZITA 400mg tablets   *RACIRAN 300mg tablets   *BIOGASTRONE 50mg tablets  
 *ZITA 800mg tablets   *ZAEDOC 150 tablets   *DUOGASTRONE 50mg tablets  
 *ULTEC 200mg tablets   *ZAEDOC 300 tablets   *PYROGASTRONE chewable tablets  
 *ULTEC 400mg tablets   *RANTEC 150mg tablets   *PYROGASTRONE liquid  
 *ULTEC 800mg tablets   *RANTEC 300mg tablets   *CARBENOXOLONE SOD 50mg tabs  
 *ACITAK-200 tablets   RANITIC 150mg tablets   LIQUORICE DEGLYCYRRHIZINISED  
 *ACITAK-400 tablets   RANITIC 300mg tablets   *CAVED-S tablets  
 *ACITAK-800 tablets   HISTAC 150mg tablets   *RABRO tablets  
 *TAGAMET DUAL ACTION liq 200mL   HISTAC 300mg tablets   FAMOTIDINE  
 *TAGAMET DUAL ACTION liq 600mL   RANITIL 150mg tablets   FAMOTIDINE 20mg tablets  
 *ALGITEC 200mg/500mg chew tabs   RANITIL 300mg tablets   FAMOTIDINE 40mg tablets  
 *ALGITEC 100mg/250mg/5mL susp   ZANTAC 75 DISSOLVE eff tabs   PEPCID 20mg tablets  
 *CIMETIDINE COMPOUND susp   RANITIDINE 75mg tablets   PEPCID 40mg tablets  
 *TAGAMET EFFERVESC 400mg tabs   GAVILAST-P 75mg tablets   NIZATIDINE  
 *PEPTIMAX 200mg tablets   RANZAC 75mg tablets   NIZATIDINE 150mg capsules  
 *PEPTIMAX 400mg tablets   ZANTAC 75 tablets   NIZATIDINE 300mg capsules  
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 *PEPTIMAX 800mg tablets   RANITIDINE 75mg eff tablets   AXID 150mg capsules  
    AXID 300mg capsules  
   *AXID 100mg/4mL injection  
 *NIZATIDINE 100mg/4mL inj   *NIZATIDINE 100mg/4mL inj   *OMEPRAZOLE 20mg e/c tablets  
 *ZINGA 150mg capsules   *ZINGA 150mg capsules   *OMEPRAZOLE 40mg e/c tablets  
 *ZINGA 300mg capsules   *ZINGA 300mg capsules   OMEPRAZOLE 10mg tablets  
 MISOPROSTOL   MISOPROSTOL   OMEPRAZOLE 20mg tablets  
 MISOPROSTOL 200mcg tablets   MISOPROSTOL 200mcg tablets   OMEPRAZOLE 40mg tablets  
 CYTOTEC 200micrograms tablets   CYTOTEC 200micrograms tablets   LANSOPRAZOLE  
 *CYTOTEC 200microgram tablets   *CYTOTEC 200microgram tablets   *ZOTON 30mg capsules  
 OMEPRAZOLE   OMEPRAZOLE   LANSOPRAZOLE 30mg capsules  
 OMEPRAZOLE 20mg e/c capsules   OMEPRAZOLE 20mg e/c capsules   LANSOPRAZOLE 15mg capsules  
 *LOSEC 20mg capsules x28   *LOSEC 20mg capsules x28   *ZOTON 15mg capsules  
 LOSEC 20mg capsules   LOSEC 20mg capsules   *LANSOPRAZOLE 30mg suspension  
 LOSEC 40mg capsules   LOSEC 40mg capsules   *ZOTON 30mg oral suspension  
 OMEPRAZOLE 40mg e/c capsules   OMEPRAZOLE 40mg e/c capsules   LANSOPRAZOLE 15mg disp tabs  
 LOSEC 10mg capsules   LOSEC 10mg capsules   LANSOPRAZOLE 30mg disp tabs  
 OMEPRAZOLE 10mg e/c capsules   OMEPRAZOLE 10mg e/c capsules   ZOTON FASTAB 15mg disp tabs  
 OMEPRAZOLE 40mg inj pdr+solv   OMEPRAZOLE 40mg inj pdr+solv   ZOTON FASTAB 30mg disp tabs  
 LOSEC 40mg inj powder+solvent   LOSEC 40mg inj powder+solvent   RANITIDINE BISMUTH CITRATE  
 OMEPRAZOLE 40mg i-v inf powder   OMEPRAZOLE 40mg i-v inf powder   RANITIDINE BISMUTH CITRATE  
 LOSEC 40mg i-v infusion powder   LOSEC 40mg i-v infusion powder   *RANITIDINE BISMUTH 400mg tabs  
 LOSEC MUPS 10mg tablets   LOSEC MUPS 10mg tablets   *RANITIDINE BISMUTH 400mg tabs  
 LOSEC MUPS 20mg tablets   LOSEC MUPS 20mg tablets   *PYLORID 400mg tablets  
 LOSEC MUPS 40mg tablets   LOSEC MUPS 40mg tablets   PANTOPRAZOLE  
 *OMERAN 10mg e/c tablets   *OMERAN 10mg e/c tablets   PANTOPRAZOLE 40mg e/c tablets  
 *OMERAN 20mg e/c tablets   *OMERAN 20mg e/c tablets   PROTIUM 40mg e/c tablets  
 *OMERAN 40mg e/c tablets   *OMERAN 40mg e/c tablets   PANTOPRAZOLE 40mg inj powder  
 ZANPROL 10mg e/c tablets   ZANPROL 10mg e/c tablets   PROTIUM I.V 40mg inj powder  
 *GALPHARM HEARTBURN 10mg tabs   *GALPHARM HEARTBURN 10mg tabs   PANTOPRAZOLE 20mg e/c tablets  
 *GALPHARM HEARTBURN 10mg tabs   *GALPHARM HEARTBURN 10mg tabs   PROTIUM 20mg e/c tablets  
 UNICHEM HRTBRN RELIEF 10mg tab   UNICHEM HRTBRN RELIEF 10mg tab   RABEPRAZOLE SODIUM  
 UNICHEM HRTBRN RELIEF 10mg tab   UNICHEM HRTBRN RELIEF 10mg tab   RABEPRAZOLE NA 10mg e/c tabs  
 VANTAGE HRTBURN RELF 10mg tabs   VANTAGE HRTBURN RELF 10mg tabs   RABEPRAZOLE NA 20mg e/c tabs  
 CARE HEARTBURN RELIF 10mg tabs   CARE HEARTBURN RELIF 10mg tabs   PARIET 10mg e/c tablets  
 NUMARK HEARTBURN RLF 10mg tabs   NUMARK HEARTBURN RLF 10mg tabs   PARIET 20mg e/c tablets  
 MEPRADEC 10mg e/c capsules   MEPRADEC 10mg e/c capsules   COMBINATION ULCER HEALING DRUG  
 MEPRADEC 20mg e/c capsules   MEPRADEC 20mg e/c capsules   *CLARITHROMY+LANSOPRZ+AMOX pck  
  OMEPRAZOLE 10mg e/c tablets   *HELICLEAR triple pack  
 *CLARITH+LANSOPRZ+METRONID pck   NEXIUM 20mg tablets   ESOMEPRAZOLE 40mg i-v inj pdr  
 *HELIMET triple pack   NEXIUM 40mg tablets   ESOMEPRAZOLE 40mg tablets  
 ESOMEPRAZOLE   NEXIUM 40mg i-v inj powder   ESOMEPRAZOLE 20mg tablets  
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(c) CFAS Medication categorisation: drugs lists used to define exposure groups. 
Antipsychotics  Tricyclic antidepressants  
d411. Chlorpromazine d7...  d771. Imipramine 
d412. Chlorpromazine d71.. Amitriptyline d772. Imipramine 
d413. Chlorpromazine d711. Amitriptyline d775. Imipramine 
d414. Chlorpromazine d712. Amitriptyline d776. Imipramine 
d415. Chlorpromazine d713. Amitriptyline d79.. Lofepramine 
d41a. Chlorpromazine d719. Amitriptyline d791. Lofepramine 
d41b. Chlorpromazine d71a. Amitriptyline d79z. Lofepramine 
d41c. Chlorpromazine d71b. Amitriptyline d7a2. Maprotiline 
d41d. Chlorpromazine d71c. Amitriptyline d7a3. Maprotiline 
d4b1. Perphenazine d71d. Amitriptyline d7b.. MIANSERIN 
d4e1. PROMAZINE d71e. Amitriptyline d7b1. MIANSERIN 
d4ex. PROMAZINE d71f. Amitriptyline d7b3. MIANSERIN 
d4g.. Thioridazine d71u. Amitriptyline d7b4. MIANSERIN 
d4g1. Thioridazine d71v. Amitriptyline d7b7. MIANSERIN 
d4g2. Thioridazine d71w. Amitriptyline d7b9. MIANSERIN 
d4g3. Thioridazine d71y. Amitriptyline d7c1. Nortriptyline 
d4g5. Thioridazine d71z. Amitriptyline d7c3. Nortriptyline 
d4g7. Thioridazine d73.. Clomipramine d7c6. Nortriptyline 
d4gp. Thioridazine d731. Clomipramine d7c8. Nortriptyline 
d4gt. Thioridazine d732. Clomipramine d7cy. Nortriptyline 
d4gu. Thioridazine d733. Clomipramine d7d3. Protriptyline 
d4gv. Thioridazine d736. Clomipramine d7f1. Trimipramine 
d4gw. Thioridazine d73s. Clomipramine d7f2. Trimipramine 
d4gz. Thioridazine d73t. Clomipramine d7f3. Trimipramine 
d4h.. Trifluoperazine d73u. Clomipramine d7fx. Trimipramine 
d4h1. Trifluoperazine d73v. Clomipramine d7fy. Trimipramine 
d4h2. Trifluoperazine d73w. Clomipramine d7fz. Trimipramine 
d4h3. Trifluoperazine d73z. Clomipramine d911. Amitriptyline 
d4h4. Trifluoperazine d75.. DOSULEPIN d913. Nortriptyline,flupenazine 
d4hs. Trifluoperazine d751. DOSULEPIN d914. Nortriptyline,flupenazine 
d4ht. Trifluoperazine d752. DOSULEPIN d916. Amitriptyline 
d4hu. Trifluoperazine d755. DOSULEPIN d917. Amitriptyline 
d4hx. Trifluoperazine d756. DOSULEPIN   
d4l2. CLOZAPINE d75y. DOSULEPIN   
d4r1. OLANZAPINE d75z. DOSULEPIN   
d4r3. OLANZAPINE d761. Doxepin   
d4r7. OLANZAPINE d762. Doxepin   
d4s1. QUETIAPINE d765. Doxepin   
d4s2. QUETIAPINE d76w. Doxepin   
d4s3. QUETIAPINE d76x. Doxepin   
d4s5. QUETIAPINE d76y. Doxepin   
d4ss. QUETIAPINE d76z. Doxepin   
d4sx. QUETIAPINE d77.. Imipramine   
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Other anticholinergics      
A4...  D28.. Hydroxyzine Gda5. Oxybutynin 
A41.. Atropine D284. Hydroxyzine Gda6. Oxybutynin 
A451. Dicyclomine D281. Hydroxyzine Gda7. Oxybutynin 
A453. Dicyclomine D282. Hydroxyzine Gda9. Oxybutynin 
A454. Dicyclomine D28x. Hydroxyzine Gdaa. Oxybutynin 
A455. Dicyclomine D28y. Hydroxyzine Gdag. Oxybutynin 
A45x. Dicyclomine Da6.. Paroxetine Gdai. Oxybutynin 
A45y. Dicyclomine Da61. Paroxetine Gdax. Oxybutynin 
A471. HYOSCINE Da62. Paroxetine Gday. Oxybutynin 
A473. HYOSCINE Da63. Paroxetine Gdaz. Oxybutynin 
A47y. HYOSCINE Da64. Paroxetine Gdb1. TROSPIUM CHLORIDE 
A4b1. Poldine methyl Da65. Paroxetine Gdby. TROSPIUM CHLORIDE 
A4by. Poldine methyl Da67. Paroxetine Gdbz. TROSPIUM CHLORIDE 
A4c1. Propantheline Da68. Paroxetine Gdc1. 
PROPIVERINE 
HYDROCHLORIDE 
A4c2. Propantheline Dh51. Dimenhydrinate Gdc2. 
PROPIVERINE 
HYDROCHLORIDE 
A821. Atropine Dias. Promethazine Gdc4. 
PROPIVERINE 
HYDROCHLORIDE 
A823. Atropine Dr11. Trihexyphenidyl Gdd1. 
SOLIFENACIN 
SUCCINATE  
Bf2f. HOMATROPINE Dr12. Trihexyphenidyl Gdd2. 
SOLIFENACIN 
SUCCINATE  
C831. Brompheniramine Dr13. Trihexyphenidyl Gddy. 
SOLIFENACIN 
SUCCINATE  
C833. Brompheniramine Dr14. Trihexyphenidyl Gddz. 
SOLIFENACIN 
SUCCINATE  
C84.. Chlorphenamine Dr1w. Trihexyphenidyl Gdfz. DARIFENACIN 
C841. Chlorphenamine Dr1x. Trihexyphenidyl Gdg2. 
FESOTERODINE 
FUMARATE 
C843. Chlorphenamine Dr22. Orphenadrine Gdgy. 
FESOTERODINE 
FUMARATE 
C84x. Chlorphenamine Dr2y. Orphenadrine Gdgz. 
FESOTERODINE 
FUMARATE 
C84y. Chlorphenamine Dr51. Anti-muscarinic J851. METHOCARBAMOL 
C851. Clemastine Dr6.. Procyclidine J85y. METHOCARBAMOL 
C85y. Clemastine Dr63. Procyclidine O311. Atropine 
C88 Diphenhydramine Dr6w. Procyclidine O522. Chlorpromazine 
C882. Diphenhydramine Dr6y. Procyclidine   
C885. Diphenhydramine Gd... Tolterodine Gda2. TOLTERODINE 
C888. Diphenhydramine Gd21.  Gda2. Oxybutynin 
C8a.. Hydroxyzine Gd41. Flavoxate Gda3. Oxybutynin 
C8i1. Promethazine Gd42. Flavoxate Gda4. Oxybutynin 
C8i2. Promethazine Gd4y. Flavoxate Gda4. TOLTERODINE 
C8i9. Promethazine Gd4z. Flavoxate Gda5. TOLTERODINE 
C8iu. Promethazine Gd92. Terodiline Gda6. TOLTERODINE 
C8iv. Promethazine Gd9z. Terodiline   
C8iw. Promethazine Gda.. Oxybutynin Ci1p. CHLORPHENAMINE 
Ch2h. Diphenhydramine Gda1. Oxybutynin Ci1q. CHLORPHENAMINE 
Ci1l. CHLORPHENAMINE Gda1. TOLTERODINE   
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Other antidepressants  Benzodiazepines  
D8...   monoamine-oxidase inhibitors  D14..  Flunitraze  
 D8...   monoamine-oxidase inhibitors   d141.  Rohypnol  
 D81..   phenelzine   d14z.  Flunitraze  
 D811.   nardil 15mg tablets   d15..  Flurazepam  
 D81z.   phenelzine 15mg tablets   d151.  Dalmane  
 D82..   *iproniazid   d152.  Dalmane  
 D821.   *marsilid 25mg tablets   d153.  Paxane  
 D822.   *marsilid 50mg tablets   d154.  Paxane  
 D82y.   *iproniazid 25mg tablets   d15y.  Flurazepam  
 D82z.   *iproniazid 50mg tablets   d15z.  Flurazepam  
 D83..   isocarboxazid   d16..  Loprazolam  
 D831.   *marplan 10mg tablets   d161.  Loprazolam  
 D83z.   isocarboxazid 10mg tablets   d162.  Dormonoct  
 D84..   tranylcypromine   d17..  Lormetazep  
 D841.   *parnate 10mg tablets   d171.  Lormetazep  
 D84z.   tranylcypromine 10mg tablets   d172.  Lormetazep  
 D85..   moclobemide   d173.    
 D851.   manerix 150mg tablets   d174.    
 D852.   moclobemide 150mg tablets   d18..  Nitrazepam  
 D853.   manerix 300mg tablets   d181.  Nitrazepam  
 D854.   moclobemide 300mg tablets   d182.  Nitrazepam  
 D9...   compound antidepressant drugs   d183.  Nitrazepam  
 D91..   compound antidepressants a-z   d184.  Nitrazepam  
 D911.   *limbitrol 5 capsules   d185.  Mogadon  
 D912.   *limbitrol 10 capsules   d186.  Mogadon  
 D913.   *motipress tablets x28cp   d187.  Nitrados  
 D914.   *motival tablets   d188.    
 D915.   *parstelin tablets   d189.  Remnos  
 D916.   triptafen tablets   d18a.  Remnos  
 D917.   triptafen-m tablets   d18b.    
 Da2..   tryptophan   d18c.  Somnite  
 Da21.   optimax 500mg tablets   d18d.    
 Da22.   *optimax 1g/6g powder   d18e.  Unisomnia  
 Da23.   *optimax wv 500mg tablets   d18f.  Nitrazepam  
 Da24.   *pacitron 500mg tablets   d1a..  Temazepam  
 Da2y.   tryptophan 500mg tablets   d1a1.  Temazepam  
 Da2z.   *tryptophan 1g/6g powder   d1a2.  Temazepam  
 Da3..   fluvoxamine maleate   d1a3.  Temazepam  
 Da31.   faverin 50mg tablets   d1a4.  Temazepam  
 Da32.   fluvoxamine maleate 50mg tabs   d1a5.  Temazepam  
 Da33.   faverin 100mg tablets   d1a6.  Normison  
 Da34.   fluvoxamine maleate 100mg tabs   d1a7.  Normison  
 Da4..   fluoxetine hydrochloride   d1a8.  Temazepam  
 Da41.   fluoxetine 20mg capsules   d1a9.  Temazepam  
 Da42.   *prozac 20mg capsules x30   d1aa.  Temazepam  
 Da43.   fluoxetine 20mg/5ml oral liq   d1ab.  Temazepam  
 Da44.   prozac 20mg/5ml oral liquid   d1ac.  Temazepam  
 Da45.   prozac 20mg capsules   d1ad.  Temazepam  
 Da46.   fluoxetine 60mg capsules   d1ae.  Temazepam  
 Da47.   *prozac 60mg capsules   d1af.  Temazepam  
 Da48.   *felicium 20mg capsules   d1ag.  Temazepam  
 Da49.   oxactin 20mg capsules   d1ah.  Temazepam  
 Da4a.   ranflutin 20mg capsules   d1ai.  Temazepam  
 Da4b.   prozit 20mg/5ml oral solution   d1aj.  Temazepam  
 Da4c.   prozep 20mg/5ml oral solution   d1ak.  Temazepam  
 Da5..   sertraline hydrochloride   d1al.  Euhypnos  
 Da51.   sertraline 50mg tablets   d1am.  Euhypnos  
 Da52.   sertraline 100mg tablets   d1an.  Euhypnos  
 Da53.   lustral 50mg tablets   d1ao.  Temazepam  
 Da54.   lustral 100mg tablets   d1b..  Triazolam  
 Da6..   paroxetine hydrochloride   d1b1.  Triazolam  
 Da61.   paroxetine 20mg tablets   d1b2.  Triazolam  
 Da62.   seroxat 20mg tablets x30   d1b3.  Halcion  
 Da63.   paroxetine 30mg tablets   d1b4.  Halcion  
 Da64.   seroxat 30mg tablets x30   d21..  Diazepam  
 Da65.   paroxetine 10mg/5ml s/f liq   d211.  Diazepam  
 Da66.   seroxat 10mg/5ml s/f liq   d212.  Diazepam  
 Da67.   paroxetine 10mg tablets   d213.  Diazepam  
 Da68.   seroxat 10mg tablets   d214.  Diazepam  
 Da7..   venlafaxine   d215.  Diazepam  
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 Da71.   venlafaxine 37.5mg tablets   d216.  Diazepam  
 Da72.   venlafaxine 75mg tablets   d217.    
 Da73.   efexor 37.5mg tablets   d218.    
 Da74.   efexor 75mg tablets   d219.    
 Da75.   *venlafaxine 50mg tablets   d21a.  Diazepam  
 Da76.   *efexor 50mg tablets   d21b.  Rimapam  
 Da77.   venlafaxine 75mg m/r capsules   d21c.  Rimapam  
 Da78.   efexor xl 75mg m/r capsules   d21d.  Rimapam  
 Da79.   venlafaxine 150mg m/r capsules   d21e.  Dialar  
 Da7a.   efexor xl 150mg m/r capsules   d21f.  Dialar  
 Da8..   nefazodone   d21g.  Valclair  
 Da81.   *nefazodone hcl 100mg tabs   d21j.  Diazepam  
 Da82.   *nefazodone hcl 200mg tabs   d21a.  Atensine  
 Da83.   *dutonin 100mg tablets   d21b.  Atensine  
 Da84.   *dutonin 200mg tablets   d21c.  Atensine  
 Da85.   *nefazodone initiation tabs pk   d21d.  Diazemuls  
 Da86.   *dutonin initiation tabs pack   d21e.    
 Da9..   citalopram   d21f.    
 Da91.   citalopram 20mg tablets   d21g.    
 Da92.   cipramil 20mg tablets   d21h.    
 Da93.   citalopram 10mg tablets   d21i.    
 Da94.   cipramil 10mg tablets   d21j.    
 Da95.   citalopram 40mg tablets   d21k.  Stesolid  
 Da96.   cipramil 40mg tablets   d21l.  Stesolid  
 Da97.   cipramil 40mg/ml drops 15ml   d21m.  Tensium  
 Da98.   paxoran 10mg tablets   d21n.  Tensium  
 Da99.   paxoran 20mg tablets   d21o.  Tensium  
 Da9a.   paxoran 40mg tablets   d21p.    
 Da9z.   citalopram 40mg/ml oral drops   d21q.    
 Daa..   REBOXETINE   D21r.  VALIUM  
 Daa1.   REBOXETINE 4mg tablets   D21s.  VALIUM  
 Daa2.   EDRONAX 4mg tablets   D21t.  VALIUM  
 Dab..   MIRTAZAPINE   D21u.  VALIUM  
 Dab1.   MIRTAZAPINE 30mg tablets   D21v.  VALIUM  
 Dab2.   *ZISPIN 30mg tablets   D21w.    
 Dab3.   MIRTAZAPINE 30mg disp tabs   D21x.    
 Dab4.   ZISPIN SOLTAB 30mg disp tabs   D21y.  VALIUM  
 Dab5.   MIRTAZAPINE 15mg disp tabs   D21z.  DIAZEPAM  
 Dab6.   ZISPIN SOLTAB 15mg disp tabs   D22..  ALPRAZOLAM  
 Dab7.   MIRTAZAPINE 45mg disp tabs   D221.  XANAX  
 Dab8.   ZISPIN SOLTAB 45mg disp tabs   D222.  XANAX  
 Daby.   MIRTAZAPINE 45mg tablets   D22y.  ALPRAZOLAM  
 Dabz.   MIRTAZAPINE 15mg tablets   D22z.  ALPRAZOLAM  
 Dac..   ESCITALOPRAM   D23..  BROMAZEPAM  
 Dac1.   ESCITALOPRAM 10mg tablets   D231.  LEXOTAN  
 Dac2.   CIPRALEX 10mg tablets   D232.  LEXOTAN  
 Dac3.   ESCITALOPRAM 20mg tablets   D23y.  BROMAZEPAM  
 Dac4.   CIPRALEX 20mg tablets   D23z.  BROMAZEPAM  
 Dac5.   ESCITALOPRAM 5mg tablets   D24..  CHLORDIAZE  
 Dac6.   CIPRALEX 5mg tablets   D241.  CHLORDIAZE  
 Dac7.   ESCITALOPRAM 10mg/ml oral dps   D241.  CHLORDIAZE  
 Dac8.   CIPRALEX 10mg/ml oral drops   D242.  CHLORDIAZE  
   D242.  CHLORDIAZE  
 Du6..   bupropion   d243.  Chlordiaze  
 Du6..   amfebutamone   d244.  Chlordiaze  
 Du61.   zyban 150mg m/r tablets   d245.  Chlordiaze  
 Du6z.   bupropion hcl 150mg m/r tabs   d246.  Chlordiaze  
 Du6z.   amfebutamon hcl 150mg m/r tabs   d247.  Chlordiaze  
   D248.  CHLORDIAZE  
 Gde..   duloxetine   d249.  Librium  
 Gde1.   yentreve 20mg g/r capsules   d24a.  Librium  
 Gde2.   yentreve 40mg g/r capsules   d24b.  Librium  
 Gde3.   cymbalta 30mg g/r capsules   d24c.  Librium  
 Gde4.   *cymbalta 60mg g/r capsules   d24d.  Librium  
 Gdew.   *duloxetine 60mg g/r capsules   d24e.    
 Gdex.   duloxetine 30mg g/r capsules   d24f.  Tropium  
 Gdey.   duloxetine 20mg g/r capsules   d24g.  Tropium  
 Gdez.   duloxetine 40mg g/r capsules   d24h.  Tropium  
   D24i.  TROPIUM  
 Dq6..   selegiline   d24j.  Tropium  
 Dq61.   eldepryl 5mg tablets   d26..  Clobazam  
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 Dq62.   eldepryl 10mg tablets   d261.  Clobazam  
 Dq63.   eldepryl 10mg/5ml syrup   d262.  Frisium  
 Dq64.   *vivapryl 5mg tablets   d263.  Clobazam  
 Dq65.   *vivapryl 10mg tablets   d264.  Frisium  
 Dq66.   *stilline 5mg tablets   d27..  Clorazepat  
 Dq67.   *stilline 10mg tablets   d271.  Tranxene  
 Dq68.   *centrapryl 5 tablets   d272.  Tranxene  
 Dq69.   *centrapryl 10 tablets   d27y.  Clorazepat  
 Dq6a.   zelapar 1.25mg tablets   d27z.  Clorazepat  
 Dq6w.   selegiline hcl 1.25mg tablets   d29..  Ketazolam  
 Dq6x.   selegiline hcl 10mg/5ml syrup   d291.    
 Dq6y.   selegiline hcl 10mg tablets   d292.    
 Dq6z.   selegiline hcl 5mg tablets   d29y.    
   D29z.    
   D2a..  LORAZEPAM  
   D2a1.  LORAZEPAM  
   D2a2.  LORAZEPAM  
   D2a3.    
   D2a4.    
   D2a5.  ATIVAN  
   D2a6.  ATIVAN  
   D2a7.  ATIVAN  
   D2ax.    
   D2az.  LORAZEPAM  
   D2b..  MEDAZEPAM  
   D2b1.  NOBRIUM  
   D2b2.  NOBRIUM  
   D2by.  MEDAZEPAM  
   D2bz.  MEDAZEPAM  
   D2d..  OXAZEPAM  
   D2d1.  OXAZEPAM  
   D2d2.  OXAZEPAM  
   D2d3.  OXAZEPAM  
   D2d4.  OXAZEPAM  
   D2d5.    
   D2d6.    
   D2d7.    
   D2e..  PRAZEPAM  
   D2e1.    
   D2ez.    
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10.06 Appendix 6: Charlson Comorbidity Index   
Charlson disease category 
Charlson score 
weight  
AIDS 6 
Cancer  2 
Cerebrovascular disease  1 
Chronic pulmonary disease  1 
Congestive heart disease  1 
Dementia 1 
Diabetes  1 
Diabetes with complications 2 
Hemiplegia  2 
Metastatic tumour  6 
Mild liver disease  1 
Mod liver disease  3 
Myocardial infarction 1 
Peptic ulcer disease 1 
Peripheral vascular disease  1 
Renal Disease  2 
Rheumatological disease  1 
Charlson Comorbidity Index, adapted version from Khan et al (2010) for use with 
Read Coded databases. The index includes over 2,300 comorbidities classified 
with individual Read Codes, falling into 17 categories listed.  
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10.07 Appendix 6: McNemar test results comparing PIM before and after the first 
record of a review: Tables  
(a) Anticholinergics  
Table 36 McNemar 2x2 contingency table presenting the number of patients who stopped or started anticholinergic 
medications after the first record of a review 
  After first dementia annual review  
  PIM No PIM  
Before first 
dementia annual  
review 
PIM 622 106  
No PIM 112 3523  
     
     
  After first medication review  
  PIM No PIM  
Before first 
medication 
review 
PIM 1141 188  
No PIM 195 5959  
     
Dementia annual review  
OR 1.01 95% CI 0.97 – 1.05  
McNemar test statistic is: !" = (%&'))%*'  
 !"= (106-112)2 / (106+112)  !"= 0.17, df(1) p=0.685 
 
Medication review  
OR 1.01 95% CI 0.98-1.01  
McNemar test statistic is: !" = (%&'))%*'  
 !"= (188-195)2 / (168+195)  !" = 0.13, df(1) p = 0.759   
 
n = number of individual patients  
 
Starting anticholinergics across study period n=2,277 
Starting anticholinergics after any medication review n=433 (2.6%), without medication review n=1,844 
(2.1%) 
Starting anticholinergics after any dementia review n=159 (1.8%), without dementia review n=2,118 
(2.2%) 
Stopping anticholinergics across study period n= 2,344 
Stopping anticholinergics after any medication review n=473 (11.8%), without medication review 
n=1,871 (10.4%) 
Stopping anticholinergics after any dementia review n=146 (8.0%), without dementia review n=2,198 
(10.9%)  
 
McNemar Chi-squared test estimating the ratio between the disconcordant pairs, where the outcome 
(record of a PIM prescription) has changed after a review. Comparing the total number of patients who 
stopped a PIM with the total number of patients who started a PIM. The remaining two cells represent 
the number of patients who did not change after the first record of a review.   
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(b) Antipsychotics  
Table 37 McNemar 2x2 contingency table presenting the number of patients who stopped or started antipsychotic 
medications after the first record of a review 
  After first dementia annual review  
  Antipsychotic No Antipsychotic  
Before first 
dementia annual  
review 
Antipsychotic 320 52  
No Antipsychotic 64 3927  
     
 
  After first medication review  
  Antipsychotic No Antipsychotic  
Before first 
medication  
review 
Antipsychotic 536 80  
No Antipsychotic 128 6739  
     
Dementia annual review  
OR 1.03 95% CI 0.97 – 1.09  
McNemar test statistic is: !" = (%&'))%*'  
 !"= (52-64)2 / (52+64)  !"= 1.24, df(1), p=0.265 
 
Medication review  
OR 1.08 95% CI 1.03-1.12  
McNemar test statistic is: !" = (%&'))%*'  
 !"= (80-128)2 / (80+128)  !"= 11.08, df(1) p = >0.001 
 
n = number of individual patients  
 
Number of patients starting antipsychotic across study period n=1,496 
Number of patients starting antipsychotics after any medication review n=285 (1.56%), starting without 
medication review n=1,211 (1.26%) 
Number of patients starting antipsychotics after dementia review n= 98 (1.07%), starting without 
dementia review n=1,398 (1.33%)  
 
Number of patients stopping antipsychotics across study period n=1,138  
Number of patients stopping antipsychotics after any medication review n= 224 (10.8%), number of 
patients stopping antipsychotics without medication review n=914 (10.3%)  
Number of patients stopping antipsychotics after dementia review n=73 (7.5%), stopping without 
dementia review 1,065 (10.7%)  
 
McNemar Chi-squared test estimating the ratio between the disconcordant pairs, where the outcome 
(record of a PIM prescription) has changed after a review. Comparing the total number of patients who 
stopped a PIM with the total number of patients who started a PIM. The remaining two cells represent 
the number of patients who did not change after the first record of a review.   
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(c) Tricyclic antidepressants  
 
Table 38 McNemar 2x2 contingency table presenting the number of patients who stopped or started tricyclic 
antidepressant medications after the first record of a review 
  After first medication review  
  Tricyclic  No Tricyclic  
Before first 
medication  
review 
Tricyclic 512 70  
No Tricyclic  79 6822  
 Total    
     
  After first dementia annual review  
  Tricyclic  No Tricyclic  
Before first 
dementia annual  
review 
Tricyclic 292 44  
No Tricyclic  53 3974  
     
Dementia annual review  
OR 1.03 95% CI 0.97 – 1.09  
McNemar test statistic is: !" = (%&'))%*'  
 !"= (44-53)2 / (44+53)  !"= 0.84, df(1) p=0.361 
 
Medication review  
OR 1.02 95% CI 0.97-1.06 9 
McNemar test statistic is: !" = (%&'))%*'  
 !"= (70-79)2 / (70+79)  !"= 0.54, df(1) p=0.471 
 
n = number of individual patients  
 
Number of patients starting tricyclic medication n=837 
Number of patients starting tricyclic after any medication review n=173 (0.9%), n starting without review 
n=664 (0.7%) 
Number of patients staring after dementia review n=64 (0.7%), n staring without dementia review n=773 
(0.7%)  
 
Number of patients stopping tricyclic medication n=925  
Number of patients stopping after medication review n= 185 (10.6%), n stopping without review n=740 
(9.2%) 
Number of patients stopping after dementia review n=58 (7.2%), n stopping without review n=867 (9.7%) 
 
McNemar Chi-squared test estimating the ratio of disconcordant pairs, where the outcome (record of a 
PIM prescription) has changed after a review. Comparing the total number of patients who stopped a 
PIM with the total number of patients who started a PIM. The remaining two cells represent the number 
of patients who did not change after the first record of a review.   
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(d) Proton Pump Inhibitors  
 
Table 39 McNemar 2x2 contingency table presenting the number of patients who stopped or started PPI for more than 8 
weeks after the first record of a dementia annual review 
  After first dementia annual review  
  PPI  No PPI  
Before first 
dementia annual  
review 
PPI 662 38  
No PPI  62 1397  
     
     
  After first medication review  
  PPI  No PPI  
Before first 
medication  
review 
PPI 1324 85  
No PPI  104 2900  
     
Dementia annual review  
OR 1.03 95% CI 1.01-1.06  
McNemar test statistic is: !" = (%&'))%*'  
 !"= (38-62)2 / (38+62)  !"= 5.76 df(1) p=0.016 
 
Medication review  
OR 1.01 95% CI 0.99-1.03  
McNemar test statistic is: !" = (%&'))%*'  
 !"= (85-104)2 / (85+104)  !" = 1.91, df(1) p=0.167 
 
n = number of individual patients  
 
Number of patients prescribed a PPI for 8 weeks or more n=1,662 
Number of patients prescribed a long-term PPI after a medication review n= 259 (1.81%), number of 
patients not prescribed PPI or prescribed for less than 8 weeks after a review n=1,403 (1.83%)  
Number of patients prescribed long-term PPI after dementia review n=91 (1.26%), n=1571 (1.87%) 
prescribed PPI for more than 8 weeks without dementia review.  
 
Number of patients stopping a long-term PPI n=1,274  
Number of patients stopping after a medication review n=261 (2.6%), number of patients stopping 
without a review n=1,013 (2.1%) 
Number of patients stopping after a dementia review n=68 (1.0%), patients stopping without a dementia 
review n=1,206 (2.3%)  
 
Long-term PPI (prescribed for more than 8 weeks)  
McNemar Chi-squared test estimating the ratio of disconcordant pairs, where the outcome (record of a 
PIM prescription) has changed after a review. Comparing the total number of patients who stopped a 
PIM with the total number of patients who started a PIM. The remaining two cells represent the number 
of patients who did not change after the first record of a review.   
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10.08 Appendix 7: Relationship between a review, clinical and demographic factors 
and odds of stopping PIMs: Tables  
Table 40 Mixed effects logistic regression model estimating the relationship between a review, clinical and demographic 
factors and odds of stopping anticholinergic medication, stratified by living situation, in people with a dementia diagnosis 
in England. Clinical Practice Research Datalink (n=2,344) 
 Unadjusted 
model  
Adjusted mixed effects 
model  
Home residence stratification  
 
VARIABLES Stopping 
anticholinergics  
Stopping Anticholinergics  
(n=2,344) 
Care Home 
 (n=1,339) 
Not in Care Home  
(n=3,172) 
     
Age (years)  1.01* 1.03* 1.00 
  (1.00 - 1.02) (1.01 - 1.05) (0.99 - 1.01) 
Female  0.82* 0.83 0.81* 
  (0.70 - 0.95) (0.60 - 1.15) (0.68 - 0.96) 
Previous review      
Medication review  1.19* 1.21* 1.64* 1.04 
 (1.06 - 1.32) (1.06 - 1.38) (1.31 - 2.07) (0.88 - 1.22) 
Dementia annual review  0.69* 0.58* 0.66* 0.55* 
 (0.58 - 0.82) (0.48 - 0.71) (0.47 - 0.94) (0.42 - 0.70) 
Total CCI score   1.00 1.04 0.98 
  (0.96 - 1.04) (0.96 - 1.12) (0.94 - 1.03) 
IMD      
3-4  1.05 1.06 1.04 
  (0.80 - 1.38) (0.62 - 1.81) (0.77 - 1.41) 
5-6  0.96 0.87 1.01 
  (0.73 - 1.26) (0.51 - 1.48) (0.75 - 1.36) 
7-8  0.90 0.86 0.95 
  (0.68 - 1.20) (0.50 - 1.50) (0.70 - 1.29) 
9-10, least deprived  1.02 1.11 0.97 
  (0.77 - 1.34) (0.66 - 1.88) (0.72 - 1.31) 
Care home  0.99   
  (0.84 - 1.16)   
Polypharmacy      
5-9  0.84* 1.11 0.77* 
  (0.73 - 0.98) (0.82 - 1.51) (0.65 - 0.91) 
10+  0.84* 1.05 0.79* 
  (0.70 - 1.00) (0.74 - 1.50) (0.64 - 0.97) 
Constant coefficient  -2.13 -2.31 -2.90 -2.13 
 (-2.18, 2.08)  (-2.59,-2.04) (-3.47,-2.33) (-2.43,-1.83) 
Random effects1      
Practice   0.09 0.22 0.76 
  (0.41-0.20) (0.08-0.64) (0.03-0.23) 
Patients nested in 
practice  
 2.14 2.53 2.06 
  (1.87-2.46) (1.96-3.26) (1.65-2.32)  
OR (95% CI) *p<0.05 
Stopping anticholinergics across study period n= 2,344 : Stopping anticholinergics after any medication review n=473 (11.8%), without 
medication review n=1,871 (10.4%): Stopping anticholinergics after any dementia review n=146 (8.0%), without dementia review n=2,198 
(10.9%)  Total number of observations n=21,975, n=2,344 stopping anticholinergic medications  
Analyses included patients transitioning into care home n=66  
Number of GP practices n=268  
1estimated variance components of the random effects equations. Variance components are estimates of the amount of variance in the 
dependant variable that is attributable to the random effects. There are two random effects equations, the first is a random intercept (constant 
only) at the practice level and the second is the random intercept at the patient level, with patients nested within practices.    
Age: centred around the sample mean age (82 years) CCI: Charlson Comorbidity Index Score: higher scores = worse comorbidity  
IMD: Indices of Multiple Deprivation  Polypharmacy excluding PIMs 
Collinearity between covariates tested, mean VIF=1.05  
Conditional on the fixed effects, the latent response within patient have a correlation of 0.40 (95% CI 0.38-0.44), whereas within practice 
correlation was 0.02 (95% CI 0.01-0.04). Model with random effects compared to model without random effects. Significant difference between 
the models and random effects remained included (LR test !" =767.92 df(2), p=>0.001) 
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Table 41 Mixed effects logistic regression model estimating the relationship between a review, clinical and demographic 
factors and odds of stopping antipsychotic medication, stratified by living situation, in people with a dementia diagnosis 
in England. Clinical Practice Research Datalink (n=1,138) 
 Unadjusted 
model  
Adjusted mixed effects 
model  
Home Residence Stratification  
 
VARIABLES Stopping 
antipsychotics  
 
Stopping 
antipsychotics  
(n=1,138) 
Care Home  
(n=1,053) 
Not in Care Home  
(n=1,434) 
     
Age (years)  1.02* 1.01 1.03* 
  (1.01 - 1.04) (0.99 - 1.03) (1.01 - 1.04) 
Female  0.99 1.26 0.88 
  (0.80 - 1.22) (0.84 - 1.89) (0.69 - 1.13) 
Previous review      
Medication review  1.08 1.07 1.45* 0.86 
 (0.93 - 1.27) (0.89 - 1.29) (1.09 - 1.94) (0.67 - 1.10) 
Dementia annual 
review  
0.67* 0.55* 0.70 0.45* 
 (0.52 - 0.86) (0.41 - 0.73) (0.46 - 1.08) (0.30 - 0.66) 
Total CCI score   1.09* 1.10 1.08* 
  (1.04 - 1.15) (1.00 - 1.21) (1.01 - 1.16) 
IMD     
3-4  0.96 0.86 1.12 
  (0.66 - 1.39) (0.42 - 1.76) (0.76 - 1.64) 
5-6  0.84 0.85 0.88 
  (0.58 - 1.21) (0.41 - 1.74) (0.60 - 1.28) 
7-8  1.04 0.73 1.34 
  (0.71 - 1.52) (0.34 - 1.58) (0.92 - 1.97) 
9-10, least 
deprived 
 0.80 0.83 0.84 
  (0.55 - 1.16) (0.41 - 1.69) (0.57 - 1.25) 
Care home  0.68*   
  (0.55 - 0.83)   
Polypharmacy     
5-9  0.83 0.84 0.82 
  (0.68 - 1.02) (0.59 - 1.20) (0.64 - 1.05) 
10+  0.75* 0.72 0.77 
  (0.58 - 0.96) (0.47 - 1.12) (0.57 - 1.04) 
Constant 
coefficient  
-2.14 -2.36 -3.24 -2.19 
 (-2.21, -2.07) (-2.73, -1.98) (-3.98, -2.49) (-2.59, -1.80) 
Random effects1     
Practice   0.14 0.59 - 
  (0.06-0.36) (0.25-1.35) - 
Patients nested in 
practice 
 1.93 2.62 1.61 
  (1.57-2.38) (1.90-3.63) (1.22-2.12) 
OR (95% CI) *p<0.05 
Number of patients stopping antipsychotics across study period n=1,138: Number of patients stopping antipsychotics after any 
medication review n= 224 (10.8%), number of patients stopping antipsychotics without medication review n=914 (10.3%) Number of 
patients stopping antipsychotics after dementia review n=73 (7.5%), stopping without dementia review 1,065 (10.7%) Number of 
observations n=2,387, n=1,138 stopping antipsychotics  
Number of GP practice n=256 Number of patients transition into care home n=100 
1estimated variance components of the random effects equations. Variance components are estimates of the amount of variance in 
the dependant variable that is attributable to the random effects. There are two random effects equations, the first is a random 
intercept (constant only) at the practice level and the second is the random intercept at the patient level, with patients nested 
within practices.    
Age: centred around the sample mean age (82 years), CCI: Charlson Comorbidity Index Score: higher scores = worse comorbidity, 
IMD: Indices of Multiple Deprivation, Polypharmacy excluding PIMs, 
Collinearity between covariates tested, mean VIF=1.05 
Conditional on the fixed effects, the latent response within patient have a correlation of 0.39 (95% CI 0.34-0.43, there was little 
effect of within practice correlation, correlation was 0.03 (95% CI 0.01-0.06). Model with random effects compared to model 
without random effects. Significant difference between the models (LR test !" = 318.20 df(2), p=>0.001) 
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Table 42 Mixed effects logistic regression model estimating the relationship between a review, clinical and demographic 
factors and odds of stopping tricyclic antidepressant medication, stratified by living situation, in people with a dementia 
diagnosis in England. Clinical Practice Research Datalink (n=925) 
 
 
Unadjusted 
model 
Adjusted mixed 
effects model  
Home Residence stratification  
 
VARIABLES Stopping 
tricyclic  
Stopping tricyclic  
(n=925) 
Care Home  
(n=654) 
Not in Care Home  
(n=1,372) 
     
Age (years)  1.00 1.02 1.00 
  (0.99 - 1.02) (0.99 - 1.06) (0.98 - 1.02) 
Female  0.68* 0.68 0.68* 
  (0.52 - 0.87) (0.39 - 1.18) (0.51 - 0.91) 
Previous review      
Medication review  1.20* 1.25* 1.62* 1.10 
 (1.01 - 1.42) (1.01 - 1.54) (1.12 - 2.36) (0.86 - 1.42) 
Dementia annual review  0.70* 0.62* 0.81 0.56* 
 (0.53 - 0.93) (0.45 - 0.86) (0.46 - 1.43) (0.38 - 0.83) 
Total CCI score   1.03 1.08 1.01 
  (0.97 - 1.09) (0.95 - 1.22) (0.94 - 1.08) 
IMD     
3-4  0.93 0.69 1.04 
  (0.64 - 1.34) (0.34 - 1.42) (0.67 - 1.61) 
5-6  0.88 0.66 1.01 
  (0.60 - 1.28) (0.31 - 1.41) (0.64 - 1.59) 
7-8  0.99 0.55 1.19 
  (0.68 - 1.46) (0.24 - 1.25) (0.76 - 1.86) 
9-10, least deprived  1.02 0.86 1.09 
  (0.70 - 1.49) (0.40 - 1.84) (0.70 - 1.70) 
Care home  0.79   
  (0.61 - 1.02)   
Polypharmacy      
5-9  0.87 0.70 0.96 
  (0.69 - 1.11) (0.45 - 1.10) (0.72 - 1.26) 
10+  0.99 0.84 1.08 
  (0.74 - 1.32) (0.49 - 1.43) (0.77 - 1.53) 
Constant coefficient  -2.27 -2.50 -2.80 -2.56 
 (-2.35, -2.19) (-2.92, -2.08) (-3.66, -1.94) (-3.04, -2.08) 
Random Effects1     
Practice   - 0.15 - 
  - (0.01-3.45) - 
Patient nested in practice  2.61 3.09 2.47 
  (2.13-3.21) (2.08-4.61) (1.93-3.16) 
Number of patients   1,964 654 1,372 
Observations 9,793 9,790 3,254 6,536 
Number of groups  254 175 249 
OR (95% CI) ** p<0.05 
Number of patients stopping tricyclic medication n=925, Number of patients stopping after medication review n= 185 (10.6%), n 
stopping without review n=740 (9.2%), Number of patients stopping after dementia review n=58 (7.2%), n stopping without review 
n=867 (9.7%), Number of observations =1,964, n stopping tricyclics n=925 
Number of patients transition into care home n=62, Number of GP practices n=254  
1estimated variance components of the random effects equations. Variance components are estimates of the amount of variance in 
the dependant variable that is attributable to the random effects. There are two random effects equations, the first is a random 
intercept (constant only) at the practice level and the second is the random intercept at the patient level, with patients nested 
within practices.    
Age: centred around the sample mean age (82 years) CCI: Charlson Comorbidity Index Score: higher scores = worse comorbidity 
IMD: Indices of Multiple Deprivation Polypharmacy excluding PIMs 
Collinearity between covariates, mean VIF=1.05 
Conditional on the fixed effects, the latent response within patient have a correlation of 0.69 (95% CI 0.65-0.71), whereas within 
practice correlation was 0.07 (95% CI 0.05-0.10). Model with random effects compared to model without random effects. Significant 
difference between the models and random effects remained included (LR test !" =1-83.43 df(2), p=>0.001) 
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Table 43 Mixed effects logistic regression model estimating the relationship between a review, clinical and demographic 
factors and odds of stopping long-term PPI, stratified by living situation, in people with a dementia diagnosis in England. 
Clinical Practice Research Datalink (n=1,274) 
 Unadjusted Model  Adjusted mixed 
effects model  
Home Residence stratification  
 
VARIABLES Stopping long-term 
PPI  
Stopping long-term 
PPI  
(n= 1,274) 
Care Home  
(n= 5,028) 
Not in Care Home  
(n=12,112) 
     
Age (years)  0.98* 0.98 0.97* 
  (0.96 - 0.99) (0.95 - 1.00) (0.96 - 0.99) 
Female  0.81* 1.13 0.76* 
  (0.67 - 1.00) (0.70 - 1.82) (0.61 - 0.95) 
Previous review      
Medication review  1.33* 1.39* 1.54* 1.31* 
 (1.16 - 1.53) (1.18 - 1.65) (1.12 - 2.13) (1.07 - 1.60) 
Dementia annual review  0.42* 0.39* 0.31* 0.42* 
 (0.33 - 0.54) (0.30 - 0.52) (0.18 - 0.55) (0.31 - 0.58) 
Total CCI score   1.11* 1.15* 1.11* 
  (1.06 - 1.17) (1.03 - 1.28) (1.04 - 1.17) 
IMD      
3-4  1.25 0.92 1.34 
  (0.75 - 2.10) (0.39 - 2.17) (0.79 - 2.28) 
5-6  1.09 1.29 0.97 
  (0.65 - 1.81) (0.56 - 2.98) (0.57 - 1.65) 
7-8  1.08 0.52 1.22 
  (0.63 - 1.83) (0.21 - 1.33) (0.71 - 2.10) 
9-10, least deprived  1.06 1.03 0.99 
  (0.63 - 1.77) (0.44 - 2.42) (0.58 - 1.68) 
Care home  1.03   
  (0.83 - 1.29)   
Polypharmacy      
5-9  0.58* 0.59* 0.58* 
  (0.48 - 0.69) (0.40 - 0.87) (0.47 - 0.71) 
10+  0.36* 0.34* 0.36* 
  (0.28 - 0.45) (0.21 - 0.55) (0.27 - 0.48) 
Constant coefficient  -3.79 -6.05 -6.68 -5.86 
 (-3.85, -3.73) (-6.57, -5.53) (-7.70, -5.67) (-6.41, -5.31) 
Random Effects1     
Practice  0.80 0.96 0.74 
  (0.54-1.20) (0.45-2.04) (0.47-1.16) 
Patients nested within 
practice  
 4.97 6.09 4.79 
  (4.32-5.72) (4.59-8.08) (4.06-5.64) 
Number of patietns   16,802 5,028 12,112 
Observations 58,523 58,492 17,317 41,175 
Number of groups  272 252 272 
OR (95% CI) ** p<0.05 
Number of patients stopping a long-term PPI n=1,274, Number of patients stopping after a medication review n=261 (2.6%), number 
of patients stopping without a review n=1,013 (2.1%), Number of patients stopping after a dementia review n=68 (1.0%), patients 
stopping without a dementia review n=1,206 (2.3%), Number of observations n=16,802, number stopping long-term PPI n= 1,274, 
Number of patients transition into care home n=338, Number of GP practices n=272  
1estimated variance components of the random effects equations. Variance components are estimates of the amount of variance in 
the dependant variable that is attributable to the random effects. There are two random effects equations, the first is a random 
intercept (constant only) at the practice level and the second is the random intercept at the patient level, with patients nested 
within practices.    
Age: centred around the sample mean age (82 years), CCI: Charlson Comorbidity Index Score: higher scores = worse comorbidity, 
IMD: Indices of Multiple Deprivation, Polypharmacy excluding PIMs 
Collinearity between covariates, mean VIF=1.05 
Conditional on the fixed effects, the latent response within patient have a correlation of 0.64 (95% CI 0.60-0.67), whereas within 
practice correlation was 0.09 (95% CI 0.06-0.13). Model with random effects compared to model without random effects. Significant 
difference between the models and random effects remained included (LR test !" =1197.09 df(2), p=>0.001) 
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10.09 Appendix 8: Relationship between a review, clinical and demographic factors 
and odds of starting PIMs: Tables  
Table 44 Mixed effects logistic regression model estimating the relationship between a review, clinical and demographic 
factors and odds of starting anticholinergic medication, stratified by living situation, in people with a dementia diagnosis 
in England. Clinical Practice Research Datalink (n=2,277) 
 Unadjusted model  Adjusted mixed effects 
model 
  
Home residence stratification  
 
VARIABLES Starting 
anticholinergics 
Starting anticholinergics  
(n= 2,277) 
Care Home 
(n=5,835) 
Not in Care Home 
(n=14,676) 
     
Age (years)  0.98* 1.00 0.97* 
  (0.97 - 0.99) (0.99 - 1.02) (0.96 - 0.98) 
Female  0.97 0.89 0.98 
  (0.85 - 1.11) (0.69 - 1.16) (0.84 - 1.14) 
Previous review      
Medication review  1.27* 1.20* 0.99 1.31* 
 (1.14 - 1.41) (1.06 - 1.36) (0.80 - 1.24) (1.13 - 1.51) 
Dementia annual 
review  
0.82* 0.77* 0.75 0.77* 
 (0.70 - 0.97) (0.64 - 0.92) (0.54 - 1.04) (0.62 - 0.96) 
Total CCI score   0.99 0.97 1.01 
  (0.96 - 1.03) (0.91 - 1.03) (0.97 - 1.05) 
IMD      
3-4  1.01 0.88 1.08 
  (0.76 - 1.33) (0.56 - 1.39) (0.78 - 1.48) 
5-6  0.85 1.01 0.81 
  (0.65 - 1.13) (0.65 - 1.57) (0.59 - 1.11) 
7-8  1.05 1.00 1.08 
  (0.79 - 1.39) (0.63 - 1.59) (0.79 - 1.49) 
9-10, least deprived  0.89 0.90 0.88 
  (0.68 - 1.18) (0.57 - 1.40) (0.64 - 1.21) 
Care home  1.15*   
  (1.00 - 1.33)   
Polypharmacy      
5-9  1.40* 1.99* 1.29* 
  (1.23 - 1.61) (1.48 - 2.68) (1.10 - 1.50) 
10+  3.16* 6.08* 2.45* 
  (2.70 - 3.71) (4.39 - 8.43) (2.03 - 2.96) 
Constant coefficient  -3.86 -5.68 -5.80 -5.70  
 (-3.90-3.81) (-5.97, -5.39) (-6.35, -5.25) (-6.03, -5.37)  
Random effects1     
Practice   0.16 0.23 0.20 
  (0.11-0.28) (0.10-0.49) (0.12-0.34) 
Patient nested in 
practice  
 3.19 3.02 3.30 
  (2.85-3.57) (2.42-3.76) (2.89-3.76)  
     
OR (95% CI) *p<0.05 
Starting anticholinergics across study period n=2,277, Starting anticholinergics after any medication review n=433 (2.6%), without 
medication review n=1,844 (2.1%), Starting anticholinergics after any dementia review n=159 (1.8%), without dementia review n=2,118 
(2.2%), Total number of observations n=19,819, 2,277 started anticholinergics over the study period. Analysis included patients transitioning 
into care home n=692 and therefore contributing to n of both stratified analyses. Number of GP practices n=272  
1estimated variance components of the random effects equations. Variance components are estimates of the amount of variance in the 
dependant variable that is attributable to the random effects. There are two random effects equations, the first is a random intercept 
(constant only) at the practice level and the second is the random intercept at the patient level, with patients nested within practices.  
Age: centred around the sample mean age (82 years) CCI: Charlson Comorbidity Index Score: higher scores = worse comorbidity, IMD: 
Indices of Multiple Deprivation, Polypharmacy excluding PIMs. Collinearity between variables: mean VIF= 1.04  
Conditional on the fixed effects covariates, the latent responses within the same patient have a correlation of 0.51 (95%CI 0.48-0.53) and of 
0.03 (95% CI 0.02-0.04) within the same practice. 
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Table 45 Mixed effects logistic regression model estimating the relationship between a review, clinical and demographic 
factors and odds of starting antipsychotic medication, stratified by living situation, in people with a dementia diagnosis 
in England. Clinical Practice Research Datalink (n=1,496) 
 Unadjusted 
model  
Adjusted mixed 
effects model  
Home Residence Stratification  
 
VARIABLES Starting 
antipsychotic  
Starting 
antipsychotic  
(n=1,496) 
Care Home  
(n= 5,835)  
Not in Care Home  
(n= 14,688) 
     
Age (years)  0.98* 0.99 0.98* 
  (0.97 - 0.99) (0.97 - 1.00) (0.97 - 1.00) 
Female  1.03 0.94 1.06 
  (0.86 - 1.22) (0.68 - 1.32) (0.87 - 1.30) 
Previous review      
Medication review  1.27* 1.19* 1.01 1.30* 
 (1.11 - 1.45) (1.03 - 1.39) (0.78 - 1.31) (1.08 - 1.56) 
Dementia annual review  0.77* 0.68* 0.76 0.62* 
 (0.63 - 0.95) (0.54 - 0.86) (0.52 - 1.12) (0.47 - 0.83) 
Total CCI score   0.95* 1.01 0.93* 
  (0.91 - 1.00) (0.94 - 1.09) (0.88 - 0.98) 
IMD     
3-4  1.01 1.16 0.98 
  (0.72 - 1.42) (0.68 - 1.97) (0.67 - 1.45) 
5-6  1.08 1.13 1.09 
  (0.77 - 1.50) (0.67 - 1.90) (0.75 - 1.60) 
7-8  1.04 1.01 1.08 
  (0.74 - 1.46) (0.58 - 1.74) (0.73 - 1.59) 
9-10, least deprived  0.74 0.87 0.70 
  (0.52 - 1.04) (0.51 - 1.48) (0.47 - 1.04) 
Care home  1.38*   
  (1.16 - 1.65)   
Polypharmacy     
5-9  1.58* 2.11* 1.45* 
  (1.33 - 1.87) (1.48 - 2.99) (1.19 - 1.77) 
10+  3.32* 4.60* 2.93* 
  (2.70 - 4.08) (3.10 - 6.83) (2.28 - 3.76) 
Constant coefficient  -4.35 -6.81 -6.86 -6.75 
 (-4.40, -4.29)  (-7.20, -6.43) (-7.56, -6.15)  (-7.19, - 6.31) 
Random Effects1     
Practice  0.21 0.20 0.23 
  (0.12-0.36) (0.07-0.61) (0.12-0.44) 
Patients nested in practice   4.61 4.43 4.81 
  (4.09-5.19) (3.55-5.52) (4.18-5.54) 
     
OR (95% CI) *p<0.05 
Number of patients starting antipsychotic across study period n=1,496 
Number of patients starting antipsychotics after any medication review n=285 (1.56%), starting without medication review n=1,211 (1.26%) 
Number of patients starting antipsychotics after dementia review n= 98 (1.07%), starting without dementia review n=1,398 (1.33%)  
Total number of observations n=19,819, n=1,496 starting antipsychotic medication   
Number of patients transition into care home n=704  
Number of GP practice n=272  
1estimated variance components of the random effects equations. Variance components are estimates of the amount of variance in the 
dependant variable that is attributable to the random effects. There are two random effects equations, the first is a random intercept 
(constant only) at the practice level and the second is the random intercept at the patient level, with patients nested within practices.    
Age: centred around the sample mean age (82 years)  
CCI: Charlson Comorbidity Index Score: higher scores = worse comorbidity  
IMD: Indices of Multiple Deprivation   
Polypharmacy excluding PIMs 
Collinearity between covariates included in model, mean VIF=1.05 
Conditional on the fixed effects, the within patient correlation was 0.59 (95% CI 0.56-0.62), the within practice correlation was 0.03 (95% CI 
0.02-0.04). Model tested without random effects (LR test !"= 1110.88 df(2) p=>0.001 
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Table 46 Mixed effects logistic regression model estimating the relationship between a review, clinical and demographic 
factors and odds of starting tricyclic antidepressant medication, stratified by living situation, in people with a dementia 
diagnosis in England. Clinical Practice Research Datalink (n=837) 
 Unadjusted 
model  
Adjusted mixed 
effects model  
Home Residence Stratification 
 
VARIABLES Starting tricyclic  Starting tricyclic  
(n=837) 
Care Home  
(n=5,835) 
Not in Care Home  
(n=14,715) 
     
Age (years)  0.96* 0.99 0.96* 
  (0.95 - 0.98) (0.96 - 1.03) (0.94 - 0.97) 
Female  1.38* 2.27* 1.28 
  (1.08 - 1.78) (1.15 - 4.47) (0.98 - 1.68) 
Previous review      
Medication review  1.39* 1.36* 1.18 1.44* 
 (1.17 - 1.64) (1.12 - 1.67) (0.75 - 1.84) (1.15 - 1.81) 
Dementia annual review  0.89 0.90 1.33 0.78 
 (0.69 - 1.16) (0.67 - 1.21) (0.76 - 2.31) (0.54 - 1.11) 
Total CCI score   1.07* 1.13 1.06 
  (1.01 - 1.14) (0.98 - 1.31) (0.99 - 1.14) 
IMD     
3-4  1.00 0.96 1.05 
  (0.58 - 1.73) (0.31 - 3.02) (0.60 - 1.83) 
5-6  0.69 0.47 0.77 
  (0.40 - 1.20) (0.14 - 1.53) (0.44 - 1.36) 
7-8  0.97 0.76 1.04 
  (0.56 - 1.69) (0.23 - 2.46) (0.59 - 1.83) 
9-10, least deprived  0.88 0.69 0.97 
  (0.51 - 1.51) (0.22 - 2.19) (0.55 - 1.68) 
Care home  0.80   
  (0.61 - 1.04)   
Polypharmacy      
5-9  1.00 1.83* 0.88 
  (0.80 - 1.24) (1.05 - 3.17) (0.69 - 1.12) 
10+  1.19 2.05* 1.09 
  (0.90 - 1.58) (1.06 - 3.98) (0.79 - 1.51) 
Constant coefficient  -4.97 -8.32 -10.23 -8.12 
 (-5.04, -4.89) (-8.91, -7.72) (-11.76, -8.69) (-8.75, -7.48)  
Random Effects1     
Practice   0.76 2.10 0.65 
  (0.50-1.16) (1.10-4.02) (0.39-1.08) 
Patients nested in practice   6.40 7.85  6.22 
  (5.56-7.34) (5.86-10.52) (5.32-7.28) 
Number of patients starting tricyclic medication n=837, Number of patients starting tricyclic after any medication 
review n=173 (0.9%), n starting without review n=664 (0.7%), Number of patients staring after dementia review n=64 
(0.7%), n staring without dementia review n=773 (0.7%) Number of observations n=19,819, n starting tricyclic n=837 
Number of GP practices n=272 Number of patients transition into care home n=731  
1estimated variance components of the random effects equations. Variance components are estimates of the amount 
of variance in the dependant variable that is attributable to the random effects. There are two random effects 
equations, the first is a random intercept (constant only) at the practice level and the second is the random intercept 
at the patient level, with patients nested within practices.    
Age: centred around the sample mean age (82 years) CCI: Charlson Comorbidity Index Score: higher scores = worse 
comorbidity IMD: Indices of Multiple Deprivation Polypharmacy excluding PIMs 
Collinearity between covariates tested, mean VIF=1.07 
Conditional on the fixed effects, the latent response within patient have a correlation of 0.44 (95% CI 0.39-0.49, there 
was little effect of within practice correlation, within practice correlation was less than 0. Model with random effects 
compared to model without random effects. Significant difference between the models (LR test !" = 352.09 df(1), 
p=>0.001) 
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Table 47 Mixed effects logistic regression model estimating the relationship between a review, clinical and demographic 
factors and odds of being prescribed a long-term PPI, stratified by living situation, in people with a dementia diagnosis in 
England. Clinical Practice Research Datalink (n=1,662) 
 
 
Unadjusted model  Adjusted mixed 
effects model  
Home residence stratification  
 
VARIABLES Starting Long-
term PPI  
Starting Long-Term 
PPI 
(n=1,662)  
Care Home  
(n=5,853) 
Not in Care Home  
(n=14,534) 
     
Age (years)  0.97* 0.96* 0.98* 
  (0.96 - 0.98) (0.93 - 0.99) (0.97 - 0.99) 
Female  0.78* 0.80 0.78* 
  (0.65 - 0.94) (0.51 - 1.27) (0.64 - 0.95) 
Previous review      
Medication review  1.01 0.95 0.91 0.95 
 (0.89 - 1.16) (0.81 - 1.11) (0.64 - 1.27) (0.79 - 1.14) 
Dementia annual review  0.67* 0.65* 0.42* 0.72* 
 (0.54 - 0.83) (0.51 - 0.83) (0.24 - 0.75) (0.55 - 0.95) 
Total CCI score   1.10* 1.15* 1.08* 
  (1.04 - 1.15) (1.04 - 1.28) (1.02 - 1.14) 
IMD     
3-4  1.09 1.29 1.00 
  (0.72 - 1.67) (0.61 - 2.73) (0.66 - 1.53) 
5-6  1.09 0.88 1.10 
  (0.72 - 1.65) (0.41 - 1.88) (0.73 - 1.67) 
7-8  0.95 0.79 0.94 
  (0.62 - 1.47) (0.36 - 1.75) (0.61 - 1.45) 
9-10, least deprived  0.92 0.74 0.90 
  (0.60 - 1.41) (0.34 - 1.59) (0.59 - 1.37) 
Care home  0.73*   
  (0.60 - 0.90)   
Polypharmacy      
5-9  2.00* 1.60* 2.11* 
  (1.69 - 2.36) (1.07 - 2.39) (1.75 - 2.55) 
10+  3.00* 2.26* 3.23* 
  (2.43 - 3.69) (1.41 - 3.62) (2.56 - 4.09) 
Constant coefficient  -3.96 -6.95 -7.59  -6.80 
 (-4.01, -3.01) (-7.39, -6.51) (-8.53, -6.65) (-7.25, -6.34)  
Random Effects     
Constant  0.47 0.52 0.38 
  (0.30-0.75) (0.18-1.50) (0.22-0.64) 
Constant  5.30 6.60 5.07 
  (4.75-5.93) (5.28-8.27) (4.47-5.76) 
OR (95% CI) ** p<0.05 
Number of patients prescribed a PPI for 8 weeks or more n=1,662, Number of patients prescribed a long-term PPI after a medication 
review n= 259 (1.81%), number of patients not prescribed PPI or prescribed for less than 8 weeks after a review n=1,403 (1.83%), 
Number of patients prescribed long-term PPI after dementia review n=91 (1.26%), n=1571 (1.87%) not prescribed PPI for more than 
8 weeks. Number of observations n=19,819, n=1,662 prescribed PPI for 8 weeks or more. Number of patients transition into care 
home n=568 Number of GP practices n=272 
1estimated variance components of the random effects equations. Variance components are estimates of the amount of variance in 
the dependant variable that is attributable to the random effects. There are two random effects equations, the first is a random 
intercept (constant only) at the practice level and the second is the random intercept at the patient level, with patients nested 
within practices.    
Age: centred around the sample mean age (82 years) CCI: Charlson Comorbidity Index Score: higher scores = worse comorbidity 
IMD: Indices of Multiple Deprivation Polypharmacy excluding PIMs 
Collinearity between covariates, mean VIF=1.05 
Conditional on the fixed effects, the latent response within patient have a correlation of 0.62 (95% CI 0.59-0.65), whereas within 
practice correlation was 0.04 (95% CI 0.03-0.07). Model with random effects compared to model without random effects. Significant 
difference between the models and random effects remained included (LR test !" =1569.10 df(2), p=>0.001) 
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